"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",52,"Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations incorporate communications, to begin the call."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's first quarter fiscal 2016 earnings call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bo",197,"Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's first quarter fiscal 2016 earnings call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some remarks than you have question-and-answer session. Our first quarter press release is available now on the investor relations section of our website. We also oppose our prepared remarks to our website shortly after we delivered them this afternoon. Finally, a replay of the call will be archived on our website through February 26. Before we begin, I'd like to inform you that certain statements made during this call will be forward-looking. These statements involve known as well as in on the risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the Safe Harbor statements in our press release and in our filings with the SEC. Also, during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. Now I'd like to turn the call over to Steve Macmillan, Hologic CEO."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers an",1507,"Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers and exceeding expectations on the bottom line based on the tremendous earnings power of the company, which has become even stronger over time than I initially thought possible. In the first quarter, total revenue grew 8.1% in constant-currency terms, driven by double-digit growth in the United States, our largest and most profitable market. Our U.S. businesses turned around more rapidly than anyone anticipated based on better commercial execution and the quality of our products. And over the last few quarters, our domestic sales and marketing teams have kicked it up a notch, generating robust growth from our key brands. This commercial improvement has led to significant benefits up and down our income statement. For example, in the first quarter, we posted non-GAAP gross and operating margins that were significantly higher than in the prior-year period. We are clearly demonstrating that despite our already sector-leading profitability, we can generate additional operating leverage by driving the growth of our most profitable products. 
Working down the income statement, earnings per share were $0.46 in the first quarter, beating our expectations again. In addition, we increased EPS at a pace that was nearly 3x the rate of revenue growth. With that introduction, let me discuss the details of our first quarter revenue performance, then Bob will take you through the rest of the income statement, the balance sheet and our updated guidance. Total revenues were $695.2 million in the first quarter, an increase of 6.5% on a reported basis and 8.1% in constant-currency terms. Geographically, our U.S. businesses performed exceptionally well in the quarter. We posted 12.8% revenue growth domestically, a slight acceleration over the fourth quarter despite a more difficult comp. This strong U.S. performance outweighed what was a mixed bag internationally in the first quarter. We showed good continued progress in cytology, molecular diagnostics and surgical outside the United States. In constant-currency terms, cytology grew high single digits. Molecular posted modest growth for the second consecutive quarter and surgical grew in the midteens, albeit from a small base. In contrast, we saw weakness in our international blood screening business, which was largely expected and which resulted mainly from fluctuations in ordering patterns by our commercial partner, Grifols. In addition, our international Breast Health results confirmed, as we have highlighted before, that we are a long way from optimizing our relationships with our dealers and distributors. Lower Breast Health and blood screening sales OUS contributed to total international sales declining 11.5% in the quarter or 5.4% in constant-currency terms. We are moving decisively to strengthen the International Breast business, drawing on the same toolkit that we employed to turn around our domestic franchises. We are unifying leadership of all global commercial activities under our COO Eric Compton so that we may share some of our U.S. best practices internationally. As part of this process, our head of international has left the company, along with our head of European Breast Health sales. In their place, Eric is diving deep to optimize our go-to-market strategy in key markets around the globe. We are highly focused on identifying the right commercial model for each country in which we operate. While there may be some short-term volatility, we remain bullish on our international opportunities in Breast Health, and we look forward to sharing more details about our plans as they come together. 
Now let's provide some more color on our divisional revenue performance in the first quarter. Our biggest division, Diagnostics, posted sales of $310.7 million in the quarter, a growth rate of 3.7% in constant-currency terms. But the 3 franchises within Diagnostics demonstrated very different results. In molecular diagnostics and cytology, where we control the commercial channel, our results were very good. The blood screening sales declined. Let's discuss each piece in turn. In molecular diagnostics, quarterly sales of $129.6 million increased 9.9% in constant-currency, our best growth rate since the GenProbe acquisition. Domestic revenues increased a stellar 11.5% and the formula was similar to recent quarters, strong placements of our fully automated Panther instrument, a healthy number of competitive wins and growing utilization of our women's health assays. We said at a recent healthcare conference that the average Panther system globally now generates more than $170,000 in annual assay revenue, despite being less than 30% utilized. This demonstrates both the current value of the system and its future potential for customers and Hologic, as we add new tests for viral load and other targets in the years ahead. Outside the United States, sales of our molecular diagnostics products grew nominally on a constant-currency basis for the second consecutive quarter as the business stabilizes after an extended period of decline. 
We're also pleased with the performance of ThinPrep, one of our largest and most profitable franchises. Global sales of cytology and perinatal products totaled $120.4 million in the first quarter. U.S. sales actually increased by a modest 0.5% as market share gains more than offset headwinds from longer screening intervals. And internationally, we are encouraged that revenue grew 8.7% in constant-currency. This drove global growth of 3.1%, our second consecutive quarter of decent constant-currency growth. Our commercial team deserves much credit for transforming a business that was declining at a high single-digit rate as recently as 2014 into a modest growth globally. 
In blood screening, worldwide sales were $60.7 million in the first quarter. This was roughly flat sequentially as sales have normalized without the benefit of growth from the Japanese Red Cross contract. Compared to the prior year however, blood screening sales declined 6.5% on a constant-currency basis. This reflects heavier ordering by our partner, Grifols, a year ago and general declines in blood usage that we are seeing in the United States and other markets. 
Now let's turn to Breast Health, where we continue to see strong adoption of our Genius 3D mammography exam in the United States. Domestic sales of breast imaging products, including our Genius systems, increased 18.7% compared to the 8.9% constant-currency decline we saw internationally. Global sales of interventional breast products increased slightly on a constant-currency basis and we are optimistic that new products will help stimulate growth in this category over the next couple of years. All this added up to total Breast Health sales of $262.2 million in the quarter, up 9.9% in constant-currency terms. We also remain enthusiastic about our future prospects in the mammography market. We continue to gain share in the United States based on a superior product profile and excellent customer service. Our prices are stable despite increasing competition, which indicates that our marketing programs are working and that our systems are providing value to customers, and Congressional action has prohibited any near term insurance changes arising from the controversial screening recommendations by the USPSTF. All in all, we have a lengthy runway ahead of us to continue upgrading older, less effective technologies to our Genius 3D exams. 
To round out the revenue discussion, we are thrilled with the progress being made by our surgical team. Although the December quarter is typically a seasonally strong one, we certainly did not predict sales of $98.8 million or a constant-currency growth rate of 18.8%. These are truly outstanding results, our best overall performance in the last several years, so congratulations to the commercial teams and new leaders who are making it happen. It's worth mentioning that surgical is Hologic's most profitable division on a gross and operating margin basis, so the magnitude of the top line growth we're now seeing is having a nice positive impact on the company's gross and operating margins, as well as earnings per share. Specifically, our MyoSure product for hysteroscopic tissue removal posted total revenue of $36.9 million in the first quarter, with accelerating growth of 46.1% in constant-currency terms. Equally impressive, global NovaSure sales of $61.7 million increased by 7.5% on a constant-currency basis. We do believe NovaSure sales benefited from the recall of the competitive product but estimate that this benefit was relatively small in the context of overall quarterly sales. 
Finally, worldwide Skeletal sales were $23.5 million in the quarter, an increase of 7.7% on a constant-currency basis, driven by continued growth of our new Horizon bone density scanner, a very solid performance. 
Before I turn the call over to Bob, let me conclude by saying that this quarter illustrates the value that our portfolio of products can provide to shareholders. Although Breast Health and blood screening declined outside the United States, we more than compensated by posting strong growth in mammography, molecular diagnostics and surgical. The net effect was top line performance slightly ahead of expectations, and a significant increase in profitability. All in all, we're off to good a good start in 2016 and remain excited about the future. 
Now I will hand the call over to Bob."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and",1550,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and percentage changes will be on a year-over-year basis. As Steve mentioned, we delivered another solid quarter on the top line, with 12.8% sales growth in the U.S., more than offsetting the international choppiness we saw in Breast Health and blood screening. Strengthened domestic revenue, combined with the early returns of our productivity effort helped drive margin improvement at the gross and operating levels, contributing to non-GAAP earnings per share of $0.46, a 17 9% increase over the prior-year period. Even with headwinds from share count and currency, EPS grew at a rate nearly 3x faster than sales. 
Moving down the income statement, our first quarter gross margin of 65.2% increased 190 basis points compared to the prior-year period. Gross margin benefited from mix, both geographic and product, and from our cost-reduction initiatives. Not only did revenue grow at a double-digit rate at the U.S., some of our highest margin products also performed well, including our ThinPrep, NovaSure and Aptima franchises; and I should point out that pricing remains stable across our product lines as our commercial teams focus on selling the clinical and economic value that our products provide. In addition, our operations and procurement teams are executing well, driving efficiencies and reducing the costs to make our products. Total operating expenses of $221 million increased by 11.3% in the first quarter. This increase was driven primarily by sales and marketing expense, which increased 15.6%. We continue to invest to extend our leadership in the mammography market and to explain like cotesting is the best route to protect women from cervical cancer. Despite these investments, better gross margins drove profitability improvement down to the operating line. Our non-GAAP operating margin was 33.4% in the quarter, an increase of 50 basis points from last year. Although our operating margin is already among the highest in our sector, the last several quarters have clearly demonstrated that they can expand further even as we fund key growth drivers. 
Moving further down the income statement, we are beginning to reap the benefits of our efforts to reduce and refinance debt. In the first quarter interest expense was $32.8 million, a reduction of 25% versus the prior-year period. In addition, we are pleased that a lot of hard work to reduce our tax rate has begun to pay off earlier than expected. We now estimate that our effective tax rate will be around 33% in fiscal 2016, lower than our initial guidance and this added about $0.01 to EPS in the first quarter. Although this is just the first step in our multiyear tax improvement strategy, we are encouraged by the progress we've made so far. 
Finally, diluted shares outstanding were 292 million in the first quarter. As you know, we are focused on minimizing share count dilution by eliminating convertible notes from our capital structure. In the fourth quarter, for example, we repurchased $300 million in principal of our most dilutive convertible notes, and this had a beneficial effect on share count in the first quarter. In addition, the recent decline in our share price had the rather perverse effect of further reducing dilution from the converts. The combined effect boosted EPS by almost $0.01 in the quarter. 
Now let's talk about cash flows in the balance sheet. Operating cash flow was strong again in the first quarter at $163.3 million [ph], an increase of 7% over the prior-year period. We spent $19.7 million on capital in the quarter, leading the free cash flow of $144.6 million. 
Turning to the balance sheet, we ended the first fiscal quarter with $650 million in cash, a 19.5% improvement over the prior-year period. This strong cash position provides us with dry powder, of potential tuck-in acquisitions even as we continue to pay down debt. At the end of the first quarter, we had total debt outstanding of $3.6 billion, a decrease of $322 million compared to a year ago, and net debt of $2.98 billion. Our leverage ratio net debt over EBITDA now stands at 3.1x and we are on track to achieve our goal of lowering our leverage ratio to 2.5x by the end of fiscal 2017. 
To wrap up the historical discussion, adjusted EBITDA was $252 million in the first quarter, up 8.1% compared to the prior-year period and we're tracking to generate EBITDA of more than $1 billion for the full year. Our consistency in delivering strong profit growth and lowering debt has allowed us to steadily improve our return on invested capital. As of our first fiscal quarter, ROIC was 11.3% on a trailing 12-month basis, 160-basis point increase over the prior year. 
Now let's shift gears and turn to our updated non-GAAP financial guidance for the full year and second quarter. We are updating our guidance based on our solid performance in the first quarter, a stronger U.S. dollar and greater than expected earnings dollar. As always, this guidance is based on recent foreign exchange rates. As you know, the dollar has strengthened since we provided our initial 2016 guidance. Compared to last year, we now expect currency to represent a $25 million top line headwind in 2016. This equates to roughly $0.03 in earnings per share. And, importantly, compared to when we initially guided in November, the stronger dollar is subtracting an incremental $11 million from our top line. So for the 2016 fiscal year, we are maintaining our guidance for constant-currency growth of between 4.4% and 5.5%, but on a reported basis, we are updating our guidance to reflect the additional currency headwind. So based solely on the stronger dollar, we now expect reported revenues of $2.8 billion to $2.83 billion, representing reported growth of 3.5% to 4.6%. As Steve said earlier, we continue to forecast improvements on both the gross and operating margin lines based on favorable geographic and product mix, as well as early returns from our productivity efforts. 
In addition, as you probably read, the Omnibus Budget Bill that was passed by Congress in December included a 2-year moratorium on medical device excise tax among other key provisions. We're thrilled that Congress has recognized the negative effects of this tax on domestic innovation and job growth. In fiscal 2015, we paid $23.6 million under this tax, which was reported under general and administrative expenses. It's important to note 2 points, however. First, since the moratorium took effect on January 1, we only recognize 3/4 [ph] of this benefit in our 2016 fiscal year. In addition, we plan to reinvest most of the benefit in some of our more attractive R&D and commercial programs. Continuing with our full year guidance, we now expect our effective tax rate to improve to approximately 33% for the year and believe diluted shares outstanding will total between $296 million and $298 million for the full year. 
Given these updates and our strong first quarter results, we are increasing our non-GAAP earnings per share guidance. For the full year, we now expect EPS of $1.86 to $1.90. This translates to growth of 13.1% to 15.5% in constant-currency terms with reported growth between 11.4% and 13.8%. So despite currency and share count headwinds, we anticipate growing EPS at more than double the rate of sales, demonstrating bottom line growth and operating leverage that seems unlikely at best just a few quarters ago. 
Turning to guidance for the second quarter of fiscal 2016, we expect revenues of $680 million to $690 million. Compared to the prior-year period, this range reflects revenue growth of 4.5% to 6% on a constant-currency basis and reported revenue growth of 3.7% to 5.3%. We expect a sequential decline in revenue for 2 main reasons. First, our surgical business is seasonally weakest in the March quarter, especially in comparison to the strength we saw in the December period. Second, we're allowing for some potential choppiness in our international business. In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.45 to $0.46 in the second quarter. This represents growth of 11.2% to 13.6% in constant-currency terms or 9.8% to 12.2% on a reported basis. It's worth mentioning that we anticipate a substantial R&D increase in spending in the second fiscal quarter based mainly on the timing of projects. 
Before opening the call for questions, I'd like to reiterate that Hologic is off to a good start in 2016. In the first quarter, our momentum continued with Genius 3D mammography and our surgical and molecular diagnostics business is provides us upside. As a whole, our domestic businesses performed great. These positives outweighed weaker than expected results in our international mammography business, which we're dealing with aggressively. In the middle of the income statement, we are demonstrating the tremendous earnings power of the company by improving gross and operating margins. And below the line, we are beginning to see the benefits from our efforts to reduce debt, as well as our effective tax rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we're ready for some of those questions."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan.",14,"[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I guess, I want to start on the International Breast Health, where we've been getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it and",60,"Steve, I guess, I want to start on the International Breast Health, where we've been getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it and what kind of cushion you're baking in for the remainder of the year?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, on the wall of worry, Tycho, it's something we think about, I wouldn't be overly freaked out by it. I think the way we're thinking about it for got just every business performing better than we expected. But I think the deeper we dug in the second ha",303,"Yes, on the wall of worry, Tycho, it's something we think about, I wouldn't be overly freaked out by it. I think the way we're thinking about it for got just every business performing better than we expected. But I think the deeper we dug in the second half of the year, you'll continue to hear us say really going back a few quarters, hey, we're probably closer to a startup than a real turnaround here, and we have a lot of work to do, even just building our relationships with the dealers. And I think as we go back and look at it, clearly, our fourth fiscal quarter was really strong and followed by a weaker quarter. And that's not what we want to be delivering and don't have that sustained relationships. So we're making some changes internally, and we're not going to blame the dealers. We can always look at ourselves and I'll say that we need to be a little closer to it. But it's the only little piece of the puzzle I think right now for us to continue to work on. I'd also say I think we're all accustomed to not every business is always firing on every cylinder. The day it does, we're probably in trouble. This is kind of one of our areas of opportunity. I think the next couple of quarters will probably be a little bit softer. We're going to plan for that while we get to the right longer term plays. As Erik first reviews of it, it obviously room as we a little bit when you walk to a door of Hologic 2 years ago some of the same rebuilding needs to occur. Things like pricing discipline, marketing, market access, just a lot of the fundamentals that we've never put in place."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, and then just follow up, the management changes you alluded to, are the changes and here? And the team in place no need for Europe?",26,"Okay, and then just follow up, the management changes you alluded to, are the changes and here? And the team in place no need for Europe?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. I think in the next quarter or 2, there will be softness and that's basically what we baked into our guidance.",44,"No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. I think in the next quarter or 2, there will be softness and that's basically what we baked into our guidance."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jonathan Groberg of UBS.",10,"And we'll go next to Jonathan Groberg of UBS."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Obviously, a lot of questions on international Breast Health but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, your operating expenses grew quite a bit more than sales. Kind of what's your ex",61,"Obviously, a lot of questions on international Breast Health but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, your operating expenses grew quite a bit more than sales. Kind of what's your expectation for OpEx growth for the year versus kind of gross margin for the year?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, John, this is Bob. As we mentioned in our prepared remarks, what we're looking at is actually very strong performance on our gross margin basis, combination of product and geographically mix, as well as some of the productivity efforts that we're doi",156,"Hey, John, this is Bob. As we mentioned in our prepared remarks, what we're looking at is actually very strong performance on our gross margin basis, combination of product and geographically mix, as well as some of the productivity efforts that we're doing. And we are looking to reinvest a portion of those. So our gross margins probably operating a little bit better than we had anticipated and we're looking to reinvest that in those growth drivers, in places our marketing and to a certain extent, some of the R&D investments to drive that growth rate on the top line. That being said, we are still expecting operating margin expansion consistent with what we had guided to in November, and we believe that we're able to do that and we demonstrated that certainly in the first quarter, continue to have operating margin leverage and we expect that throughout the course of the rest of the year."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So just to follow up on that and kind of to add into the first part of the conversation around international, is it more about getting the right people? I know you thought you have the right person in your first hire, but is it more about getting the righ",89,"So just to follow up on that and kind of to add into the first part of the conversation around international, is it more about getting the right people? I know you thought you have the right person in your first hire, but is it more about getting the right people or is it more about throwing the right money at the issue? And have you contemplated that guidance now, the outlook for how much you may need to spend in order to get this start up going internationally?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's all about the right people, it's not about the spending, Jonathan, so we'll have it nailed.",18,"It's all about the right people, it's not about the spending, Jonathan, so we'll have it nailed."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jack Meehan of Barclays.",10,"And we'll go next to Jack Meehan of Barclays."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just want to ask about the U.S. mammography business and just curious on your view for the landscape issue whether it's hospital CapEx, CapEx trends or the competitive dynamic? Just your view on the rate of placements from here.",40,"Just want to ask about the U.S. mammography business and just curious on your view for the landscape issue whether it's hospital CapEx, CapEx trends or the competitive dynamic? Just your view on the rate of placements from here."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging businesses of 18.7% in the quarter. That's coming off of some pretty good comps and everything we're seeing and hearing is we continue to feel we are making very good progres",136,"Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging businesses of 18.7% in the quarter. That's coming off of some pretty good comps and everything we're seeing and hearing is we continue to feel we are making very good progress, both with our own customers, as well as competitive in runs. And I think we feel as good, if not better, about that business and the fact that we're going to end up. By the end of the 3D curve, I said early on, we think we'll end up with a little bit higher share than we started, and I think if anything, we feel better and better about that prediction, more and more confident every day that goes by. We continue to hear great stories from our teams."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. Just curious as you see hospitals taking on the new 3D units, do you still see them adding new capacity or are you seeing some replacements of 3D units as well?",33,"Got it. Just curious as you see hospitals taking on the new 3D units, do you still see them adding new capacity or are you seeing some replacements of 3D units as well?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today.",35,"It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Doug Schenkel of Cowen & Company.",12,"And we'll go next to Doug Schenkel of Cowen & Company."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I just wanted to cover really 2 topics. One is really just a math on guidance and really the other topic is pricing and sort of product categories. So first on guidance. Just to try to run through the waterfall, the deep earnings guidance with the high-en",138,"I just wanted to cover really 2 topics. One is really just a math on guidance and really the other topic is pricing and sort of product categories. So first on guidance. Just to try to run through the waterfall, the deep earnings guidance with the high-end by $0.04 this quarter. You increased EPS guidance for the year at the midpoint by $0.06. We estimate lower share count gets you $0.03 to $0.05 and lower tax rate gets $0.03 to $0.04. So it seems like we might be missing something here. Is there a change in mix that you expect to occur? Are there areas that maybe you're investing a little bit more in, either in sales or R&D relative to your last guidance? What are the clause there, and I will come back with a pricing question."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Now, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to, the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and sh",77,"Now, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to, the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and share count, roughly we think about $0.06, offset by about $0.02 of FX. And then the operational beat in the Q1, that gives about [ph] $0.06 growth. [indiscernible]."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then on pricing, really quickly, some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors particularly [indiscernible] Can you talk about if you seeing anything that's really different fro",66,"Okay. And then on pricing, really quickly, some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors particularly [indiscernible] Can you talk about if you seeing anything that's really different from kind of the normal pricing pressures you see in the market? If there is, basically what's baked into your guidance outlook for pricing changes in molecular?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","I think we feel as good as we felt since we've been here about pricing. I think there's a much more discipline. I think we are hearing more and more competitive attempts, frankly, on both the molecular side, as well as on the mammography side, where there",162,"I think we feel as good as we felt since we've been here about pricing. I think there's a much more discipline. I think we are hearing more and more competitive attempts, frankly, on both the molecular side, as well as on the mammography side, where there's some pretty big disparities and with Bob McMahon and Eric Compton's leadership and the divisional we have been doing a much better job of price fighting on price -- not fighting on price, fighting on future price increases and not going down there. I think it is part of the hidden piece we are seeing in gross margin expansion. As we talk about the gross margin piece, clearly, the incredible progress we're making on the operational side, it's a mix benefit but also, frankly, I think much better pricing discipline and we're holding pricing far better, in some cases, getting a little bit of upticks, even in what is a much more competitive environment."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Isaac Ro with Goldman Sachs.",11,"And we'll go next to Isaac Ro with Goldman Sachs."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context from what we're seeing from the other major equipment players this quarter. And specifically curious if you're se",71,"I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context from what we're seeing from the other major equipment players this quarter. And specifically curious if you're seeing any more signs of aggressive bundling or pricing practices from those players and whether or not that's a fact that we should be considering in the market?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're seeing it, and Isaac, I'll tell you we're really, really  proud of our team fighting it off. I think we're actually way more based on the overall success of the business. The combination of our product, our label, the ease of use, and our genius mar",131,"We're seeing it, and Isaac, I'll tell you we're really, really  proud of our team fighting it off. I think we're actually way more based on the overall success of the business. The combination of our product, our label, the ease of use, and our genius marketing campaigns which frankly has probably been the single biggest differentiator of hospitals understanding. They're better aligned with us in the mammography space than anybody else, because we're driving patients to the hospitals that have our systems. And I think it's been a dramatic step change in our own organization's ability to off going price down the pricing games. And I've heard more and more anecdotes of much bigger pricing discounts from competitors on accounts that we've not lost, and in fact, we've won."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Just to build on that, Steve. Over the last 18 months we've had 2 competitors come into a market where we would be the sole competitor. We've not only maintained stable pricing, but we've gained share. That's a huge credit to our domestic Breast Health te",56,"Just to build on that, Steve. Over the last 18 months we've had 2 competitors come into a market where we would be the sole competitor. We've not only maintained stable pricing, but we've gained share. That's a huge credit to our domestic Breast Health team led by Pete and the team, just a tremendous job."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful. Maybe just a separate question on the balance sheet and M&A, didn't come up so far this quarter, I'm curious if it's possible that we went to you guys get in the marketplace this year with a tuck in deal or 2 to augment the business? And i",67,"That's helpful. Maybe just a separate question on the balance sheet and M&A, didn't come up so far this quarter, I'm curious if it's possible that we went to you guys get in the marketplace this year with a tuck in deal or 2 to augment the business? And if so, kind of how the shipping will flip, how do you characterize evaluation into your funnel?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Isaac. I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the",150,"Sure, Isaac. I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the shopping list. But I'll put it really in probably the first inning. We started to look at a few things and said no to. I do think valuations are going to be our friend as we go forward, and obviously, with the tremendous cash generation and getting our balance sheet cleaned up, we're going to be ready. I think our teams have been so focus on great commercial execution and getting the R&D pipelines back in shape. That's sort of the next piece that will start to play out. But we're probably still a little slower so I wouldn't anticipate anything super quick on that front."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to the Gulf Piper Jaffray.",10,"And we'll go next to the Gulf Piper Jaffray."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","First question, Bob, you mentioned that obviously there's a number of factors that help drive the gross margin from year-over-year. You alluded to the fact that we're kind in the early days from the supply chain standpoint. So, I guess, 2 part question he",90,"First question, Bob, you mentioned that obviously there's a number of factors that help drive the gross margin from year-over-year. You alluded to the fact that we're kind in the early days from the supply chain standpoint. So, I guess, 2 part question here, one, can you help break this down a little bit further in terms of what the contribution was from aligning your supply chain, and then I don't want to put words in your mouth, but it sounds like it's really the early days for this initiative."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I'm not going to give you the level of specificity that you probably would like to have there. I would say it is the productivity enhancements that we're talking about are through our sourcing organization, as well as looking at running our factories",188,"Yes, I'm not going to give you the level of specificity that you probably would like to have there. I would say it is the productivity enhancements that we're talking about are through our sourcing organization, as well as looking at running our factories more efficiently. And I think our operations team has done a great job of driving that. Obviously, we started that last year. We're seeing one, a full year benefit and we're starting to see the full annualized effect of that this year. And it felt really good about that. And I would say it was a fairly meaningful component of the gross margin expansion. Obviously with our U.S. business driving significant growth. That also had a big impact as well, and as we're thinking about the way that the U.S. business grew with the higher margin products in our surgical business and so forth, that actually helped us overall as well. So it was a nice balance between kind of the 3 of those things, but I think we are in the early innings of sustained kind of improvement on the gross margin basis."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Bill, I would add to that. You heard me say, certainly, a year ago, I didn't think as a company we'll probably see much gross margin expansion, and if I say things that have changed over the last year in my own outlook, that's one that I think we're seein",77,"Bill, I would add to that. You heard me say, certainly, a year ago, I didn't think as a company we'll probably see much gross margin expansion, and if I say things that have changed over the last year in my own outlook, that's one that I think we're seeing much better opportunity than I ever imagined possible. So it's back to there's always puts and takes. That's one of the really good guys coming our way."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Good to hear. Second, just kind of a bigger picture question on blood screening and blood utilization in general. Certainly we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may be starting t",86,"Good to hear. Second, just kind of a bigger picture question on blood screening and blood utilization in general. Certainly we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may be starting to see this internationally as well. So just to kind a similar question here, guys, and how much through the process are we both in the U.S. and OUS, just be curious what your partner, Grifols, has been telling you on that."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","I think we see, in the U.S., I think we see continued low single-digit declines probably in the blood screening business. International, it's probably more flattish as more countries adopt our net testing but some more advanced ones start to cut back a bi",144,"I think we see, in the U.S., I think we see continued low single-digit declines probably in the blood screening business. International, it's probably more flattish as more countries adopt our net testing but some more advanced ones start to cut back a bit, I think we tried to see the international business more flattish. Having said that, we got a couple of quarters right now, that we're absorbing the inventory fluctuations, particularly from a year ago with the JRC where, frankly, we were both doing consumption plus inventory build. And now as the inventories contracting back, we have a couple of rougher comps and that we're getting through. The underlying business, slightly down, but still a very good business for us. But certainly it's not going to be accretive to our top line growth rate over time. It would be dilutive to that."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Richard Newitter of Leerink Partners.",11,"And we'll go next to Richard Newitter of Leerink Partners."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I was hoping just to start off on the investments that you guys are making and one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out of t",110,"I was hoping just to start off on the investments that you guys are making and one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out of the other side of kind of the tumble ramp. So first, just can you give us any sense as to where -- whether organic or external, where the priority is? You alluded to some of that, Steve, earlier. And then two, any color on when we'll learn about the pipeline in greater detail? And what can you give us today?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, sure, Rich. Clearly, the primary focus is on the rebuilding of the organic growth pipeline. I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good we're puttin",299,"Sure, sure, Rich. Clearly, the primary focus is on the rebuilding of the organic growth pipeline. I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good we're putting in place. The other piece that I start to give you a little bit of a tidbit in, what we're working on this one recall singles and doubles. The company was built historically on every 8 years will launch a mega product like 2D and then 3D tomo and a lot of what we are looking at is how do we cushion the blow in between and looking at some smaller things that we can be doing to bring in between those big cycles. And on the diagnostics business, it's about building out menu. In the Breast Health business, it's not just what's the replacement for 3D tomo, there's a lot of other stuff we can bring in, IDS and other stuff along the way. So I think what you'll start to see, and as you know, with me, stylistically, I'd like to get a few points on the board before we start talking about them. And given an organization we inherited that had a few launches on the table that we have to scrap when we got here because they weren't really ready for primetime, you want to make sure we have our ducks in a row before we, a, start talking about more. But I will tell you that we feel better and better but it is going to be more singles and doubles then probably triples and home runs. So we'll continue to update you as we go but. Definitely will give you a little bit more flavor what we have historically."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful. And just maybe one more on the surgical business, nice growth acceleration there and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory going forwar",57,"That's helpful. And just maybe one more on the surgical business, nice growth acceleration there and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory going forward? And then do you have the portfolio you need to achieve that?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, thanks, Rich, I wouldn't go there yet to the sustainable double-digit. Having said that, we posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all the",350,"Yes, thanks, Rich, I wouldn't go there yet to the sustainable double-digit. Having said that, we posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all the changes we make, but that business actually, just in the last 6 months, we have a new VP of marketing, a new President, a new head of business development, a new head of R&D, and I'm more bullish and excited the team Eric has put in place there is really, really good. And they're doing that with just 2 products today. We stopped the declines in NovaSure, you know it better than most, just 2 years ago, NovaSure was a high digit decliner. We stopped that one and actually turned it into a positive. And in MyoSure, I know when I first came here, it was growing at 20%. People figured we were about maxed out last year we went to 30%, and just had a 40% growth in the quarter. That's asked us in the markets size a year or 2 ago. And I couldn't quite answer it, I think we are seeing there may be more potential there. And then it's a great sales team that clearly could take on another product. So I think that's an area we're very willing and stepping up our activities when looking at bolt-on acquisitions. It's an area we're in the nascent stages, frankly started to expand internationally. And it's a business that can do a lot for the profit pmargin and profitability profile of the company. So it's one we're more and more excited about. I'd still model single-digit growth, but like everything, we're certainly aspiring to continue the great trend. But clearly we did mention there was a competitive recall we think helped us in that last quarter. And so that we certainly don't see the 18.8% growth as sustainable. Aspirational, yes, and we'll take the fact that the division had, that isn't a new go but pragmatically speaking, we're not that good yet."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","I guess, the only thing I'd add on surgical is the quarter we're in now, which is the second fiscal quarter, does tend to be the seasonally weakest quarter for us and typically the first quarter of our fiscal year is the strongest one.",44,"I guess, the only thing I'd add on surgical is the quarter we're in now, which is the second fiscal quarter, does tend to be the seasonally weakest quarter for us and typically the first quarter of our fiscal year is the strongest one."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis.",25,"This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Brian Weinstein from William Blair.",11,"And we'll go next to Brian Weinstein from William Blair."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders and how should never be higher, I'm just kind of what your backlog looks like right now. And have you seen any impact at all in terms of time to close any d",81,"Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders and how should never be higher, I'm just kind of what your backlog looks like right now. And have you seen any impact at all in terms of time to close any discussion around the task force or any of these insurance companies that have been kind of  reiterating nonpayment for tomo. Is there anything in the field that you're picking up from that."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Brand, it's Bob. What I would say is our backlog continues to be very robust and we have not seen any extension of time to close or anything like that. I think it's a lot of noise that people may hear about kind of in the press but when it actually comes",66,"Brand, it's Bob. What I would say is our backlog continues to be very robust and we have not seen any extension of time to close or anything like that. I think it's a lot of noise that people may hear about kind of in the press but when it actually comes to actually making purchase decisions and so forth, that hasn't affected us one bit."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Great, I'm going to say on cytology, you continue to reference share gains. Can you kind of talk about what inning you are in share gains, where you think you're in terms of market share at this point?",38,"Great, I'm going to say on cytology, you continue to reference share gains. Can you kind of talk about what inning you are in share gains, where you think you're in terms of market share at this point?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. We're not quite sure on market share but we feel very good. We are obviously very strong leader and probably in the 3/4 [ph] of the market share range, so up in the 70-plus percent certainly in the U.S. We think we're much lower outside, and I think",136,"Sure. We're not quite sure on market share but we feel very good. We are obviously very strong leader and probably in the 3/4 [ph] of the market share range, so up in the 70-plus percent certainly in the U.S. We think we're much lower outside, and I think part of where we're really encouraged and where I think we have made great progress internationally, over the last year, 1.5 years, is starting to get the belief and the conviction of what we need to do to grow the cytology business outside. And if you remember, we said, one of the first things we could do to return this company to growth would stop the sharp declines on the ThinPrep business. And I think we feel very good about what we're doing there, actually feel great."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Raj Denhoy from Jefferies.",10,"And we'll go next to Raj Denhoy from Jefferies."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","What if given this metric now, $170,000 per machine, any update you can give us in terms of timing on when you can get the menu expanded? When do expect in United States and subsequent tests beyond that?",38,"What if given this metric now, $170,000 per machine, any update you can give us in terms of timing on when you can get the menu expanded? When do expect in United States and subsequent tests beyond that?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're just rolling viral load outside the U.S., we have the CE marking so we're rolling that out off up, and I think that will help our mammography business, we are obviously coming off of a pretty weak base, candidly, internationally. It's not like what",144,"We're just rolling viral load outside the U.S., we have the CE marking so we're rolling that out off up, and I think that will help our mammography business, we are obviously coming off of a pretty weak base, candidly, internationally. It's not like what we have here. And really it's going to be a fiscal '18/'19 event in terms of the true viral load impact in the U.S. The HIV approved sooner but, frankly, we ultimately want to have the full range of HIV, HPV, HCV which we don't have really until later on in '18. So the way we think about that is it's probably going to end up hitting at a beautiful time for us in some of them mammography business may be slowing a bit in the U.S. That 1 kicks in and provide another leg up for us."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful, just another question, too on R&D spending was actually down this quarter relative to last year, and although you did make a comment that you expect to step up pretty dramatically as you move through the back half of the year, is there any",64,"That's helpful, just another question, too on R&D spending was actually down this quarter relative to last year, and although you did make a comment that you expect to step up pretty dramatically as you move through the back half of the year, is there anything you can give us in terms of what dramatically stepping up means? And relative to this point?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Raj, it's Bob. It's simply timing. When we look at the clinical programs that we have, we expect a ramp-up in Q2. So don't read anything into that other than it was just timing.",34,"Raj, it's Bob. It's simply timing. When we look at the clinical programs that we have, we expect a ramp-up in Q2. So don't read anything into that other than it was just timing."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jonathan Block from Stifel.",10,"And we'll go next to Jonathan Block from Stifel."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe just the first one, Bob, for you, constant-currency is not going to change for 2016 but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again GYN was still big, international Breast Health",74,"Maybe just the first one, Bob, for you, constant-currency is not going to change for 2016 but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again GYN was still big, international Breast Health was maybe a little shy, should we just know that through the best we can an end efficiency change to get to the components of the top line?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No specifics. I think you would flow those in, obviously. We were pleasantly surprised on the upside on the surgical business and in the U.S., I think our U.S. business is doing a little better than what we anticipated in our international business, a lit",96,"No specifics. I think you would flow those in, obviously. We were pleasantly surprised on the upside on the surgical business and in the U.S., I think our U.S. business is doing a little better than what we anticipated in our international business, a little more choppy and so forth. Outside of that, we're not going to give specific guidance to the individual components, other than to say that any softness that we may be seeing in the near term or the short-term internationally is going to be offset by the strength in the U.S. business."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, got it. And then Steve, apologies if I missed this on some of your color, but we have seen the international Breast Health bounce around a good amount before, but when you talked about what's currently going on and we have a headline risk of interna",109,"Okay, got it. And then Steve, apologies if I missed this on some of your color, but we have seen the international Breast Health bounce around a good amount before, but when you talked about what's currently going on and we have a headline risk of international and what we deal with everyday from where we sit, can you just give a little bit more detail, in other words, is it the way you're working with dealers, the relationships that you think you guys can strengthen in the coming quarters, or has there been any change to call it end user demand out in the field in certain countries?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, I think this is more an internal execution issue plus dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger words in some of the emerging markets this year, and we'll probably just backing off that,",134,"Sure, I think this is more an internal execution issue plus dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger words in some of the emerging markets this year, and we'll probably just backing off that, we're making some progress in Brazil and places like that. We're probably being a little more cautious about as we go in. But it's much more our own execution. And, frankly, again it's a small part of our business that we know has great potential and we would realize it. It is more that than anything I think anything external or macro at this point. It could be macro but we're not going to look to say if it's in that. I think the opportunity is still there."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Vijay Kumar of Evercore ISI are.",12,"And we'll go next to Vijay Kumar of Evercore ISI are."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","One on breast imaging just to sort of pick on this, but the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a sharper mission?It looks like in the U.S. and growth slowed down sequentially.",61,"One on breast imaging just to sort of pick on this, but the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a sharper mission?It looks like in the U.S. and growth slowed down sequentially. So I'm just wondering if you can give some color on what happened U.S. versus OUS?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, [indiscernible]. I think first of U.S., we continue to feel really, really good. Obviously the growth rates, Vijay, we should pointed out, the going against a monster comps especially when we come into the second half of this year but really already",156,"Yes, [indiscernible]. I think first of U.S., we continue to feel really, really good. Obviously the growth rates, Vijay, we should pointed out, the going against a monster comps especially when we come into the second half of this year but really already from here on, we're against much tougher comps in year. We're still growing the business but we're not going to be putting 20% growth rate on top of strong growth rates from a year ago. The outside the U.S., I look at this folks, it's just like every other issue we face since we came to the company. We're not a perfectly well-oiled machine. I think we're making a little bit of progress. Haven't made the progress that we would like to see, and it's just a matter of better execution, which is something we know how to do. And it just required a little greater focus than probably what I was providing."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","One follow up on Diagnostics. Clearly, this is a monster diagnostic quarter. In the U.S. business, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how sustainable that the share gai",77,"One follow up on Diagnostics. Clearly, this is a monster diagnostic quarter. In the U.S. business, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how sustainable that the share gain because when you look at sort of the Aptima franchise, those are some pretty big product lines and pretty mature. So I'm just wondering why this business is strong and what's going on."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I think it's been the hidden piece and back to the focus on execution where we've clearly been the focus than in the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. And obviousl",135,"Vijay, I think it's been the hidden piece and back to the focus on execution where we've clearly been the focus than in the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. And obviously, you know us well enough to know we're not one of these out there trumpeting gee we're #1, we beat this person, we got this competitive win. But quietly, we're really proud of what we've done on the HPV franchise in the U.S. and combined with cytology, combined with the cotesting message, combined with Panther placements, they're all no one thing is magic, but when you systematically pile them up, it provides a very nice outlook and has still a pretty good -- this strength is going to continue."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Derik De Bruin with Bank of America.",13,"And we'll go next to Derik De Bruin with Bank of America."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So one of the questions have been asked, but let me just a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, some of the",76,"So one of the questions have been asked, but let me just a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, some of the systems that you placed earlier start paying for service contract. Can we think about instrument placement services services and how it goes in the mix?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in. And",123,"I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in. And we will say this. We are seeing a higher attach rate on the 3D service revenue contracts than we did on 2D. So, a, it's a little bit higher. So I think it's sort of one of those pieces that we'll kick in and we feel really good about on the future.  And the team is doing a better job of actually selling service contracts today, probably in a tougher environment than we ever have."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Just one other thing, Derik, just to kind of give you a little color on that. Total service when you look at it from a total company only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest component of that which is our",97,"Just one other thing, Derik, just to kind of give you a little color on that. Total service when you look at it from a total company only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest component of that which is our domestic U.S. mammography, that grew in the mid-single digits consistent with what we've been talking about is in that business with that high attach rate, higher ASP relative to the service contracts on the lower ASP 2D. So we continue to feel good about that business."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a little clarification from me on this. So why was the 2D attachment rate on the service runs over historically?",21,"Just a little clarification from me on this. So why was the 2D attachment rate on the service runs over historically?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It wasn't well.",4,"It wasn't well."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It was extremely high and we're going from an extremely high level to actually an even higher level. It was well into the 80s percent and we're doing even better than that.",33,"It was extremely high and we're going from an extremely high level to actually an even higher level. It was well into the 80s percent and we're doing even better than that."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","85-plus percent.",3,"85-plus percent."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Mark Massaro of Canaccord Genuity.",11,"And we'll go next to Mark Massaro of Canaccord Genuity."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I want to ask and acknowledge that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you gained share. Just wondering if you could just talk about the dynamics, internationally. Is the bundling",73,"I want to ask and acknowledge that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you gained share. Just wondering if you could just talk about the dynamics, internationally. Is the bundling occurring more frequently internationally, than it is in the U.S.? And can you just help us understand some of the pressures you saw internationally, in context of gaining market share?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, I think it's less bundling internationally than it's still the stage of development, internationally. We've not been nearly as good a job of selling the benefits of 3D, just when government a fair standpoint, from a marketing standpoint. A lot of wh",201,"Sure, I think it's less bundling internationally than it's still the stage of development, internationally. We've not been nearly as good a job of selling the benefits of 3D, just when government a fair standpoint, from a marketing standpoint. A lot of what we have going in the U.S. we're doing a great job of internationally, because we're true leaders. We've not worked with them closely enough to really segment the market. We were starting, obviously, there's a lot of opportunities for 2D. We need to do that, but we have so much focus on 3D and I don't think we've done as good a job of fully marketing it through. So that's a part of the whole issue of consolidating the international business under Eric. We kind of I set it up when I first got here, to have Eric really focus on the U.S. Claus focus internationally. It probably led to 2 silos more than sharing the learning across the geographies. And frankly I feel like it's a great job overall, but it probably would have left a little bit on the table as we're doing on the international development. So Eric's on the case an here we go."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Maybe a little outside the box here, would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?",26,"Maybe a little outside the box here, would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're looking at it everywhere as to what's really the best model. And that will be something I think you expect us to report back on over time. I will tell you there's a lot more complexity to it all in that, candidly in a number of geographies, we had g",170,"We're looking at it everywhere as to what's really the best model. And that will be something I think you expect us to report back on over time. I will tell you there's a lot more complexity to it all in that, candidly in a number of geographies, we had given the marketing authorizations to the dealers. So the dealers actually own the marketing authorizations which is not something you would typically expect of a company this size. But, a, it's one of this yet, you go on the onion and peel it back a little bit more, more work to be done which is why we just think it's been at it is a little bit longer. I kind of view it as it will be great thing to have in the outyears when things go down in the U.S. We probably are not getting there as fast as I'd like to but we'll probably end up getting there at time ultimately actually pretty well-timed for the company."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","At and we'll take our final question from Jayson Bedford of Raymond James.",14,"At and we'll take our final question from Jayson Bedford of Raymond James."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","And I'll ask 2 questions that require one word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what's your latest thoughts on gross margin expectations for '16?",46,"And I'll ask 2 questions that require one word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what's your latest thoughts on gross margin expectations for '16?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Higher and higher.",3,"Higher and higher."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","You got better words than that, Steve?",7,"You got better words than that, Steve?"
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","You asked for one-word answer, Jason. As a reminder, we're only going to give the placement numbers on an annual basis rather than giving the quarterly pieces. But we're very pleased with the additional placements of certainly the Genius, frankly, Panther",74,"You asked for one-word answer, Jason. As a reminder, we're only going to give the placement numbers on an annual basis rather than giving the quarterly pieces. But we're very pleased with the additional placements of certainly the Genius, frankly, Panthers as well the looking at the Diagnostics business and then gross margin, I think we're basically guiding to there's 100 basis points of improvement year-over-year, and feeling very encouraged by that opportunity."
108544,321211701,921789,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","That is all the time we have for questions today. This now concludes Hologic's first quarter fiscal 2016 earnings call. Have a good evening.",24,"That is all the time we have for questions today. This now concludes Hologic's first quarter fiscal 2016 earnings call. Have a good evening."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",53,"Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's First Quarter Fiscal 2016 Earnings Call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bo",199,"Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's First Quarter Fiscal 2016 Earnings Call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks then we'll have a question-and-answer session. 
Our first quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them this afternoon. Finally, a replay of the call will be archived on our website through February 26. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward-looking. These statements involve known as well as unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's in our press release and in our filings with the SEC. 
Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve Macmillan, Hologic's CEO."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers an",1524,"Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers and exceeding expectations on the bottom line based on the tremendous earnings power of the company, which has become even stronger over time than I initially thought possible. 
In the first quarter, total revenue grew 8.1% in constant currency terms, driven by double-digit growth in the United States, our largest and most profitable market. Our U.S. businesses have turned around more rapidly than anyone anticipated, based on better commercial execution and the quality of our products. And over the last few quarters, our domestic sales and marketing teams have kicked it up a notch, generating robust growth from our key brands. 
This commercial improvement has led to significant benefits up and down our income statement. For example, in the first quarter, we posted non-GAAP gross and operating margins that were significantly higher than in the prior-year period. We are clearly demonstrating that despite our already sector-leading profitability, we can generate additional operating leverage by driving the growth of our most profitable products. 
Working down the income statement, earnings per share were $0.46 in the first quarter, beating our expectations again. In addition, we increased EPS at a pace that was nearly 3x the rate of revenue growth. 
With that introduction, let me discuss the details of our first quarter revenue performance. Then Bob will take you through the rest of the income statement, the balance sheet and our updated guidance. 
Total revenues were $695.2 million in the first quarter, an increase of 6.5% on a reported basis and 8.1% in constant currency terms. 
Geographically, our U.S. businesses performed exceptionally well in the quarter. We posted 12.8% revenue growth domestically, a slight acceleration over the fourth quarter despite a more difficult comp. 
This strong U.S. performance outweighed what was a mixed bag internationally in the first quarter. We showed good continued progress in cytology, molecular diagnostics and surgical outside the United States. In constant currency terms, cytology grew high single digits. Molecular posted modest growth for the second consecutive quarter, and surgical grew in the mid-teens, albeit from a small base. In contrast, we saw weakness in our international blood screening business, which was largely expected and which resulted mainly from fluctuations in ordering patterns by our commercial partner, Grifols. 
In addition, our international Breast Health results confirmed, as we have highlighted before, that we are a long way from optimizing our relationships with our dealers and distributors. Lower Breast Health and blood screening sales OUS contributed to total international sales declining 11.5% in the quarter, or 5.4% in constant currency terms. 
We are moving decisively to strengthen the international breast business, drawing on the same toolkit that we employed to turn around our domestic franchises. We are unifying leadership of all global commercial activities under our COO, Eric Compton, so that we may share some of our U.S. best practices internationally. 
As part of this process, our head of international has left the company, along with our head of European Breast Health sales. In their place, Eric is diving deep to optimize our go-to-market strategy in key markets around the globe. 
We are highly focused on identifying the right commercial model for each country in which we operate. While there may be some short-term volatility, we remain bullish on our international opportunities in Breast Health, and we look forward to sharing more details about our plans as they come together. 
Now let's provide some more color on our divisional revenue performance in the first quarter. 
Our biggest division, Diagnostics, posted sales of $310.7 million in the quarter, a growth rate of 3.7% in constant currency terms. But the 3 franchises within Diagnostics demonstrated very different results. In molecular diagnostics and cytology, where we control the commercial channel, our results were very good. But blood screening sales declined. Let's discuss each piece in turn. 
In molecular diagnostics, quarterly sales of $129.6 million increased 9.9% in constant currency, our best growth rate since the GenProbe acquisition. Domestic revenues increased a stellar 11.5%, and the formula was similar to recent quarters: strong placements of our fully automated Panther instrument, a healthy number of competitive wins and growing utilization of our women's health assays. 
We said at a recent healthcare conference that the average Panther system globally now generates more than $170,000 in annual assay revenue, despite being less than 30% utilized. This demonstrates both the current value of the system and its future potential for customers and Hologic, as we add new tests for viral load and other targets in the years ahead. Outside the United States, sales of our molecular diagnostics products grew nominally on a constant currency basis for the second consecutive quarter, as the business stabilizes after an extended period of decline. 
We're also pleased with the performance of ThinPrep, one of our largest and most profitable franchises. Global sales of cytology and perinatal products totaled $120.4 million in the first quarter. U.S. sales actually increased by a modest 0.5%, as market share gains more than offset headwinds from longer screening intervals. And internationally, we are encouraged that revenue grew 8.7% in constant currency. This drove global growth of 3.1%, our second consecutive quarter of decent constant currency growth. Our commercial team deserves much credit for transforming a business that was declining at a high single-digit rate as recently as 2014, into a modest grower globally. 
In blood screening, worldwide sales were $60.7 million in the first quarter. This was roughly flat sequentially, as sales have normalized without the benefit of growth from the Japanese Red Cross contract. Compared to the prior year, however, blood screening sales declined 6.5% on a constant currency basis. This reflects heavier ordering by our partner Grifols a year ago and general declines in blood usage that we are seeing in the United States and other markets. 
Now let's turn to Breast Health, where we continue to see strong adoption of our Genius 3D Mammography exams in the United States. Domestic sales of breast imaging products, including our Genius systems, increased 18.7% compared to the 8.9% constant currency decline we saw internationally. Global sales of interventional breast products increased slightly on a constant currency basis, and we are optimistic that new products will help stimulate growth in this category over the next couple of years. All this added up to total Breast Health sales of $262.2 million in the quarter, up 9.9% in constant currency terms. 
We also remain enthusiastic about our future prospects in the mammography market. We continue to gain share in the United States based on a superior product profile and excellent customer service. Our prices are stable despite increasing competition, which indicates that our marketing programs are working and that our systems are providing value to customers. And Congressional action has prohibited any near-term insurance changes arising from the controversial screening recommendations by the USPSTF. All in all, we have a lengthy runway ahead of us to continue upgrading older, less effective technologies to our Genius 3D exams. 
To round out the revenue discussion, we are thrilled with the progress being made by our surgical team. Although the December quarter is typically a seasonally strong one, we certainly did not predict sales of $98.8 million, or a constant currency growth rate of 18.8%. These are truly outstanding results, our best overall performance in the last several years, so congratulations to the commercial teams and new leaders who are making it happen. 
It's worth mentioning that surgical is Hologic's most profitable division on a gross and operating margin basis, so the magnitude of the top line growth we're now seeing is having a nice positive impact on the company's gross and operating margins, as well as earnings per share. Specifically, our MyoSure product for hysteroscopic tissue removal posted total revenue of $36.9 million in the first quarter, with accelerating growth of 46.1% in constant currency terms. Equally impressive, global NovaSure sales of $61.7 million increased by 7.5% on a constant currency basis. We do believe NovaSure sales benefited from the recall of a competitive product, but estimate that this benefit was relatively small in the context of overall quarterly sales. 
Finally, worldwide Skeletal sales were $23.5 million in the quarter, an increase of 7.7% on a constant currency basis, driven by continued growth of our new Horizon bone density scanner, a very solid performance. 
Before I turn the call over to Bob, let me conclude by saying that this quarter illustrates the value that our portfolio of products can provide to shareholders. Although Breast Health and blood screening declined outside the United States, we more than compensated by posting strong growth in mammography, molecular diagnostics and surgical. The net effect was top line performance slightly ahead of expectations, and a significant increase in profitability. All in all, we're off to good a good start in 2016, and remain excited about the future. 
Now I will hand the call over to Bob."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and",1561,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and percentage changes will be on a year-over-year basis. 
As Steve mentioned, we delivered another solid quarter on the top line, with 12.8% sales growth in the U.S. more than offsetting the international choppiness we saw in Breast Health and blood screening. Strengthen in domestic revenue, combined with the early returns of our productivity efforts, helped drive margin improvement at the gross and operating levels, contributing to non-GAAP earnings per share of $0.46, a 17.9% increase over the prior year period. Even with headwinds from share count and currency, EPS grew at a rate nearly 3x faster than sales. 
Moving down the income statement, our first quarter gross margin of 65.2% increased 190 basis points compared to the prior year period. Gross margin benefited from mix, both geographic and product, and from our cost reduction initiatives. Not only did revenue grow at a double-digit rate in U.S., some of our highest margin products also performed well, including our ThinPrep, NovaSure and Aptima franchises. And I should point out that pricing remains stable across our product lines as our commercial teams focus on selling the clinical and economic value that our products provide. In addition, our operations and procurement teams are executing well, driving efficiencies and reducing the cost to make our products. 
Total operating expenses of $221 million increased by 11.3% in the first quarter. This increase was driven primarily by sales and marketing expense, which increased 15.6%. We continue to invest to extend our leadership in the mammography market, and to explain why co-testing is the best way to protect women from cervical cancer. 
Despite these investments, better gross margins drove profitability improvement down to the operating line. Our non-GAAP operating margin was 33.4% in the quarter, an increase of 50 basis points from last year. Although our operating margin is already among the highest in our sector, the last several quarters have clearly demonstrated that they can expand further even as we fund key growth drivers. 
Moving further down the income statement, we are beginning to reap the benefits of our efforts to reduce and refinance debt. In the first quarter, interest expense was $32.8 million, a reduction of 25% versus the prior year period. 
In addition, we are pleased that a lot of hard work to reduce our tax rate has begun to pay off earlier than expected. We now estimate that our effective tax rate will be around 33% in fiscal 2016, lower than our initial guidance, and this added about $0.01 to EPS in the first quarter. Although this is just a first step in our multi-year tax improvement strategy, we are encouraged by the progress we've made so far. 
Finally, diluted shares outstanding were 292 million in the first quarter. As you know, we are focused on minimizing share count dilution by eliminating the convertible notes from our capital structure. In the fourth quarter, for example, we repurchased $300 million in principal of our most dilutive convertible notes, and this had a beneficial effect on share count in the first quarter. In addition, the recent decline in our share price had the rather perverse effect of further reducing dilution from the converts. The combined effect boosted EPS by almost $0.01 in the quarter. 
Now let's talk about cash flows and the balance sheet. 
Operating cash flow was strong again in the first quarter at $164.3 million, an increase of 7% over the prior year period. We spent $19.7 million on capital in the quarter, leading to free cash flow of $144.6 million. 
Turning to the balance sheet. We ended the first fiscal quarter with $650 million in cash, a 19.5% improvement over the prior year period. This strong cash position provides us with dry powder for potential tuck-in acquisitions, even as we continue to pay down debt. 
At the end of the first quarter, we had total debt outstanding of $3.6 billion, a decrease of $322 million compared to a year ago, and net debt of $2.98 billion. Our leverage ratio, net debt over EBITDA, now stands at 3.1x. And we are on track to achieve our goal of lowering our leverage ratio to 2.5x by the end of fiscal 2017. 
To wrap up the historical discussion, adjusted EBITDA was $252 million in the first quarter, up 8.1% compared to the prior year period, and we're tracking to generate EBITDA of more than $1 billion for the full year. 
Our consistency in delivering strong profit growth and lowering debt has allowed us to steadily improve our return on invested capital. As of our first fiscal quarter, ROIC was 11.3% on a trailing 12-month basis, a 160 basis point increase over the prior year. 
Now let's shift gears and turn to our updated non-GAAP financial guidance for the full year and second quarter. 
We are updating our guidance based on our solid performance in the first quarter, a stronger U.S. dollar and greater than expected earnings power. 
As always, this guidance is based on recent foreign exchange rates. As you know, the dollar has strengthened since we provided our initial 2016 guidance. Compared to last year, we now expect currency to represent a $25 million top line headwind in 2016. This equates to roughly $0.03 in earnings per share. And importantly, compared to when we initially guided in November, the stronger dollar is subtracting an incremental $11 million from our top line. 
So for the 2016 fiscal year, we are maintaining our guidance for constant currency growth of between 4.4% and 5.5%. But on a reported basis, we are updating our guidance to reflect the additional currency headwind. So based solely on the stronger dollar, we now expect reported revenues of $2.8 billion to $2.83 billion, representing reported growth of 3.5% to 4.6%. 
As Steve said earlier, we continue to forecast improvements on both the gross and operating margin lines, based on favorable geographic and product mix, as well as early returns from our productivity efforts. 
In addition, as you probably read, the omnibus budget bill that was passed by Congress in December included a 2-year moratorium on the medical device excise tax among other key provisions. We're thrilled that Congress has recognized the negative effects of this tax on domestic innovation and job growth. In fiscal 2015, we paid $23.6 million under this tax, which was reported under general and administrative expenses. It's important to note 2 points, however: first, since the moratorium took effect on January 1, we only recognize 3/4 of this benefit in our 2016 fiscal year. In addition, we plan to reinvest most of the benefit in some of our more attractive R&D and commercial programs. 
Continuing with our full year guidance, we now expect our effective tax rate to improve to approximately 33% for the year, and believe diluted shares outstanding will total between $296 million and $298 million for the full year. 
Given these updates and our strong first quarter results, we are increasing our non-GAAP earnings per share guidance. For the full year, we now expect EPS of $1.86 to $1.90. This translates to growth of 13.1% to 15.5% in constant currency terms, or reported growth between 11.4% and 13.8%. So despite currency and share count headwinds, we anticipate growing EPS at more than double the rate of sales, demonstrating bottom line growth and operating leverage that seems unlikely, at best, just a few quarters ago. 
Turning to guidance for the second quarter of fiscal 2016. We expect revenues of $680 million to $690 million. Compared to the prior year period, this range reflects revenue growth of 4.5% to 6% on a constant currency basis, and reported revenue growth of 3.7% to 5.3%. 
We expect a sequential decline in revenue for 2 main reasons. First, our surgical business is seasonally weakest in the March quarter, especially in comparison to the strength we saw in the December period. Second, we are allowing for some potential choppiness in our international business. 
In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.45 to $0.46 in the second quarter. This represents growth of 11.2% to 13.6% in constant currency terms, or 9.8% to 12.2% on a reported basis. It's worth mentioning that we anticipate a substantial R&D increase in spending in the second fiscal quarter based mainly on the timing of projects. 
Before opening the call for questions, I'd like to reiterate that Hologic is off to a good start in 2016. In the first quarter, our momentum continued with Genius 3D Mammography and our surgical and molecular diagnostics business surprised to the upside. As a whole, our domestic businesses performed great. These positives outweighed weaker-than-expected results in our international mammography business, which we're dealing with aggressively. In the middle of the income statement, we are demonstrating the tremendous earnings power of the company by improving gross and operating margins. And below the line, we are beginning to see the benefits from our efforts to reduce debt, as well as our effective tax rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we're ready for the first question."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan.",14,"[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I guess, I want to start on the international Breast Health, where you'll be getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it? And",60,"Steve, I guess, I want to start on the international Breast Health, where you'll be getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it? And what kind of cushion you're baking in for the remainder of the year?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. On the wall of worry, Tycho, it's something we think about. I wouldn't be overly freaked out by it. I think the way we're thinking about it is, we've got just about every business performing better than we expected. But I think the deeper we dug in t",315,"Yes. On the wall of worry, Tycho, it's something we think about. I wouldn't be overly freaked out by it. I think the way we're thinking about it is, we've got just about every business performing better than we expected. But I think the deeper we dug in the second half of the year, and you'll continue to hear us say, really going back a few quarters, hey, we're probably closer to a startup than a real turnaround here. And we have a lot of work to do even on building our relationships with the dealers. And I think as we go back and look at it, clearly, our fourth fiscal quarter was really strong and followed by a weaker quarter, and that's not what we want to be delivering and don't have that sustained relationships. So we're making some changes internally, and we're not going to blame the dealers. We can always look at ourselves, and I'll say that we need to be a little closer to it. But it's the only little piece of the puzzle, I think, right now for us to continue to work on. I'd also say, I think, we're all accustomed to not every business is always firing on every cylinder. The day it does, we're probably in trouble. This is kind of one of our areas of opportunity. I think the next couple of quarters will probably be a little bit softer. We're going to plan for that while we get to the right longer-term plays. But as Eric -- as Eric Compton, after his first reviews of it, said, it obviously reminds me a little bit of when you walked in the door of Hologic 2 years ago and sort of the same rebuilding needs to occur, and things like pricing discipline, marketing, market access, just a lot of the fundamentals that we've never put in place."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just to follow up. The management changes you alluded to, are the changes done? Do you have the team in place now you need for Europe?",29,"Okay. And then just to follow up. The management changes you alluded to, are the changes done? Do you have the team in place now you need for Europe?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. So that's why I think over the next quarter or 2 price still will have a little softness, and that's basically what we bake into our g",50,"No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. So that's why I think over the next quarter or 2 price still will have a little softness, and that's basically what we bake into our guidance."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jonathan Groberg of UBS.",10,"And we'll go next to Jonathan Groberg of UBS."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Obviously, a lot of questions on international Breast Health, but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, at least at start of year, your operating expenses grew quite a bit more than s",67,"Obviously, a lot of questions on international Breast Health, but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, at least at start of year, your operating expenses grew quite a bit more than sales. Kind of what's your expectation for OpEx growth for the year versus kind of gross margin for the year?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Hey Jonathan, it's Bob. So as we mentioned in our prepared remarks, what we're looking at is -- actually it's very strong performance on our gross margin basis, combination of product and geography mix as well as some of the productivity efforts that we'r",161,"Hey Jonathan, it's Bob. So as we mentioned in our prepared remarks, what we're looking at is -- actually it's very strong performance on our gross margin basis, combination of product and geography mix as well as some of the productivity efforts that we're doing, and we are looking to reinvest a portion of those. So our gross margin is probably operating a little bit better than what we had anticipated. And we're looking to reinvest that in those growth drivers in places like our marketing and, to a certain extent, some of the R&D investments to drive that growth rate on the top line. That being said, we are still expecting operating margin expansion consistent with what we had guided to in November, and we believe that we're able to do that. And we've demonstrated that certainly in the first quarter, continued to have operating margin leverage, and we expect that throughout the course of the rest of the year."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So just to follow up on that and kind of tie it into the first part of the conversation around international. Is it more about getting the right people? I know you thought you have the right person in your first hire. But is it more about getting the righ",94,"So just to follow up on that and kind of tie it into the first part of the conversation around international. Is it more about getting the right people? I know you thought you have the right person in your first hire. But is it more about getting the right people? Or is it more about throwing more money at the issue? And have you contemplated how -- that kind of -- and your guidance now, the outlook for how much you might need to spend in order to get this startup going internationally?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's all about the right people, it's not about the spending, Jonathan. So we'll have it nailed.",18,"It's all about the right people, it's not about the spending, Jonathan. So we'll have it nailed."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jack Meehan of Barclays.",10,"And we'll go next to Jack Meehan of Barclays."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So just wanted to ask about the U.S. mammography business, and just curious on your view for the landscape this year whether it's hospital CapEx -- CapEx trends or the competitive dynamic? Just your view on the rate of placements from here.",43,"So just wanted to ask about the U.S. mammography business, and just curious on your view for the landscape this year whether it's hospital CapEx -- CapEx trends or the competitive dynamic? Just your view on the rate of placements from here."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","So Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging business was up 18.7% in the quarter. That's coming off of some pretty good comps. And everything we're seeing and hearing is we continue to feel we are making very good p",140,"So Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging business was up 18.7% in the quarter. That's coming off of some pretty good comps. And everything we're seeing and hearing is we continue to feel we are making very good progress, both with our own customers as well as competitive inroads. And I think we feel as good, if not better, about that business and the fact that we're going to end up -- by the end of the 3D curve, I had said early on, we think we'll end up with a little bit higher share than we started, and I think if anything, we feel better and better about that prediction and more and more confident every day that goes by. We continue to hear great stories from our teams."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. And then just curious, as you see hospitals taking on the new 3D units, do you still see them adding new capacity? Or are you seeing some replacements of 2D units as well?",35,"Got it. And then just curious, as you see hospitals taking on the new 3D units, do you still see them adding new capacity? Or are you seeing some replacements of 2D units as well?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today.",35,"It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Doug Schenkel of Cowen  and Company.",12,"And we'll go next to Doug Schenkel of Cowen  and Company."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I just wanted to cover really 2 topics. One is really just a math on guidance and then really the other topic is just on pricing and sort of product categories. So first on guidance. Just to try to run through the waterfall. You beat earnings guidance at",142,"I just wanted to cover really 2 topics. One is really just a math on guidance and then really the other topic is just on pricing and sort of product categories. So first on guidance. Just to try to run through the waterfall. You beat earnings guidance at the high end by $0.04 this quarter. You increased EPS guidance for the year at the midpoint by $0.06. We estimate lower share count gets you $0.03 to $0.05, and lower tax rate gets $0.03 to $0.04. So it seems like we might be missing something here. Is there a change in mix that you expect to occur? Are there areas that maybe you're investing a little bit more in, either in sales or R&D relative to your last guidance? What are the clause there, and I will come back with a pricing question."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Doug, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to is the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and",78,"Doug, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to is the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and share count, roughly we think about $0.06, offset by about $0.02 of FX. And then we up the operational beat in the Q1, that gives you $0.06 growth."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Gets you in the neighborhood. Okay. And then on pricing, really quickly. Some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors, particularly in Chlamydia gonorrhea CT/NG. Can you talk about if yo",76,"Gets you in the neighborhood. Okay. And then on pricing, really quickly. Some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors, particularly in Chlamydia gonorrhea CT/NG. Can you talk about if you're seeing anything that's really different from kind of the normal pricing pressures you see in the market? And if there is -- basically what's baked into your guidance outlook for pricing changes in molecular?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I'll tell you. I think we feel as good as we felt since we've been here about pricing. And I think we've got so much more discipline. I'll tell you, we are hearing more and more competitive attempts, frankly, on both the molecular side as well as on",174,"Yes. I'll tell you. I think we feel as good as we felt since we've been here about pricing. And I think we've got so much more discipline. I'll tell you, we are hearing more and more competitive attempts, frankly, on both the molecular side as well as on the mammography side, where there's some pretty big disparities. And with Bob McMahon and Eric Compton's leadership and the divisional presidents [ph], we've been doing a much better job of fighting on price -- not fighting on price, fighting on the features and benefits and not going down there. And it's part of the hidden piece I think that we're seeing in our gross margin expansion. As we talk about the gross margin piece, clearly, it's the -- the incredible progress we're making on the operational side, it's a mix benefit but also, frankly, I think much better pricing discipline. And we're holding pricing far better, and in some cases getting a little bit of upticks even in what is a much more competitive environment."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Isaac Ro of Goldman Sachs.",11,"And we'll go next to Isaac Ro of Goldman Sachs."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context with what we're seeing from the other major equipment players this quarter. And I'm specifically curious if you'r",72,"I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context with what we're seeing from the other major equipment players this quarter. And I'm specifically curious if you're seeing any more signs of aggressive bundling or pricing practices from those players, and whether or not that's a fact that we should be considering in the market?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're seeing it. And Isaac, I'll tell you what I'm really, really proud of our team fighting it off. I think we're actually winning more based on the overall success of our business. The combination of our product, our label, the ease of use and our geniu",133,"We're seeing it. And Isaac, I'll tell you what I'm really, really proud of our team fighting it off. I think we're actually winning more based on the overall success of our business. The combination of our product, our label, the ease of use and our genius marketing campaigns, which frankly has probably been the single biggest differentiator of hospitals understanding, they're better aligned with us in the mammography space than with anybody else, because we're driving patients to the hospitals that have our systems. And I think it's been a dramatic step change in our own organization's ability to ward off going down the pricing games. And I've heard more and more anecdotes of much bigger pricing discounts from competitors on accounts that we've not lost, and in fact, we've won."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just to build on that, Steve. I mean, over the last 18 months we've had 2 competitors come into a market where we were the sole competitor. We've not only maintained stable pricing, but we've gained share. I think that's a huge credit to our domestic",62,"Yes. Just to build on that, Steve. I mean, over the last 18 months we've had 2 competitors come into a market where we were the sole competitor. We've not only maintained stable pricing, but we've gained share. I think that's a huge credit to our domestic Breast Health team led by Pete Valenti and that guy -- team, just tremendous job."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful. And then maybe just a separate question on the balance sheet and M&A didn't come up so far this quarter. I'm curious if it's possible that we went to you guys get in the marketplace this year with 1 tuck-in deal or 2 to augment the busines",75,"That's helpful. And then maybe just a separate question on the balance sheet and M&A didn't come up so far this quarter. I'm curious if it's possible that we went to you guys get in the marketplace this year with 1 tuck-in deal or 2 to augment the business? And if so, kind of what -- how does the shopping list look? How do you -- how would you characterize evaluations into your funnel?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Isaac, I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the",151,"Sure. Isaac, I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the shopping list. But I'll put it really in probably the first inning. And we started to look at a few things we said no to. I do think valuations are going to be our friend as we go forward, and obviously, with the tremendous cash generation and getting our balance sheet cleaned up, we're going to be ready. I think our teams have been so focused on great commercial execution and getting the R&D pipelines back in shape. That's sort of the next piece that will start to play out. But we're probably still a little slower, so I wouldn't anticipate anything super quick on that front."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Bill Quirk of Piper Jaffray.",11,"And we'll go next to Bill Quirk of Piper Jaffray."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","First question, Bob. You mentioned that, obviously, there's a number of factors that helped to drive the gross margin from year-over-year. And you alluded to the fact that we're in kind of the early days from a supply chain standpoint. So I guess, 2-part",91,"First question, Bob. You mentioned that, obviously, there's a number of factors that helped to drive the gross margin from year-over-year. And you alluded to the fact that we're in kind of the early days from a supply chain standpoint. So I guess, 2-part question here. One, can you help break this down a little bit further in terms of what the contribution was from aligning your supply chain? And then, again, I don't want to put words in your mouth, but it sounds like really early days for this initiative."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, we're -- I'm not going to give you the level of specificity that you probably would like to have there. I would say it is a -- the productivity enhancements that we're talking about are through our sourcing organization as well as looking at running",191,"Yes, we're -- I'm not going to give you the level of specificity that you probably would like to have there. I would say it is a -- the productivity enhancements that we're talking about are through our sourcing organization as well as looking at running our factories more efficiently, and I think our operations team has done a great job of driving that. Obviously, we started that last year. We're seeing, one, a full year benefit. We're starting to see the full annualized effect of that this year, and we feel really good about that. And I would say it was a fairly meaningful component of the gross margin expansion, obviously with our U.S. business driving significant growth. That also had a big impact as well. And as we're thinking about the way that the U.S. business grew with the higher margin products in our surgical business and so forth, that actually helped us overall as well. So it was a nice balance between kind of the 3 of those things, but I think we are in the early innings of sustained kind of improvement on the gross margin basis."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Bill, I would add to that. When you heard me say, certainly, a year ago, I didn't think as a company we'd probably see much gross margin expansion. And if I say things that have changed over the last year in my own outlook, that's one that -- I think we'r",79,"Bill, I would add to that. When you heard me say, certainly, a year ago, I didn't think as a company we'd probably see much gross margin expansion. And if I say things that have changed over the last year in my own outlook, that's one that -- I think we're seeing much better opportunity than I ever imagined possible. So it's back to there's always puts and takes, that's one of the really good guys coming our way."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Good to hear. Second, this is kind of a bigger picture question on blood screening and blood utilization in general. I mean, certainly, we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may b",92,"Good to hear. Second, this is kind of a bigger picture question on blood screening and blood utilization in general. I mean, certainly, we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may be starting to see this internationally as well. So I guess kind of similar question here guys, kind of how much through the process are we both in the U.S. and OUS? It just would be curious what your partner, Grifols, has been telling you on that."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think we see -- in the U.S., I think we see continued low single-digit declines, probably in the blood screening business. International, probably more flattish as more countries adopt our net testing, but some more advanced ones start to cut back",145,"Yes. I think we see -- in the U.S., I think we see continued low single-digit declines, probably in the blood screening business. International, probably more flattish as more countries adopt our net testing, but some more advanced ones start to cut back a little bit. So I think we see the international business more flattish. Having said that, we've got a couple of quarters right now that we're absorbing the inventory fluctuations, particularly from a year ago with the JRC, where, frankly, we were both doing consumption plus inventory build. And now as the inventories contracting back, we've just got a couple of rougher comps that we're getting through. The underlying business slightly down, but still a very good business for us. But certainly, it's not going to be accretive to our top line growth rate over time, it would be dilutive to that."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Richard Newitter of Leerink Partners.",11,"And we'll go next to Richard Newitter of Leerink Partners."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I was hoping just to start off on the investments that you guys are making. And one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out on",109,"I was hoping just to start off on the investments that you guys are making. And one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out on the other side of kind of the tumble ramp. So first, just can you give us any sense as to where -- whether organic or external, where the priority is? You alluded to some of that, Steve, earlier. And then two, any color on when we'll learn about the pipeline in greater detail? And what can you give us today?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, sure, Rich. Clearly, the primary focus has been on rebuilding the organic growth pipeline. And I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good what we'r",308,"Sure, sure, Rich. Clearly, the primary focus has been on rebuilding the organic growth pipeline. And I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good what we're putting in place. The other piece that I'd start to give you a little bit of a tidbit in is a lot of what we're working on are what I'd call singles and doubles. And -- the company was built historically, and every 8 years we launch a mega product like 2D and then 3D tomo, and a lot of what we are looking at is how do we cushion the blow in between and looking at some smaller things that we can be doing to bring in between those big cycles. And on the diagnostics business, it's about building out menu. In the Breast Health business, it's not just what's the replacement for 3D tomo, there's a lot of other stuff we can bring out in IBS and other stuff along the way. So I think what you'll start to see, and as you know, with me, stylistically, I'd like to get a few points on the board before we start talking about them. And given an organization we inherited that had a few launches on the table that we had to scrap when I got here because they weren't really ready for prime time. You want to make sure we really have our ducks in a row before we, a, start talking a lot more. But I'll tell you we feel better and better but it's going to be more singles and doubles than probably triples and home runs. So we'll continue to update you as we go, but that may gave you a little more flavor from what you've had historically."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful, Steve. And then just maybe one more on the surgical business. Nice growth acceleration there, and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory",59,"That's helpful, Steve. And then just maybe one more on the surgical business. Nice growth acceleration there, and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory going forward? And then do you have the portfolio you need to achieve that?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, thanks, Rich. I wouldn't go there yet to the sustainable double digit. Having said that, they posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all t",359,"Yes, thanks, Rich. I wouldn't go there yet to the sustainable double digit. Having said that, they posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all the changes we make, but that business actually, just in the last 6 months, we have a new VP of marketing, a new president, a new head of business development, a new head of R&D. And I'm more bullish and excited the team that Eric has put in place there is really, really good, and they're doing that with just 2 products today. We stopped the declines in NovaSure. You know it better than most. Just 2 years ago NovaSure was a high single-digit decliner. We stopped that one and actually turned it into a positive. And the -- in MyoSure, I know when I first came here, it was growing at 20%. People figured we were about maxed out. Last year it went to 30%, and we just had a 46% growth quarter, and that's even when the people asked us the market size 1 year or 2 ago. And I couldn't quite answer it. I think we are seeing there may be more potential there. And then it's a great sales team that clearly could take on another product. So I think that's an area we're very willing and stepping up our activities of looking at bolt-on acquisitions. It's an area we're in the nascent stages, frankly, have started to expand internationally. And it's a business that can do a lot for the profit margin and profitability profile of the company. So it's one we're more and more excited about. I'd still model single-digit growth, but like everything, we're certainly aspiring to continue the great trend. But clearly we did mention, there was a competitive recall we think helped us in that last quarter, and so that we certainly don't see the 18.8% growth as sustainable. Aspirational, yes, and we'll take it back to the division head, set that as a new goal, but pragmatically speaking, we're not that good yet."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","And Rich, I guess the only thing I'd add to that on surgical is the quarter that we're in now, which is our second fiscal quarter, does tend to be the seasonally weakest quarter for us, and typically the first quarter of our fiscal year is the strongest o",49,"And Rich, I guess the only thing I'd add to that on surgical is the quarter that we're in now, which is our second fiscal quarter, does tend to be the seasonally weakest quarter for us, and typically the first quarter of our fiscal year is the strongest one."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis.",26,"Yes. This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Brian Weinstein of William Blair.",11,"And we'll go next to Brian Weinstein of William Blair."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders in-house should never be higher. I'm curious kind of what your backlog looks like right now. And have you seen any impact at all in terms of time to close f",81,"Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders in-house should never be higher. I'm curious kind of what your backlog looks like right now. And have you seen any impact at all in terms of time to close from any discussion around the task force or any of these insurance companies that have been kind of  reiterating nonpayment for tomo? Is there anything in the field that you're picking up on that?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Brian, this is Bob. What I would say is our backlog continues to be very robust, and we have not seen any extension of time to close or anything like that. I think that's a lot of noise that people may hear about kind of in the press, but when it actually",67,"Brian, this is Bob. What I would say is our backlog continues to be very robust, and we have not seen any extension of time to close or anything like that. I think that's a lot of noise that people may hear about kind of in the press, but when it actually comes to actually making purchase decisions and so forth, that hasn't affected us one bit."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then on cyto -- I'm going to say on cytology, you continue to reference share gains. Can you kind of talk about [indiscernible] share gains where you think you're in terms of market share at this point?",39,"Great. And then on cyto -- I'm going to say on cytology, you continue to reference share gains. Can you kind of talk about [indiscernible] share gains where you think you're in terms of market share at this point?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. We're not quite sure on market share, but we feel very good. We are obviously very strong leading, I think, probably in the 3/4 of the market share range, so up in that 70-plus percent, certainly in the U.S. We think we're much lower outside. And I",135,"Sure. We're not quite sure on market share, but we feel very good. We are obviously very strong leading, I think, probably in the 3/4 of the market share range, so up in that 70-plus percent, certainly in the U.S. We think we're much lower outside. And I think part of where we're really encouraged, and where I think we have made great progress internationally, over the last year, 1.5 years, is starting to get the belief and the conviction of what we need to do to grow the cytology business outside. And you remember, we said, one of the first things we could do to return this company to growth would stop the sharp declines on the ThinPrep business, and I think we feel pretty good about what we're doing there, actually feel great."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Raj Denhoy from Jefferies.",10,"And we'll go next to Raj Denhoy from Jefferies."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","What if I could ask -- maybe I'll start with Panther. You've given this metric now of $170,000 per machine. Is there any updates you can give us in terms of timing on when you can get the menu expanded? When do you expect viral load in United States and t",55,"What if I could ask -- maybe I'll start with Panther. You've given this metric now of $170,000 per machine. Is there any updates you can give us in terms of timing on when you can get the menu expanded? When do you expect viral load in United States and then subsequent tests beyond that?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. We're just rolling out viral load outside the U.S. We've got the CE marking and so we're rolling that out off of, and I think that will help our molecular business. We are obviously coming off of a pretty weak base, candidly, internationally. It's no",149,"Yes. We're just rolling out viral load outside the U.S. We've got the CE marking and so we're rolling that out off of, and I think that will help our molecular business. We are obviously coming off of a pretty weak base, candidly, internationally. It's nothing like what we have here. And really it's going to be a fiscal '18/'19 event in terms of the true viral load impact for us in the U.S. We'll get HIV approved sooner but, frankly, we ultimately want to have the full range of HIV, HPV, HCV, which we don't have really until later on in '18. So the way we think about that is it's probably going to end up hitting at a beautiful time for us. Some of the mammography business may be slowing a bit in the U.S., and that one kicks in and provides another leg up for us."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. That's helpful. Maybe just another question too on. R&D spending was actually down this quarter relative to last year. And although you did make a comment that you expect to step up pretty dramatically as you move through the back half of the year,",71,"Okay. That's helpful. Maybe just another question too on. R&D spending was actually down this quarter relative to last year. And although you did make a comment that you expect to step up pretty dramatically as you move through the back half of the year, is there anything you can give us in terms of what dramatically stepping up means? And why it has been somewhat low up to this point?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Raj, this is Bob. It's simply timing. When we look at the clinical programs that we have, we expect to ramp-up in Q2. So don't read anything into that other than it was timing.",35,"Yes. Raj, this is Bob. It's simply timing. When we look at the clinical programs that we have, we expect to ramp-up in Q2. So don't read anything into that other than it was timing."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jon Block of Stifel.",10,"And we'll go next to Jon Block of Stifel."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe just the first one, Bob, for you, constant-currency is not going to change for 2016, but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again, GYN was still big, international Breast Heal",73,"Maybe just the first one, Bob, for you, constant-currency is not going to change for 2016, but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again, GYN was still big, international Breast Health was maybe a little shy. Should we just flow that through the best we can? Or any official changes, again, to the components of the top line?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No specifics. I mean, I think you would flow those in. Obviously, we were pleasantly surprised to the upside on the surgical business. And in U.S., I think our U.S. business is doing a little better than what we anticipated. Our international business is",99,"No specifics. I mean, I think you would flow those in. Obviously, we were pleasantly surprised to the upside on the surgical business. And in U.S., I think our U.S. business is doing a little better than what we anticipated. Our international business is a little more choppy and so forth. Outside of that, we're not going to give specific guidance to the individual components, other than to say that any softness that we may be seeing in the near term or the short-term internationally is going to be offset we expect by the strength in the U.S. business."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, got it. And then Steve, my apologies if I missed this on some of your color, but we've seen the international Breast Health bounce around a good amount before. But when you talk about what's currently going on, and we have the headline risk of inter",110,"Okay, got it. And then Steve, my apologies if I missed this on some of your color, but we've seen the international Breast Health bounce around a good amount before. But when you talk about what's currently going on, and we have the headline risk of international as what we deal with every day from where we sit. Can you just give a little bit more detail? In other words, is it the way that you're working with dealers, the relationships that you think you guys can strengthen in the coming quarters? Or has there been any change to call it end-user demand out in the field in certain countries?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Jon, I think this is more an internal execution issue plus dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger awards in some of the emerging markets this year, and we'll probably just backing off",136,"Sure. Jon, I think this is more an internal execution issue plus dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger awards in some of the emerging markets this year, and we'll probably just backing off that. We're making some progress in Brazil and places like that, that we're probably being a little more cautious about as we go in, but it's much more our own execution. And frankly, again, it's a small part of our business that we know has great potential, and we will realize it. But it's more than I think than anything external or macro that we'd really point to. It could be macro, but we're not going to look to say it's that. I think that the opportunity is still there."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Vijay Kumar of Evercore ISI.",11,"And we'll go next to Vijay Kumar of Evercore ISI."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe one on breast imaging and -- sorry to sort of pick on this. But the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a short formation? It looks like the U.S. growth slowed down se",64,"So maybe one on breast imaging and -- sorry to sort of pick on this. But the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a short formation? It looks like the U.S. growth slowed down sequentially. So I'm just wondering if you can give some color on what happened U.S. versus OUS?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, 2 pieces. I think first of U.S., we continue to feel really, really good. I mean, obviously, the growth rate, Vijay, which you pointed out, will be slowing down as we're going against some monster comps especially when we come into the second half of",167,"Yes, 2 pieces. I think first of U.S., we continue to feel really, really good. I mean, obviously, the growth rate, Vijay, which you pointed out, will be slowing down as we're going against some monster comps especially when we come into the second half of this year, but really already from here on we're now going in against much tougher comps from here. We're still growing the business, but we're not going to be putting 20% growth rate up on top of strong growth rates from a year ago. The outside the U.S., I look at this folks, it's just like every other issue we face since we came to the company. We're not the perfectly well-oiled machine. I think we're making a little bit of progress. Haven't made the progress that I'd like to see, and it's just a matter of better execution, which is something we know how to do. And it just requires a little greater focus than probably what I was providing."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then one follow-up on diagnostics. Clearly, this is a monster diagnostic quarter. In that U.S. business, I mean, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how susta",84,"Great. And then one follow-up on diagnostics. Clearly, this is a monster diagnostic quarter. In that U.S. business, I mean, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how sustainable that the share gain? Because when you look at sort of the Aptima franchise, I mean, those are some pretty big product lines and pretty mature. So I'm just wondering why this business is so strong, and what's going on."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I think it's been the hidden piece and back to the focus on execution, where we've clearly been a little more focused than the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. An",137,"Vijay, I think it's been the hidden piece and back to the focus on execution, where we've clearly been a little more focused than the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. And obviously, you know us well enough to know we're not one of these out there trumpeting, gee, we're #1, we beat this person, we got this competitive win. But quietly, we're really proud of what we've done on the HPV franchise in the U.S. and combined with cytology, combined with the co-testing message, combined with Panther placements, they're all -- no one thing is magic, but when you systematically pile them up, it provides a very nice outlook and has still a pretty good -- this strength is going to continue."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Derik De Bruin of Bank of America.",13,"And we'll go next to Derik De Bruin of Bank of America."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So one of the questions have been asked, but let me just do a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, some of t",85,"So one of the questions have been asked, but let me just do a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, some of the systems sort of that you placed earlier now start -- you have to start paying for service contracts. Can we think about instrument placements versus services, and how it goes in the mix?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in.",124,"Yes. I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in. And we will say this. We are seeing a higher attach rate on the 3D service revenue contracts than we did on 2D. So, a, it's a little bit higher. So I think it's sort of one of those pieces that will kick in, and we feel very good about for the future.  And the team is doing a better job of actually selling service contracts today, probably in a tougher environment than we ever have."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just one other thing, Derik, just to kind of give you a little more color on that. While our total service, when you looked at it for the total company, only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest compo",103,"Yes. Just one other thing, Derik, just to kind of give you a little more color on that. While our total service, when you looked at it for the total company, only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest component of that, which is our domestic U.S. mammography business, that grew in the mid-single digits, which is consistent with what we've been talking about as that business, with that high attach rate, higher ASP relative to the service contracts on the lower ASP 2D. So we continue to feel good about that business."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just sort of a little clarification for me on this. So why was the 2D attachment rate on services so well historically?",22,"Just sort of a little clarification for me on this. So why was the 2D attachment rate on services so well historically?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It wasn't well.",4,"It wasn't well."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It was extremely high, and we're going from an extremely high level to actually an even extremely higher level. It was well into the 80s percent, and we're doing even better than that.",33,"It was extremely high, and we're going from an extremely high level to actually an even extremely higher level. It was well into the 80s percent, and we're doing even better than that."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","85-plus percent.",3,"85-plus percent."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Mark Massaro of Canaccord Genuity.",11,"And we'll go next to Mark Massaro of Canaccord Genuity."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I want to ask -- you acknowledged that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you gained share. Just wondering if you could just talk about the dynamics internationally. Is the bundl",73,"I want to ask -- you acknowledged that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you gained share. Just wondering if you could just talk about the dynamics internationally. Is the bundling occurring more frequently internationally than it is in the U.S.? And can you just help us understand some of the pressures you saw internationally, in context of gaining market share?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. I think it's less bundling internationally than it's still -- the stage of development are internationally. We've not done nearly as good a job of selling the benefits of 3D, just when government a fair standpoint, from a marketing standpoint. A lot",208,"Sure. I think it's less bundling internationally than it's still -- the stage of development are internationally. We've not done nearly as good a job of selling the benefits of 3D, just when government a fair standpoint, from a marketing standpoint. A lot of what we have going in the U.S. We're doing a great job of internationally because we're through dealers. We've not worked with them closely enough to really segment the market. We were starting to -- obviously, there's a lot of opportunities for 2D. We need to do that. But we've had so much focus on 3D, and I don't think we've just done as good a job of fully marketing it through. So that's a part of the whole issue of consolidating the international business under Eric. We kind of -- I set it up when I first got here to have Eric really focus on the U.S. Claus focus internationally. It probably led to 2 silos more than sharing the learning across the geographies. And frankly, I feel like it's done a great job overall, but it -- we probably left a little bit on the table as related to our international development. So now Eric's on the case and here we go."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe a little outside the box here, but would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?",27,"Maybe a little outside the box here, but would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're looking at it everywhere as to what's really the best model, and that will be something I think you can expect us to report back on over time. I will tell you there's a lot more complexity to it all in that. Candidly, in a number of geographies we h",175,"We're looking at it everywhere as to what's really the best model, and that will be something I think you can expect us to report back on over time. I will tell you there's a lot more complexity to it all in that. Candidly, in a number of geographies we had given the marketing authorizations to the dealers. So the dealers actually own the marketing authorizations, which is not something you would typically expect of a company this size. But, a, it's one of these as yet, you go into the onion and peel it back a little more, more work to be done, which is why we just think it's going to take us a little bit longer. I kind of view it as it will be a great thing to have in the out-years when things slowdown in the U.S. We probably aren't getting there as fast as I'd like to, but we'll probably end up getting there at a time that will be ultimately actually pretty well-timed for the total company."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll take our final question from Jayson Bedford of Raymond James.",14,"[Operator Instructions] And we'll take our final question from Jayson Bedford of Raymond James."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll ask 2 questions that require one-word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what are the -- what's your latest thoughts on gross margin expectations for '16?",48,"I'll ask 2 questions that require one-word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what are the -- what's your latest thoughts on gross margin expectations for '16?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Higher and higher.",3,"Higher and higher."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Do you have better words than that, Steve?",8,"Do you have better words than that, Steve?"
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","You asked for one-word answer, Jayson. As a reminder, we're only going to give the placement numbers on an annual basis rather than giving into quarterly pieces. But we were very pleased with the additional placements of certainly the Genius and frankly,",78,"You asked for one-word answer, Jayson. As a reminder, we're only going to give the placement numbers on an annual basis rather than giving into quarterly pieces. But we were very pleased with the additional placements of certainly the Genius and frankly, Panthers as well looking at their diagnostics business. And then gross margin, I think, we're basically guiding to -- we think there's 100 basis points of improvement year-over-year and feeling very encouraged by that opportunity."
108544,321211701,921932,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","That is all the time we have for questions today. This now concludes Hologic's First Quarter Fiscal 2016 Earnings Call. Have a good evening.",24,"That is all the time we have for questions today. This now concludes Hologic's First Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",53,"Good afternoon, and welcome to the Hologic Inc. First Quarter Fiscal 2016 Earnings Conference Call. My name is Cassandra, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's First Quarter Fiscal 2016 Earnings Call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bo",199,"Thank you, Cassandra. Good afternoon, and thanks for joining us for Hologic's First Quarter Fiscal 2016 Earnings Call. With me today are Steve Macmillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks then we'll have a question-and-answer session. 
Our first quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them this afternoon. Finally, a replay of the call will be archived on our website through February 26. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward-looking. These statements involve known as well as unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's in our press release and in our filings with the SEC. 
Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve Macmillan, Hologic's CEO."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers an",1524,"Thank you, Mike, and good afternoon, everyone. We're very pleased to discuss Hologic's financial results for the first quarter of fiscal 2016. In short, the company is off to a good start to the year. We are executing on our key top line growth drivers and exceeding expectations on the bottom line based on the tremendous earnings power of the company, which has become even stronger over time than I initially thought possible. 
In the first quarter, total revenue grew 8.1% in constant currency terms, driven by double-digit growth in the United States, our largest and most profitable market. Our U.S. businesses have turned around more rapidly than anyone anticipated, based on better commercial execution and the quality of our products. And over the last few quarters, our domestic sales and marketing teams have kicked it up a notch, generating robust growth from our key brands. 
This commercial improvement has led to significant benefits up and down our income statement. For example, in the first quarter, we posted non-GAAP gross and operating margins that were significantly higher than in the prior-year period. We are clearly demonstrating that despite our already sector-leading profitability, we can generate additional operating leverage by driving the growth of our most profitable products. 
Working down the income statement, earnings per share were $0.46 in the first quarter, beating our expectations again. In addition, we increased EPS at a pace that was nearly 3x the rate of revenue growth. 
With that introduction, let me discuss the details of our first quarter revenue performance. Then Bob will take you through the rest of the income statement, the balance sheet and our updated guidance. 
Total revenues were $695.2 million in the first quarter, an increase of 6.5% on a reported basis and 8.1% in constant currency terms. 
Geographically, our U.S. businesses performed exceptionally well in the quarter. We posted 12.8% revenue growth domestically, a slight acceleration over the fourth quarter despite a more difficult comp. 
This strong U.S. performance outweighed what was a mixed bag internationally in the first quarter. We showed good continued progress in cytology, molecular diagnostics and surgical outside the United States. In constant currency terms, cytology grew high single digits. Molecular posted modest growth for the second consecutive quarter, and surgical grew in the mid-teens, albeit from a small base. In contrast, we saw weakness in our international blood screening business, which was largely expected and which resulted mainly from fluctuations in ordering patterns by our commercial partner, Grifols. 
In addition, our international Breast Health results confirmed, as we have highlighted before, that we are a long way from optimizing our relationships with our dealers and distributors. Lower Breast Health and blood screening sales OUS contributed to total international sales declining 11.5% in the quarter, or 5.4% in constant currency terms. 
We are moving decisively to strengthen the international breast business, drawing on the same toolkit that we employed to turn around our domestic franchises. We are unifying leadership of all global commercial activities under our COO, Eric Compton, so that we may share some of our U.S. best practices internationally. 
As part of this process, our head of international has left the company, along with our head of European Breast Health sales. In their place, Eric is diving deep to optimize our go-to-market strategy in key markets around the globe. 
We are highly focused on identifying the right commercial model for each country in which we operate. While there may be some short-term volatility, we remain bullish on our international opportunities in Breast Health, and we look forward to sharing more details about our plans as they come together. 
Now let's provide some more color on our divisional revenue performance in the first quarter. 
Our biggest division, Diagnostics, posted sales of $310.7 million in the quarter, a growth rate of 3.7% in constant currency terms. But the 3 franchises within Diagnostics demonstrated very different results. In molecular diagnostics and cytology, where we control the commercial channel, our results were very good. But blood screening sales declined. Let's discuss each piece in turn. 
In molecular diagnostics, quarterly sales of $129.6 million increased 9.9% in constant currency, our best growth rate since the GenProbe acquisition. Domestic revenues increased a stellar 11.5%, and the formula was similar to recent quarters: strong placements of our fully automated Panther instrument, a healthy number of competitive wins and growing utilization of our women's health assays. 
We said at a recent healthcare conference that the average Panther system globally now generates more than $170,000 in annual assay revenue, despite being less than 30% utilized. This demonstrates both the current value of the system and its future potential for customers and Hologic, as we add new tests for viral load and other targets in the years ahead. Outside the United States, sales of our molecular diagnostics products grew nominally on a constant currency basis for the second consecutive quarter, as the business stabilizes after an extended period of decline. 
We're also pleased with the performance of ThinPrep, one of our largest and most profitable franchises. Global sales of cytology and perinatal products totaled $120.4 million in the first quarter. U.S. sales actually increased by a modest 0.5%, as market share gains more than offset headwinds from longer screening intervals. And internationally, we are encouraged that revenue grew 8.7% in constant currency. This drove global growth of 3.1%, our second consecutive quarter of decent constant currency growth. Our commercial team deserves much credit for transforming a business that was declining at a high single-digit rate as recently as 2014, into a modest grower globally. 
In blood screening, worldwide sales were $60.7 million in the first quarter. This was roughly flat sequentially, as sales have normalized without the benefit of growth from the Japanese Red Cross contract. Compared to the prior year, however, blood screening sales declined 6.5% on a constant currency basis. This reflects heavier ordering by our partner Grifols a year ago and general declines in blood usage that we are seeing in the United States and other markets. 
Now let's turn to Breast Health, where we continue to see strong adoption of our Genius 3D Mammography exams in the United States. Domestic sales of breast imaging products, including our Genius systems, increased 18.7% compared to the 8.9% constant currency decline we saw internationally. Global sales of interventional breast products increased slightly on a constant currency basis, and we are optimistic that new products will help stimulate growth in this category over the next couple of years. All this added up to total Breast Health sales of $262.2 million in the quarter, up 9.9% in constant currency terms. 
We also remain enthusiastic about our future prospects in the mammography market. We continue to gain share in the United States based on a superior product profile and excellent customer service. Our prices are stable despite increasing competition, which indicates that our marketing programs are working and that our systems are providing value to customers. And Congressional action has prohibited any near-term insurance changes arising from the controversial screening recommendations by the USPSTF. All in all, we have a lengthy runway ahead of us to continue upgrading older, less effective technologies to our Genius 3D exams. 
To round out the revenue discussion, we are thrilled with the progress being made by our surgical team. Although the December quarter is typically a seasonally strong one, we certainly did not predict sales of $98.8 million, or a constant currency growth rate of 18.8%. These are truly outstanding results, our best overall performance in the last several years, so congratulations to the commercial teams and new leaders who are making it happen. 
It's worth mentioning that surgical is Hologic's most profitable division on a gross and operating margin basis, so the magnitude of the top line growth we're now seeing is having a nice positive impact on the company's gross and operating margins, as well as earnings per share. Specifically, our MyoSure product for hysteroscopic tissue removal posted total revenue of $36.9 million in the first quarter, with accelerating growth of 46.1% in constant currency terms. Equally impressive, global NovaSure sales of $61.7 million increased by 7.5% on a constant currency basis. We do believe NovaSure sales benefited from the recall of a competitive product, but estimate that this benefit was relatively small in the context of overall quarterly sales. 
Finally, worldwide Skeletal sales were $23.5 million in the quarter, an increase of 7.7% on a constant currency basis, driven by continued growth of our new Horizon bone density scanner, a very solid performance. 
Before I turn the call over to Bob, let me conclude by saying that this quarter illustrates the value that our portfolio of products can provide to shareholders. Although Breast Health and blood screening declined outside the United States, we more than compensated by posting strong growth in mammography, molecular diagnostics and surgical. The net effect was top line performance slightly ahead of expectations, and a significant increase in profitability. All in all, we're off to good a good start in 2016, and remain excited about the future. 
Now I will hand the call over to Bob."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and",1562,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our first quarter income statement, the balance sheet and our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results, and percentage changes will be on a year-over-year basis. 
As Steve mentioned, we delivered another solid quarter on the top line, with 12.8% sales growth in the U.S. more than offsetting the international choppiness we saw in Breast Health and blood screening. Strength in domestic revenue, combined with the early returns of our productivity efforts, helped drive margin improvement at the gross and operating levels, contributing to non-GAAP earnings per share of $0.46, a 17.9% increase over the prior year period. Even with headwinds from share count and currency, EPS grew at a rate nearly 3x faster than sales. 
Moving down the income statement, our first quarter gross margin of 65.2% increased 190 basis points compared to the prior year period. Gross margin benefited from mix, both geographic and product, and from our cost reduction initiatives. Not only did revenue grow at a double-digit rate in the U.S., some of our highest margin products also performed well, including our ThinPrep, NovaSure and Aptima franchises. And I should point out that pricing remains stable across our product lines as our commercial teams focus on selling the clinical and economic value that our products provide. In addition, our operations and procurement teams are executing well, driving efficiencies and reducing the cost to make our products. 
Total operating expenses of $221 million increased by 11.3% in the first quarter. This increase was driven primarily by sales and marketing expense, which increased 15.6%. We continue to invest to extend our leadership in the mammography market, and to explain why co-testing is the best way to protect women from cervical cancer. 
Despite these investments, better gross margins drove profitability improvement down to the operating line. Our non-GAAP operating margin was 33.4% in the quarter, an increase of 50 basis points from last year. Although our operating margin is already among the highest in our sector, the last several quarters have clearly demonstrated that they can expand further even as we fund key growth drivers. 
Moving further down the income statement, we are beginning to reap the benefits of our efforts to reduce and refinance debt. In the first quarter, interest expense was $32.8 million, a reduction of 25% versus the prior year period. 
In addition, we are pleased that a lot of hard work to reduce our tax rate has begun to pay off earlier than expected. We now estimate that our effective tax rate will be around 33% in fiscal 2016, lower than our initial guidance, and this added about $0.01 to EPS in the first quarter. Although this is just a first step in our multi-year tax improvement strategy, we are encouraged by the progress we've made so far. 
Finally, diluted shares outstanding were 292 million in the first quarter. As you know, we are focused on minimizing share count dilution by eliminating the convertible notes from our capital structure. In the fourth quarter, for example, we repurchased $300 million in principal of our most dilutive convertible notes, and this had a beneficial effect on share count in the first quarter. In addition, the recent decline in our share price had the rather perverse effect of further reducing dilution from the converts. The combined effect boosted EPS by almost $0.01 in the quarter. 
Now let's talk about cash flows and the balance sheet. 
Operating cash flow was strong again in the first quarter at $164.3 million, an increase of 7% over the prior year period. We spent $19.7 million on capital in the quarter, leading to free cash flow of $144.6 million. 
Turning to the balance sheet. We ended the first fiscal quarter with $650 million in cash, a 19.5% improvement over the prior year period. This strong cash position provides us with dry powder for potential tuck-in acquisitions, even as we continue to pay down debt. 
At the end of the first quarter, we had total debt outstanding of $3.6 billion, a decrease of $322 million compared to a year ago, and net debt of $2.98 billion. Our leverage ratio, net debt over EBITDA, now stands at 3.1x. And we are on track to achieve our goal of lowering our leverage ratio to 2.5x by the end of fiscal 2017. 
To wrap up the historical discussion, adjusted EBITDA was $252 million in the first quarter, up 8.1% compared to the prior year period, and we're tracking to generate EBITDA of more than $1 billion for the full year. 
Our consistency in delivering strong profit growth and lowering debt has allowed us to steadily improve our return on invested capital. As of our first fiscal quarter, ROIC was 11.3% on a trailing 12-month basis, a 160 basis point increase over the prior year. 
Now let's shift gears and turn to our updated non-GAAP financial guidance for the full year and second quarter. 
We are updating our guidance based on our solid performance in the first quarter, a stronger U.S. dollar and greater than expected earnings power. 
As always, this guidance is based on recent foreign exchange rates. As you know, the dollar has strengthened since we provided our initial 2016 guidance. Compared to last year, we now expect currency to represent a $25 million top line headwind in 2016. This equates to roughly $0.03 in earnings per share. And importantly, compared to when we initially guided in November, the stronger dollar is subtracting an incremental $11 million from our top line. 
So for the 2016 fiscal year, we are maintaining our guidance for constant currency growth of between 4.4% and 5.5%. But on a reported basis, we are updating our guidance to reflect the additional currency headwind. So based solely on the stronger dollar, we now expect reported revenues of $2.8 billion to $2.83 billion, representing reported growth of 3.5% to 4.6%. 
As Steve said earlier, we continue to forecast improvements on both the gross and operating margin lines, based on favorable geographic and product mix, as well as early returns from our productivity efforts. 
In addition, as you probably read, the omnibus budget bill that was passed by Congress in December included a 2-year moratorium on the medical device excise tax among other key provisions. We're thrilled that Congress has recognized the negative effects of this tax on domestic innovation and job growth. In fiscal 2015, we paid $23.6 million under this tax, which was reported under general and administrative expenses. It's important to note 2 points, however: first, since the moratorium took effect on January 1, we only recognize 3/4 of this benefit in our 2016 fiscal year. In addition, we plan to reinvest most of the benefit in some of our more attractive R&D and commercial programs. 
Continuing with our full year guidance, we now expect our effective tax rate to improve to approximately 33% for the year, and believe diluted shares outstanding will total between $296 million and $298 million for the full year. 
Given these updates and our strong first quarter results, we are increasing our non-GAAP earnings per share guidance. For the full year, we now expect EPS of $1.86 to $1.90. This translates to growth of 13.1% to 15.5% in constant currency terms, or reported growth between 11.4% and 13.8%. So despite currency and share count headwinds, we anticipate growing EPS at more than double the rate of sales, demonstrating bottom line growth and operating leverage that seemed unlikely, at best, just a few quarters ago. 
Turning to guidance for the second quarter of fiscal 2016. We expect revenues of $680 million to $690 million. Compared to the prior year period, this range reflects revenue growth of 4.5% to 6% on a constant currency basis, and reported revenue growth of 3.7% to 5.3%. 
We expect a sequential decline in revenue for 2 main reasons. First, our surgical business is seasonally weakest in the March quarter, especially in comparison to the strength we saw in the December period. Second, we are allowing for some potential choppiness in our international business. 
In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.45 to $0.46 in the second quarter. This represents growth of 11.2% to 13.6% in constant currency terms, or 9.8% to 12.2% on a reported basis. It's worth mentioning that we anticipate a substantial R&D increase in spending in the second fiscal quarter based mainly on the timing of projects. 
Before opening the call for questions, I'd like to reiterate that Hologic is off to a good start in 2016. In the first quarter, our momentum continued with Genius 3D Mammography and our surgical and molecular diagnostics business surprised to the upside. As a whole, our domestic businesses performed great. These positives outweighed weaker-than-expected results in our international mammography business, which we're dealing with aggressively. In the middle of the income statement, we are demonstrating the tremendous earnings power of the company by improving gross and operating margins. And below the line, we are beginning to see the benefits from our efforts to reduce debt, as well as our effective tax rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we're ready for the first question."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan.",14,"[Operator Instructions] And we'll go to our first question from Tycho Peterson of JPMorgan."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I guess, I want to start on the international Breast Health, where we've been getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it? An",60,"Steve, I guess, I want to start on the international Breast Health, where we've been getting a lot of questions on the decline. Can you maybe just walk through the extent of the dealer issues? How contained this is? How quickly you can work through it? And what kind of cushion you're baking in for the remainder of the year?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. On the wall of worry, Tycho, it's something we think about. I wouldn't be overly freaked out by it. I think the way we're thinking about it is, we've got just about every business performing better than we expected. But I think the deeper we dug in t",315,"Yes. On the wall of worry, Tycho, it's something we think about. I wouldn't be overly freaked out by it. I think the way we're thinking about it is, we've got just about every business performing better than we expected. But I think the deeper we dug in the second half of the year, and you'll continued to hear us say, really going back a few quarters, hey, we're probably closer to a startup than a real turnaround here. And we have a lot of work to do even on building our relationships with the dealers. And I think as we go back and look at it, clearly, our fourth fiscal quarter was really strong and followed by a weaker quarter, and that's not what we want to be delivering and don't have that sustained relationships. So we're making some changes internally, and we're not going to blame the dealers. We can always look at ourselves, and I'll say that we need to be a little closer to it. But it's the only little piece of the puzzle, I think, right now for us to continue to work on. I'd also say, I think, we're all accustomed to not every business is always firing on every cylinder. The day it does, we're probably in trouble. This is kind of one of our areas of opportunity. I think the next couple of quarters will probably be a little bit softer. We're going to plan for that while we get to the right longer-term plays. But as Eric -- as Eric Compton, after his first reviews of it, said, it obviously reminds him a little bit of when you walked in the door of Hologic 2 years ago and sort of the same rebuilding needs to occur, and things like pricing discipline, marketing, market access, just a lot of the fundamentals that we've never put in place."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just to follow up. The management changes you alluded to, are the changes done? Do you have the team in place now you need for Europe?",29,"Okay. And then just to follow up. The management changes you alluded to, are the changes done? Do you have the team in place now you need for Europe?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. So that's why I think over the next quarter or 2 we'll probably still have a little softness, and that's basically what we baked into",50,"No, we're putting those in place. So we've exited a couple of people, and we're in the process of putting new into them. So that's why I think over the next quarter or 2 we'll probably still have a little softness, and that's basically what we baked into our guidance."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jonathan Groberg of UBS.",10,"And we'll go next to Jonathan Groberg of UBS."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Obviously, a lot of questions on international Breast Health, but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, at least to start the year, your operating expenses grew quite a bit more than",67,"Obviously, a lot of questions on international Breast Health, but you just answered some of those. So can you maybe talk a little bit about your -- looks like for the quarter, at least to start the year, your operating expenses grew quite a bit more than sales. Kind of what's your expectation for OpEx growth for the year versus kind of gross margin for the year?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Hey Jonathan, it's Bob. So as we mentioned in our prepared remarks, what we're looking at is -- actually it's very strong performance on our gross margin basis, combination of product and geography mix as well as some of the productivity efforts that we'r",161,"Hey Jonathan, it's Bob. So as we mentioned in our prepared remarks, what we're looking at is -- actually it's very strong performance on our gross margin basis, combination of product and geography mix as well as some of the productivity efforts that we're doing, and we are looking to reinvest a portion of those. So our gross margin is probably operating a little bit better than what we had anticipated. And we're looking to reinvest that in those growth drivers in places like our marketing and, to a certain extent, some of the R&D investments to drive that growth rate on the top line. That being said, we are still expecting operating margin expansion consistent with what we had guided to in November, and we believe that we're able to do that. And we've demonstrated that certainly in the first quarter, continued to have operating margin leverage, and we expect that throughout the course of the rest of the year."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So just to follow up on that and kind of tie it into the first part of the conversation around international. Is it more about getting the right people? I know you thought you have the right person in your first hire. But is it more about getting the righ",94,"So just to follow up on that and kind of tie it into the first part of the conversation around international. Is it more about getting the right people? I know you thought you have the right person in your first hire. But is it more about getting the right people? Or is it more about throwing more money at the issue? And have you contemplated how -- that kind of -- and your guidance now, the outlook for how much you might need to spend in order to get this startup going internationally?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's all about the right people, it's not about the spending, Jonathan. So we'll have it nailed.",18,"It's all about the right people, it's not about the spending, Jonathan. So we'll have it nailed."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jack Meehan of Barclays.",10,"And we'll go next to Jack Meehan of Barclays."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So just wanted to ask about the U.S. mammography business, and just curious on your view for the landscape this year whether it's hospital CapEx -- CapEx trends or the competitive dynamic? Just your view on the rate of placements from here.",43,"So just wanted to ask about the U.S. mammography business, and just curious on your view for the landscape this year whether it's hospital CapEx -- CapEx trends or the competitive dynamic? Just your view on the rate of placements from here."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","So Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging business was up 18.7% in the quarter. That's coming off of some pretty good comps. And everything we're seeing and hearing is we continue to feel we are making very good p",140,"So Jack, we still feel really good. The U.S. -- as we said, the U.S. breast imaging business was up 18.7% in the quarter. That's coming off of some pretty good comps. And everything we're seeing and hearing is we continue to feel we are making very good progress, both with our own customers as well as competitive inroads. And I think we feel as good, if not better, about that business and the fact that we're going to end up -- by the end of the 3D curve, I had said early on, we think we'll end up with a little bit higher share than we started, and I think if anything, we feel better and better about that prediction and more and more confident every day that goes by. We continue to hear great stories from our teams."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. And then just curious, as you see hospitals taking on the new 3D units, do you still see them adding new capacity? Or are you seeing some replacements of 2D units as well?",35,"Got it. And then just curious, as you see hospitals taking on the new 3D units, do you still see them adding new capacity? Or are you seeing some replacements of 2D units as well?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today.",35,"It's largely replacement is the way to think about it. I don't think we see the number of gantries being significantly different at the end of the 3D curve versus where we are today."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Doug Schenkel of Cowen  and Company.",12,"And we'll go next to Doug Schenkel of Cowen  and Company."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I just wanted to cover really 2 topics. One is really just a math on guidance and then really the other topic is just on pricing in certain product categories. So first on guidance. Just to try to run through the waterfall. You beat earnings guidance at t",141,"I just wanted to cover really 2 topics. One is really just a math on guidance and then really the other topic is just on pricing in certain product categories. So first on guidance. Just to try to run through the waterfall. You beat earnings guidance at the high end by $0.04 this quarter. You increased EPS guidance for the year at the midpoint by $0.06. We estimate lower share count gets you $0.03 to $0.05, and lower tax rate gets $0.03 to $0.04. So it seems like we might be missing something here. Is there a change in mix that you expect to occur? Are there areas that maybe you're investing a little bit more in, either in sales or R&D relative to your last guidance? What are the pause there, and I will come back with a pricing question."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Doug, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to is the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and",78,"Doug, this is Bob. You're generally on top of it for both the share count and the tax benefit. I think what the other piece that we alluded to is the incremental headwinds associated with FX. So if you think about at a very high level, the tax benefit and share count, roughly we think about $0.06, offset by about $0.02 of FX. And then we up the operational beat in the Q1, that gives you $0.06 growth."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Gets you in the neighborhood. Okay. And then on pricing, really quickly. Some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors, particularly in Chlamydia gonorrhea CT/NG. Can you talk about if yo",76,"Gets you in the neighborhood. Okay. And then on pricing, really quickly. Some of our recent checks suggest that there may have been a pickup with more aggressive pricing from competitors, particularly in Chlamydia gonorrhea CT/NG. Can you talk about if you're seeing anything that's really different from kind of the normal pricing pressures you see in the market? And if there is -- basically what's baked into your guidance outlook for pricing changes in molecular?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I'll tell you. I think we feel as good as we felt since we've been here about pricing. And I think we've gotten so much more discipline. I'll tell you, we are hearing more and more competitive attempts, frankly, on both the molecular side as well as",173,"Yes. I'll tell you. I think we feel as good as we felt since we've been here about pricing. And I think we've gotten so much more discipline. I'll tell you, we are hearing more and more competitive attempts, frankly, on both the molecular side as well as on the mammography side, where there's some pretty big disparities. And with Bob McMahon and Eric Compton's leadership and the divisional presidents, we've been doing a much better job of fighting on price -- not fighting on price, fighting on the features and benefits and not going down there. And it's part of the hidden piece I think that we're seeing in our gross margin expansion. As we talk about the gross margin piece, clearly, it's the -- the incredible progress we're making on the operational side, it's a mix benefit but also, frankly, I think much better pricing discipline. And we're holding pricing far better, and in some cases getting a little bit of upticks even in what is a much more competitive environment."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Isaac Ro of Goldman Sachs.",11,"And we'll go next to Isaac Ro of Goldman Sachs."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context with what we're seeing from the other major equipment players this quarter. And I'm specifically curious if you'r",71,"I wanted to maybe just come back to the breast imaging comments that you guys touched on earlier. Wondering if you could put those in context with what we're seeing from the other major equipment players this quarter. And I'm specifically curious if you're seeing any more signs of aggressive bundling or pricing practices from those players, and whether or not that's a factor we should be considering in the market?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're seeing it. And Isaac, I'll tell you what I'm really, really proud of our team fighting it off. I think we're actually winning more based on the overall success of our business. The combination of our product, our label, the ease of use and our geniu",133,"We're seeing it. And Isaac, I'll tell you what I'm really, really proud of our team fighting it off. I think we're actually winning more based on the overall success of our business. The combination of our product, our label, the ease of use and our genius marketing campaigns, which frankly has probably been the single biggest differentiator of hospitals understanding, they're better aligned with us in the mammography space than with anybody else, because we're driving patients to the hospitals that have our systems. And I think it's been a dramatic step change in our own organization's ability to ward off going down the pricing games. And I've heard more and more anecdotes of much bigger pricing discounts from competitors on accounts that we've not lost, and in fact, we've won."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just to build on that, Steve. I mean, over the last 18 months we've had 2 competitors come into a market where we were the sole competitor. We've not only maintained stable pricing, but we've gained share. I think that's a huge credit to our domestic",62,"Yes. Just to build on that, Steve. I mean, over the last 18 months we've had 2 competitors come into a market where we were the sole competitor. We've not only maintained stable pricing, but we've gained share. I think that's a huge credit to our domestic Breast Health team led by Pete Valenti and that guy -- team, just tremendous job."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful. And then maybe just a separate question on the balance sheet and M&A didn't come up so far this quarter. I'm curious if it's possible that we went to you guys get in the marketplace this year with 1 tuck-in deal or 2 to augment the busines",75,"That's helpful. And then maybe just a separate question on the balance sheet and M&A didn't come up so far this quarter. I'm curious if it's possible that we went to you guys get in the marketplace this year with 1 tuck-in deal or 2 to augment the business? And if so, kind of what -- how does the shopping list look? How do you -- how would you characterize valuations and deal funnel?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Isaac, I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the",151,"Sure. Isaac, I think we're still in the earlier stages probably than I prefer to be on the true business development side. We've rebuilt the capabilities, aligned them with the divisions. I think the divisions are starting to look and starting to get the shopping list. But I'd put it really in probably the first inning. And we started to look at a few things we said no to. I do think valuations are going to be our friend as we go forward, and obviously, with the tremendous cash generation and getting our balance sheet cleaned up, we're going to be ready. I think our teams have been so focused on great commercial execution and getting the R&D pipelines back in shape. That's sort of the next piece that will start to play out. But we're probably still a little slower, so I wouldn't anticipate anything super quick on that front."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Bill Quirk of Piper Jaffray.",11,"And we'll go next to Bill Quirk of Piper Jaffray."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","First question, Bob. You mentioned that, obviously, there's a number of factors that helped to drive the gross margin from year-over-year. And you alluded to the fact that we're in kind of the early days from a supply chain standpoint. So I guess, 2-part",91,"First question, Bob. You mentioned that, obviously, there's a number of factors that helped to drive the gross margin from year-over-year. And you alluded to the fact that we're in kind of the early days from a supply chain standpoint. So I guess, 2-part question here. One, can you help break this down a little bit further in terms of what the contribution was from aligning your supply chain? And then, again, I don't want to put words in your mouth, but it sounds like really early days for this initiative."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, we're -- I'm not going to give you the level of specificity that you probably would like to have there. I would say it is a -- the productivity enhancements that we're talking about are through our sourcing organization as well as looking at running",191,"Yes, we're -- I'm not going to give you the level of specificity that you probably would like to have there. I would say it is a -- the productivity enhancements that we're talking about are through our sourcing organization as well as looking at running our factories more efficiently, and I think our operations team has done a great job of driving that. Obviously, we started that last year. We're seeing, one, a full year benefit. We're starting to see the full annualized effect of that this year, and we feel really good about that. And I would say it was a fairly meaningful component of the gross margin expansion, obviously with our U.S. business driving significant growth. That also had a big impact as well. And as we're thinking about the way that the U.S. business grew with the higher margin products in our surgical business and so forth, that actually helped us overall as well. So it was a nice balance between kind of the 3 of those things, but I think we are in the early innings of sustained kind of improvement on the gross margin basis."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Bill, I would add to that. When you heard me say, certainly, a year ago, I didn't think as a company we'd probably see much gross margin expansion. And if I say things that have changed over the last year in my own outlook, that's one that -- I think we'r",79,"Bill, I would add to that. When you heard me say, certainly, a year ago, I didn't think as a company we'd probably see much gross margin expansion. And if I say things that have changed over the last year in my own outlook, that's one that -- I think we're seeing much better opportunity than I ever imagined possible. So it's back to there's always puts and takes, that's one of the really good guys coming our way."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Good to hear. Second, this is kind of a bigger picture question on blood screening and blood utilization in general. I mean, certainly, we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may b",92,"Good to hear. Second, this is kind of a bigger picture question on blood screening and blood utilization in general. I mean, certainly, we've had the trend of the lower hemoglobin transfusion triggers in the U.S. for a while. You alluded too that we may be starting to see this internationally as well. So I guess kind of similar question here guys, kind of how much through the process are we both in the U.S. and OUS? It just would be curious what your partner, Grifols, has been telling you on that."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think we see -- in the U.S., I think we see continued low single-digit declines, probably in the blood screening business. International, probably more flattish as more countries adopt our net testing, but some more advanced ones start to cut back",145,"Yes. I think we see -- in the U.S., I think we see continued low single-digit declines, probably in the blood screening business. International, probably more flattish as more countries adopt our net testing, but some more advanced ones start to cut back a little bit. So I think we see the international business more flattish. Having said that, we've got a couple of quarters right now that we're absorbing the inventory fluctuations, particularly from a year ago with the JRC, where, frankly, we were both doing consumption plus inventory build. And now as the inventories contracting back, we've just got a couple of rougher comps that we're getting through. The underlying business slightly down, but still a very good business for us. But certainly, it's not going to be accretive to our top line growth rate over time, it will be dilutive to that."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Richard Newitter of Leerink Partners.",11,"And we'll go next to Richard Newitter of Leerink Partners."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I was hoping just to start off on the investments that you guys are making. And one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out on",109,"I was hoping just to start off on the investments that you guys are making. And one of the more frequent questions we get are about your pipeline and when we'll get greater visibility into kind of what you guys have in store as you eventually come out on the other side of kind of the tumble ramp. So first, just can you give us any sense as to where -- whether organic or external, where the priority is? You alluded to some of that, Steve, earlier. And then two, any color on when we'll learn about the pipeline in greater detail? And what can you give us today?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, sure, Rich. Clearly, the primary focus has been on rebuilding the organic growth pipeline. And I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good what we'r",308,"Sure, sure, Rich. Clearly, the primary focus has been on rebuilding the organic growth pipeline. And I think the simplest way to think about that is probably also why we're not further along on the business development front. We feel pretty good what we're putting in place. The other piece that I'd start to give you a little bit of a tidbit in is a lot of what we're working on are what I'd call singles and doubles. And -- the company was built historically, and every 8 years we launch a mega product like 2D and then 3D tomo, and a lot of what we are looking at is how do we cushion the blow in between and looking at some smaller things that we can be doing to bring in between those big cycles. And on the diagnostics business, it's about building out menu. In the Breast Health business, it's not just what's the replacement for 3D tomo, there's a lot of other stuff we can bring out in IBS and other stuff along the way. So I think what you'll start to see, and as you know, with me, stylistically, I'd like to get a few points on the board before we start talking about them. And given an organization we inherited that had a few launches on the table that we had to scrap when I got here because they weren't really ready for prime time. You want to make sure we really have our ducks in a row before we, a, start talking a lot more. But I'll tell you we feel better and better, but it's going to be more singles and doubles than probably triples and home runs. So we'll continue to update you as we go, but that may give you a little more flavor from what you've had historically."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","That's helpful, Steve. And then just maybe one more on the surgical business. Nice growth acceleration there, and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory",59,"That's helpful, Steve. And then just maybe one more on the surgical business. Nice growth acceleration there, and I'm just trying to get a sense for how sustainable this is. Should we be thinking of this business on a kind of newer double-digit trajectory going forward? And then do you have the portfolio you need to achieve that?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, thanks, Rich. I wouldn't go there yet to the sustainable double digit. Having said that, they posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all t",359,"Yes, thanks, Rich. I wouldn't go there yet to the sustainable double digit. Having said that, they posted several quarters in a row. The 18.8% clearly shocked us. We quietly put a new leader in that business late last summer, and we don't talk about all the changes we make, but that business actually, just in the last 6 months, we have a new VP of marketing, a new president, a new head of business development, a new head of R&D. And I'm more bullish and excited. The team that Eric has put in place there is really, really good, and they're doing that with just 2 products today. We stopped the declines on NovaSure. You know it better than most. Just 2 years ago NovaSure was a high single-digit decliner. We stopped that one and actually turned it into a positive. And the -- in MyoSure, I know when I first came here, it was growing at 20%. People figured we were about maxed out. Last year it went to 30%, and we just had a 46% growth quarter, and that's even when the people asked us the market size 1 year or 2 ago. And I couldn't quite answer it. I think we are seeing there may be more potential there. And then it's a great sales team that clearly could take on another product. So I think that's an area we're very willing and stepping up our activities of looking at bolt-on acquisitions. It's an area we're in the nascent stages, frankly, of starting to expand internationally. And it's a business that can do a lot for the profit margin and profitability profile of the company. So it's one we're more and more excited about. I'd still model single-digit growth, but like everything, we're certainly aspiring to continue the great trend. But clearly we did mention, there was a competitive recall we think helped us in that last quarter, and so that we certainly don't see the 18.8% growth as sustainable. Aspirational, yes, and we'll take it back to the division head, set that as his new goal, but pragmatically speaking, we're not that good yet."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","And Rich, I guess the only thing I'd add to that on surgical is the quarter that we're in now, which is our second fiscal quarter, does tend to be the seasonally weakest quarter for us, and typically the first quarter of our fiscal year is the strongest o",49,"And Rich, I guess the only thing I'd add to that on surgical is the quarter that we're in now, which is our second fiscal quarter, does tend to be the seasonally weakest quarter for us, and typically the first quarter of our fiscal year is the strongest one."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis.",26,"Yes. This quarter is typically a 7% to 10% decline just because of the reset of insurance plans and all that stuff from a sequential basis."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Brian Weinstein of William Blair.",11,"And we'll go next to Brian Weinstein of William Blair."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders in-house should never be higher. I'm curious kind of what your backlog looks like right now. And if you've seen any impact at all in terms of time to close",81,"Just wanted to ask a little bit about breast imaging again. You commented last quarter that orders in-house should never be higher. I'm curious kind of what your backlog looks like right now. And if you've seen any impact at all in terms of time to close from any discussion around the task force or any of these insurance companies that have been kind of reiterating nonpayment for tomo? Is there anything in the field that you're picking up on that?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Brian, this is Bob. What I would say is our backlog continues to be very robust, and we have not seen any extension of time to close or anything like that. I think that's a lot of noise that people may hear about kind of in the press, but when it actually",67,"Brian, this is Bob. What I would say is our backlog continues to be very robust, and we have not seen any extension of time to close or anything like that. I think that's a lot of noise that people may hear about kind of in the press, but when it actually comes to actually making purchase decisions and so forth, that hasn't affected us one bit."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then on cyto -- I'm going to say on cytology, you continue to reference share gains. Can you kind of talk what inning you're in on those share gains, where you think you are in terms of market share at this point?",44,"Great. And then on cyto -- I'm going to say on cytology, you continue to reference share gains. Can you kind of talk what inning you're in on those share gains, where you think you are in terms of market share at this point?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. We're not quite sure on market share, but we feel very good. We are obviously very strong leading, I think, probably in the 3/4 of the market share range, so up in that 70-plus percent, certainly in the U.S. We think we're much lower outside. And I",135,"Sure. We're not quite sure on market share, but we feel very good. We are obviously very strong leading, I think, probably in the 3/4 of the market share range, so up in that 70-plus percent, certainly in the U.S. We think we're much lower outside. And I think part of where we're really encouraged, and where I think we have made great progress internationally, over the last year, 1.5 years, is starting to get the belief and the conviction of what we need to do to grow the cytology business outside. And you remember, we said, one of the first things we could do to return this company to growth was stop the sharp declines on the ThinPrep business, and I think we feel pretty good about what we're doing there, actually feel great."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Raj Denhoy from Jefferies.",10,"And we'll go next to Raj Denhoy from Jefferies."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","What if I could ask -- maybe I'll start with Panther. You've given this metric now of $170,000 per machine. Is there any updates you can give us in terms of timing on when you can get the menu expanded? When do you expect viral load in United States and t",55,"What if I could ask -- maybe I'll start with Panther. You've given this metric now of $170,000 per machine. Is there any updates you can give us in terms of timing on when you can get the menu expanded? When do you expect viral load in United States and then subsequent tests beyond that?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. We're just rolling out viral load outside the U.S. We've got the CE marking and so we're rolling that out off of, and I think that will help our molecular business. We are obviously coming off of a pretty weak base, candidly, internationally. It's no",149,"Yes. We're just rolling out viral load outside the U.S. We've got the CE marking and so we're rolling that out off of, and I think that will help our molecular business. We are obviously coming off of a pretty weak base, candidly, internationally. It's nothing like what we have here. And really it's going to be a fiscal '18/'19 event in terms of the true viral load impact for us in the U.S. We'll get HIV approved sooner but, frankly, we ultimately want to have the full range of HIV, HPV, HCV, which we don't have really until later on in '18. So the way we think about that is it's probably going to end up hitting at a beautiful time for us. Some of the mammography business may be slowing a bit in the U.S., and that one kicks in and provides another leg up for us."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. That's helpful. Maybe just another question too on. R&D spending was actually down this quarter relative to last year. And although you did make a comment that you expect it to step up pretty dramatically as you move through the back half of the yea",72,"Okay. That's helpful. Maybe just another question too on. R&D spending was actually down this quarter relative to last year. And although you did make a comment that you expect it to step up pretty dramatically as you move through the back half of the year, is there anything you can give us in terms of what dramatically stepping up means? And why it has been somewhat low up to this point?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Raj, this is Bob. It's simply timing. When we look at the clinical programs that we have, we expect to ramp-up in Q2. So don't read anything into that other than it was timing.",35,"Yes. Raj, this is Bob. It's simply timing. When we look at the clinical programs that we have, we expect to ramp-up in Q2. So don't read anything into that other than it was timing."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Jon Block of Stifel.",10,"And we'll go next to Jon Block of Stifel."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe just the first one, Bob, for you, constant-currency growth was left unchanged for 2016, but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again, GYN was still big, international Breast H",72,"Maybe just the first one, Bob, for you, constant-currency growth was left unchanged for 2016, but how do we think about the changes to the components of the guidance that you broke out last quarter? I mean, again, GYN was still big, international Breast Health was maybe a little shy. Should we just flow that through the best we can? Or any official changes, again, to the components of the top line?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","No specifics. I mean, I think you would flow those in. Obviously, we were pleasantly surprised to the upside on the surgical business. And in U.S., I think our U.S. business is doing a little better than what we anticipated. Our international business is",99,"No specifics. I mean, I think you would flow those in. Obviously, we were pleasantly surprised to the upside on the surgical business. And in U.S., I think our U.S. business is doing a little better than what we anticipated. Our international business is a little more choppy and so forth. Outside of that, we're not going to give specific guidance to the individual components, other than to say that any softness that we may be seeing in the near term or the short-term internationally is going to be offset, we expect, by the strength in the U.S. business."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, got it. And then Steve, my apologies if I missed this on some of your color, but we've seen the international Breast Health bounce around a good amount before. But when you talk about what's currently going on, and we have the headline risk of inter",110,"Okay, got it. And then Steve, my apologies if I missed this on some of your color, but we've seen the international Breast Health bounce around a good amount before. But when you talk about what's currently going on, and we have the headline risk of international as what we deal with every day from where we sit. Can you just give a little bit more detail? In other words, is it the way that you're working with dealers, the relationships that you think you guys can strengthen in the coming quarters? Or has there been any change to call it end-user demand out in the field in certain countries?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Jon, I think this is more an internal execution issue of us dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger awards in some of the emerging markets this year, and we'll probably just backing off",137,"Sure. Jon, I think this is more an internal execution issue of us dealing with our dealers versus the market per se. Having said that, we were hopeful to get some bigger awards in some of the emerging markets this year, and we'll probably just backing off that. We're making some progress in Brazil and places like that, that we're probably being a little more cautious about as we go in, but it's much more our own execution. And frankly, again, it's a small part of our business that we know has great potential, and we will realize it. But it's more than I think than anything external or macro that we'd really point to. It could be macro, but we're not going to look to say it's that. I think that the opportunity is still there."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Vijay Kumar of Evercore ISI.",11,"And we'll go next to Vijay Kumar of Evercore ISI."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe one on breast imaging and -- sorry to sort of pick on this. But the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a short term issue? It looks like the U.S. growth slowed down s",65,"So maybe one on breast imaging and -- sorry to sort of pick on this. But the dealer issues that you're having in international, sort of what gives us the confidence or visibility that this is a short term issue? It looks like the U.S. growth slowed down sequentially. So I'm just wondering if you can give some color on what happened U.S. versus OUS?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, 2 pieces. I think first of U.S., we continue to feel really, really good. I mean, obviously, the growth rate, Vijay, which you pointed out, will be slowing down as we're going against some monster comps especially when we come into the second half of",167,"Yes, 2 pieces. I think first of U.S., we continue to feel really, really good. I mean, obviously, the growth rate, Vijay, which you pointed out, will be slowing down as we're going against some monster comps especially when we come into the second half of this year, but really already from here on we're now going in against much tougher comps from here. We're still growing the business, but we're not going to be putting 20% growth rate up on top of strong growth rates from a year ago. The outside the U.S., I look at this folks, it's just like every other issue we face since we came to the company. We're not the perfectly well-oiled machine. I think we're making a little bit of progress. Haven't made the progress that I'd like to see, and it's just a matter of better execution, which is something we know how to do. And it just requires a little greater focus than probably what I was providing."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then one follow-up on diagnostics. Clearly, this is a monster diagnostic quarter. In that U.S. business, I mean, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how susta",84,"Great. And then one follow-up on diagnostics. Clearly, this is a monster diagnostic quarter. In that U.S. business, I mean, you grew high singles. Feels like you're clearly gaining share. Can you provide some color on sort of what's going on and how sustainable is the share gain? Because when you look at sort of the Aptima franchise, I mean, those are some pretty big product lines and pretty mature. So I'm just wondering why this business is so strong, and what's going on."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I think it's been the hidden piece and back to a focus on execution, where we've clearly been a little more focused in the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. And ob",137,"Vijay, I think it's been the hidden piece and back to a focus on execution, where we've clearly been a little more focused in the U.S. What our team has been continuing to place Panthers, continuing to speak to the benefits that our products bring. And obviously, you know us well enough to know we're not one of these out there trumpeting, gee, we're #1, we beat this person, we got this competitive win. But quietly, we're really proud of what we've done on the HPV franchise in the U.S. and combined with cytology, combined with the co-testing message, combined with Panther placements, they're all -- no one thing is magic, but when you systematically pile them up, it provides a very nice outlook and has still a pretty good -- this strength is going to continue."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Derik De Bruin of Bank of America.",13,"And we'll go next to Derik De Bruin of Bank of America."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","So a lot of the questions have been asked, but let me just do a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, as some",87,"So a lot of the questions have been asked, but let me just do a couple here. So can you talk a little bit about the contribution to services for the Breast Health business? I know it's going to be a more of an impact on the business going forward, as some of the systems sort of that you placed earlier now start -- you have to start paying for service contracts. Can we think about instrument placements versus services, and how it goes in the mix?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in.",124,"Yes. I think we feel pretty good, obviously. The service revenue in the quarter was not as strong as the overall product revenue. But that will be a great kicker as basically every system, for the most part, in the second year, is when those will kick in. And we will say this. We are seeing a higher attach rate on the 3D service revenue contracts than we did on 2D. So, a, it's a little bit higher. So I think it's sort of one of those pieces that will kick in, and we feel very good about for the future.  And the team is doing a better job of actually selling service contracts today, probably in a tougher environment than we ever have."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just one other thing, Derik, just to kind of give you a little more color on that. While our total service, when you looked at it for the total company, only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest compo",103,"Yes. Just one other thing, Derik, just to kind of give you a little more color on that. While our total service, when you looked at it for the total company, only grew roughly kind of 2%. When you actually peel the onion back and look at the biggest component of that, which is our domestic U.S. mammography business, that grew in the mid-single digits, which is consistent with what we've been talking about as that business, with that high attach rate, higher ASP relative to the service contracts on the lower ASP 2D. So we continue to feel good about that business."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Just sort of a little clarification for me on this. So why was the 2D attachment rate on services so low historically?",22,"Just sort of a little clarification for me on this. So why was the 2D attachment rate on services so low historically?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It wasn't low.",4,"It wasn't low."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","It was extremely high, and we're going from an extremely high level to actually an even extremely higher level. It was well into the 80s percent, and we're doing even better than that.",33,"It was extremely high, and we're going from an extremely high level to actually an even extremely higher level. It was well into the 80s percent, and we're doing even better than that."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","85-plus percent.",3,"85-plus percent."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","And we'll go next to Mark Massaro of Canaccord Genuity.",11,"And we'll go next to Mark Massaro of Canaccord Genuity."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I want to ask -- you acknowledged that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you've gained share. Just wondering if you could just talk about the dynamics internationally. Is the bu",73,"I want to ask -- you acknowledged that you've seen some bundling from some of the competition in Breast Health and, meanwhile, you've also stated that you've gained share. Just wondering if you could just talk about the dynamics internationally. Is the bundling occurring more frequently internationally than it is in the U.S.? And can you just help us understand some of the pressures you saw internationally, in context of gaining market share?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. I think it's less bundling internationally than it's still -- the stage of development are internationally. We've not done nearly as good a job of selling the benefits of 3D, just from a government affairs standpoint, from a marketing standpoint. A",208,"Sure. I think it's less bundling internationally than it's still -- the stage of development are internationally. We've not done nearly as good a job of selling the benefits of 3D, just from a government affairs standpoint, from a marketing standpoint. A lot of what we have going in the U.S,  we're doing a great job of. Internationally, because we're through dealers, we've not worked with them closely enough to really segment the market. We were starting to -- obviously, there's a lot of opportunities for 2D. We need to do that. But we've had so much focus on 3D, and I don't think we've just done as good a job of fully marketing it through. So that's a part of the whole issue of consolidating the international business under Eric. We kind of -- I set it up when I first got here to have Eric really focus on the U.S. Claus focus internationally. It probably led to 2 silos more than sharing the learning across the geographies. And frankly, I feel like it's done a great job overall, but it -- we probably left a little bit on the table as related to our international development. So now Eric's on the case and here we go."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe a little outside the box here, but would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?",27,"Maybe a little outside the box here, but would you consider identifying countries in Europe where you could go direct in the Breast Health side in particular?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","We're looking at it everywhere as to what's really the best model, and that will be something I think you can expect us to report back on over time. I will tell you there's a lot more complexity to it all. In that candidly, in a number of geographies we h",174,"We're looking at it everywhere as to what's really the best model, and that will be something I think you can expect us to report back on over time. I will tell you there's a lot more complexity to it all. In that candidly, in a number of geographies we had given the marketing authorizations to the dealers. So the dealers actually own the marketing authorizations, which is not something you would typically expect of a company this size. But, a, it's one of these as you go into the onion and peel it back a little more, more work to be done, which is why we just think it's going to take us a little bit longer. I kind of view it as it will be a great thing to have in the out-years when things slowdown in the U.S. We probably aren't getting there as fast as I'd like to, but we'll probably end up getting there at a time that will be ultimately actually pretty well-timed for the total company."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll take our final question from Jayson Bedford of Raymond James.",14,"[Operator Instructions] And we'll take our final question from Jayson Bedford of Raymond James."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll ask 2 questions that require one-word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what are the -- what's your latest thoughts on gross margin expectations for '16?",48,"I'll ask 2 questions that require one-word answers, so we can keep it within an hour here. So what was the installed base of Genius at the end of the quarter? And then what are the -- what's your latest thoughts on gross margin expectations for '16?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","Higher and higher.",3,"Higher and higher."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Analysts","Do you have better words than that, Steve?",8,"Do you have better words than that, Steve?"
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Executives","You asked for one-word answers, Jayson. As a reminder, we're only going to give the placement numbers on an annual basis rather than getting into quarterly pieces. But we were very pleased with the additional placements of certainly the Genius and frankly",78,"You asked for one-word answers, Jayson. As a reminder, we're only going to give the placement numbers on an annual basis rather than getting into quarterly pieces. But we were very pleased with the additional placements of certainly the Genius and frankly, Panthers as well looking at their diagnostics business. And then gross margin, I think, we're basically guiding to -- we think there's 100 basis points of improvement year-over-year and feeling very encouraged by that opportunity."
108544,321211701,922023,"Hologic Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Hologic, Inc.","Operator","That is all the time we have for questions today. This now concludes Hologic's First Quarter Fiscal 2016 Earnings Call. Have a good evening.",24,"That is all the time we have for questions today. This now concludes Hologic's First Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Incorporated Second Quarter 2016 Earnings Conference Call. My name is Rene, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",53,"Good afternoon, and welcome to the Hologic Incorporated Second Quarter 2016 Earnings Conference Call. My name is Rene, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Renee. Good afternoon, and thank you for joining us for Hologic's second quarter fiscal 2016 earnings call. With me today are Steve Macmillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial O",199,"Thank you, Renee. Good afternoon, and thank you for joining us for Hologic's second quarter fiscal 2016 earnings call. With me today are Steve Macmillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks and then you have a question-and-answer session. Our second quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through May 27. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and our filings with the SEC. Also, during this call, we will be discussing certain non-GAAP financial measures, a reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve Macmillan, Hologic's CEO."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our",1803,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our business model was evident on 3 levels in the quarter. First, our U.S. businesses grew revenue at a low double-digit rate, continuing a recent pattern of outstanding commercial execution. Second, we again improved both gross and operating margins while making significant investments in our future. And third, we entered a new phase of our capital allocation strategy by repurchasing our common stock while continuing to pay down our convertible notes. Together, these strategic actions drove EPS growth more than double the rate of sales. More specifically, domestic revenue increased 10.6% in the quarter led by strong performances by our Breast Health and Surgical businesses. International sales were lower, mainly due to expected declines in blood screening and the discontinued products we discussed in our initial guidance. But international Breast Health showed signs of stabilization, which I'll discuss in a moment. 
Globally, total revenues grew 5.8% on a reported basis or 6.3% in constant-currency terms. And if we were to exclude the headwind from discontinued products, second quarter revenue would have increased more than 7% in constant-currency. Non-GAAP gross margin was 65.8% in the quarter, a significant improvement of 240 basis points compared to the prior-year period. We reinvested much of this incremental profitability for future growth and will continue to do so in the future, but still increased non-GAAP operating margin to 33.9% in the quarter, 40 basis points higher than last year. At the same time, our strong cash flows enabled us to be opportunistic in buying back our common stock as well as our convertible debt to continue improving our capital structure and to enhance future earnings power. Bob will cover the details in a moment, but net income represented a very robust 19.6% of sales and grew 14.1%, while non-GAAP EPS totaled $0.47, up 14.6% compared to the prior year. 
With that introduction and overview out of the way, I'd like to cover 5 subjects in my comments today. The first 2 have been topical over the last quarter, our Domestic and International Breast Health businesses, and obviously, these franchises will continue to be important to our future as well. But as we write new chapters in the Hologic story, the discourse is broadening as we build on our successes and add new strategic tools. With that in mind, today, I'd like to highlight our Surgical business, gross margin improvement opportunities and the research and development pipeline. Hopefully, this discussion will provide a little incremental color into the multiple levers we can pull to generate sustainable revenue and earnings growth over time. 
Let's start with our Domestic Breast Health business, which grew a very solid 11.2% based on continued adoption of our Genius 3D mammography systems. Genius placements were strong, increasing both sequentially and year-over-year, and we saw a good increase in service revenue as well. We continue to gain market share, and our investments in customer marketing are enabling us to do that while maintaining stable prices amid fierce competition. As a result, domestic imaging sales grew at a healthy midteens rate. We believe we still have runway ahead of us as our 3D systems are only about 1/3 penetrated into our own installed base and roughly 20% into the market as a whole. We remain confident in the long-term opportunity as customer interest and orders in house remain high and as clinical evidence continues to mount on the benefits of Hologic's exams for patients and physicians. Specifically, a longitudinal study published in February in the peer-reviewed journal gem oncology, showed that the benefits of our Genius exams, fewer recalls and improved cancer detection can be sustained and even improved over time, with consecutive use. In addition, a separate study published just yesterday in JAMA showed that these benefits held true for women with both dense and non-dense breasts, further bolstering the case for widespread adoption. 
Now let's turn to our International Breast Health business, which generated a lot of attention last quarter. While we still have a significant amount of work to do here, we did see signs of stabilization in the second quarter and are optimistic that we will see further signs of progress and predictability in the quarters ahead. While revenue declined by low single digits on a constant-currency basis in the second quarter, it's important to note that last year's results benefited from sales of products that we have since discontinued. If we back out this headwind, International Breast Health sales would have increased at a mid-single digit rate in constant-currency, a materially better performance than the decline we saw last quarter. As always, business improvement starts with people, and our Chief Operating Officer, Eric Compton, has made several important organizational changes internationally in recent months. We moved one of our key U.S. Breast Health leaders to Europe, and he is now in charge of building stronger, mutually productive relationships with our dealer network. Toward that end, we have signed several new performance-based contract with our top dealers. In addition, we've hired a new European head of service, which we have identified as a critical role to support our dealers and direct customers. We also have brought on new leaders of marketing, molecular diagnostics, surgical and regulatory. So the team is coming together nicely. 
Now let me turn to those 3 new topics, Surgical, gross margins and R&D. Let's cover Surgical first. Global sales were $90.9 million in the quarter and grew 15.9% in constant-currency. Surgical has exemplified the tremendous commercial turnaround that has occurred at Hologic, with the second quarter representing the fifth consecutive quarter of double-digit growth in the United States. It wasn't too long ago that surgical was viewed as a non-strategic asset that should be divested. Today, however, surgical is a vibrant business with strong profitability and cash flows plus good growth potential, and I couldn't be prouder of the team who has made it happen. Their formula for success has been straightforward. Stabilization of our NovaSure franchise, which was declining at a high single-digit rate only a couple of years ago, combined with excellent growth from our MyoSure products for uterine fibroid removal. We remain enthusiastic about the potential for MyoSure as we seek to expand the addressable market and replace all their treatments. And now, with the market withdrawal of a competitor to NovaSure, we have an opportunity to drive material growth for that product as well. We believe that NovaSure sales benefited from the competitive recall by a few million dollars in the quarter, and we are investing in marketing and physician outreach programs to ensure this continues for the balance of the year. 
The second topic I want to cover is our ability to improve gross margins. A year ago, we weren't overly bullish in this regard, but our operations team deserves a tremendous amount of credit for improving upon already strong profitability. To highlight what we've been able to achieve, in the second quarter, non-GAAP cost of goods sold for our products was lower in absolute terms than it was in the prior-year period despite an increase in sales. This is far bigger than a mix shift story. It is reflecting tremendous work by our teams. To make this possible, new leadership has instituted productivity improvement targets for each of our plants, and local managers have responded with scores of specific projects. We are closing our Bedford facility, our former corporate headquarters and moving the skeletal manufacturing that was done there to a contract manufacturer. And as we have discussed previously, we are doing a much better job of leveraging our corporate purchasing power across the business. 
The third area I want to discuss is our research and development pipeline, and it's important to begin with a bit of context. The unfortunate truth is that our R&D pipeline was weak, reflecting years of a growth by acquisition mindset. Too often, R&D spending was viewed as a plug in the income statement. The amount that was left over while attempting to meet short term financial goals. To reverse this mentality, we have been adding talent and rebuilding processes across the company to make R&D a driver of sustainable growth again. Although this process is far from complete, we are beginning to see the fruits of our labor. In diagnostics, for example, we now have a robust menu of molecular assays available on Panther in Europe, spanning women's health as well as virology. Recently we have secured CE Marks for new tests for HIV-1, hepatitis C, hepatitis B and the sexually transmitted disease called mycoplasma genitalia. In the United States, we are already the leader in women's health. We have filed the premarket approval application for our HIV viral load assay, and the PMA for our hepatitis C assay is scheduled to be submitted late this calendar year. Finally, our Panther Fusion platform, which will provide customers the flexibility to perform PCR testing in a single unit dose format is on track to be introduced internationally next year. 
In Surgical, we are now in the process of launching a line extension called MyoSure Reach. MyoSure Reach increases clinical utility by providing surgeons access to polyps and fibroids in more areas of the uterus, and we believe it will play an important role in extending our leadership position in the field. Finally, in Breast Health, we are excited about 2 new biopsy products that will further build on our position as the innovative leader in the market. Our new 3D-enabled Affirm Prone Biopsy system was introduced in Europe in March, and is being launched domestically now. Affirm represents the first real innovation in the biopsy space in roughly 20 years and leverages our growing installed base of Genius systems by enabling physicians to perform a more accurate biopsy using 3D technology. To further enhance our biopsy business, we expect to launch an entirely new biopsy tool named Brevera next year. Brevera has breakthrough potential as it allows realtime analysis of the biopsy sample, thereby vastly improving the patient experience. Stay tuned for more information on this. 
Before I turn the call over to Bob, let me conclude by saying that we are pleased with our second quarter financial results, which in some ways opened a new chapter in the Hologic story. As in recent quarters, our commercial teams generated robust growth in the United States. At the same time, we generated operating leverage through productivity improvements, while simultaneously investing for the future. And we boosted our bottom line performance by opportunistically deploying capital. All in all, a solid, well-rounded performance. 
Now I will hand the call over to Bob"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my remar",1836,"Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results and percentage changes will be on a year-over-year basis. Overall, we had a strong second quarter, with double-digit growth in the U.S. In addition, 3 of our 4 businesses demonstrated global growth in the quarter. Steve already discussed Breast Health and Surgical, so I will focus on Diagnostics and Skeletal. Diagnostics, our largest business, reported sales of $304.4 million in the second quarter, growing 3.2% in constant-currency terms. We're pleased to report another positive quarter on our cytology and perinatal business, which generated $116.1 million in sales, growing 3.5% in constant-currency. U.S. sales grew in mid-single digits, which was by far, our highest growth in several years, even with lingering headwinds from pap interval extension. 
Turning to mammography diagnostics, we posted sales up $126.1 million, up 5.8% in constant-currency. Domestic sales increased at a faster rate as our fully automated Panther system continues to accumulate new placements and competitive wins. In addition, utilization and sales of our assays for Trichomonas, HPV and chlamydia and gonorrhea continue to grow. Internationally, we had another solid quarter of Panther placements. This keeps us optimistic about our future growth potential in Europe, where we now have a full menu of women's health and viral load assays, as Steve mentioned. In blood screening, worldwide revenue of $62.2 million decreased 2.4% in constant-currency as expected. While there were some geography shifts as our partner Grifols balanced inventory, the overall decline was mainly due to stronger ordering in the prior-year period to support the rollout of our business with the Japanese Red Cross. We do continue to see however trends towards lower blood utilization worldwide, and therefore, anticipate that quarterly blood screening sales will settle in the mid-$50 million range as the market and customer usage patterns mature. 
In Skeletal Health, we had $22.2 million in global sales, a decline of 8.2% in constant-currency. Domestically, sales increased at a low single-digit rate, but international sales were negatively affected by distributor ordering patterns. Because this business is so small, it is not uncommon to see these kinds of fluctuations, and we do expect that Skeletal will be a solid contributor to growth over time. 
Now let me switch gears and discuss operating expenses in the second quarter. Total expenses of $221.2 million increased 12.9%, mainly as a result of our continued investment in Breast Health and diagnostic marketing programs, along with the timing of R&D programs which we foreshadowed last quarter. This increase in spending, which will continue into the second half of the year is planned and deliberate and a key component of our strategy to generate long-term sustainable growth. Two factors contribute to our willingness to support these incremental investments. First, and most importantly, we see good returns on the specific projects we're pursuing. For example, our investments in consumer marketing for Genius are enabling us to gain market share while maintaining stable price in the face of new competition. Second, we already have an industry-leading operating margin and have shown that we can and will increase this margin over time. But our goal is not to drive operating margins to unprecedented levels for our industry. Instead, we want to steadily improve them while also investing appropriately in DCF positive projects for long-term growth. At the same time, our goal is to allocate capital to enhance shareholder returns, and during the second quarter, we accelerated our efforts in this regard. For the last few years, our primary use of excess cash has been to pay down debt, and our long-standing goal of reducing net debt to 2.5x EBITDA by the end of '17 remains in effect. As evidence of this, we spent $311.4 million in the second quarter to repurchase convertible notes with the principal value of $226.6 million. While our convertible debt totaled over $1.3 billion in principle less than 12 months ago, it is now down to $793.3 million, a reduction of more than $0.5 billion. And given the continuing strength of our cash flows, we are in a position to supplement debt reduction with opportunistic repurchases of our common stock. Specifically in the second quarter, we bought back 4.3 million shares of our stock for $148.8 million. While stock buybacks have always been part of our long-term plan, market weakness in the second quarter enabled us to pounce a little earlier than expected. These strategic actions enabled us to sequentially reduce our share count in the second quarter, the first time in a long while that our diluted share count declined. In fact, diluted shares outstanding of 288 million were basically flat compared to the prior-year period, no longer diluting EPS growth. Specifically non-GAAP EPS increased 14.6%, about 2.5x the rate of sales. 
Let me just emphasize that our debt reduction and buyback activities will not prohibit us from seeking out opportunities for tuck-in acquisitions. Our divisional business development teams are settling in, and while no transactions are imminent, we are actively evaluating opportunities across our businesses. 
Before I move on to guidance, let me cover a few other financial metrics from the second quarter. Improvements made to our balance sheet contributed to a total debt outstanding of $3.4 billion, a decrease of $534.1 million compared to a year ago and net debt of $3.1 billion. Our leverage ratio net debt over EBITDA now stands at 3.1x. In the second quarter, adjusted EBITDA was $253.8 million, up 6.4% compared to the prior-year period. In addition, our trailing 12-month EBITDA surpassed $1 billion this quarter, a nice milestone for the company. Our ability to generate strong profits while lowering debt has again allowed us to increase return on invested capital. As our second fiscal quarter, ROIC was 11.7% on a trailing 12-month basis, 170 basis point improvement over the prior year. 
Finally, let's turn to our updated non-GAAP financial guidance for the full year and third quarter. Starting with the full year, we are raising the low end of our revenue guidance by $12 million to reflect the solid performance in the first half of the year. We now expect reported revenue of $2.81 billion to $2.83 billion in fiscal 2016, representing reported growth of 3.9% to 4.6%. Based on recent exchange rates, this equates to constant-currency growth of between 4.6% and 5.4%. Compared to our last guidance, there are a few puts and takes related to revenue. On the positive side, the market withdrawal of a competing surgical products should provide a tailwind to NovaSure and the dollar has weakened slightly. The currency benefit for us is less than you might expect however, since much of the dollar weakeningis  related to the Japanese yen and other currencies where we have minimal exposure. In terms of headwinds, we are more cautious on near-term blood screening revenue given macro trends in the market and we derisked our international forecast slightly. I should also mention we have made a voluntary decision to stop selling PF in flex, our test for cystic fibrosis due to manufacturing quality issues at a key component supplier that recently resulted in a recall. This would represent a headwind of several million dollars to our U.S. molecular diagnostics revenue in the second half of the year but shouldn't have much effect on margins. 
In terms of earnings for the full year, we now expect EPS of between $1.89 and $1.91, which translates to reported growth between 13.2% and 14.4%, a constant-currency growth of 15.6% to 15.8%. This is based on an effective tax rate of approximately 33% and diluted shares outstanding of roughly $292 million for the full year. As you work through your models, you will see that our increased EPS guidance implies a healthy expansion of already industry-leading operating margins, while accommodating increased investment. Specifically, we intend to continue investing behind our Genius campaign in breast health and surgical cancer cotesting and diagnostics. We will aggressively fund the commercial activities to launch important new products such as our Affirm Probe biopsy systems and capitalize on the competitive investment environment surrendering NovaSure. We also expect to make some key hires in our international business which typically come in with initial sign-on costs for relocation and the like. And we are pursuing some entirely new R&D initiatives, such as developing a blood screening test for the Zika virus while also seeking out opportunities to accelerate R&D timelines for existing initiatives, for example, by increasing the breadth of outside support. Not all of these investments are permanent in nature, but we do expect them to push operating expenses upward in the second half of the year. At the same time however our capital deployment activities are effectively offsetting the impact of these strategic investments on the bottom line. 
Now turning to guidance for the third quarter of fiscal 2016, we expect revenues of $695 million to $705 million. Compared to the prior-year period, this range reflects a reported growth of 0.2% to 1.6% or 0.6% to 2% on a constant-currency basis. As a reminder, these lower growth rates are due to a much tougher comparable in the prior-year period when revenue jumped almost $40 million on a sequential basis. In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.47 to $0.48 in the third quarter. This represents continued strong growth of 9.3% to 11.6% on a reported basis or 10.1% to 12.4% in constant-currency terms. Our full year guidance obviously implies a sequential step up in the fourth quarter revenue. This is due to normal sequential business momentum that we expect, contributions from new product launches and the timing of some royalty revenue that is expected later this year. 
Before opening up the call for questions, I would like to reiterate that our view on the second quarter is one of a good multilevel execution. Revenue grew at a solid rate based on continued outperformance domestically and stabilization outside the United States. We improved already strong operating margins while accommodating increased investment in key growth drivers. And our capital deployment activities helped to pay for these investments at the EPS line while setting the stage for leveraged growth over the long term. 
Now that we're halfway through our fiscal year, we're optimistic about our full year forecast. We're anticipating solid mid-single digit revenue growth in line with our original expectations as strength in the U.S. offsets the weakness we have seen internationally. We forecast solid expansion of operating margins while simultaneously investing for the future; and we expect the acceleration of our capital redeployment activities to allow us leverage operating gains all the way down to EPS, which should grow at a midteens rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we're ready for the first question"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And our first question comes from Isaac Ro of Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Isaac Ro of Goldman Sachs."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with the outlook in the ex-U.S. business, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out and curious if you talked a little bit ab",66,"I wanted to start with the outlook in the ex-U.S. business, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out and curious if you talked a little bit about how the changes in the team will juxtapose with just the operating environment, just so we understand the guidance better."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","yes, I would say it's still very conservative near-term. I think as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a startup than a turnaround. We got our 3 franchi",158,"yes, I would say it's still very conservative near-term. I think as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a startup than a turnaround. We got our 3 franchises across the geographies, and so what Eric is really doing and part of what precipitated the change is we need to really build out a team, not just get a team that was in place operating differently. And so Eric is really going out, we're already recruiting and bringing in different people, different leaders, but it's going to take -- that's going to be more a '17, '18 event. I think really what we're thinking about international is drivers, especially, frankly, '18, or '19, '20 and not as focused on the near-term so I think the near-term is pretty cautious and conservative but it will be coming through right when we need it."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. And the second question would be on tomosynthesis. Just curious if you could update us on what you learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color in the",97,"Got it. That's helpful. And the second question would be on tomosynthesis. Just curious if you could update us on what you learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color in the last couple of quarters, but curious for an update there, especially when you put in context of the JAMA study earlier this week and just what you're seeing in terms of how effectively your customers are able to get [indiscernible] and all that. Just an update on how that's going."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","If you go back 2 years, and I described it at that time we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our sales efforts really dramatically accele",250,"If you go back 2 years, and I described it at that time we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our sales efforts really dramatically accelerated that instead of a freight train, it definitely looked more like an airplane taking off. You saw that especially as you know in our third quarter last year, we started really posting this 20% growth numbers. I think what we see is we still feel very good about the order trends and about, frankly, the biggest piece I think we're incredibly excited about it, is the way we're holding pricing. And the demand still looks very good. Having said that, we're going against obviously now as we go into this third quarter. We're going against the huge comps and therefore, again as we try to signal in July of last year the absolute growth rates will probably be slower here for the U.S. Breast Health business, certainly as we go into the coming quarters. But I still feeling really good that there's a lot of runway ahead. And I think when we talked to investors, I think people often think there's going to be a peak and a huge trough. I think what we're seeing is probably going to be much more of a plateau but as we hit a peak, there's still a lot of runway that should have us last for quite a while here."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Isaac, this is Bob, just a follow-up to what Steve was saying, the numbers were where we expected them to be and what I would say is also in terms of the placements while we're not going to give up a specific number, it was up sequentially as we expected",68,"Isaac, this is Bob, just a follow-up to what Steve was saying, the numbers were where we expected them to be and what I would say is also in terms of the placements while we're not going to give up a specific number, it was up sequentially as we expected and also up versus prior year. So we feel good about our continued adoption in driving that business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jonathan Groberg from UBS.",9,"Our next question comes from Jonathan Groberg from UBS."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, just 2 question for me both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the key t",127,"Congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, just 2 question for me both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the key tests there, both in the U.S. and internationally? Because I think you specifically mentioned you had some pretty good uptake on the menu and Panther in Europe. Then two, if you could just clarify, Bob, on the cystic fibrosis tests that you're exiting. Are you exiting or is it just a recall or because of the recall, are you now exiting that business? Was that a few million dollars on an annual basis? Was that going to be the headwind?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Actually we are exiting it -- I take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it will be more larger than that on an annual basis. It was roughly a $10 millio",61,"Actually we are exiting it -- I take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it will be more larger than that on an annual basis. It was roughly a $10 million annual number, annual product. So we'll absorb that."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And then in terms of the other test, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making sur",115,"And then in terms of the other test, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making sure we're not declaring victory until we start to string together a number of quarters. But I think we're starting to see some better Panther placements, we have a new leader on our molecular business in Europe who actually came later last year. So he's starting to get his traction and driving it. So we're feeling pretty good about where that business should be going."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we continue to feel good about gaining share here in the U.S. here as well and across the major assets that we have.",26,"I think we continue to feel good about gaining share here in the U.S. here as well and across the major assets that we have."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We are seeing the road, nice growth we across each of the assets.",13,"We are seeing the road, nice growth we across each of the assets."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?",26,"Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter and it's actually increased from there this quarter. In the U.S. being higher than that in terms of the average sales per Panther.",35,"We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter and it's actually increased from there this quarter. In the U.S. being higher than that in terms of the average sales per Panther."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","If I give you the highest level of how we're feeling about the diagnostics business right now, we're incredibly thrilled to what ThinPrep was doing. Remember, that was a really ugly situation just a couple of years ago. That business is now, clearly flat",103,"If I give you the highest level of how we're feeling about the diagnostics business right now, we're incredibly thrilled to what ThinPrep was doing. Remember, that was a really ugly situation just a couple of years ago. That business is now, clearly flat to modest growth. Molecular is looking good, and blood screening's probably a little bit behind. Blood screening unless the one we don't control the commercial channel on, we're seeing probably greater inventory reductions. Certainly than what we expected start of the year and we will be absorbing based on the strength of the other parts of the business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Tycho Peterson of JPMorgan.",9,"Our next question comes from Tycho Peterson of JPMorgan."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, on margin if you can make comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus some of the operational improvements? And what should we expect for gros",50,"Bob, on margin if you can make comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus some of the operational improvements? And what should we expect for gross margins going forward?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So we're not going to give a specific target on gross margin going forward, Tycho. But I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that, roughly about 25% of tha",128,"So we're not going to give a specific target on gross margin going forward, Tycho. But I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that, roughly about 25% of that improvement was due to geography. And the rest being between product and productivity and what I would say is probably equally split between those 2. And we feel good about our continued improvement there with the initiatives that Steve talked about across all of the functions of our business. Our operations teams are really executing well, and identifying opportunities to continue to improve efficiencies, and obviously, as our sales growth drives more units to the factory, that also helps as well."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, and then question for Steve, I know you get a lot of question managing the firm Tomo cliff but just wondering the pipeline components you laid out today plus the service business that you guys continue to highlight, you feel like you've got in your",101,"Okay, and then question for Steve, I know you get a lot of question managing the firm Tomo cliff but just wondering the pipeline components you laid out today plus the service business that you guys continue to highlight, you feel like you've got in your line of sight that it is in the be a smooth transition? If not, can you maybe just touch on capital deployment? I mean, you talk more about buybacks today, but how do you view the opportunity set and do you need to rely on tuck-ins to effectively manage the tomo  cliff when that comes."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","First, going to try to suede you from using the word cliff because we have been working very hard to make sure that it won't be a cliff and I'd say, that in all seriousness. We have been very focused on what happened with the 2D curve and everything else,",506,"First, going to try to suede you from using the word cliff because we have been working very hard to make sure that it won't be a cliff and I'd say, that in all seriousness. We have been very focused on what happened with the 2D curve and everything else, and by thinking about how we extend out and do some line extensions and other things, that's been a huge part of our focus, to be able to add more of a plateau. We have very soft decline in that segment of the business at some point of time as opposed to a real cliff. Part of what we have coming I think is in biopsy and frankly [indiscernible] is running that business for us. Have long good track record of being able to put even some singles and doubles on the board in addition to just the every 5 or 8 year homerun that we tended to have in this business. So I would tell you I'm feeling incrementally better everytime Bob and I and Eric Compton are down meeting our business what's happened in our pipeline and we'll talk more and more about that certainly in the coming quarters and years. But I think we're feeling better about being able to mitigate that. The other piece, I just want to jump back even on your question on margin to Bob, because you know I was very adamant early on when I came, I was probably not expecting much margin expansion. This has been one of the very positive surprises to me, and I think the big piece that I want to be clear on is we're going to use a lot of this gross margin expansion to continue to invest into the business, which leads to the second part of your follow-up question there, which is as we go forward, we're certainly spending more on R&D, more on marketing and it will allow us to do tuck-in acquisitions based on the cash generation. And so I think we're really opening up a new leg in the stool where we got more levers available to us than we did 2 years ago. Two years ago, we were still hamstrung with debt and the converts and everything else, we didn't have really an ability to potentially manage, because as we all know, we're going to see some ups and downs in the rate of sales growth. We're going to continue to grow. We are going to have some period where it will be a little bit slower while we wait for the next new products to come through. I think we're feeling better and better that we're going to be able to deliver very strong earnings growth consistently and in the periods when we're growing faster, we'll probably reinvest a little bit more in the periods that are smaller. We may not have quite the accelerated investments in that time. So, hopefully, that will start to give a little more longer-term of what we're thinking about."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jack Meehan with Barclays.",9,"Our next question comes from Jack Meehan with Barclays."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just want to ask get a little bit more of granularity on the blood screening business and what you're seeing in the market today, and I think I caught a mid-$50 million number you referenced, just what is the trajectory of that business look like over the",54,"Just want to ask get a little bit more of granularity on the blood screening business and what you're seeing in the market today, and I think I caught a mid-$50 million number you referenced, just what is the trajectory of that business look like over the next maybe 3 to 6 quarters?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S., clearly hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their",200,"I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S., clearly hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their use of blood. So I think we're forecasting that the U.S. is a slight decliner. This quarter, our U.S. business was actually up fairly significantly in blood, that was more an inventory  correction. But I think the way we're thinking about it is that this is a low single-digit decliner. Internationally, I think we see the business very slight grower, but globally, I think because of the declines in the U.S., we think about blood screening as a flattish to slightly down business. And that's -- you go back to the headwinds we had as a company facing us a few years ago. It was blood, it was NovaSure, it was MyoSure -- I'm sorry, it was blood, NovaSure and ThinPrep. The 2 that we control the commercial channel, feel great about changing the long-term trajectory. I don't think we're quite as ready to declare a change in the trajectory of blood screening."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think the other thing that's important to note, Jack, there, this is a macro trend, we're not losing contracts, we have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's important to say th",78,"I think the other thing that's important to note, Jack, there, this is a macro trend, we're not losing contracts, we have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's important to say that we continue to feel good about continuing to secure the contracts that we have and this is more a utilization factor as opposed to losing contracts to be competitive."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it, that's helpful. Just one on Panther, the incremental Panthers you're placing in the field now, I'm just curious, what's the mix that the customers look like? Is it existing customers adding capacity? Is it new customers? How much drivers has been",51,"Got it, that's helpful. Just one on Panther, the incremental Panthers you're placing in the field now, I'm just curious, what's the mix that the customers look like? Is it existing customers adding capacity? Is it new customers? How much drivers has been in Europe? Any additional detail would be great."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","It's a bit of growth in terms of existing and new work and to some degree you started to see some slightly smaller accounts. We penetrated most of the large ones, and part of it is we look at the menu in the future and what we have coming we realized we c",113,"It's a bit of growth in terms of existing and new work and to some degree you started to see some slightly smaller accounts. We penetrated most of the large ones, and part of it is we look at the menu in the future and what we have coming we realized we can have a few more Panthers placed even in midsize accounts, hospital labs, other reference labs. That's going to benefit us as well. And, frankly, Panther has a got a pretty good footprint, OUS but we would never really put the resources behind it. And so we are starting to place a few more internationally, especially in Europe right now."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Doug Schenkel with Cowen and Company.",11,"Our next question comes from Doug Schenkel with Cowen and Company."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our amounts are just that just the share count reduction relative to the prior guidance should yet get you about $0.03 of benefit, [indiscernible]",76,"This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our amounts are just that just the share count reduction relative to the prior guidance should yet get you about $0.03 of benefit, [indiscernible] EPS by $0.02 at the midpoint and this is despite this quarter. I guess, the question is are you changing any other operating investment or assumptions that would impact EPS growth?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02 and we talked about the increased investment that we plan to make in our -- are going to be delivered about makin",114,"So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02 and we talked about the increased investment that we plan to make in our -- are going to be delivered about making in both R&D and marketing in the second half of the year. And that's essentially the math that you should be able to walk through. We're expecting higher operating expenses in the second half as a result of the benefits that we're seeing to generate long-term sustainable growth, both in R&D and marketing. And so we're taking some of that benefit and reinvesting it in the business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Chris, the way I can add to that is think about group EPS about 14-ish percent last year. At the high end of the range of this year, it is going to be another 14 on top of 14. There's a point at which you don't want to go too far because you're thinking a",60,"Chris, the way I can add to that is think about group EPS about 14-ish percent last year. At the high end of the range of this year, it is going to be another 14 on top of 14. There's a point at which you don't want to go too far because you're thinking about this over the long haul."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Hopefully, I'm right on this, but can you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?",37,"Hopefully, I'm right on this, but can you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think, we probably, with some distributor changes and everything else, there was a little more inventory probably in the channel there than we can fully g",100,"You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think, we probably, with some distributor changes and everything else, there was a little more inventory probably in the channel there than we can fully grasp. So I think it is underlying consumption looks good and I think we may have another quarter or so of a little bit of an adjustment here and then probably be, as Eric has dug in deeper and deeper, we're getting better granularity, better visibility, and I think it's more of an inventory contraction issue."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors introduced it in some other part of the country but just kind of thinking about timing around that rollout. And I guess, seco",89,"First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors introduced it in some other part of the country but just kind of thinking about timing around that rollout. And I guess, second part to that question is the testing strategy here has been a little bit different than what we've seen historically, where it looks like we're doing region-by-region testing rather than the whole country. So love to hear your comments on those 2."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via IND for use here in the coming months by early summer certainly by the peak, in time for mosquito se",140,"Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via IND for use here in the coming months by early summer certainly by the peak, in time for mosquito season. We don't yet know exactly how the market is going to play out. We've been through this script before with Dengue and West Nile, not being quite sure. Clearly, it looks like there was a regionality to this and we are prepared with various centers to be ready and responsive to what is needed to be done. And our primary focus initially is on blood screening. We are also, as part of the additional investment [indiscernible] also looking on the diagnostics side of it as well will be further out time-wise."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. A real quick follow up, the PNA that's filed on the viral load. I'm assuming that happened during the quarter and you can you give us any color there.",31,"Got it. A real quick follow up, the PNA that's filed on the viral load. I'm assuming that happened during the quarter and you can you give us any color there."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No, it will be.",4,"No, it will be."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just about a 12 months turn around time on that, I guess,.",12,"Just about a 12 months turn around time on that, I guess,."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Bill, just to clarify, HIV has been filed in recent months. For PMA, it typically took us about a year.",20,"Bill, just to clarify, HIV has been filed in recent months. For PMA, it typically took us about a year."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Vijay Kumar from Evercore ISI.",10,"Our next question comes from Vijay Kumar from Evercore ISI."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me Steve or Bob, it just seems to be 3Q to 4Q seems to be slightly higher than normal sort of the Q-on-Q ra",57,"I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me Steve or Bob, it just seems to be 3Q to 4Q seems to be slightly higher than normal sort of the Q-on-Q ramp."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Hi, Vijay, this is Bob. Obviously, the sequential spike is great when you're modeling on top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big piece",117,"Hi, Vijay, this is Bob. Obviously, the sequential spike is great when you're modeling on top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big piece of it, as well as the other businesses. So the impact of our new product launches such as the Affirm biopsy, which have been built into our plan. Some of the growth in the NovaSure business, as you recall, that would be strong there. And then we also have some royalty revenue that shows up in our molecular diagnostics in the fourth quarter, again, which we have anticipated this year."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And maybe one big-picture question for us, Steve, on capital deployment. I saw that you guys took out in the Q I'm just curious at what point do you feel Steve being comfortable on maybe deploying capital for M&A versus lowering the debt load.",45,"Great. And maybe one big-picture question for us, Steve, on capital deployment. I saw that you guys took out in the Q I'm just curious at what point do you feel Steve being comfortable on maybe deploying capital for M&A versus lowering the debt load."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're ready and willing to spend it on M&A, actually we did make an acquisition on our own stock in the quarter. That was actually a pretty good acquisition that we made, feeling pretty good about that. The teams are definitely looking, and where Bob and",175,"We're ready and willing to spend it on M&A, actually we did make an acquisition on our own stock in the quarter. That was actually a pretty good acquisition that we made, feeling pretty good about that. The teams are definitely looking, and where Bob and Eric and I will review now a regular basis, ideas, we also just look and so they're not get it away. Ultimately, I look forward to the day where we have no converts left on the balance sheet, but I would suspect we would be doing some acquisitions along the way while we're continuing to clean those up. So still in the way. At this point in time, still focusing with visions on what we call bite-size, things that supplement the existing businesses. And we're very willing and ready to go. But I would say, as Bob said in his script, nothing imminent. I wouldn't necessarily expect anything much in this fiscal year necessarily. So we thought mop up some shares while the market gives us nice opportunity."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Brian Weinstein from William Blair.",10,"Our next question comes from Brian Weinstein from William Blair."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Can you give me a little bit more granularity on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- there are sometimes in 2017, do you think it's a longer ramp",66,"Can you give me a little bit more granularity on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- there are sometimes in 2017, do you think it's a longer ramp than that? anything that you can help us triangulate on when you hit that plateau?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, it probably is '17, at some point in '17. I thought originally, it would've been '18 or beyond. I think the success and the faster climb. We're getting to 35,000 feet faster. Probably a good year faster than what I would have imagined, but I think w",68,"Sure, it probably is '17, at some point in '17. I thought originally, it would've been '18 or beyond. I think the success and the faster climb. We're getting to 35,000 feet faster. Probably a good year faster than what I would have imagined, but I think we will be able to stay up there for a while. And then we're starting to think '17 is probably it."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, that's helpful. And then on the repurchases, can you remind me, you have anything on your covenants that restrict the repurchase amounts that you have and what your current authorization is for share repurchases?",35,"Okay, that's helpful. And then on the repurchases, can you remind me, you have anything on your covenants that restrict the repurchase amounts that you have and what your current authorization is for share repurchases?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Brian, this is Bob. We currently have an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size or nature.",40,"Hey, Brian, this is Bob. We currently have an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size or nature."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Raj Denhoy of Jeffrey.",9,"Our next question comes from Raj Denhoy of Jeffrey."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In order to explore this idea, you guys are plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17 though, is the growth that you implied for",104,"In order to explore this idea, you guys are plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17 though, is the growth that you implied for the back half of the year which is something in the 2% to 3% range really what we should think about for the business until you get to this next product cycle, whether it's in diagnostic or otherwise? Is that how we should think about the business over the next 12 to 18 months or so?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Raj. I think we've not quite plateaued yet, we're still implying some growth in the final couple of quarters but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where we've been",99,"Sure, Raj. I think we've not quite plateaued yet, we're still implying some growth in the final couple of quarters but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where we've been over the last 4, 5, 6 quarters, I guess, just being pragmatic about it and that's part of the investments we're making today so that we know we can set ourselves up to continue to deliver frankly very healthy EPS growth even in what might be a slightly lower top line growth environment."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?",26,"But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're just not ready to get in the preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was and probably not a horrible number to use at this point in time.",39,"We're just not ready to get in the preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was and probably not a horrible number to use at this point in time."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from David use of Morgan Stanley.",10,"Our next question comes from David use of Morgan Stanley."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","This is Scott on for David. I think your guidance implies comp stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's driving that in fact?",43,"This is Scott on for David. I think your guidance implies comp stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's driving that in fact?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit, the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income that",74,"Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit, the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income that shows up in the fourth quarter as well as the new product -- products like the Affirm Probe biopsy table, that will show up more in the fourth quarter than in the third quarter."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a follow up, I guess, on the surgical part of our NovaSure, I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here? And do you expect kin",58,"Just a follow up, I guess, on the surgical part of our NovaSure, I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here? And do you expect kind out pro rata share going forward, or higher share going forward?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you with our surgical team is weak and they are kind of in a loss doing tremendous job on both NovaSure and Myo",86,"We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you with our surgical team is weak and they are kind of in a loss doing tremendous job on both NovaSure and MyoSure and it's clearly been one of the more positive upsides to the business again if you look over the last 2 years, where surgical was and where it's going, we're feeling really good about the trajectory."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","But that is one of the areas we're making incremental operating investments to capture that. And so that's part of the second half investments as well as the 3D Genius campaign and the cotesting on the marketing side on the Diagnostics business.",43,"But that is one of the areas we're making incremental operating investments to capture that. And so that's part of the second half investments as well as the 3D Genius campaign and the cotesting on the marketing side on the Diagnostics business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Derik De Bruin from Bank of America.",12,"Our next question comes from Derik De Bruin from Bank of America."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're cotesting isn't suffering from th",67,"So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're cotesting isn't suffering from this. Can you just talk about, first of all, certainly share gains in the cytology market and just on the primary testing situation."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we're feeling pretty good about -- ultimately, you know the science as well as many, probably some of the best, I think the science is very much on our side in cotesting but we feel very good about what we're seeing both on the cytology side and,",63,"I think we're feeling pretty good about -- ultimately, you know the science as well as many, probably some of the best, I think the science is very much on our side in cotesting but we feel very good about what we're seeing both on the cytology side and, frankly, on our HPV side. So we certainly don't see us losing share."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market.",15,"I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great, that's helpful. Just one quick follow-up, I guess, when you look at where you are in Panther placements versus of the total addressable market, I mean, how far would you say is Panther penetrated?",35,"Great, that's helpful. Just one quick follow-up, I guess, when you look at where you are in Panther placements versus of the total addressable market, I mean, how far would you say is Panther penetrated?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Fifth or sixth inning there, in the U.S?",8,"Fifth or sixth inning there, in the U.S?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In the U.S?",4,"In the U.S?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","In earlier innings OUS. We have to fill the capabilities outside the U.S.",13,"In earlier innings OUS. We have to fill the capabilities outside the U.S."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Rich Newitter from leaving partner.",10,"Our next question comes from Rich Newitter from leaving partner."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to make sure that I have the buckets right for the moving parts on your constant-currency guidance and what went up and what's kind of good and what's good and what's bad and incrementally good and incrementally bad and it sounds like the bloo",176,"Just wanted to make sure that I have the buckets right for the moving parts on your constant-currency guidance and what went up and what's kind of good and what's good and what's bad and incrementally good and incrementally bad and it sounds like the blood screen reduced outlook is, call it, maybe $10 million in the back half at the bad guy. You don't have FX, which is a good guy. If you can quantify that on some level or quantify each of these buckets, that would be great. It sounds like you have a little bit better of an outlook in GYN, your competitor up the market, to maybe incremental better there and you also have your MyoSure product plus a third bucket, that's a good guy. And then you said you have a slightly weaker or more conservative OUS outlook, and I'd love to know just kind of where that factors in, in magnitude relative to the blood screen which in my math is getting me to about $10 million incremental weakness."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're probably not going to -- we'll hold to that level of detail.",14,"We're probably not going to -- we'll hold to that level of detail."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Because no matter what we do, we'll be wrong.",9,"Because no matter what we do, we'll be wrong."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Exactly. I think your numbers are not that far off, I would say the FX is probably a little smaller than you may estimate for others because we do have about a little over 1/3 of our international business is actually based in U.S. dollars. The other piec",87,"Exactly. I think your numbers are not that far off, I would say the FX is probably a little smaller than you may estimate for others because we do have about a little over 1/3 of our international business is actually based in U.S. dollars. The other piece is the CF recall and market withdrawal that we mentioned before which is -- we mentioned that's a $10 million annual business. So think about that as roughly a $5 million headwind in the back half of the year."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, and just a the weaker OUS, or more conservative OUS outlook is that from blood screening or was that part of that?",23,"Okay, and just a the weaker OUS, or more conservative OUS outlook is that from blood screening or was that part of that?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","It is a little bit different but it's not that -- it small. You capture all the other big pieces.",21,"It is a little bit different but it's not that -- it small. You capture all the other big pieces."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Jon Block with Stifel.",10,"And our next question comes from Jon Block with Stifel."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe the first one for you and I get on the airplane analogies but at the end of the day we're still a tomo product cycle that's arguably 20% penetrated for the industry. That is sort of filling the 2D and this massive inflection point and so I get that",92,"Maybe the first one for you and I get on the airplane analogies but at the end of the day we're still a tomo product cycle that's arguably 20% penetrated for the industry. That is sort of filling the 2D and this massive inflection point and so I get that tough comps and maybe wanting to plateau than a cliff but can you just talk to why the 2017 revenue growth plateau in tomo would gain arguably when when I took that's really saw the incremental penetrations are to take off."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think if you really look, I mean, we had such a positive inflection point in the third quarter last year. We didn't run off right now. I think we always rather be a little conservative on potentially preannounced -- the fundamental reality is we're not",158,"I think if you really look, I mean, we had such a positive inflection point in the third quarter last year. We didn't run off right now. I think we always rather be a little conservative on potentially preannounced -- the fundamental reality is we're not totally sure the dynamics are different than they were at that point in time from both a competitive set, as well as where hospitals stand and everything else. We do think they probably have some upside in private sector insurance, that will continue to kick in as it plays out. And I think that is why we still feel very good about where it's going. But I think pragmatically, we're picturing is less of this incredible spike and probably just reaching kind of a new level where it's continuing to increase slightly for a while but not the 20% growth rates that we were getting for a few quarters in a row."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. Perfect, and just one more, it is a little  granular, but international molecular, I know it's small but were the revenues up year-over-year like prior 2 quarters, and then just a higher level, can you talk about what you're seeing with internatio",71,"Got it. Perfect, and just one more, it is a little  granular, but international molecular, I know it's small but were the revenues up year-over-year like prior 2 quarters, and then just a higher level, can you talk about what you're seeing with international molecular, you got the viral load assays over there. Are you seeing that help sort of gain market share on the heels of some of those approvals?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, as a backdrop, remember our international molecular business is still, frankly, way to small. So it was roughly flattish in the quarter. We're seeing growth in Europe and that's where we really want to see the growth. Probably it's taking more of an",197,"Yes, as a backdrop, remember our international molecular business is still, frankly, way to small. So it was roughly flattish in the quarter. We're seeing growth in Europe and that's where we really want to see the growth. Probably it's taking more of an opportunity. Still some fluctuations in some of the other smaller markets around the world, but I think what we expect over time is we're placing -- we actually started to replacing Panthers in Europe. I think we'll see that as Europe beachhead building out that international molecular business. It also start to provide steadier growth and a steadier foundation to the business to build out. But fundamentally, what we lack in the company is a true foundational business for really any of our franchises outside of the U.S. We get sales here and there from certain tenders, but we haven't had the fundamental strength where you're starting each quarter knowing that you got a nice book of business that's automatically coming in. Maybe in the old days we had to sell the Panthers instead of rentals and things like that. Just trying to get a lot more disciplined in a much healthier business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jayson Bedford with Raymond James.",10,"Our next question comes from Jayson Bedford with Raymond James."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I noticed you guys have become aggressive with the marketing side there.",36,"Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I noticed you guys have become aggressive with the marketing side there."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, we see it probably as additional upside.",33,"We feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, we see it probably as additional upside."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","And then just to follow up on the international build out, I realized that it's a long-term initiative, but when do you think Steve, you'll have the team in place internationally?",31,"And then just to follow up on the international build out, I realized that it's a long-term initiative, but when do you think Steve, you'll have the team in place internationally?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We'll have most of the team in place by the end of this fiscal year. And we got a lot of the key team. We have quietly started to rebuild the team particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. The n",163,"We'll have most of the team in place by the end of this fiscal year. And we got a lot of the key team. We have quietly started to rebuild the team particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. The new service leader was hired in the last quarter, our new Breast Health person came over. I think we feel pretty good about the team coming together by the end of this fiscal year and some of them are already hitting the ground and getting it. It is more of the '17, '18, '19 as we really get into the longer term planning and we're really upsizing that team. We don't want just some quick wins for the sake of wins. We want it to be the enduring business because part of what we got the last couple of years was the occasional big win but it didn't necessarily translate to ongoing business."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Mark Massaro with Canaccord Genuity.",10,"Our next question comes from Mark Massaro with Canaccord Genuity."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So you noted that you're closing the Bedford facility, can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?",36,"So you noted that you're closing the Bedford facility, can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?"
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part of what I might have missed in my script and probably the part that shocked me most when I was going through the financials on",196,"I think starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part of what I might have missed in my script and probably the part that shocked me most when I was going through the financials on the quarter, our absolute cost of goods is lower this year than last. So we are producing more product at less absolute money than last. And that's clearly a result of some of the procurement and productivity initiatives that Mike Kelley, our supply chain leader, put in place under Bob McMahon's guidance and a lot of confidence as well. The Bedford facility will be closing later this year. Candidly, it is going to have a fairly minimal impact on the true P&L because it is a leased facility and we are stuck with a bunch of lease cost and other stuff in there. But we're still just doing a lot of cleaning up through the company, and we've consistently said we've made a lot of progress in the last couple of years, and there's still a lot of opportunity ahead to be that are on so many fronts."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think that wraps it up.",6,"I think that wraps it up."
108544,329827217,964867,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter 2016 Earnings Call. Have a good evening.",25,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter 2016 Earnings Call. Have a good evening."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduc",54,"Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Offi",198,"Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks, then we'll have a question-and-answer session. Our second quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through May 27. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our",1798,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our business model was evident on 3 levels in the quarter. First, our U.S. businesses grew revenue at a low double-digit rate, continuing a recent pattern of outstanding commercial execution. Second, we again improved both gross and operating margins, while making significant investments in our future. And third, we entered a new phase of our capital allocation strategy by repurchasing our common stock, while continuing to pay down our convertible notes. Together, these strategic actions drove EPS growth more than double the rate of sales. More specifically, domestic revenue increased 10.6% in the quarter, led by strong performances by our Breast Health and Surgical businesses. International sales were lower, mainly due to expected declines in blood screening and the discontinued products we discussed in our initial guidance. But international Breast Health showed signs of stabilization, which I'll discuss in a moment. 
Globally, total revenues grew 5.8% on a reported basis or 6.3% in constant-currency terms. And if we were to exclude the headwind from discontinued products, second quarter revenue would have increased more than 7% in constant-currency. Non-GAAP gross margin was 65.8% in the quarter, a significant improvement of 240 basis points compared to the prior year period. We reinvested much of this incremental profitability for future growth and will continue to do so in the future, but still increased non-GAAP operating margin to 33.9% in the quarter, 40 basis points higher than last year. At the same time, our strong cash flows enabled us to be opportunistic in buying back our common stock, as well as our convertible debt to continue improving our capital structure and to enhance future earnings power. Bob will cover the details in a moment, but net income represented a very robust 19.6% of sales and grew 14.1%, while non-GAAP EPS totaled $0.47, up 14.6% compared to the prior year. 
With that introduction and overview out of the way, I'd like to cover 5 subjects in my comments today. The first 2 have been topical over the last quarter, our domestic and international Breast Health businesses, and obviously, these franchises will continue to be important to our future as well. But as we write new chapters in the Hologic story, the discourse is broadening as we build on our successes and add new strategic tools. With that in mind, today, I'd like to highlight our Surgical business, gross margin improvement opportunities and the research and development pipeline. Hopefully, this discussion will provide a little incremental color into the multiple levers we can pull to generate sustainable revenue and earnings growth over time. 
Let's start with our domestic Breast Health business, which grew a very solid 11.2% based on continued adoption of our Genius 3D Mammography systems. Genius placements were strong, increasing both sequentially and year-over-year, and we saw a good increase in service revenue as well. We continue to gain market share, and our investments in customer marketing are enabling us to do that, while maintaining stable prices amid fierce competition. As a result, domestic imaging sales grew at a healthy mid-teens rate. We believe we still have runway ahead of us as our 3D systems are only about 1/3 penetrated into our own installed base, and roughly 20% into the market as a whole. We remain confident in the long-term opportunity as customer interest and orders in-house remain high, and as clinical evidence continues to mount on the benefits of Hologic's exams for patients and physicians. Specifically, a longitudinal study published in February in the peer-reviewed journal, JAMA Oncology, showed that the benefits of our Genius exams, fewer recalls and improved cancer detection can be sustained and even improved over time with consecutive use. In addition, a separate study published just yesterday in JAMA showed that these benefits hold true for women with both dense and non-dense breasts, further bolstering the case for widespread adoption. 
Now let's turn to our international Breast Health business, which generated a lot of attention last quarter. While we still have a significant amount of work to do here, we do see signs of stabilization in the second quarter and are optimistic that we will see further signs of progress and predictability in the quarters ahead. While revenue declined by low single digits on a constant-currency basis in the second quarter, it's important to note that last year's results benefited from sales of products that we have since discontinued. If we back out this headwind, international Breast Health sales would have increased at a mid-single-digit rate in constant currency, a materially better performance than the decline we saw last quarter. As always, business improvement starts with people, and our Chief Operating Officer, Eric Compton, has made several important organizational changes internationally in recent months. We moved one of our key U.S. Breast Health leaders to Europe, and he is now in-charge of building stronger, mutually productive relationships with our dealer network. Towards that end, we have signed several new performance-based contracts with our top dealers. In addition, we've hired a new European head of service, which we have identified as a critical role to support our dealers and direct customers. We also have brought on new leaders of marketing, molecular diagnostics, surgical and regulatory. So the team is coming together nicely. 
Now let me turn to those 3 new topics: Surgical, gross margins and R&D. Let's cover Surgical first. Global sales were $90.9 million in the quarter and grew 15.9% in constant-currency. Surgical has exemplified the tremendous commercial turnaround that has occurred at Hologic, with the second quarter representing the fifth consecutive quarter of double-digit growth in the United States. It wasn't too long ago that surgical was viewed as a non-strategic asset that should be divested. Today, however, surgical is a vibrant business with strong profitability and cash flows plus good growth potential, and I couldn't be prouder of the team who has made it happen. Their formula for success has been straightforward. Stabilization of our NovaSure franchise, which was declining at a high single-digit rate only a couple of years ago, combined with excellent growth from our MyoSure products for uterine fibroid removal. We remain enthusiastic about the potential for MyoSure as we seek to expand the addressable market and replace older treatments. And now, with the market withdrawal of a competitor to NovaSure, we have an opportunity to drive material growth for that product as well. We believe that NovaSure sales benefited from the competitive recall by a few million dollars in the quarter, and we are investing in marketing and physician outreach programs to ensure this continues for the balance of the year. 
The second topic I want to cover is our ability to improve gross margins. A year ago, we weren't overly bullish in this regard, but our operations team deserves a tremendous amount of credit for improving upon already strong profitability. To highlight what we've been able to achieve, in the second quarter, non-GAAP cost of goods sold for our products was lower in absolute terms than it was in the prior year period despite an increase in sales. This is far bigger than a mix shift story. It is reflecting tremendous work by our teams. To make this possible, new leadership has instituted productivity improvement targets for each of our plants, and local managers have responded with scores of specific projects. We are closing our Bedford facility, our former corporate headquarters, and moving the skeletal manufacturing that was done there to a contract manufacturer. And as we have discussed previously, we are doing a much better job of leveraging our corporate purchasing power across the business. 
The third area I want to discuss is our research and development pipeline, and it's important to begin with a bit of context. The unfortunate truth is that our R&D pipeline was weak, reflecting years of a growth by acquisition mindset. Too often, R&D spending was viewed as a plug in the income statement. The amount that was left over, while attempting to meet short-term financial goals. To reverse this mentality, we have been adding talent and rebuilding processes across the company to make R&D a driver of sustainable growth again. Although this process is far from complete, we are beginning to see the fruits of our labor. In diagnostics, for example, we now have a robust menu of molecular assays available on Panther in Europe, spanning women's health as well as virology. Recently, we have secured CE-marks for new tests for HIV-1, hepatitis C, hepatitis B and a sexually transmitted disease called Mycoplasma genitalium. In the United States, we are already the leader in women's health. We have filed the premarket approval application for our HIV viral load assay, and the PMA for our hepatitis C assay is scheduled to be submitted late this calendar year. Finally, our Panther Fusion platform, which will provide customers the flexibility to perform PCR testing in a single-unit-dose format, is on track to be introduced internationally next year. 
In Surgical, we are now in the process of launching a line extension called MyoSure Reach. MyoSure Reach increases clinical utility by providing surgeons access to polyps and fibroids in more areas of the uterus, and we believe it will play an important role in extending our leadership position in the field. Finally, in Breast Health, we are excited about 2 new biopsy products that will further build on our position as the innovative leader in the market. Our new 3D-enabled Affirm prone biopsy system was introduced in Europe in March, and is being launched domestically now. Affirm represents the first real innovation in the biopsy space in roughly 20 years and leverages our growing installed base of Genius systems by enabling physicians to perform a more accurate biopsy using 3D technology. To further enhance our biopsy business, we expect to launch an entirely new biopsy tool named Brevera next year. Brevera has breakthrough potential as it allows real-time analysis of the biopsy sample, thereby vastly improving the patient experience. Stay tuned for more information on this. 
Before I turn the call over to Bob, let me conclude by saying that we are pleased with our second quarter financial results, which in some ways opened a new chapter in the Hologic story. As in recent quarters, our commercial teams generated robust growth in the United States. At the same time, we generated operating leverage through productivity improvements, while simultaneously investing for the future. And we boosted our bottom line performance by opportunistically deploying capital. All in all, a solid, well-rounded performance. 
Now I will hand the call over to Bob"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my rema",1837,"Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results and percentage changes will be on a year-over-year basis. Overall, we had a strong second quarter, with double-digit growth in the U.S. In addition, 3 of our 4 businesses demonstrated global growth in the quarter. Steve already discussed Breast Health and Surgical, so I will focus on Diagnostics and Skeletal. Diagnostics, our largest business, reported sales of $304.4 million in the second quarter, growing 3.2% in constant-currency terms. We're pleased to report another positive quarter on our cytology and perinatal business, which generated $116.1 million in sales, growing 3.5% in constant currency. U.S. sales grew mid-single digits, which was by far our highest growth in several years, even with lingering headwinds from Pap interval expansion. 
Turning to the molecular diagnostics. We posted sales of $126.1 million, up 5.8% in constant currency. Domestic sales increased at a faster rate as our fully automated Panther system continues to accumulate new placements and competitive wins. In addition, utilization and sales of our assays for Trichomonas, HPV and chlamydia and gonorrhea continue to grow. Internationally, we had another solid quarter of Panther placements. This keeps us optimistic about our future growth potential in Europe, where we now have a full menu of women's health and viral load assays, as Steve mentioned. In blood screening, worldwide revenue of $62.2 million, decreased 2.4% in constant currency, as expected. While there were some geography shifts as our partner Grifols balanced inventory, the overall decline was mainly due to stronger ordering in the prior year period to support the rollout of our business with the Japanese Red Cross. We do continue to see, however, trends towards lower blood utilization worldwide, and therefore, anticipate that quarterly blood screening sales will settle in the mid-$50 million range as the market and customer usage patterns mature. 
In Skeletal Health, we had $22.2 million in global sales, a decline of 8.2% in constant currency. Domestically, sales increased at a low single-digit rate, but international sales were negatively affected by distributor ordering patterns. Because this business is so small, it is not uncommon to see these kinds of fluctuations, and we do expect that Skeletal will be a solid contributor to growth over time. 
Now let me switch gears and discuss operating expenses in the second quarter. Total expenses of $221.2 million, increased 12.9%, mainly as a result of our continued investments in Breast Health and diagnostic marketing programs, along with the timing of R&D programs which we foreshadowed last quarter. This increase in spending, which will continue into the second half of the year, is planned and deliberate, and a key component of our strategy to generate long-term sustainable growth. Two factors contribute to our willingness to support these incremental investments. First, and most importantly, we see good returns on the specific projects we're pursuing. For example, our investments in consumer marketing for Genius are enabling us to gain market share, while maintaining stable price in the face of new competition. Second, we already have an industry-leading operating margin and have shown that we can and will increase this margin over time. But our goal is not to drive operating margins to unprecedented levels for our industry. Instead, we want to steadily improve them, while also investing appropriately in DCF-positive projects for long-term growth. At the same time, our goal is to allocate capital to enhance shareholder returns, and during the second quarter, we accelerated our efforts in this regard. For the last few years, our primary use of excess cash has been to pay down debt, and our longstanding goal of reducing net debt to 2.5x EBITDA by the end of 2017 remains in effect. As evidence of this, we spent $311.4 million in the second quarter to repurchase convertible notes with the principal value of $226.6 million. While our convertible debt totaled over $1.3 billion in principle less than 12 months ago, it is now down to $793.3 million, a reduction of more than $0.5 billion. And given the continuing strength of our cash flows, we are in a position to supplement debt reduction with opportunistic repurchases of our common stock. Specifically in the second quarter, we bought back 4.3 million shares of our stock for $148.8 million. While stock buybacks have always been part of our long-term plan, market weakness in the second quarter enabled us to pounce a little earlier than expected. These strategic actions enabled us to sequentially reduce our share count in the second quarter, the first time in a long while that our diluted share count declined. In fact, diluted shares outstanding of 288 million were basically flat compared to the prior year period, no longer diluting EPS growth. Specifically, non-GAAP EPS increased 14.6%, about 2.5x the rate of sales. 
Let me just emphasize that our debt reduction and buyback activities will not prohibit us from seeking out opportunities for tuck-in acquisitions. Our divisional business development teams are settling in, and while no transactions are imminent, we are actively evaluating opportunities across our businesses. 
Before I move on to guidance, let me cover a few other financial metrics from the second quarter. Improvements made to our balance sheet contributed to a total debt outstanding of $3.4 billion, a decrease of $534.1 million compared to a year ago, and net debt of $3.1 billion. Our leverage ratio, net debt over EBITDA, now stands at 3.1x. In the second quarter, adjusted EBITDA was $253.8 million, up 6.4% compared to the prior year period. In addition, our trailing 12-month EBITDA surpassed $1 billion this quarter, a nice milestone for the company. Our ability to generate strong profits, while lowering debt, has again allowed us to increase return on invested capital. As our second fiscal quarter, ROIC was 11.7% on a trailing 12-month basis, 170 basis point improvement over the prior year. 
Finally, let's turn to our updated non-GAAP financial guidance for the full year and third quarter. Starting with the full year, we are raising the low end of our revenue guidance by $10 million to reflect the solid performance in the first half of the year. We now expect reported revenue of $2.81 billion to $2.83 billion in fiscal 2016, representing reported growth of 3.9% to 4.6%. Based on recent exchange rates, this equates to constant-currency growth of between 4.6% and 5.4%. Compared to our last guidance, there are a few puts and takes related to revenue. On the positive side, the market withdrawal of a competing surgical products should provide a tailwind to NovaSure, and the dollar has weakened slightly. The currency benefit for us is less than you might expect, however, since much of the dollar weakening has been relative to the Japanese yen and other currencies where we have minimal exposure. In terms of headwinds, we are more cautious on near-term blood screening revenue given macro trends in the market, and we've derisked our international forecast slightly. I should also mention we have made a voluntary decision to stop selling CF InPlex, our test for cystic fibrosis, due to manufacturing quality issues at a key component supplier that recently resulted in a recall. This will represent a headwind of several million dollars to our U.S. molecular diagnostics revenue in the second half of the year, but shouldn't have much effect on margins. 
In terms of earnings for the full year, we now expect EPS of between $1.89 and $1.91, which translates to reported growth between 13.2% and 14.4%, or constant-currency growth of 14.6% to 15.8%. This is based on an effective tax rate of approximately 33% and diluted shares outstanding of roughly $292 million for the full year. As you work through your models, you will see that our increased EPS guidance implies a healthy expansion of already industry-leading operating margins, while accommodating increased investment. Specifically, we intend to continue investing behind our Genius campaign in Breast Health and cervical cancer co-testing in Diagnostics. We will aggressively fund the commercial activities to launch important new products, such as our Affirm prone biopsy system, and capitalize on the competitive investment environment surrounding NovaSure. We also expect to make some key hires in our international business, which typically come in with initial sign-on costs for relocation and the like. And we are pursuing some entirely new R&D initiatives, such as developing a blood screening test for the Zika virus, while also seeking out opportunities to accelerate R&D time lines for existing initiatives, for example, by increasing the breadth of outside support. Not all of these investments are permanent in nature, but we do expect them to push operating expenses upward in the second half of the year. At the same time, however, our capital deployment activities are effectively offsetting the impact of these strategic investments on the bottom line. 
Now turning to guidance for the third quarter of fiscal 2016, we expect revenues of $695 million to $705 million. Compared to the prior year period, this range reflects a reported growth of 0.2% to 1.6% or 0.6% to 2% on a constant-currency basis. As a reminder, these lower growth rates are due to a much tougher comparable in the prior year period when revenue jumped almost $40 million on a sequential basis. In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.47 to $0.48 in the third quarter. This represents continued strong growth of 9.3% to 11.6% on a reported basis or 10.1% to 12.4% in constant-currency terms. Our full year guidance obviously implies a sequential step up in the fourth quarter revenue. This is due to normal sequential business momentum that we expect, contributions from new product launches and the timing of some royalty revenue that is expected later this year. 
Before opening up the call for questions, I would like to reiterate that our view on the second quarter is one of a good multilevel execution. Revenue grew at a solid rate based on continued outperformance domestically and stabilization outside the United States. We improved already strong operating margins, while accommodating increased investment in key growth drivers. And our capital deployment activities helped to pay for these investments at the EPS line, while setting the stage for leveraged growth over the long term. 
Now that we're halfway through our fiscal year, we're optimistic about our full year forecast. We're anticipating solid mid-single-digit revenue growth in line with our original expectations as strength in the U.S. offsets the weakness we have seen internationally. We forecast solid expansion of operating margins, while simultaneously investing for the future, and we expect the acceleration of our capital redeployment activities to allow us to leverage operating gains all the way down to EPS, which should grow at a mid-teens rate. 
With that, I will ask the operator to open up the call for questions."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Please limit your questions to one plus a related follow-up, then return to the queue. Operator, we are ready for the first question. [Operator Instructions]",26,"Please limit your questions to one plus a related follow-up, then return to the queue. Operator, we are ready for the first question. [Operator Instructions]"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with the outlook in the ex-U.S. business, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out and curious if you talk a little bit abou",66,"I wanted to start with the outlook in the ex-U.S. business, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out and curious if you talk a little bit about how the changes in the team will juxtapose just the operating environment, just so we understand the guidance little better?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I would say it's still very conservative near-term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 f",159,"Yes, I would say it's still very conservative near-term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 franchises across the geographies, and so what Eric is really doing and part of what precipitated the change is we need to really build out a team, not just get a team that was in place operating differently. And so Eric is really going out, we're already recruiting and bringing in different people, different leaders, but it's going to take -- that's going to be more a '17, '18 event. I think and really we're thinking about international as drivers in especially, frankly, '18, '19, '20 and not as focused on the near-term. So I think the near-term is pretty cautious and conservative, but it will be coming through right when we need it."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over the",97,"Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over the last couple of quarters, but curious for an update there, especially if you put in context with the JAMA study earlier this week and then just what you're seeing in terms of how effectively your customers are able to get reimbursement and all that. Just an update on how that's going?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales e",262,"Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales efforts really dramatically accelerated that, and instead of a freight train, it definitely looked more like an airplane, I think, taking off. And you saw that especially as you know in our third quarter last year, we started really posting this 20% growth numbers. I think what we see is we still feel very good about the order trends and about, frankly, the biggest piece I think we're incredibly excited about is the way we're holding pricing. And the demand still looks very good. Having said that, we're going against obviously now as we go into this third quarter. We're going against the huge comps and therefore, again as we try to signal in July of last year, the absolute growth rates will probably be slower here for the U.S. Breast Health business, certainly as we go into the coming quarters. But I think still feeling really good that there's a lot of runway ahead. And I think when we talked to investors, I think people often think there's going to be a peak and then a huge trough. I think we're seeing it is probably going to be much more of a plateau, but as we hit a peak, there's still a lot of runway that should have us last for quite a while here."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Isaac, this is Bob, just to follow up on what Steve was saying, the numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected an",70,"Isaac, this is Bob, just to follow up on what Steve was saying, the numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected and also up versus prior year. So we feel continued -- good about our continued adoption in driving that business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jonathan Groberg with UBS.",9,"Our next question comes from Jonathan Groberg with UBS."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, just 2 question for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the k",131,"So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, just 2 question for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the key tests there, both in the U.S. and internationally? Because I think you specifically mentioned you had some pretty good uptake on the menu in Panther in Europe. Then two, if you could just clarify, Bob, on the cystic fibrosis tests that you're exiting. Are you exiting or is it just a recall or because of the recall, are you now exiting that business? And was that a few million dollars on an annual basis? Was that kind of going to be the headwind?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- little larger than that on an annual",68,"Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- little larger than that on an annual basis. It was roughly a $10 million annual number, annual product. So we'll absorb that."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making su",116,"And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making sure we're not declaring victory until we start to string together a number of quarters. But I think we're starting to see some better Panther placements. We have a new leader on molecular business in Europe who actually came later last year. And so he's starting to get his traction and driving it. So I think, feeling pretty good about where that business should be going."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we continue to feel good about gaining share here in the U.S. as well, and across the major assets that we have.",25,"I think we continue to feel good about gaining share here in the U.S. as well, and across the major assets that we have."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We started breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets.",20,"We started breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where we are in terms of the annual utilization?",25,"Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where we are in terms of the annual utilization?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther.",35,"We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flatt",104,"If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flattened to modest growth. Molecular is looking good, and blood screening's probably a little bit behind. Blood screening unless the one we don't control the commercial channel on, we're seeing probably greater inventory reductions. Certainly than what we expected at start of the year, and we are absorbing this based on the strength in the other parts of the business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Tycho Peterson with JPMorgan.",9,"Our next question comes from Tycho Peterson with JPMorgan."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, one of you, if you can, made comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect",52,"Bob, one of you, if you can, made comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect for gross margins going forward?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that, roughly about 25% o",130,"So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that, roughly about 25% of that improvement was due to geography. And the rest being between product and productivity, and what I would say is just probably equally split between those 2. And we feel good about our continued improvement there with the initiatives that Steve talked about across all of the functions of our business. Our operations teams are really executing well, and identifying opportunities to continue to improve efficiencies, and obviously, as our sales growth drives more units to the factory, that also helps as well."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, and then question for Steve, I know you get a lot of question on managing kind of the tomo cliff, and just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, you feel like you've",107,"Okay, and then question for Steve, I know you get a lot of question on managing kind of the tomo cliff, and just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, you feel like you've got enough of a line of sight that, that's going to be kind of a smooth transition, and if not, can you maybe just touch on capital deployment? I mean, you talked more about buybacks today, but how do you view the opportunity set, and do you need to rely on tuck-ins to effectively manage the tomo cliff when that comes?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Tycho. Now first, I'm going to try to swayed you from using the word cliff because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D curve",520,"Sure, Tycho. Now first, I'm going to try to swayed you from using the word cliff because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D curve and everything else, and by thinking about how we extend out and do some line extensions and other things, that's been a huge part of our focus to be able to have more of a plateau where a very soft decline in that segment of the business at some point of time as opposed to a real cliff. I think it's part of what we have coming. I think is in biopsy and frankly, Pete Valenti is running that business for us. He has had a long good track record of being able to put even some singles and doubles on the board in addition to just the every 5 or 8 year homerun that we've tended to have in this business. So I would tell you I'm feeling incrementally better. Everytime Bob and I and Eric Compton are down meeting with that business on what's happening in our pipeline, and we'll talk more and more about that certainly in the coming quarters and years. But I think we're feeling better about being able to mitigate that. The other piece, I just want to jump back even on your question on margin to Bob, because you know I was very adamant early on when I came, I was probably not expecting much margin expansion. This has been one of the very positive surprises to me, and I think the big piece that I want to be clear on is we're going to use a lot of this gross margin expansion to continue to invest into the business, which leads to the second part of your follow-up question there, which is as we go forward, we're certainly spending more on R&D, more on marketing and it will allow us to do tuck-in acquisitions based on the cash generation. And so I think we're really opening up a new leg in the stool where we've got more levers available to us than we did 2 years ago. Two years ago, we were still hamstrung with debt and the converts and everything else. We didn't have really an ability to potentially manage, because as we all know, we're going to see some ups and downs in the rate of sales growth. We're going to continue to grow. We are going to have some periods where it will be a little bit slower, while we wait for the next new products to come through. I think we're feeling better and better that we're going to be able to deliver very strong earnings growth consistently, and in the periods when we're growing faster, we'll probably reinvest a little bit more into the periods that are slower. We may not have quite the accelerated investments in that time. So hopefully, that will start to give a little more of longer-term of what we're thinking about."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jack Meehan with Barclays.",9,"Our next question comes from Jack Meehan with Barclays."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced, just what is the trajectory of that business look like ove",55,"I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced, just what is the trajectory of that business look like over the next maybe 3 to 6 quarters?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S., clearly hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their",199,"I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S., clearly hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their use of blood. So I think we're forecasting that the U.S. is a slight decliner. This quarter, our U.S. business was actually up fairly significantly in blood, that was more an inventory correction. But I think the way we're thinking about it is this is a low single-digit decliner. Internationally, I think we see the business very slight grower, but globally, I think because of the declines in the U.S., we think about blood screening as a flattish to slightly down business. And that's -- you go back to the headwinds we had as a company facing us a few years ago. It was blood, it was NovaSure, it was MyoSure -- I'm sorry, it was blood, NovaSure and ThinPrep. The 2 that we control the commercial channel, feel great about changing the long-term trajectory. I don't think we're quite as ready to declare a change in the trajectory of blood screening."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think the other thing that's important to note, Jack, there that this is a macro trend. We're not losing [indiscernible] contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think th",80,"And I think the other thing that's important to note, Jack, there that this is a macro trend. We're not losing [indiscernible] contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's important to say that we continue to feel good about continuing to secure the contracts that we have, and this is more a utilization factor as opposed to losing contracts to competitive."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it, that's helpful. And then just one on Panther, the incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a",56,"Got it, that's helpful. And then just one on Panther, the incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a driver has been in Europe? Any additional detail would be great."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we",115,"Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we realized if we can get a few more Panthers placed even in midsize accounts, hospital labs, other reference labs, that's going to benefit us as well. And frankly, Panther has a got a pretty good footprint, or OUS, but we would never really put the resources behind it. And so we are starting to place a few more internationally, especially in Europe right now."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Doug Schenkel with Cowen and Company.",11,"Our next question comes from Doug Schenkel with Cowen and Company."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02",74,"This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02 at the midpoint and this was despite this quarter. I guess, the question is are you changing any other operating investment or assumptions that would impact EPS growth?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about maki",116,"So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about making in both R&D and marketing in the second half of the year. And that's essentially the math that you should be able to walk through. We're expecting higher operating expenses in the second half as a result of the benefits that we're seeing in those to generate long-term sustainable growth, both in R&D and marketing. And so we're taking some of that benefit and reinvesting it in the business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Chris, the way I'd add to that is to think about group EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14 on top of 14. There's a point at which, you don't want to go too far because we're thinking abo",59,"Chris, the way I'd add to that is to think about group EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14 on top of 14. There's a point at which, you don't want to go too far because we're thinking about this over the long haul."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great, that's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?",41,"Great, that's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think, we probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we had ful",100,"You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think, we probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we had fully grasped. So I think it's is underlying consumption looks good, and I think we may have another quarter or so of a little bit of adjustment here and then probably be, as Eric has dug in deeper and deeper, we're getting better granularity, better visibility, and I think it's more of an inventory contraction issue."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout, and then I",91,"First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout, and then I guess, the second part to that question is the testing strategy here has been a little different than what we've seen historically, where it looks like we're doing region-by-region testing rather than the whole country. So love to hear your comments on those 2?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito",146,"Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito season. We don't yet know exactly how the market is going to play out. We've been through this script before with Dengue and West Nile, and not being quite sure. Clearly, it does look like there was a regionality to this, and we are prepared with various centers to be ready and responsive to what is needed to be done. And our primary focus initially is on blood screening. We are also, as part of the additional investment in second half, also looking on the Diagnostics side of it as well that would be further out time-wise."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible].",32,"Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible]."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No, it will be.",4,"No, it will be."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just about a 12 months turn around time on that, I guess.",12,"Just about a 12 months turn around time on that, I guess."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, sorry, Bill, just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year.",23,"Yes, sorry, Bill, just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Vijay Kumar with Evercore ISI.",10,"Our next question comes from Vijay Kumar with Evercore ISI."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, it comfort on sort of it just seems to be 3Q to 4Q seems to be slightly higher than norma",62,"I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, it comfort on sort of it just seems to be 3Q to 4Q seems to be slightly higher than normal sort of the Q-on-Q ramp."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big pie",118,"Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big piece of it, as well as the other businesses. So the impact of our new product launches, such as the Affirm biopsy, which had been built into our plan. Some of the growth in the NovaSure business, as you recall, that would be strong there. And then, we also have some royalty revenue that shows up in our molecular diagnostics business in the fourth quarter, again, which we had anticipated this year."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?",45,"Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figure that was actually a pretty good acquisition that we made, we're feeling pretty good about that. The teams are definitely look",185,"Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figure that was actually a pretty good acquisition that we made, we're feeling pretty good about that. The teams are definitely looking, and where Bob and Eric and I are now reviewing on a more regular basis, ideas, we also just looked in, and so we will not let it getting away. Ultimately, I look forward to the day that we've no converts left on the balance sheet, but I would suspect we would be doing some acquisitions along the way, while we're continuing to clean those up. So still in the way. At this point in time, still focusing with visions on what we call bite-size, things that supplement the existing businesses. And we're very willing and ready to go. But I would say, as Bob said in his script, nothing imminent. And I wouldn't even necessarily expect anything much in this fiscal year necessarily. So we thought mop up some shares, while the market gave us a nice opportunity."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Brian Weinstein with William Blair.",10,"Our next question comes from Brian Weinstein with William Blair."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, can you give me a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- there are sometimes in 2017, do you think it's a longer r",67,"Steve, can you give me a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- there are sometimes in 2017, do you think it's a longer ramp than that? Anything that you can help us triangulate on when you hit that plateau?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, it probably is '17, at some point in '17. And we've thought originally it would've been '18 or beyond. I think the success and the faster climb, we're getting to 35,000 feet faster. Probably a good year faster than what we would have imagined, but I",70,"Sure, it probably is '17, at some point in '17. And we've thought originally it would've been '18 or beyond. I think the success and the faster climb, we're getting to 35,000 feet faster. Probably a good year faster than what we would have imagined, but I think we will definitely be able to stay up there for a while. And then we're starting to think '17 is probably it."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay, that's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?",36,"Okay, that's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size of nature.",39,"Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size of nature."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Raj Denhoy with Jefferies Investments.",10,"Our next question comes from Raj Denhoy with Jefferies Investments."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In order if I could explore this idea, you guys are plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17 though, is the growth that you impl",106,"In order if I could explore this idea, you guys are plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17 though, is the growth that you implied for the back half of the year which is something in the 2% to 3% range really what we should think about for the business until you get to this next product cycle, whether it's in Diagnostic or otherwise? Is that how we should think about the business over the next 12 to 18 months or so?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where",101,"Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where we've been over the last 4, 5, 6 quarters, I think, just being pragmatic about it and that's part of the investments we're making today so that we know we can set ourselves up to continue to deliver frankly very healthy EPS growth even in what might be a slightly lower top line growth environment."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?",26,"But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're just not ready to get in the preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time.",39,"We're just not ready to get in the preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from David Lewis with Morgan Stanley.",10,"Our next question comes from David Lewis with Morgan Stanley."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's",49,"It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's driving that effect?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income tha",76,"Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income that shows up in the fourth quarter as well as the new product -- products like the Affirm prone biopsy table, that show up more in the fourth quarter than it do in the third quarter."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Understood. And just a follow-up, I guess, on the guidance surgical part on our NovaSure, I think yourself mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity fr",60,"Understood. And just a follow-up, I guess, on the guidance surgical part on our NovaSure, I think yourself mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here? And do you expect kind of pro rata share going forward or higher share going forward?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just with our surgical team this week and they are having a lot of success doing tremendous job on bo",87,"We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just with our surgical team this week and they are having a lot of success doing tremendous job on both NovaSure and MyoSure. It's clearly been one of the more positive upsides to the business again if you look over the last 2 years, where Surgical was and where it's going, we're feeling really good about the trajectory."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics",47,"But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Derik De Bruin with Bank of America.",12,"Our next question comes from Derik De Bruin with Bank of America."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from t",71,"So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from this? So could you just talk about, first of all, I guess, certainly share gains in the cytology market and then just on the primary testing situation?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best, I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the cy",68,"I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best, I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the cytology side and, frankly, on our HPV side. So we certainly don't see us losing share on HPV."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market.",16,"No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great, that's helpful. And just one quick follow-up, I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?",35,"Great, that's helpful. And just one quick follow-up, I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Fifth or sixth inning there in the U.S.?",9,"Fifth or sixth inning there in the U.S.?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In the U.S?",4,"In the U.S?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","In earlier innings OUS. We got to fill the capabilities outside the U.S.",13,"In earlier innings OUS. We got to fill the capabilities outside the U.S."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Rich Newitter with Leerink Partners.",10,"Our next question comes from Rich Newitter with Leerink Partners."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to make sure that I had the buckets right for the moving parts on your constant-currency guidance and what went up and what's kind of good and what's bad or incrementally good and incrementally bad? So it sounds like the blood screening reduce",176,"Just wanted to make sure that I had the buckets right for the moving parts on your constant-currency guidance and what went up and what's kind of good and what's bad or incrementally good and incrementally bad? So it sounds like the blood screening reduced outlook is, call it, maybe $10 million in the back half of the bad guy. You don't have FX, which is a good guy. If you could quantify that on some level or quantify each of these buckets that would be great? It sounds like you have a little bit better of an outlook in GYN, your competitor off the market, so maybe incrementally better there, and then you also have the new MyoSure product plus a third bucket, that's a good guy. And then you said that you had a slightly weaker or more conservative OUS outlook, and I'd love to know just kind of where that factors in, in magnitude relative to the blood screening, which on my math is getting me to about $10 million incremental weakness?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're probably not going to give it. We'll hold that level of detail.",14,"We're probably not going to give it. We'll hold that level of detail."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Because no matter what we do, we'll be wrong [indiscernible].",10,"Because no matter what we do, we'll be wrong [indiscernible]."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have about a little over 1/3 of our international business is actually based in U.S. dollars. The other piec",88,"Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have about a little over 1/3 of our international business is actually based in U.S. dollars. The other piece is the CF recall and market withdrawal that we mentioned before which is -- we mentioned that, that's a $10 million annual business. So think about that as roughly a $5 million headwind in the back half of the year."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And just the weaker OUS kind of or more conservative OUS outlook, is that from blood screening? Or is that part of that?",24,"Okay. And just the weaker OUS kind of or more conservative OUS outlook, is that from blood screening? Or is that part of that?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a little different, but it's not that much. It's small. You captured the other big pieces.",18,"Yes. It's a little different, but it's not that much. It's small. You captured the other big pieces."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Jon Block with Stifel.",10,"And our next question comes from Jon Block with Stifel."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe the first one for you and I get on the airplane analogies, but at the end of the day we're still at tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you've had filling the 2D [indiscernible] mas",101,"Maybe the first one for you and I get on the airplane analogies, but at the end of the day we're still at tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you've had filling the 2D [indiscernible] massive inflection point and so I get that tough comps and maybe wanting to plateau than the cliff, but can you just talk to why the 2017 growth plateau in tomo would gain arguably when I took back at least at the last product cycle that's really where you saw the incremental penetrations are to take off?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we",161,"I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we're not totally sure. The dynamics are different than they were at that point in time from both a competitive set, as well as where hospitals stand and everything else. We do think there is probably some upside in private sector insurance, that will continue to kick in as it plays out. And I think it's why we still feel really good about where it's going. But I think pragmatically, we're picturing it as less of this incredible spike and probably just reaching kind of a new level where it's continuing to increase slightly for a while, but not the 20% growth rates that we were getting for a few quarters in a row."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. Perfect, and then just one more is a little bit more granular, but international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters, and then just at a higher level, can you talk about what you're seeing wi",75,"Got it. Perfect, and then just one more is a little bit more granular, but international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters, and then just at a higher level, can you talk about what you're seeing with international molecular? And you've got the viral load assays over there. Are you seeing that help sort of gain market share on the heels of some of those approvals?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, as a backdrop, remember our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably i",213,"Yes, as a backdrop, remember our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably is taking a little more of an opportunity. Still some fluctuations in some of the other smaller markets around the world, but I think what we expect over time is we're placing -- we actually have started to really replacing Panthers in Europe. I think we'll see that as Europe [indiscernible] beachhead for building out that international molecular business. It also should start to provide some steadier growth and a steadier foundation to the business to build out. Fundamentally, what we lacked in the company is a true foundational business for really any of our franchises outside of the U.S. We get sales here and there from certain tenders, but we haven't had the fundamental strength where you're starting each quarter knowing that you got a nice book of business that's automatically coming in. Even in the old days, we used to sell the Panthers instead of [indiscernible] rentals and things like that. So we're just trying to get a lot more disciplined to get a much healthier business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jayson Bedford with Raymond James.",10,"Our next question comes from Jayson Bedford with Raymond James."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there.",38,"Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside.",40,"We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","And then just to follow up on the international buildout, I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?",30,"And then just to follow up on the international buildout, I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We have quietly started to rebuild the team particularly in Europe late last year. That's when we brought the new molecular diagnostics leade",166,"I think we'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We have quietly started to rebuild the team particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. The new service leader was hired in the last quarter, our new Breast Health person over so. I think we feel pretty good about the team coming together by the end of this fiscal year and some of them are already hitting the ground and getting it. But it's definitely more of a '17, '18, '19 as we really get into the longer term planning, and we're really upsizing that team. We don't want just some quick wins for the sake of wins. We want it to be the enduring business because part of what we got the last couple of years was the occasional big win, but it didn't necessarily translate into ongoing business."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Mark Massaro with Canaccord Genuity.",10,"Our next question comes from Mark Massaro with Canaccord Genuity."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So you noted that you're closing the Bedford mass facility, can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?",37,"So you noted that you're closing the Bedford mass facility, can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?"
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through th",198,"I think starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through the financials for the quarter. Our absolute cost of goods is lower this year than last. So we are producing more product at less absolute money than last. And that's clearly a result of some of the procurement and productivity initiatives that Mike Kelly, our supply chain leader, put in place under Bob McMahon's guidance and a lot help from their confidence well. The Bedford facility will be closing later this year. Candidly, it is going to have a fairly minimal impact on the true P&L because it is a leased facility and we are stuck with a bunch of lease cost and other stuff in there. But we're still just doing a lot of cleaning up through the company, and we've consistently said we've made a lot of progress in the last couple of years, and there's still a lot of opportunity ahead to be better on so many fronts."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think that wraps it up.",7,"And I think that wraps it up."
108544,329827217,965179,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",54,"Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] 
I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Offi",198,"Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks, then we'll have a question-and-answer session. Our second quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through May 27. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our",1801,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our business model was evident on 3 levels in the quarter. First, our U.S. businesses grew revenue at a low double-digit rate, continuing a recent pattern of outstanding commercial execution. Second, we again improved both gross and operating margins, while making significant investments in our future. And third, we entered a new phase of our capital allocation strategy by repurchasing our common stock, while continuing to pay down our convertible notes. Together, these strategic actions drove EPS growth more than double the rate of sales. More specifically, domestic revenue increased 10.6% in the quarter, led by strong performances by our Breast Health and Surgical businesses. International sales were lower, mainly due to expected declines in blood screening and the discontinued products we discussed in our initial guidance. But international Breast Health showed signs of stabilization, which I'll discuss in a moment. 
Globally, total revenues grew 5.8% on a reported basis or 6.3% in constant-currency terms. And if we were to exclude the headwind from discontinued products, second quarter revenue would have increased more than 7% in constant-currency. Non-GAAP gross margin was 65.8% in the quarter, a significant improvement of 240 basis points compared to the prior year period. We reinvested much of this incremental profitability for future growth and will continue to do so in the future, but still increased non-GAAP operating margin to 33.9% in the quarter, 40 basis points higher than last year. At the same time, our strong cash flows enabled us to be opportunistic in buying back our common stock, as well as our convertible debt to continue improving our capital structure and to enhance future earnings power. Bob will cover the details in a moment, but net income represented a very robust 19.6% of sales and grew 14.1%, while non-GAAP EPS totaled $0.47, up 14.6% compared to the prior year. 
With that introduction and overview out of the way, I'd like to cover 5 subjects in my comments today. The first 2 have been topical over the last quarter, our domestic and international Breast Health businesses, and obviously, these franchises will continue to be important to our future as well. But as we write new chapters in the Hologic story, the discourse is broadening as we build on our successes and add new strategic tools. With that in mind, today I'd like to highlight our Surgical business, gross margin improvement opportunities and the research and development pipeline. Hopefully, this discussion will provide a little incremental color into the multiple levers we can pull to generate sustainable revenue and earnings growth over time. 
Let's start with our domestic Breast Health business, which grew a very solid 11.2% based on continued adoption of our Genius 3D Mammography systems. Genius placements were strong, increasing both sequentially and year-over-year, and we saw a good increase in service revenue as well. We continue to gain market share, and our investments in customer marketing are enabling us to do that, while maintaining stable prices amid fierce competition. As a result, domestic imaging sales grew at a healthy mid-teens rate. We believe we still have runway ahead of us as our 3D systems are only about 1/3 penetrated into our own installed base, and roughly 20% into the market as a whole. We remain confident in the long-term opportunity as customer interest and orders in-house remain high, and as clinical evidence continues to mount on the benefits of Hologic's exams for patients and physicians. Specifically, a longitudinal study published in February in the peer-review journal, JAMA Oncology, showed that the benefits of our Genius exams, fewer recalls and improved cancer detection can be sustained and even improved over time with consecutive use. In addition, a separate study published just yesterday in JAMA showed that these benefits hold true for women with both dense and non-dense breasts, further bolstering the case for widespread adoption. 
Now let's turn to our international Breast Health business, which generated a lot of attention last quarter. While we still have a significant amount of work to do here, we do see signs of stabilization in the second quarter and are optimistic that we will see further signs of progress and predictability in the quarters ahead. While revenue declined by low single digits on a constant-currency basis in the second quarter, it's important to note that last year's results benefited from sales of products that we have since discontinued. If we back out this headwind, international Breast Health sales would have increased at a mid-single-digit rate in constant currency, a materially better performance than the decline we saw last quarter. As always, business improvement starts with people, and our Chief Operating Officer, Eric Compton, has made several important organizational changes internationally in recent months. We moved one of our key U.S. Breast Health leaders to Europe, and he is now in charge of building stronger, mutually productive relationships with our dealer network. Toward that end, we have signed several new performance-based contracts with our top dealers. In addition, we've hired a new European head of service, which we have identified as a critical role to support our dealers and direct customers. We also have brought on new leaders of marketing, molecular diagnostics, surgical and regulatory. So the team is coming together nicely. 
Now let me turn to those 3 new topics: Surgical, gross margins and R&D. Let's cover Surgical first. Global sales were $90.9 million in the quarter and grew 15.9% in constant currency. Surgical has exemplified the tremendous commercial turnaround that has occurred at Hologic, with the second quarter representing the fifth consecutive quarter of double-digit growth in the United States. It wasn't too long ago that surgical was viewed as a non-strategic asset that should be divested. Today, however, surgical is a vibrant business with strong profitability and cash flows plus good growth potential, and I couldn't be prouder of the team who has made it happen. Their formula for success has been straightforward: stabilization of our NovaSure franchise, which was declining at a high single-digit rate only a couple of years ago, combined with excellent growth from our MyoSure products for uterine fibroid removal. We remain enthusiastic about the potential for MyoSure as we seek to expand the addressable market and replace older treatments. And now, with the market withdrawal of a competitor to NovaSure, we have an opportunity to drive material growth for that product as well. We believe that NovaSure sales benefited from the competitive recall by a few million dollars in the quarter, and we are investing in marketing and physician outreach programs to ensure that this continues for the balance of the year. 
The second topic I want to cover is our ability to improve gross margins. A year ago, we weren't overly bullish in this regard, but our operations team deserves a tremendous amount of credit for improving upon already strong profitability. To highlight what we've been able to achieve, in the second quarter  non-GAAP cost of goods sold for our products was lower in absolute terms than it was in the prior year period despite an increase in sales. This is far bigger than a mix shift story. It is reflecting tremendous work by our teams. To make this possible, new leadership has instituted productivity improvement targets for each of our plants, and local managers have responded with scores of specific projects. We are closing our Bedford facility, our former corporate headquarters, and moving the skeletal manufacturing that was done there to a contract manufacturer. And as we have discussed previously, we are doing a much better job of leveraging our corporate purchasing power across the business. 
The third area I want to discuss is our research and development pipeline, and it's important to begin with a bit of context. The unfortunate truth is that our R&D pipeline was weak, reflecting years of a growth by acquisition mindset. Too often, R&D spending was viewed as a plug in the income statement; the amount that was left over, while attempting to meet short-term financial goals. To reverse this mentality, we have been adding talent and rebuilding processes across the company to make R&D a driver of sustainable growth again. Although this process is far from complete, we are beginning to see the fruits of our labor. In diagnostics, for example, we now have a robust menu of molecular assays available on Panther in Europe, spanning women's health as well as virology. Recently, we have secured CE-marks for new tests for HIV-1, hepatitis C, hepatitis B and a sexually transmitted disease called Mycoplasma genitalium. In the United States, we are already the leader in women's health. We have filed the premarket approval application for our HIV viral load assay, and the PMA for our hepatitis C assay is scheduled to be submitted late this calendar year. Finally, our Panther Fusion platform, which will provide customers the flexibility to perform PCR testing in a single-unit-dose format, is on track to be introduced internationally next year. 
In Surgical, we are now in the process of launching a line extension called MyoSure Reach. MyoSure Reach increases clinical utility by providing surgeons access to polyps and fibroids in more areas of the uterus, and we believe it will play an important role in extending our leadership position in the field. Finally, in Breast Health, we are excited about 2 new biopsy products that will further build on our position as the innovative leader in the market. Our new 3D-enabled Affirm prone biopsy system was introduced in Europe in March and is being launched domestically now. Affirm represents the first real innovation in the biopsy space in roughly 20 years and leverages our growing installed base of Genius systems by enabling physicians to perform a more accurate biopsy using 3D technology. To further enhance our biopsy business, we expect to launch an entirely new biopsy tool named Brevera next year. Brevera has breakthrough potential as it allows real-time analysis of the biopsy sample, thereby vastly improving the patient experience. Stay tuned for more information on this. 
Before I turn the call over to Bob, let me conclude by saying that we are pleased with our second quarter financial results, which in some ways opened a new chapter in the Hologic story. As in recent quarters, our commercial teams generated robust growth in the United States. At the same time, we generated operating leverage through productivity improvements, while simultaneously investing for the future. And we boosted our bottom line performance by opportunistically deploying capital. All in all, a solid, well-rounded performance. 
Now I will hand the call over to Bob."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my rema",1863,"Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results and percentage changes will be on a year-over-year basis. Overall, we had a strong second quarter, with double-digit growth in the U.S. In addition, 3 of our 4 businesses demonstrated global growth in the quarter. Steve already discussed Breast Health and Surgical, so I will focus on Diagnostics and Skeletal. Diagnostics, our largest business, reported sales of $304.4 million in the second quarter, growing 3.2% in constant currency terms. We're pleased to report another positive quarter on our cytology and perinatal business, which generated $116.1 million in sales, growing 3.5% in constant currency. U.S. sales grew mid-single digits, which was by far our highest growth in several years, even with lingering headwinds from Pap interval expansion. 
Turning to the molecular diagnostics. We posted sales of $126.1 million, up 5.8% in constant currency. Domestic sales increased at a faster rate as our fully automated Panther system continues to accumulate new placements and competitive wins. In addition, utilization and sales of our assays for Trichomonas, HPV and chlamydia and gonorrhea continue to grow. Internationally, we had another solid quarter of Panther placements. This keeps us optimistic about our future growth potential in Europe, where we now have a full menu of women's health and viral load assays, as Steve mentioned. In blood screening, worldwide revenue of $62.2 million, decreased 2.4% in constant currency, as expected. While there were some geography shifts as our partner Grifols balanced inventory, the overall decline was mainly due to stronger ordering in the prior year period to support the rollout of our business with the Japanese Red Cross. We do continue to see, however, trends towards lower blood utilization worldwide, and therefore, anticipate that quarterly blood screening sales will settle in the mid-$50 million range as the market and customer usage patterns mature. 
In Skeletal Health, we had $22.2 million in global sales, a decline of 8.2% in constant currency. Domestically, sales increased at a low single-digit rate, but international sales were negatively affected by distributor ordering patterns. Because this business is so small, it is not uncommon to see these kinds of fluctuations, and we do expect that Skeletal will be a solid contributor to growth over time. 
Now let me switch gears and discuss operating expenses in the second quarter. Total expenses of $221.2 million increased 12.9%, mainly as a result of our continued investments in Breast Health and diagnostic marketing programs, along with the timing of R&D programs which we foreshadowed last quarter. This increase in spending, which will continue into the second half of the year, is planned and deliberate, and a key component of our strategy to generate long-term sustainable growth. Two factors contribute to our willingness to support these incremental investments. First, and most importantly, we see good returns on the specific projects we're pursuing. For example, our investments in consumer marketing for Genius are enabling us to gain market share, while maintaining stable price in the face of new competition. Second, we already have an industry-leading operating margin and have shown that we can and will increase this margin over time. But our goal is not to drive operating margins to unprecedented levels for our industry. Instead, we want to steadily improve them, while also investing appropriately in DCF-positive projects for long-term growth. At the same time, our goal is to allocate capital to enhance shareholder returns, and during the second quarter, we accelerated our efforts in this regard. For the last few years, our primary use of excess cash has been to pay down debt, and our longstanding goal of reducing net debt to 2.5x EBITDA by the end of 2017 remains in effect. As evidence of this, we spent $311.4 million in the second quarter to repurchase convertible notes with the principal value of $226.6 million. While our convertible debt totaled over $1.3 billion in principle less than 12 months ago, it is now down to $793.3 million, a reduction of more than $0.5 billion. And given the continuing strength of our cash flows, we are in a position to supplement debt reduction with opportunistic repurchases of our common stock. Specifically in the second quarter, we bought back 4.3 million shares of our stock for $148.8 million. While stock buybacks have always been part of our long-term plan, market weakness in the second quarter enabled us to pounce a little earlier than expected. These strategic actions enabled us to sequentially reduce our share count in the second quarter, the first time in a long while that our diluted share count declined. In fact, diluted shares outstanding of 288 million were basically flat compared to the prior year period, no longer diluting EPS growth. Specifically, non-GAAP EPS increased 14.6%, about 2.5x the rate of sales. 
Let me just emphasize that our debt reduction and buyback activities will not prohibit us from seeking out opportunities for tuck-in acquisitions. Our divisional business development teams are settling in, and while no transactions are imminent, we are actively evaluating opportunities across our businesses. 
Before I move on to guidance, let me cover a few other financial metrics from the second quarter. Improvements made to our balance sheet contributed to a total debt outstanding of $3.4 billion, a decrease of $534.1 million compared to a year ago, and net debt of $3.1 billion. Our leverage ratio, net debt over EBITDA, now stands at 3.1x. In the second quarter, adjusted EBITDA was $253.8 million, up 6.4% compared to the prior year period. In addition, our trailing 12-month EBITDA surpassed $1 billion this quarter, a nice milestone for the company. Our ability to generate strong profits, while lowering debt, has again allowed us to increase return on invested capital. As our second fiscal quarter, ROIC was 11.7% on a trailing 12-month basis, 170 basis point improvement over the prior year. 
Finally, let's turn to our updated non-GAAP financial guidance for the full year and third quarter. Starting with the full year, we are raising the low end of our revenue guidance by $10 million to reflect the solid performance in the first half of the year. We now expect reported revenue of $2.81 billion to $2.83 billion in fiscal 2016, representing reported growth of 3.9% to 4.6%. Based on recent exchange rates, this equates to constant currency growth of between 4.6% and 5.4%. Compared to our last guidance, there are a few puts and takes related to revenue. On the positive side, the market withdrawal of a competing surgical products should provide a tailwind to NovaSure, and the dollar has weakened slightly. The currency benefit for us is less than you might expect, however, since much of the dollar weakening has been relative to the Japanese yen and other currencies where we have minimal exposure. 
In terms of headwinds, we are more cautious on near-term blood screening revenue given macro trends in the market, and we've derisked our international forecast slightly. I should also mention we have made a voluntary decision to stop selling CF InPlex, our test for cystic fibrosis, due to manufacturing quality issues at a key component supplier that recently resulted in a recall. This will represent a headwind of several million dollars to our U.S. molecular diagnostics revenue in the second half of the year, but shouldn't have much effect on margins. 
In terms of earnings for the full year, we now expect EPS of between $1.89 and $1.91, which translates to reported growth between 13.2% and 14.4%, or constant currency growth of 14.6% to 15.8%. This is based on an effective tax rate of approximately 33% and diluted shares outstanding of roughly $292 million for the full year. As you work through your models, you will see that our increased EPS guidance implies a healthy expansion of already industry-leading operating margins, while accommodating increased investment. Specifically, we intend to continue investing behind our Genius campaign in Breast Health and cervical cancer co-testing in Diagnostics. We will aggressively fund commercial activities to launch important new products, such as our Affirm prone biopsy system, and capitalize on the competitive investment environment surrounding NovaSure. We also expect to make some key hires in our international business, which typically come in with initial sign-on costs for relocation and the like. And we are pursuing some entirely new R&D initiatives, such as developing a blood screening test for the Zika virus, while also seeking out opportunities to accelerate R&D time lines for existing initiatives; for example, by increasing the breadth of outside support. Not all of these investments are permanent in nature, but we do expect them to push operating expenses upward in the second half of the year. At the same time, however, our capital deployment activities are effectively offsetting the impact of these strategic investments on the bottom line. 
Now turning to guidance for the third quarter of fiscal 2016, we expect revenues of $695 million to $705 million. Compared to the prior year period, this range reflects a reported growth of 0.2% to 1.6% or 0.6% to 2% on a constant currency basis. As a reminder, these lower growth rates are due to a much tougher comparable in the prior year period when revenue jumped almost $40 million on a sequential basis. In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.47 to $0.48 in the third quarter. This represents continued strong growth of 9.3% to 11.6% on a reported basis or 10.1% to 12.4% in constant-currency terms. Our full year guidance obviously implies a sequential step up in the fourth quarter revenue. This is due to normal sequential business momentum that we expect, contributions from new product launches and the timing of some royalty revenue that is expected later this year. 
Before opening up the call for questions, I would like to reiterate that our view on the second quarter is one of a good multilevel execution. Revenue grew at a solid rate based on continued outperformance domestically and stabilization outside the United States. We improved already strong operating margins, while accommodating increased investment in key growth drivers. And our capital deployment activities helped to pay for these investments at the EPS line, while setting the stage for leveraged growth over the long term. 
Now that we're halfway through our fiscal year, we're optimistic about our full year forecast. We're anticipating solid mid-single-digit revenue growth in line with our original expectations as strength in the U.S. offsets the weakness we have seen internationally. We forecast solid expansion of operating margins, while simultaneously investing for the future, and we expect the acceleration of our capital redeployment activities to allow us to leverage operating gains all the way down to EPS, which should grow at a mid-teens rate. 
With that, I will ask the operator to open up the call for questions. 
Please limit your questions to one plus a related follow-up, then return to the queue. 
Operator, we are ready for the first question."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with the outlook in the ex-U.S. businesses, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out, and curious if you talk a little bit a",68,"I wanted to start with the outlook in the ex-U.S. businesses, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out, and curious if you talk a little bit about how the changes in the team will juxtapose with just the operating environment, just so we understand the guidance a little better?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I would say it's still very conservative near-term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 f",159,"Yes. I would say it's still very conservative near-term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 franchises across the geographies, and so what Eric is really doing and part of what precipitated the change is we need to really build out a team, not just get a team that was in place operating differently. And so Eric is really going out; we're already recruiting and bringing in different people, different leaders, but it's going to take -- that's going to be more a '17, '18 event. I think and really we're thinking about international as drivers in especially, frankly, '18, '19, '20 and not as focused on the near-term. So I think the near-term is pretty cautious and conservative, but it will be coming through right when we need it."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you've learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over",97,"Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you've learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over the last couple of quarters, but curious for an update there, especially if we put in context with the JAMA study earlier this week and then just what you're seeing in terms of how effectively your customers are able to get reimbursement and all that. Just an update on how that's going."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales e",263,"Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales efforts really dramatically accelerated that, and instead of a freight train, it definitely looked more like an airplane, I think, taking off. And you saw that especially as you know in our third quarter last year, we started really posting this 20% growth numbers. I think what we see is we still feel very good about the order trends and about, frankly, the biggest piece I think we're incredibly excited about is the way we're holding pricing. And the demand still looks very good. Having said that, we're going against obviously -- now as we go into this third quarter, we're going against the huge comps and therefore, again as we try to signal in July of last year, the absolute growth rates will probably be slower here for the U.S. Breast Health business, certainly as we go into the coming quarters. But I think still feeling really good that there's a lot of runway ahead. And I think when we talked to investors, I think people often think there's going to be a peak and then a huge trough. I think we're seeing it is probably what will be much more of a plateau, but as we hit a peak, there's still a lot of runway that should have us last for quite a while here."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Isaac, this is Bob, just to follow up on what Steve was saying,. The numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected a",70,"Isaac, this is Bob, just to follow up on what Steve was saying,. The numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected and also up versus prior year. So we feel continued -- good about our continued adoption in driving that business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jonathan Groberg with UBS.",9,"Our next question comes from Jonathan Groberg with UBS."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, there's 2 questions for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of t",131,"So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, there's 2 questions for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the key tests there, both in the U.S. and internationally? Because I think you specifically mentioned you had some pretty good uptake on the menu in Panther in Europe. 
Then two, if you could just clarify, Bob, on the cystic fibrosis tests that you're exiting. Are you exiting or is it just a recall or because of the recall, are you now exiting that business? And was that a few million dollars on an annual basis? Was that kind of going to be the headwind?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- a little larger than that on an annu",69,"Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- a little larger than that on an annual basis.  It was roughly a $10 million annual number, annual product. So we'll absorb that."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making su",116,"And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making sure we're not declaring victory until we start to string together a number of quarters. But I think we're starting to see some better Panther placements. We have a new leader on molecular business in Europe who actually came later last year. And so he's starting to get his traction and driving it. So I think, feeling pretty good about where that business should be going."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we continue to feel good about gaining share here in the U.S. as well, and across the major asset that we have.",25,"I think we continue to feel good about gaining share here in the U.S. as well, and across the major asset that we have."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We start breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets.",20,"We start breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?",26,"Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther.",35,"We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flatt",107,"If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flattened to modest growth. Molecular is looking good, and blood screening's probably a little bit behind. Blood screening --  and that's the one we don't control the commercial channel on -- we're seeing probably greater inventory reductions, certainly than what we expected at start of the year, and we are absorbing this based on the strength in the other parts of the business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Tycho Peterson with JPMorgan.",9,"Our next question comes from Tycho Peterson with JPMorgan."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, I wondering if you can maybe comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect",51,"Bob, I wondering if you can maybe comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect for gross margins going forward?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that. Roughly about 25% o",130,"So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that. Roughly about 25% of that improvement was due to geography and the rest being between product and productivity. And what I would say is it's probably equally split between those 2. And we feel good about our continued improvement there with the initiatives that Steve talked about across all of the functions of our business. Our operations teams are really executing well, and identifying opportunities to continue to improve efficiencies, and obviously, as our sales growth drives more units to the factory, that also helps as well."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then question for Steve. I know you get a lot of questions on managing kind of the tomo cliff. I'm just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, do you feel like yo",108,"Okay. And then question for Steve. I know you get a lot of questions on managing kind of the tomo cliff. I'm just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, do you feel like you've got enough of a line of sight that, that's going to be kind of a smooth transition? And if not, can you maybe just touch on capital deployment? I mean, you talked more about buybacks today, but how do you view the opportunity set, and do you need to rely on tuck-ins to effectively manage the tomo cliff when that comes?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Tycho. First of all, I'm going to try to sway you from using the word ""cliff"" because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D cur",525,"Sure, Tycho. First of all, I'm going to try to sway you from using the word ""cliff"" because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D curve and everything else, and by thinking about how we extend out and do some line extensions and other things, that's been a huge part of our focus to be able to have more of a plateau or a very soft decline in that segment of the business at some point of time as opposed to a real cliff. I think it's part of what we have coming, things in biopsy and, frankly, Pete Valenti is running that business for us. He has had a long good track record of being able to put even some singles and doubles on the board in addition to just the every 5 or 8 year home run that we've tended to have in this business. So I would tell you I'm feeling incrementally better. Every time Bob and I and Eric Compton are down meeting with that business on what's happening in their pipeline, and we'll talk more and more about that certainly in the coming quarters and years. But I think we're feeling better about being able to mitigate that. 
The other piece -- I just want to jump back even on your question on margin to Bob, because you know I was very adamant early on when I came. I was probably not expecting much margin expansion. This has been one of the very positive surprises to me, and I think the big piece that I want to be clear on is we're going to use a lot of this gross margin expansion to continue to invest into the business, which leads to the second part of your follow-up question there, which is as we go forward, we're certainly spending more on R&D, more on marketing and it will allow us to do tuck-in acquisitions based on the cash generation. And so I think we're really opening up a new leg in the stool where we've got more levers available to us than we did 2 years ago. Two years ago, we were so hamstrung with the debt and the converts and everything else, we didn't have really an ability to potentially manage, because as we all know, we're going to see some ups and downs in the rate of sales growth. We're going to continue to grow. We are going to have some periods where it will be a little bit slower, while we wait for the next new products to come through. I think we're feeling better and better that we're going to be able to deliver very strong earnings growth consistently. And in the periods when we're growing faster, we'll probably reinvest a little bit more into the periods that are slower. We may not have quite the accelerated investments in that time. So hopefully, that should start to give a little more of a longer-term view of what we're thinking about."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jack Meehan with Barclays.",9,"Our next question comes from Jack Meehan with Barclays."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced. Just what is the trajectory of that business look like ove",55,"I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced. Just what is the trajectory of that business look like over the next maybe 3 to 6 quarters?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S. -- clearly, hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit th",200,"I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S. -- clearly, hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their use of blood. So I think we're forecasting that the U.S. is a slight decliner. This quarter, our U.S. business was actually up fairly significantly in blood; that was more an inventory correction. But I think the way we're thinking about it is this is a low single-digit decliner. Internationally, I think we see the business very slight grower, but globally, I think because of the declines in the U.S., we think about blood screening as a flattish to slightly down business. And that's -- you go back to the headwinds we had as a company facing us a few years ago. It was blood, it was NovaSure, it was MyoSure -- I'm sorry, it was blood, NovaSure and ThinPrep. The 2 that we control the commercial channel feel great about changing the long-term trajectory. I don't think we're quite as ready to declare a change in the trajectory of blood screening."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think the other thing that's important to note, Jack, there that this is a macro trend. We are not losing the contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's import",81,"And I think the other thing that's important to note, Jack, there that this is a macro trend. We are not losing the contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's important to say that we continue to feel good about continuing to secure the contracts that we have, and this is more a utilization factor as opposed to losing contracts to competitive."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. And then just one on Panther. The incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a",56,"Got it. That's helpful. And then just one on Panther. The incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a driver has been in Europe? Any additional detail would be great."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we",114,"Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we realize if we can get a few more Panthers placed even in midsize accounts, hospital labs, other reference labs, that's going to benefit us as well. And frankly, Panther has a got a pretty good footprint, or OUS, but we never really put the resources behind it. And so we are starting to place a few more internationally, especially in Europe right now."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Doug Schenkel with Cowen and Company.",11,"Our next question comes from Doug Schenkel with Cowen and Company."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02",73,"This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02 at midpoint and this was despite this quarter. I guess, the question is: Are you changing any other operating investment or assumptions that would impact EPS growth?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about maki",116,"So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about making in both R&D and marketing in the second half of the year. And that's essentially the math that you should be able to walk through. We're expecting higher operating expenses in the second half as a result of the benefits that we're seeing in those to generate long-term sustainable growth, both in R&D and marketing. And so we're taking some of that benefit and reinvesting it in the business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Chris, the way I'd add to that is to think about group, EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14% on top of 14%. There's a point at which you don't want to go too far because we're thinking a",59,"Chris, the way I'd add to that is to think about group, EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14% on top of 14%. There's a point at which you don't want to go too far because we're thinking about this over the long haul."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?",41,"Great. That's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think we -- probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we fully",100,"You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think we -- probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we fully grasped. So I think its underlying consumption looks good, and I think we may have another quarter or so of a little bit of adjustment here and then probably be -- as Eric has dug in deeper and deeper, we're getting better granularity, better visibility, and I think it's more of an inventory contraction issue."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout. And then I",91,"First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout. And then I guess, the second part to that question is the testing strategy here has been a little different than what we've seen historically, where it looks like we're doing region-by-region testing rather than the whole country. So love to hear your comments on those two."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito",146,"Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito season. We don't yet know exactly how the market is going to play out. We've been through this script before with Dengue and West Nile, and not being quite sure. Clearly, it does look like there's a regionality to this, and we are prepared with the various centers to be ready and responsive to what is needed to be done. And our primary focus initially is on blood screening. We are also, as part of the additional investment in second half, also looking on the Diagnostics side of it as well that would be further out time-wise."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible].",32,"Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible]."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No. It will be.",4,"No. It will be."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just about a 12 month turnaround time on that, I guess.",11,"Just about a 12 month turnaround time on that, I guess."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Sorry, Bill. Just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year.",23,"Yes. Sorry, Bill. Just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Vijay Kumar with Evercore ISI.",10,"Our next question comes from Vijay Kumar with Evercore ISI."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, any comfort on sort of -- it just seems to be -- the 3Q to 4Q seems to be slightly higher",65,"I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, any comfort on sort of -- it just seems to be -- the 3Q to 4Q seems to be slightly higher than normal, sort of the Q-on-Q ramp."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big pie",118,"Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big piece of it, as well as the other businesses; so the impact of our new product launches, such as the Affirm biopsy, which had been built into our plan. Some of the growth in the NovaSure business, as you recall, that would be strong there. And then, we also have some royalty revenue that shows up in our molecular diagnostics business in the fourth quarter, again, which we had anticipated this year."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?",45,"Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figured that was actually a pretty good acquisition that we made; we're feeling pretty good about that. The teams are definitely loo",188,"Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figured that was actually a pretty good acquisition that we made; we're feeling pretty good about that. The teams are definitely looking, and where Bob and Eric and I are now reviewing on a more regular basis, ideas, we also just looked in -- and so we will not let it get in the way.  Ultimately, I look forward to the day that we have no converts left on the balance sheet, but I would suspect we'll be doing some acquisitions along the way, while we're continuing to clean those up. So still in the way. At this point in time, still focusing with visions on what we call bite-size, things that supplement the existing businesses. And we're very willing and ready to go. But I would say, as Bob said in his script, nothing imminent. And I wouldn't even necessarily expect anything much in this fiscal year necessarily. So we thought mop up some shares, while the market gave us a nice opportunity."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Brian Weinstein with William Blair.",10,"Our next question comes from Brian Weinstein with William Blair."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","See if we can get maybe a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- sometime in 2017?  Do you think it's a longer ramp than",67,"See if we can get maybe a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- sometime in 2017?  Do you think it's a longer ramp than that? Anything that you can help us triangulate on and when you hit that plateau?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It probably is '17, at some point in '17. And I would've thought originally it would've been '18 or beyond. I think the success and the faster climb -- we're getting to 35,000 feet faster, probably a good year faster than what we would have imagined",72,"Sure. It probably is '17, at some point in '17. And I would've thought originally it would've been '18 or beyond. I think the success and the faster climb -- we're getting to 35,000 feet faster, probably a good year faster than what we would have imagined, but I think we will definitely be able to stay up there for a while. And then I'm starting to think '17 is probably it."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. That's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?",36,"Okay. That's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size and nature.",39,"Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size and nature."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Raj Denhoy with Jefferies Investments.",10,"Our next question comes from Raj Denhoy with Jefferies Investments."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In order [ph] if I could explore this idea of you guys plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17, though, is the growth that you",107,"In order [ph] if I could explore this idea of you guys plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17, though, is the growth that you implied for the back half of the year, which is something in the 2% to 3% range, really what we should think about for the business until you get to this next product cycle, whether it's in Diagnostic or otherwise? Is that how we should think about the business over the next 12 to 18 months or so?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where",101,"Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where we've been over the last 4, 5, 6 quarters, I think, just being pragmatic about it and that's part of the investments we're making today so that we know we can set ourselves up to continue to deliver, frankly, very healthy EPS growth even in what might be a slightly lower top line growth environment."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?",26,"But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're just not ready to get in preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time.",38,"We're just not ready to get in preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from David Lewis with Morgan Stanley.",10,"Our next question comes from David Lewis with Morgan Stanley."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's",49,"It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's driving that effect?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income tha",76,"Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income that shows up in the fourth quarter as well as the new product -- products like the Affirm prone biopsy table, that show up more in the fourth quarter than they do in the third quarter."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Understood. And just a follow-up, I guess, on the guidance surgical part on NovaSure. I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here?",60,"Understood. And just a follow-up, I guess, on the guidance surgical part on NovaSure. I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here? And do you expect kind of pro rata share going forward or a higher share going forward?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just -- with our surgical team this week and they are having a lot of success doing tremendous job on",88,"We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just -- with our surgical team this week and they are having a lot of success doing tremendous job on both NovaSure and MyoSure. It's clearly been one of the more positive upsides to the business. Again, if you look over the last 2 years, where Surgical was and where it's going, we're feeling really good about the trajectory."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics",47,"But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Derik De Bruin with Bank of America.",12,"Our next question comes from Derik De Bruin with Bank of America."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from t",71,"So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from this. So could you just talk about, first of all, I guess, certainly share gains in the cytology market and then just on the primary testing situation?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best -- I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the",69,"I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best -- I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the cytology side and, frankly, on our HPV side. So we certainly don't see us losing share on HPV."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market.",16,"No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And just one quick follow-up.  I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?",35,"Great. That's helpful. And just one quick follow-up.  I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Fifth or sixth inning, Derik, in the U.S.",8,"Fifth or sixth inning, Derik, in the U.S."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In the U.S?",4,"In the U.S?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","In earlier innings OUS. In that advantage, we got to build the capabilities outside the U.S.",16,"In earlier innings OUS. In that advantage, we got to build the capabilities outside the U.S."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Rich Newitter with Leerink Partners.",10,"Our next question comes from Rich Newitter with Leerink Partners."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to make sure that I had the buckets right for the moving parts on your constant currency guidance and what went up and what's kind of good and what's bad -- or incrementally good and incrementally bad? So it sounds like the blood screening red",179,"Just wanted to make sure that I had the buckets right for the moving parts on your constant currency guidance and what went up and what's kind of good and what's bad -- or incrementally good and incrementally bad? So it sounds like the blood screening reduced outlook is, call it, maybe $10 million in the back half of the bad guy. You didn't have FX, which is a good guy. If you could quantify that on some level or quantify each of these buckets, that would be great.  It sounds like you have a little bit better of an outlook in GYN, your competitor off [ph] the market, so maybe incrementally better there, and then you also have the new MyoSure product, that's the third bucket;  That's a good guy. And then you said that you had a slightly weaker or more conservative OUS outlook. And I'd love to know just kind of where that factors in, in magnitude relative to the blood screening, which on my math is getting me to about $10 million incremental weakness?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're probably not going to give it. We'll hold that level of detail.",14,"We're probably not going to give it. We'll hold that level of detail."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Because no matter what we do, we'll be wrong [indiscernible].",10,"Because no matter what we do, we'll be wrong [indiscernible]."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have -- about a little over 1/3 of our international business is actually based in U.S. dollars. The other p",90,"Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have -- about a little over 1/3 of our international business is actually based in U.S. dollars. The other piece is the CF recall and market withdrawal that we mentioned before which is roughly -- we mentioned that, that's a $10 million annual business. So think about that as roughly a $5 million headwind in the back half of the year."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And just the weaker OUS kind of -- or more conservative OUS outlook, is that different from blood screening? Or is that part of that?",26,"Okay. And just the weaker OUS kind of -- or more conservative OUS outlook, is that different from blood screening? Or is that part of that?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a little different, but it's not that -- it's small. You captured the other big pieces.",18,"Yes. It's a little different, but it's not that -- it's small. You captured the other big pieces."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Jon Block with Stifel.",10,"And our next question comes from Jon Block with Stifel."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe the first one for you -- and I get all the airplane analogies -- but at the end of the day we're still in a tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you had, filmed [ph] the 2D at this m",107,"Maybe the first one for you -- and I get all the airplane analogies -- but at the end of the day we're still in a tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you had, filmed [ph] the 2D at this massive inflection point. And so I get the tough comps and maybe wanting to plateau than the cliff word, but can you just talk to why the 2017 growth plateau in tomo when, again, arguably when I look back at least at the last product cycle, that's really where you saw the incremental penetrations are to take off?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we",160,"I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we're not totally sure. The dynamics are different than they were at that point in time from both a competitive set, as well as where hospitals stand and everything else. We do think there is probably some upside from private sector insurance  that will continue to kick in as it plays out. And I think it's why we still feel really good about where it's going. But I think pragmatically, we're picturing as less of this incredible spike and probably just reaching kind of a new level where it's continuing to increase slightly for a while, but not the 20% growth rates that we were getting for a few quarters in a row."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. Perfect. And then just one more.  It's a little bit more granular. But international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters? And then just at a higher level, can you talk about what you're seein",75,"Got it. Perfect. And then just one more.  It's a little bit more granular. But international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters? And then just at a higher level, can you talk about what you're seeing with international molecular? And you've got the viral load assays over there. Are you seeing that help sort of gain market share on the heels of some of those approvals?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. As a backdrop, remember, our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably",215,"Yes. As a backdrop, remember, our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably is taking a little more of an opportunity; still some fluctuations in some of the other smaller markets around the world. But I think what we expect over time is we're placing -- we actually have started to really place some Panthers in Europe. I think we'll see that as Europe probably being the  beachhead for building out that international molecular business. It also should start to provide some steadier growth and a steadier foundation to the business to build out. Fundamentally, what we've lacked in the company is a true foundational business for really any of our franchises outside of the U.S. We get sales here and there from certain tenders, but we haven't had the fundamental strength where you're starting each quarter knowing you got a nice book of business that's automatically coming in. Even in the old days, we used to sell the Panthers instead of [indiscernible] rentals and things like that. So we're just trying to get a lot more disciplined to get a much healthier business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jayson Bedford with Raymond James.",10,"Our next question comes from Jayson Bedford with Raymond James."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there.",38,"Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside.",40,"We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","And then just to follow up on the international buildout.  I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?",30,"And then just to follow up on the international buildout.  I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We had quietly started to rebuild the team, particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. Th",164,"We'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We had quietly started to rebuild the team, particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. The new service leader was hired in the last quarter, our new Breast Health person over. So I think we feel pretty good about the team coming together by the end of this fiscal year and some of them are already hitting the ground and getting it. But it's definitely more of a '17, '18, '19 as we really get into the longer term planning, and we're really upsizing that team. We don't want just some quick wins for the sake of wins. We want it to be the enduring business because part of what we got the last couple of years was the occasional big win, but it didn't necessarily translate into ongoing business."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Mark Massaro with Canaccord Genuity.",10,"Our next question comes from Mark Massaro with Canaccord Genuity."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So you noted that you're closing the Bedford, Mass. facility. Can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?",37,"So you noted that you're closing the Bedford, Mass. facility. Can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?"
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think -- starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through",201,"I think -- starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through the financials for the quarter, our absolute cost of goods is lower this year than last. So we are producing more product at less absolute money than last. And that's clearly a result of some of the procurement and productivity initiatives that Mike Kelly, our supply chain leader, put in place under Bob McMahon's guidance and a lot of help from Eric Compton as well. The Bedford facility will be closing later this year. Candidly, it is going to have a fairly minimal impact on the true P&L because it is a leased facility and we are stuck with a bunch of lease costs and other stuff in there. But we're still just doing a lot of cleaning up through the company, and we've consistently said we've made a lot of progress in the last couple of years, and there's still a lot of opportunity ahead to be better on so many fronts."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think that wraps it up.",7,"And I think that wraps it up."
108544,329827217,965257,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",54,"Good afternoon, and welcome to the Hologic Inc. Second Quarter Fiscal 2016 Earnings Conference Call. My name is Renee, and I am your operator for today's call. Today's conference call is being recorded. [Operator Instructions] 
I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Offi",198,"Thank you, Renee. Good afternoon, and thanks for joining us for Hologic's Second Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks, then we'll have a question-and-answer session. Our second quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through May 27. 
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation from GAAP can be found in our earnings release. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our",1801,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the second quarter of fiscal 2016. We posted very good results overall, highlighted by 14.6% growth in non-GAAP earnings per share. The strength of our business model was evident on 3 levels in the quarter. First, our U.S. businesses grew revenue at a low double-digit rate, continuing a recent pattern of outstanding commercial execution. Second, we again improved both gross and operating margins, while making significant investments in our future. And third, we entered a new phase of our capital allocation strategy by repurchasing our common stock, while continuing to pay down our convertible notes. Together, these strategic actions drove EPS growth more than double the rate of sales. More specifically, domestic revenue increased 10.6% in the quarter, led by strong performances by our Breast Health and Surgical businesses. International sales were lower, mainly due to expected declines in blood screening and the discontinued products we discussed in our initial guidance. But international Breast Health showed signs of stabilization, which I'll discuss in a moment. 
Globally, total revenues grew 5.8% on a reported basis or 6.3% in constant-currency terms. And if we were to exclude the headwind from discontinued products, second quarter revenue would have increased more than 7% in constant-currency. Non-GAAP gross margin was 65.8% in the quarter, a significant improvement of 240 basis points compared to the prior year period. We reinvested much of this incremental profitability for future growth and will continue to do so in the future, but still increased non-GAAP operating margin to 33.9% in the quarter, 40 basis points higher than last year. At the same time, our strong cash flows enabled us to be opportunistic in buying back our common stock, as well as our convertible debt to continue improving our capital structure and to enhance future earnings power. Bob will cover the details in a moment, but net income represented a very robust 19.6% of sales and grew 14.1%, while non-GAAP EPS totaled $0.47, up 14.6% compared to the prior year. 
With that introduction and overview out of the way, I'd like to cover 5 subjects in my comments today. The first 2 have been topical over the last quarter, our domestic and international Breast Health businesses, and obviously, these franchises will continue to be important to our future as well. But as we write new chapters in the Hologic story, the discourse is broadening as we build on our successes and add new strategic tools. With that in mind, today I'd like to highlight our Surgical business, gross margin improvement opportunities and the research and development pipeline. Hopefully, this discussion will provide a little incremental color into the multiple levers we can pull to generate sustainable revenue and earnings growth over time. 
Let's start with our domestic Breast Health business, which grew a very solid 11.2% based on continued adoption of our Genius 3D Mammography systems. Genius placements were strong, increasing both sequentially and year-over-year, and we saw a good increase in service revenue as well. We continue to gain market share, and our investments in customer marketing are enabling us to do that, while maintaining stable prices amid fierce competition. As a result, domestic imaging sales grew at a healthy mid-teens rate. We believe we still have runway ahead of us as our 3D systems are only about 1/3 penetrated into our own installed base, and roughly 20% into the market as a whole. We remain confident in the long-term opportunity as customer interest and orders in-house remain high, and as clinical evidence continues to mount on the benefits of Hologic's exams for patients and physicians. Specifically, a longitudinal study published in February in the peer-review journal, JAMA Oncology, showed that the benefits of our Genius exams, fewer recalls and improved cancer detection can be sustained and even improved over time with consecutive use. In addition, a separate study published just yesterday in JAMA showed that these benefits hold true for women with both dense and non-dense breasts, further bolstering the case for widespread adoption. 
Now let's turn to our international Breast Health business, which generated a lot of attention last quarter. While we still have a significant amount of work to do here, we do see signs of stabilization in the second quarter and are optimistic that we will see further signs of progress and predictability in the quarters ahead. While revenue declined by low single digits on a constant-currency basis in the second quarter, it's important to note that last year's results benefited from sales of products that we have since discontinued. If we back out this headwind, international Breast Health sales would have increased at a mid-single-digit rate in constant currency, a materially better performance than the decline we saw last quarter. As always, business improvement starts with people, and our Chief Operating Officer, Eric Compton, has made several important organizational changes internationally in recent months. We moved one of our key U.S. Breast Health leaders to Europe, and he is now in charge of building stronger, mutually productive relationships with our dealer network. Toward that end, we have signed several new performance-based contracts with our top dealers. In addition, we've hired a new European head of service, which we have identified as a critical role to support our dealers and direct customers. We also have brought on new leaders of marketing, molecular diagnostics, surgical and regulatory. So the team is coming together nicely. 
Now let me turn to those 3 new topics: Surgical, gross margins and R&D. Let's cover Surgical first. Global sales were $90.9 million in the quarter and grew 15.9% in constant currency. Surgical has exemplified the tremendous commercial turnaround that has occurred at Hologic, with the second quarter representing the fifth consecutive quarter of double-digit growth in the United States. It wasn't too long ago that surgical was viewed as a non-strategic asset that should be divested. Today, however, surgical is a vibrant business with strong profitability and cash flows plus good growth potential, and I couldn't be prouder of the team who has made it happen. Their formula for success has been straightforward: stabilization of our NovaSure franchise, which was declining at a high single-digit rate only a couple of years ago, combined with excellent growth from our MyoSure products for uterine fibroid removal. We remain enthusiastic about the potential for MyoSure as we seek to expand the addressable market and replace older treatments. And now, with the market withdrawal of a competitor to NovaSure, we have an opportunity to drive material growth for that product as well. We believe that NovaSure sales benefited from the competitive recall by a few million dollars in the quarter, and we are investing in marketing and physician outreach programs to ensure that this continues for the balance of the year. 
The second topic I want to cover is our ability to improve gross margins. A year ago, we weren't overly bullish in this regard, but our operations team deserves a tremendous amount of credit for improving upon already strong profitability. To highlight what we've been able to achieve, in the second quarter non-GAAP cost of goods sold for our products was lower in absolute terms than it was in the prior year period despite an increase in sales. This is far bigger than a mix shift story. It is reflecting tremendous work by our teams. To make this possible, new leadership has instituted productivity improvement targets for each of our plants, and local managers have responded with scores of specific projects. We are closing our Bedford facility, our former corporate headquarters, and moving the skeletal manufacturing that was done there to a contract manufacturer. And as we have discussed previously, we are doing a much better job of leveraging our corporate purchasing power across the business. 
The third area I want to discuss is our research and development pipeline, and it's important to begin with a bit of context. The unfortunate truth is that our R&D pipeline was weak, reflecting years of a growth by acquisition mindset. Too often, R&D spending was viewed as a plug in the income statement; the amount that was left over, while attempting to meet short-term financial goals. To reverse this mentality, we have been adding talent and rebuilding processes across the company to make R&D a driver of sustainable growth again. Although this process is far from complete, we are beginning to see the fruits of our labor. In diagnostics, for example, we now have a robust menu of molecular assays available on Panther in Europe, spanning women's health as well as virology. Recently, we have secured CE-marks for new tests for HIV-1, hepatitis C, hepatitis B and a sexually transmitted disease called Mycoplasma genitalium. In the United States, we are already the leader in women's health. We have filed the premarket approval application for our HIV viral load assay, and the PMA for our hepatitis C assay is scheduled to be submitted late this calendar year. Finally, our Panther Fusion platform, which will provide customers the flexibility to perform PCR testing in a single-unit-dose format, is on track to be introduced internationally next year. 
In Surgical, we are now in the process of launching a line extension called MyoSure Reach. MyoSure Reach increases clinical utility by providing surgeons access to polyps and fibroids in more areas of the uterus, and we believe it will play an important role in extending our leadership position in the field. Finally, in Breast Health, we are excited about 2 new biopsy products that will further build on our position as the innovative leader in the market. Our new 3D-enabled Affirm prone biopsy system was introduced in Europe in March and is being launched domestically now. Affirm represents the first real innovation in the biopsy space in roughly 20 years and leverages our growing installed base of Genius systems by enabling physicians to perform a more accurate biopsy using 3D technology. To further enhance our biopsy business, we expect to launch an entirely new biopsy tool named Brevera next year. Brevera has breakthrough potential as it allows real-time analysis of the biopsy sample, thereby vastly improving the patient experience. Stay tuned for more information on this. 
Before I turn the call over to Bob, let me conclude by saying that we are pleased with our second quarter financial results, which in some ways opened a new chapter in the Hologic story. As in recent quarters, our commercial teams generated robust growth in the United States. At the same time, we generated operating leverage through productivity improvements, while simultaneously investing for the future. And we boosted our bottom line performance by opportunistically deploying capital. All in all, a solid, well-rounded performance. 
Now I will hand the call over to Bob."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my rema",1863,"Thank you, Steve, and good afternoon, everyone. In my remarks today, I am going to highlight our other divisional sales drivers, then some key financial metrics and then wrap up with our updated financial guidance for 2016. Unless otherwise noted, my remarks will focus on non-GAAP results and percentage changes will be on a year-over-year basis. Overall, we had a strong second quarter, with double-digit growth in the U.S. In addition, 3 of our 4 businesses demonstrated global growth in the quarter. Steve already discussed Breast Health and Surgical, so I will focus on Diagnostics and Skeletal. Diagnostics, our largest business, reported sales of $304.4 million in the second quarter, growing 3.2% in constant currency terms. We're pleased to report another positive quarter on our cytology and perinatal business, which generated $116.1 million in sales, growing 3.5% in constant currency. U.S. sales grew mid-single digits, which was by far our highest growth in several years, even with lingering headwinds from Pap interval expansion. 
Turning to the molecular diagnostics. We posted sales of $126.1 million, up 5.8% in constant currency. Domestic sales increased at a faster rate as our fully automated Panther system continues to accumulate new placements and competitive wins. In addition, utilization and sales of our assays for Trichomonas, HPV and chlamydia and gonorrhea continue to grow. Internationally, we had another solid quarter of Panther placements. This keeps us optimistic about our future growth potential in Europe, where we now have a full menu of women's health and viral load assays, as Steve mentioned. In blood screening, worldwide revenue of $62.2 million, decreased 2.4% in constant currency, as expected. While there were some geography shifts as our partner Grifols balanced inventory, the overall decline was mainly due to stronger ordering in the prior year period to support the rollout of our business with the Japanese Red Cross. We do continue to see, however, trends towards lower blood utilization worldwide, and therefore, anticipate that quarterly blood screening sales will settle in the mid-$50 million range as the market and customer usage patterns mature. 
In Skeletal Health, we had $22.2 million in global sales, a decline of 8.2% in constant currency. Domestically, sales increased at a low single-digit rate, but international sales were negatively affected by distributor ordering patterns. Because this business is so small, it is not uncommon to see these kinds of fluctuations, and we do expect that Skeletal will be a solid contributor to growth over time. 
Now let me switch gears and discuss operating expenses in the second quarter. Total expenses of $221.2 million increased 12.9%, mainly as a result of our continued investments in Breast Health and diagnostic marketing programs, along with the timing of R&D programs which we foreshadowed last quarter. This increase in spending, which will continue into the second half of the year, is planned and deliberate, and a key component of our strategy to generate long-term sustainable growth. Two factors contribute to our willingness to support these incremental investments. First, and most importantly, we see good returns on the specific projects we're pursuing. For example, our investments in consumer marketing for Genius are enabling us to gain market share, while maintaining stable price in the face of new competition. Second, we already have an industry-leading operating margin and have shown that we can and will increase this margin over time. But our goal is not to drive operating margins to unprecedented levels for our industry. Instead, we want to steadily improve them, while also investing appropriately in DCF-positive projects for long-term growth. At the same time, our goal is to allocate capital to enhance shareholder returns, and during the second quarter, we accelerated our efforts in this regard. For the last few years, our primary use of excess cash has been to pay down debt, and our longstanding goal of reducing net debt to 2.5x EBITDA by the end of 2017 remains in effect. As evidence of this, we spent $311.4 million in the second quarter to repurchase convertible notes with the principal value of $226.6 million. While our convertible debt totaled over $1.3 billion in principle less than 12 months ago, it is now down to $793.3 million, a reduction of more than $0.5 billion. And given the continuing strength of our cash flows, we are in a position to supplement debt reduction with opportunistic repurchases of our common stock. Specifically in the second quarter, we bought back 4.3 million shares of our stock for $148.8 million. While stock buybacks have always been part of our long-term plan, market weakness in the second quarter enabled us to pounce a little earlier than expected. These strategic actions enabled us to sequentially reduce our share count in the second quarter, the first time in a long while that our diluted share count declined. In fact, diluted shares outstanding of 288 million were basically flat compared to the prior year period, no longer diluting EPS growth. Specifically, non-GAAP EPS increased 14.6%, about 2.5x the rate of sales. 
Let me just emphasize that our debt reduction and buyback activities will not prohibit us from seeking out opportunities for tuck-in acquisitions. Our divisional business development teams are settling in, and while no transactions are imminent, we are actively evaluating opportunities across our businesses. 
Before I move on to guidance, let me cover a few other financial metrics from the second quarter. Improvements made to our balance sheet contributed to a total debt outstanding of $3.4 billion, a decrease of $534.1 million compared to a year ago, and net debt of $3.1 billion. Our leverage ratio, net debt over EBITDA, now stands at 3.1x. In the second quarter, adjusted EBITDA was $253.8 million, up 6.4% compared to the prior year period. In addition, our trailing 12-month EBITDA surpassed $1 billion this quarter, a nice milestone for the company. Our ability to generate strong profits, while lowering debt, has again allowed us to increase return on invested capital. As our second fiscal quarter, ROIC was 11.7% on a trailing 12-month basis, 170 basis point improvement over the prior year. 
Finally, let's turn to our updated non-GAAP financial guidance for the full year and third quarter. Starting with the full year, we are raising the low end of our revenue guidance by $10 million to reflect the solid performance in the first half of the year. We now expect reported revenue of $2.81 billion to $2.83 billion in fiscal 2016, representing reported growth of 3.9% to 4.6%. Based on recent exchange rates, this equates to constant currency growth of between 4.6% and 5.4%. Compared to our last guidance, there are a few puts and takes related to revenue. On the positive side, the market withdrawal of a competing surgical products should provide a tailwind to NovaSure, and the dollar has weakened slightly. The currency benefit for us is less than you might expect, however, since much of the dollar weakening has been relative to the Japanese yen and other currencies where we have minimal exposure. 
In terms of headwinds, we are more cautious on near-term blood screening revenue given macro trends in the market, and we've derisked our international forecast slightly. I should also mention we have made a voluntary decision to stop selling CF InPlex, our test for cystic fibrosis, due to manufacturing quality issues at a key component supplier that recently resulted in a recall. This will represent a headwind of several million dollars to our U.S. molecular diagnostics revenue in the second half of the year, but shouldn't have much effect on margins. 
In terms of earnings for the full year, we now expect EPS of between $1.89 and $1.91, which translates to reported growth between 13.2% and 14.4%, or constant currency growth of 14.6% to 15.8%. This is based on an effective tax rate of approximately 33% and diluted shares outstanding of roughly $292 million for the full year. As you work through your models, you will see that our increased EPS guidance implies a healthy expansion of already industry-leading operating margins, while accommodating increased investment. Specifically, we intend to continue investing behind our Genius campaign in Breast Health and cervical cancer co-testing in Diagnostics. We will aggressively fund commercial activities to launch important new products, such as our Affirm prone biopsy system, and capitalize on the competitive investment environment surrounding NovaSure. We also expect to make some key hires in our international business, which typically come in with initial sign-on costs for relocation and the like. And we are pursuing some entirely new R&D initiatives, such as developing a blood screening test for the Zika virus, while also seeking out opportunities to accelerate R&D time lines for existing initiatives; for example, by increasing the breadth of outside support. Not all of these investments are permanent in nature, but we do expect them to push operating expenses upward in the second half of the year. At the same time, however, our capital deployment activities are effectively offsetting the impact of these strategic investments on the bottom line. 
Now turning to guidance for the third quarter of fiscal 2016, we expect revenues of $695 million to $705 million. Compared to the prior year period, this range reflects a reported growth of 0.2% to 1.6% or 0.6% to 2% on a constant currency basis. As a reminder, these lower growth rates are due to a much tougher comparable in the prior year period when revenue jumped almost $40 million on a sequential basis. In terms of the bottom line, we forecast diluted non-GAAP earnings per share of $0.47 to $0.48 in the third quarter. This represents continued strong growth of 9.3% to 11.6% on a reported basis or 10.1% to 12.4% in constant-currency terms. Our full year guidance obviously implies a sequential step up in the fourth quarter revenue. This is due to normal sequential business momentum that we expect, contributions from new product launches and the timing of some royalty revenue that is expected later this year. 
Before opening up the call for questions, I would like to reiterate that our view on the second quarter is one of a good multilevel execution. Revenue grew at a solid rate based on continued outperformance domestically and stabilization outside the United States. We improved already strong operating margins, while accommodating increased investment in key growth drivers. And our capital deployment activities helped to pay for these investments at the EPS line, while setting the stage for leveraged growth over the long term. 
Now that we're halfway through our fiscal year, we're optimistic about our full year forecast. We're anticipating solid mid-single-digit revenue growth in line with our original expectations as strength in the U.S. offsets the weakness we have seen internationally. We forecast solid expansion of operating margins, while simultaneously investing for the future, and we expect the acceleration of our capital redeployment activities to allow us to leverage operating gains all the way down to EPS, which should grow at a mid-teens rate. 
With that, I will ask the operator to open up the call for questions. 
Please limit your questions to one plus a related follow-up, then return to the queue. 
Operator, we are ready for the first question."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Isaac Ro with Goldman Sachs."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with the outlook in the ex-U.S. businesses, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out, and curious if you talk a little bit a",68,"I wanted to start with the outlook in the ex-U.S. businesses, specifically understand kind of what's embedded in your outlook for this quarter? You've obviously made some changes to the team there as you pointed out, and curious if you talk a little bit about how the changes in the team will juxtapose with just the operating environment, just so we understand the guidance a little better?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I would say it's still very conservative near term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 f",162,"Yes. I would say it's still very conservative near term. And I think, as we started to signal about this time last year, the deeper we've dug in international, international, for context, is really much more of a start-up than a turnaround. We got our 3 franchises across the geographies, and so what Eric is really doing and part of what precipitated the change is we need to really build out a team, not just get a team that was in place operating differently. And so Eric is really going out; we're already recruiting and bringing in different people, different leaders, but it's going to take -- that's going to be more a '17, '18 event. I think and really we're thinking about international as drivers in especially, frankly, '18, '19, '20 and not as focused on the near term. So I think the near term is pretty cautious and conservative, but it will be coming through right when we need it."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you've learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over",97,"Got it. That's helpful. Maybe second question would be on tomosynthesis. Just curious if you could update us on what you've learned about the nature of the product cycle here in terms of the pace and magnitude of adoption. You've given us some color over the last couple of quarters, but curious for an update there, especially if we put in context with the JAMA study earlier this week and then just what you're seeing in terms of how effectively your customers are able to get reimbursement and all that. Just an update on how that's going."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales e",263,"Sure, Isaac. I think -- if you go back 2 years, and I described it at that time that we probably saw it building as a freight train, clearly, I think the combination of better reimbursement and especially our consumer marketing efforts and our own sales efforts really dramatically accelerated that, and instead of a freight train, it definitely looked more like an airplane, I think, taking off. And you saw that especially as you know in our third quarter last year, we started really posting this 20% growth numbers. I think what we see is we still feel very good about the order trends and about, frankly, the biggest piece I think we're incredibly excited about is the way we're holding pricing. And the demand still looks very good. Having said that, we're going against obviously -- now as we go into this third quarter, we're going against the huge comps and therefore, again as we try to signal in July of last year, the absolute growth rates will probably be slower here for the U.S. Breast Health business, certainly as we go into the coming quarters. But I think still feeling really good that there's a lot of runway ahead. And I think when we talked to investors, I think people often think there's going to be a peak and then a huge trough. I think we're seeing it is probably what will be much more of a plateau, but as we hit a peak, there's still a lot of runway that should have us last for quite a while here."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Isaac, this is Bob, just to follow up on what Steve was saying,. The numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected a",70,"Isaac, this is Bob, just to follow up on what Steve was saying,. The numbers where we expected them to be and what I would say is also in terms of the placements, while we're not going to give out a specific number, it was up sequentially as we expected and also up versus prior year. So we feel continued -- good about our continued adoption in driving that business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jonathan Groberg with UBS.",9,"Our next question comes from Jonathan Groberg with UBS."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, there's 2 questions for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of t",131,"So congratulations on a solid quarter and on hitting on a lot of these important themes. I guess, there's 2 questions for me, both on the molecular diagnostics front. One, can you maybe talk about x blood screening, kind of what you're seeing in some of the key tests there, both in the U.S. and internationally? Because I think you specifically mentioned you had some pretty good uptake on the menu in Panther in Europe. 
Then two, if you could just clarify, Bob, on the cystic fibrosis tests that you're exiting. Are you exiting or is it just a recall or because of the recall, are you now exiting that business? And was that a few million dollars on an annual basis? Was that kind of going to be the headwind?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- a little larger than that on an annu",69,"Actually, it's going to be few -- we are exiting it -- I'll take your second question first on the CF. We are exiting it permanently, and it will be a few million just in the second half of the year. So it'd be more -- a little larger than that on an annual basis. It was roughly a $10 million annual number, annual product. So we'll absorb that."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making su",116,"And then in terms of the other tests, I think we feel really good about the continued uptake of both the full menu in the U.S. and starting to see some encouraging signs on the uptake of the menu in Europe. But again, we want to be very careful, making sure we're not declaring victory until we start to string together a number of quarters. But I think we're starting to see some better Panther placements. We have a new leader on molecular business in Europe who actually came later last year. And so he's starting to get his traction and driving it. So I think, feeling pretty good about where that business should be going."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we continue to feel good about gaining share here in the U.S. as well, and across the major asset that we have.",25,"I think we continue to feel good about gaining share here in the U.S. as well, and across the major asset that we have."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We start breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets.",20,"We start breaking [indiscernible] trick all the things. We're seeing growth -- nice growth really across each of the assets."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?",26,"Could you just maybe comment on the annual consumable run rate? Is it increasing in Panther? Where are we at in terms of the annual utilization?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther.",35,"We spoke, Jonathan. We mentioned $170,000 on a worldwide basis last quarter, and it's actually increased from there this quarter. And the U.S. being higher than that in terms of the average sales per Panther."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flatt",107,"If I give you the highest level of how we're feeling about the Diagnostics business right now, we're incredibly thrilled with what ThinPrep is doing. Remember, that was a really ugly situation just a couple of years ago. That business is now clearly flattened to modest growth. Molecular is looking good, and blood screening's probably a little bit behind. Blood screening -- and that's the one we don't control the commercial channel on -- we're seeing probably greater inventory reductions, certainly than what we expected at start of the year, and we are absorbing this based on the strength in the other parts of the business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Tycho Peterson with JPMorgan.",9,"Our next question comes from Tycho Peterson with JPMorgan."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, I wondering if you can maybe comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect",51,"Bob, I wondering if you can maybe comment on gross margins. You guys were about 150 basis points of what we've been modeling. Just wondering how much of this is a function of mix versus maybe some of the operational improvements? And what should we expect for gross margins going forward?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that. Roughly about 25% o",130,"So we're not going to give a specific target on gross margin going forward, Tycho. But what I would say is it is an element of both geography mix, product mix and productivity. Actually, geography mix is the smallest component of that. Roughly about 25% of that improvement was due to geography and the rest being between product and productivity. And what I would say is it's probably equally split between those 2. And we feel good about our continued improvement there with the initiatives that Steve talked about across all of the functions of our business. Our operations teams are really executing well, and identifying opportunities to continue to improve efficiencies, and obviously, as our sales growth drives more units to the factory, that also helps as well."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then question for Steve. I know you get a lot of questions on managing kind of the tomo cliff. I'm just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, do you feel like yo",108,"Okay. And then question for Steve. I know you get a lot of questions on managing kind of the tomo cliff. I'm just wondering with the pipeline components you laid out today plus the service business which you guys continue to highlight, do you feel like you've got enough of a line of sight that, that's going to be kind of a smooth transition? And if not, can you maybe just touch on capital deployment? I mean, you talked more about buybacks today, but how do you view the opportunity set, and do you need to rely on tuck-ins to effectively manage the tomo cliff when that comes?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Tycho. First of all, I'm going to try to sway you from using the word ""cliff"" because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D cur",525,"Sure, Tycho. First of all, I'm going to try to sway you from using the word ""cliff"" because we have been working very hard to make sure that it won't be a cliff, and I say that in all seriousness. We have been very focused on what happened with the 2D curve and everything else, and by thinking about how we extend out and do some line extensions and other things, that's been a huge part of our focus to be able to have more of a plateau or a very soft decline in that segment of the business at some point of time as opposed to a real cliff. I think it's part of what we have coming, things in biopsy and, frankly, Pete Valenti is running that business for us. He has had a long good track record of being able to put even some singles and doubles on the board in addition to just the every 5 or 8 year home run that we've tended to have in this business. So I would tell you I'm feeling incrementally better. Every time Bob and I and Eric Compton are down meeting with that business on what's happening in their pipeline, and we'll talk more and more about that certainly in the coming quarters and years. But I think we're feeling better about being able to mitigate that. 
The other piece -- I just want to jump back even on your question on margin to Bob, because you know I was very adamant early on when I came. I was probably not expecting much margin expansion. This has been one of the very positive surprises to me, and I think the big piece that I want to be clear on is we're going to use a lot of this gross margin expansion to continue to invest into the business, which leads to the second part of your follow-up question there, which is as we go forward, we're certainly spending more on R&D, more on marketing and it will allow us to do tuck-in acquisitions based on the cash generation. And so I think we're really opening up a new leg in the stool where we've got more levers available to us than we did 2 years ago. Two years ago, we were so hamstrung with the debt and the converts and everything else, we didn't have really an ability to potentially manage, because as we all know, we're going to see some ups and downs in the rate of sales growth. We're going to continue to grow. We are going to have some periods where it will be a little bit slower, while we wait for the next new products to come through. I think we're feeling better and better that we're going to be able to deliver very strong earnings growth consistently. And in the periods when we're growing faster, we'll probably reinvest a little bit more into the periods that are slower. We may not have quite the accelerated investments in that time. So hopefully, that should start to give a little more of a longer-term view of what we're thinking about."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jack Meehan with Barclays.",9,"Our next question comes from Jack Meehan with Barclays."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced. Just what is the trajectory of that business look like ove",55,"I just want to ask -- get a little bit more of granularity on the blood screening business and what you're seeing in the market today? And I think I caught a mid-$50 million number you referenced. Just what is the trajectory of that business look like over the next maybe 3 to 6 quarters?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S. -- clearly, hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit th",200,"I think it's going to be slightly down. I think if we look, Jack, at the global market, let's take it by U.S. The U.S. -- clearly, hospitals are getting better and better at managing their inventory at minimally invasive surgery, at being able to limit their use of blood. So I think we're forecasting that the U.S. is a slight decliner. This quarter, our U.S. business was actually up fairly significantly in blood; that was more an inventory correction. But I think the way we're thinking about it is this is a low single-digit decliner. Internationally, I think we see the business very slight grower, but globally, I think because of the declines in the U.S., we think about blood screening as a flattish to slightly down business. And that's -- you go back to the headwinds we had as a company facing us a few years ago. It was blood, it was NovaSure, it was MyoSure -- I'm sorry, it was blood, NovaSure and ThinPrep. The 2 that we control the commercial channel feel great about changing the long-term trajectory. I don't think we're quite as ready to declare a change in the trajectory of blood screening."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think the other thing that's important to note, Jack, there that this is a macro trend. We are not losing the contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's import",81,"And I think the other thing that's important to note, Jack, there that this is a macro trend. We are not losing the contracts. We have not lost any contracts. We are the market leader, so as the market goes, so goes our business. And I think that's important to say that we continue to feel good about continuing to secure the contracts that we have, and this is more a utilization factor as opposed to losing contracts to competitive."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. That's helpful. And then just one on Panther. The incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a",56,"Got it. That's helpful. And then just one on Panther. The incremental Panthers that you're placing in the field now, I'm just curious, what's the mix of the customers look like? Is it existing customers adding capacity? Is it new customers? How much of a driver has been in Europe? Any additional detail would be great."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we",114,"Yes. It's a bit of both in terms of existing and newer, and to some degree you're starting to go into some slightly smaller accounts. We penetrated most of the large ones, and part of this is we look at our menu for the future, and what we have coming we realize if we can get a few more Panthers placed even in midsize accounts, hospital labs, other reference labs, that's going to benefit us as well. And frankly, Panther has a got a pretty good footprint, or OUS, but we never really put the resources behind it. And so we are starting to place a few more internationally, especially in Europe right now."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Doug Schenkel with Cowen and Company.",11,"Our next question comes from Doug Schenkel with Cowen and Company."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02",73,"This is actually Chris on for Doug today. Bob, can you help us walk through the bridge for the EPS guidance? Our math suggests that just the share count reduction relative to the prior guidance should get you about $0.03 of benefit, increase EPS by $0.02 at midpoint and this was despite this quarter. I guess, the question is: Are you changing any other operating investment or assumptions that would impact EPS growth?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about maki",116,"So your math is very similar to our math. We calculate that the change in share count calculates about $0.03. We've raised the midpoint $0.02, and we talked about the increased investment that we plan to make in our -- are going to be delivered about making in both R&D and marketing in the second half of the year. And that's essentially the math that you should be able to walk through. We're expecting higher operating expenses in the second half as a result of the benefits that we're seeing in those to generate long-term sustainable growth, both in R&D and marketing. And so we're taking some of that benefit and reinvesting it in the business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Chris, the way I'd add to that is to think about group, EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14% on top of 14%. There's a point at which you don't want to go too far because we're thinking a",59,"Chris, the way I'd add to that is to think about group, EPS about 14-ish percent last year. At the high end of the range this year, it is going to be another 14% on top of 14%. There's a point at which you don't want to go too far because we're thinking about this over the long haul."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?",41,"Great. That's helpful. And hopefully, I'm right on this, but could you talk about the OUS cytology perinatal growth? It appears OUS growth for that business slowed on a sequential basis. Is this right and what was the cause of this?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think we -- probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we fully",100,"You're exactly right. I think we saw a little bit of inventory correction in China, primarily, and I think we -- probably with some distributor changes and everything else, there was a little more inventory probably in the channel there than what we fully grasped. So I think its underlying consumption looks good, and I think we may have another quarter or so of a little bit of adjustment here and then probably be -- as Eric has dug in deeper and deeper, we're getting better granularity, better visibility, and I think it's more of an inventory contraction issue."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout. And then I",91,"First question is timing around the Zika virus assay. I know you guys have one in development, and I know one of your competitors has introduced it in the Southern part of the country, but just kind of thinking about timing around that rollout. And then I guess, the second part to that question is the testing strategy here has been a little different than what we've seen historically, where it looks like we're doing region-by-region testing rather than the whole country. So love to hear your comments on those two."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito",146,"Sure, Bill. On the first part, we have been working very aggressively with both CDC and FDA on the topic, and we should have a blood screening product via I&D for use here in the coming months by early summer, certainly by the peak -- in time for mosquito season. We don't yet know exactly how the market is going to play out. We've been through this script before with Dengue and West Nile, and not being quite sure. Clearly, it does look like there's a regionality to this, and we are prepared with the various centers to be ready and responsive to what is needed to be done. And our primary focus initially is on blood screening. We are also, as part of the additional investment in second half, also looking on the Diagnostics side of it as well that would be further out time-wise."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible].",32,"Got it. And then just a real quick follow-up. The PMA that was filed on HIV viral load. I'm assuming that happened during the quarter. Can you give us any comment [indiscernible]."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No. It will be.",4,"No. It will be."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just about a 12 month turnaround time on that, I guess.",11,"Just about a 12 month turnaround time on that, I guess."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Sorry, Bill. Just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year.",23,"Yes. Sorry, Bill. Just to clarify. So HIV has been filed in recent months. For a PMA, you typically assume about a year."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Vijay Kumar with Evercore ISI.",10,"Our next question comes from Vijay Kumar with Evercore ISI."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, any comfort on sort of -- it just seems to be -- the 3Q to 4Q seems to be slightly higher",65,"I'll make sure I have a better one for you guys. Returning to the guidance, when you look at the 3Q to 4Q sort of the ramp, can you just explain to me, Steve or Bob, any comfort on sort of -- it just seems to be -- the 3Q to 4Q seems to be slightly higher than normal, sort of the Q-on-Q ramp."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big pie",118,"Vijay, this is Bob. Obviously, the sequential spike is greater when you're modeling at the top of the guidance range. So I would suggest that you model kind of to the midpoint. But it's driven by our confidence in sequential growth in 3D, that's a big piece of it, as well as the other businesses; so the impact of our new product launches, such as the Affirm biopsy, which had been built into our plan. Some of the growth in the NovaSure business, as you recall, that would be strong there. And then, we also have some royalty revenue that shows up in our molecular diagnostics business in the fourth quarter, again, which we had anticipated this year."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?",45,"Great. And maybe one big-picture question for, Steve, on cap deployment. I saw that you guys took out the converts in the Q. I'm just curious at what point do you feel, Steve, comfortable on maybe deploying capital for M&A versus lowering the debt load?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figured that was actually a pretty good acquisition that we made; we're feeling pretty good about that. The teams are definitely loo",188,"Yes. We're ready and willing to spend it on M&A, and actually, we did make an acquisition of our own stock in the quarter. Figured that was actually a pretty good acquisition that we made; we're feeling pretty good about that. The teams are definitely looking, and where Bob and Eric and I are now reviewing on a more regular basis, ideas, we also just looked in -- and so we will not let it get in the way. Ultimately, I look forward to the day that we have no converts left on the balance sheet, but I would suspect we'll be doing some acquisitions along the way, while we're continuing to clean those up. So still in the way. At this point in time, still focusing with visions on what we call bite-size, things that supplement the existing businesses. And we're very willing and ready to go. But I would say, as Bob said in his script, nothing imminent. And I wouldn't even necessarily expect anything much in this fiscal year necessarily. So we thought mop up some shares, while the market gave us a nice opportunity."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Brian Weinstein with William Blair.",10,"Our next question comes from Brian Weinstein with William Blair."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","See if we can get maybe a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- sometime in 2017? Do you think it's a longer ramp than t",67,"See if we can get maybe a little bit more granular on Genius? If we use the airplane analogy, when do you guys think that you would level off at 35,000 feet, in other words? Do you think you have -- sometime in 2017? Do you think it's a longer ramp than that? Anything that you can help us triangulate on and when you hit that plateau?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It probably is '17, at some point in '17. And I would've thought originally it would've been '18 or beyond. I think the success and the faster climb -- we're getting to 35,000 feet faster, probably a good year faster than what we would have imagined",72,"Sure. It probably is '17, at some point in '17. And I would've thought originally it would've been '18 or beyond. I think the success and the faster climb -- we're getting to 35,000 feet faster, probably a good year faster than what we would have imagined, but I think we will definitely be able to stay up there for a while. And then I'm starting to think '17 is probably it."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. That's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?",36,"Okay. That's helpful. And then on the repurchases, can you remind me, do you have anything in your covenants that restrict the repurchase amounts that you have, and what your current authorization is for share repurchases?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size and nature.",39,"Brian, this is Bob. We have currently an authorization for 250, so we roughly have about 100 million at the end of the quarter. There's nothing significant in our covenants that would prohibit anything of that size and nature."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Raj Denhoy with Jefferies Investments.",10,"Our next question comes from Raj Denhoy with Jefferies Investments."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In order [ph] if I could explore this idea of you guys plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17, though, is the growth that you",107,"In order [ph] if I could explore this idea of you guys plateauing a bit in tomo. The guidance you gave for the third quarter as well as the fourth quarter sort of implies that it's happening, right. When we think about '17, though, is the growth that you implied for the back half of the year, which is something in the 2% to 3% range, really what we should think about for the business until you get to this next product cycle, whether it's in Diagnostic or otherwise? Is that how we should think about the business over the next 12 to 18 months or so?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where",101,"Sure, Raj. I think first off, we're not quite plateaued yet. We're still implying some growth in the final couple of quarters, but definitely much slower growth. And I do think we're preparing for a '17 that's going to be slower top line growth than where we've been over the last 4, 5, 6 quarters, I think, just being pragmatic about it and that's part of the investments we're making today so that we know we can set ourselves up to continue to deliver, frankly, very healthy EPS growth even in what might be a slightly lower top line growth environment."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?",26,"But is something in that sort of 3-ish percent range the way we should think about '17 for you guys from a revenue growth standpoint?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're just not ready to get in preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time.",38,"We're just not ready to get in preannouncing '17 guidance at this point, but it's certainly going to be lower than where it was, and probably not a horrible number to use at this point in time."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from David Lewis with Morgan Stanley.",10,"Our next question comes from David Lewis with Morgan Stanley."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's",49,"It's actually Scott in for David. Steve and Bob, I think guidance for this year implies comp adjusted stability into third quarter versus second quarter, and then kind of a sharp acceleration into the fourth quarter. Can you just give us an idea of what's driving that effect?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income tha",76,"Scott, in the fourth quarter, we talked about continued growth in 3D sequentially. We also have the benefit -- the continued benefit of some tailwinds around our NovaSure business with the competitive market withdrawal, and we have some royalty income that shows up in the fourth quarter as well as the new product -- products like the Affirm prone biopsy table, that show up more in the fourth quarter than they do in the third quarter."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Understood. And just a follow-up, I guess, on the guidance surgical part on NovaSure. I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here?",60,"Understood. And just a follow-up, I guess, on the guidance surgical part on NovaSure. I think you mentioned in your commentary earlier that the impact from the competitive recall was about $1 million to $2 million. Can you size the opportunity from here? And do you expect kind of pro rata share going forward or a higher share going forward?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just -- with our surgical team this week and they are having a lot of success doing tremendous job on",88,"We will always expect a higher share. We don't have a completely great handle on exactly what that number will be going forward. But I can tell you we're just -- with our surgical team this week and they are having a lot of success doing tremendous job on both NovaSure and MyoSure. It's clearly been one of the more positive upsides to the business. Again, if you look over the last 2 years, where Surgical was and where it's going, we're feeling really good about the trajectory."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics",47,"But there is -- that is one of the areas we're making incremental operating investments in to capture that. And so that's part of the second half in investments as well as the 3D Genius campaign and the co-testing in the marketing side on the Diagnostics business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Derik De Bruin with Bank of America.",12,"Our next question comes from Derik De Bruin with Bank of America."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from t",71,"So in HPV, one of your competitors mentioned they have seen some share gains in the U.S. on their primary testing assay. Can you sort of comment on that? I mean, obviously, your gains in cytology would suggest that you're co-testing isn't suffering from this. So could you just talk about, first of all, I guess, certainly share gains in the cytology market and then just on the primary testing situation?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best -- I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the",69,"I think we're feeling pretty good about -- ultimately, the science -- you know the science as well as many, probably some of the best -- I think the science is very much on our side on co-testing, and we feel very good about what we're seeing both on the cytology side and, frankly, on our HPV side. So we certainly don't see us losing share on HPV."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market.",16,"No. I would say both on HPV and ThinPrep, Derik, in the quarter, grew above market."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And just one quick follow-up. I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?",35,"Great. That's helpful. And just one quick follow-up. I guess, when you look at where you are in Panther placements versus the total addressable market, I mean, how far would you say is Panther penetrated?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Fifth or sixth inning, Derik, in the U.S.",8,"Fifth or sixth inning, Derik, in the U.S."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","In the U.S?",4,"In the U.S?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","In earlier innings OUS. In that advantage, we got to build the capabilities outside the U.S.",16,"In earlier innings OUS. In that advantage, we got to build the capabilities outside the U.S."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Rich Newitter with Leerink Partners.",10,"Our next question comes from Rich Newitter with Leerink Partners."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Just wanted to make sure that I had the buckets right for the moving parts on your constant currency guidance and what went up and what's kind of good and what's bad -- or incrementally good and incrementally bad? So it sounds like the blood screening red",179,"Just wanted to make sure that I had the buckets right for the moving parts on your constant currency guidance and what went up and what's kind of good and what's bad -- or incrementally good and incrementally bad? So it sounds like the blood screening reduced outlook is, call it, maybe $10 million in the back half of the bad guy. You didn't have FX, which is a good guy. If you could quantify that on some level or quantify each of these buckets, that would be great. It sounds like you have a little bit better of an outlook in GYN, your competitor off [ph] the market, so maybe incrementally better there, and then you also have the new MyoSure product, that's the third bucket; That's a good guy. And then you said that you had a slightly weaker or more conservative OUS outlook. And I'd love to know just kind of where that factors in, in magnitude relative to the blood screening, which on my math is getting me to about $10 million incremental weakness?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We're probably not going to give it. We'll hold that level of detail.",14,"We're probably not going to give it. We'll hold that level of detail."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Because no matter what we do, we'll be wrong [indiscernible].",10,"Because no matter what we do, we'll be wrong [indiscernible]."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have -- about a little over 1/3 of our international business is actually based in U.S. dollars. The other p",90,"Exactly. I think your numbers are not that far off. I would say the FX is probably a little smaller than you may estimate for others because we do have -- about a little over 1/3 of our international business is actually based in U.S. dollars. The other piece is the CF recall and market withdrawal that we mentioned before which is roughly -- we mentioned that, that's a $10 million annual business. So think about that as roughly a $5 million headwind in the back half of the year."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And just the weaker OUS kind of -- or more conservative OUS outlook, is that different from blood screening? Or is that part of that?",26,"Okay. And just the weaker OUS kind of -- or more conservative OUS outlook, is that different from blood screening? Or is that part of that?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. It's a little different, but it's not that -- it's small. You captured the other big pieces.",18,"Yes. It's a little different, but it's not that -- it's small. You captured the other big pieces."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Jon Block with Stifel.",10,"And our next question comes from Jon Block with Stifel."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe the first one for you -- and I get all the airplane analogies -- but at the end of the day we're still in a tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you had, filmed [ph] the 2D at this m",107,"Maybe the first one for you -- and I get all the airplane analogies -- but at the end of the day we're still in a tomo product cycle that's arguably 20% penetrated for the industry. [indiscernible] that's what sort of you had, filmed [ph] the 2D at this massive inflection point. And so I get the tough comps and maybe wanting to plateau than the cliff word, but can you just talk to why the 2017 growth plateau in tomo when, again, arguably when I look back at least at the last product cycle, that's really where you saw the incremental penetrations are to take off?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we",160,"I think if you really look -- I mean, we had such a positive inflection point in the third quarter last year. We are in that run up right now. I think we'd always rather be a little conservative on potentially preannounced -- the fundamental reality is we're not totally sure. The dynamics are different than they were at that point in time from both a competitive set, as well as where hospitals stand and everything else. We do think there is probably some upside from private sector insurance that will continue to kick in as it plays out. And I think it's why we still feel really good about where it's going. But I think pragmatically, we're picturing as less of this incredible spike and probably just reaching kind of a new level where it's continuing to increase slightly for a while, but not the 20% growth rates that we were getting for a few quarters in a row."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Got it. Perfect. And then just one more. It's a little bit more granular. But international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters? And then just at a higher level, can you talk about what you're seeing",75,"Got it. Perfect. And then just one more. It's a little bit more granular. But international molecular, I know it's small, but were the revenues up year-over-year like prior 2 quarters? And then just at a higher level, can you talk about what you're seeing with international molecular? And you've got the viral load assays over there. Are you seeing that help sort of gain market share on the heels of some of those approvals?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. As a backdrop, remember, our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably",215,"Yes. As a backdrop, remember, our international molecular business is still, frankly, way too small. So it was roughly flattish in the quarter. We're seeing some growth in Europe, and I think that's where we really want to see the growth. And it probably is taking a little more of an opportunity; still some fluctuations in some of the other smaller markets around the world. But I think what we expect over time is we're placing -- we actually have started to really place some Panthers in Europe. I think we'll see that as Europe probably being the beachhead for building out that international molecular business. It also should start to provide some steadier growth and a steadier foundation to the business to build out. Fundamentally, what we've lacked in the company is a true foundational business for really any of our franchises outside of the U.S. We get sales here and there from certain tenders, but we haven't had the fundamental strength where you're starting each quarter knowing you got a nice book of business that's automatically coming in. Even in the old days, we used to sell the Panthers instead of [indiscernible] rentals and things like that. So we're just trying to get a lot more disciplined to get a much healthier business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jayson Bedford with Raymond James.",10,"Our next question comes from Jayson Bedford with Raymond James."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there.",38,"Wanted to follow-up on the 3D discussion. Do you think the lack of widespread private payer coverage is impacting the uptake of 3D? I've noticed that you guys have become more aggressive on the marketing side there."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside.",40,"We don't think it's -- we feel pretty good about the uptick, and I think it's an incremental opportunity. I don't see -- we don't see it as a real barrier, but we see it probably as additional upside."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","And then just to follow up on the international buildout. I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?",30,"And then just to follow up on the international buildout. I realized that it's a long-term initiative, but when do you think, Steve, you'll have the team in place internationally?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","We'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We had quietly started to rebuild the team, particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. Th",164,"We'll have most of the team in place by the end of this fiscal year. And we've got a lot of the key team. We had quietly started to rebuild the team, particularly in Europe late last year. That's when we brought the new molecular diagnostics leader in. The new service leader was hired in the last quarter, our new Breast Health person over. So I think we feel pretty good about the team coming together by the end of this fiscal year and some of them are already hitting the ground and getting it. But it's definitely more of a '17, '18, '19 as we really get into the longer term planning, and we're really upsizing that team. We don't want just some quick wins for the sake of wins. We want it to be the enduring business because part of what we got the last couple of years was the occasional big win, but it didn't necessarily translate into ongoing business."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Mark Massaro with Canaccord Genuity.",10,"Our next question comes from Mark Massaro with Canaccord Genuity."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Analysts","So you noted that you're closing the Bedford, Mass. facility. Can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?",37,"So you noted that you're closing the Bedford, Mass. facility. Can you comment on timing and cost savings? And related to that, have you been able to realize any benefits related to optimizing your supply chain?"
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","I think -- starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through",201,"I think -- starting on the second part, optimizing the supply chain, you're clearly seeing it in our gross margin. I think the part that might have gotten missed in my script and that was the part that probably shocked me the most when I was going through the financials for the quarter, our absolute cost of goods is lower this year than last. So we are producing more product at less absolute money than last. And that's clearly a result of some of the procurement and productivity initiatives that Mike Kelly, our supply chain leader, put in place under Bob McMahon's guidance and a lot of help from Eric Compton as well. The Bedford facility will be closing later this year. Candidly, it is going to have a fairly minimal impact on the true P&L because it is a leased facility and we are stuck with a bunch of lease costs and other stuff in there. But we're still just doing a lot of cleaning up through the company, and we've consistently said we've made a lot of progress in the last couple of years, and there's still a lot of opportunity ahead to be better on so many fronts."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Executives","And I think that wraps it up.",7,"And I think that wraps it up."
108544,329827217,965927,"Hologic Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Second Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike W",52,"Good afternoon, and welcome to the Hologic Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial",202,"Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks today, then we'll have a question-and-answer session.
Our third quarter press release is available now on the Investor Relations of our website, and we also will post our prepared remarks to our website shortly after we deliver them today. Finally, replay of this call will be archived on our website through August 26.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release.
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from t",2327,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from turnaround story to sustainable growth company. 
Revenues of $717.4 million exceeded expectations as all 4 of our businesses grew on a global basis, despite a difficult comparison resulting from very strong results in the prior year period. 
In our last call, we focused on the emergence of our surgical business as a growth driver. This quarter, surgical lead the way with exceptional performance. But we're also pleased with how our breast imaging, molecular diagnostics and cytology businesses performed. And we made progress in strengthening our international franchises, which we believe will be important contributors to future growth.
Our performance this quarter highlighted the breadth of our top line growth drivers, which is often overlooked. Even as performance has improved ahead of schedule in many areas, new drivers are beginning to emerge, thanks to the deliberate and proactive efforts of our team. And while this quarter is only a single data point, our results do give us increased confidence that revenue growth can continue at a healthy pace in the future. 
Our third quarter results also demonstrated once again our ability to increase profitability above and beyond already high levels. We boosted both gross and the operating margins even while reinvesting aggressively to drive future growth. We've been pleasantly surprised that our ability to achieve productivity gains and enjoying many other levers to drive earnings growth.
For example, strategies that we had expected to play out over the longer term horizon are materializing sooner than expected. Various internal restructuring yielded a lower tax rate in the quarter. And the combination of strong cash flows and market volatility enabled us to buy back more shares. Together, all these efforts led to a very robust net margin of 20.2% in the quarter, non-GAAP earnings per share of $0.51 and excellent EPS growth of 18.6% on a non-GAAP basis.
Based on the strong earnings performance, we are raising our financial guidance for the year and now expect non-GAAP EPS of between $1.93 and $1.94. As a reminder, the mid-point of this new guidance is roughly $0.12 above our guidance at the beginning of our year. We're clearly exceeding our own expectations for sustainable bottom line growth and feel good about our future prospects in this regard as well.
With that introduction out of the way, I'd like to walk through our revenue highlights in the balance of my remarks, then Bob will discuss expenses, the rest of our financials and our updated guidance. Unless otherwise noted, percentage changes will be on a year-over-year basis. 
Starting with the big picture. Total revenues were $717.4 million in the third quarter, an increase of 3.4% on a reported basis or 3.6% in constant currency terms. These figures include a roughly $8 million headwind from divested and discontinued products, such as sentinel breast coils and the molecular test for cystic fibrosis. If we were to back out this headwind, total revenues would have been grown 4.8% in constant currency terms.
These growth rates are stacked on top of a very difficult comp from the prior year. As a reminder, in the third quarter of 2015, total revenues increased 12.2% in constant currency. So our ability to jump over a high bar this quarter gives us increasing confidence in the ability of our commercial organization to drive solid growth next year and beyond.
In terms of geography. U.S. sales grew 4.7% in the third quarter, continuing a string of good results and indicating the improvements we've made in commercial execution. We continued to enjoy strong leadership positions and good momentum in the domestic marketplace. 
International sales declined 1.2% on a reported basis, driven primarily by blood screening, as expected. In constant currency, international sales declined 0.4%, essentially flat. And if we were to normalize for divested and discontinued products, international sales would have increased slightly. It's also worth mentioning that international sales increased sequentially as well, an encouraging sign. 
Overall, we believe our international results in the third quarter show we are building a foundation for strong and consistent growth over time. Toward that end, our Chief Operating Officer, Eric Compton, has made good progress filling out our international leadership team in recent months. In last quarter's call, we highlighted new executives in charge of European Breast Health and Service, as well as marketing, molecular diagnostics, surgical and regulatory. More recently, we have added new geographic sales leaders to run Latin America, Canada and Asia Pacific. So our efforts to upgrade talent are coming together nicely. 
Shifting to the types of revenue we generate. I want to emphasize that for all the attention our mammography systems receive, capital equipment represented just 23.4% of revenue in the third quarter. Said another way, more than 76% of our sales were recurring. More specifically, disposables, such as our diagnostic assays and surgical tools, represented 60.4% of sales, while service and other totaled 16.2% of sales.
Now let me discuss divisional revenues in the third quarter. I'll start with the growth leader in the quarter, our GYN Surgical business. A couple of years ago, no one would have said those words in the same sentence. But today, our team has achieved what others thought impossible. Worldwide surgical sales were $102 million, surpassing $100 million on a quarterly basis for the first time. Sales grew 19.8% in constant currency, the fastest growth rate for this division in recent memory. 
In the United States, the team delivered double-digit growth for the sixth consecutive quarter. And internationally, the business grew by nearly 40%, albeit off of very small base. 
As many of you know, a competitor recently withdrew its endo mistral oblation product from the market. And to capitalize on this, we increased marketing and sales activities in the quarter. As a result, global sales for our NovaSure product totaled $61 million, an increase of 14.6% in constant currency. Not to be overlooked, sales of our MyoSure product for urine fibrin removal also continued to show strength. Global MyoSure sales of $40.8 million increased 29.8% in constant currency. 
Now let's turn to Breast Health, which has received a lot of attention in recent months. While this is understandable and appropriate, it's just as important to appreciate that Hologic is much more than a mammography company today. Hopefully, our results this quarter help illustrate that point and provide confidence that the entire company can continue to grow revenue solidly and EPS much faster even as growth from 3D adoption naturally slows.
We're very pleased with our Breast Health performance in the quarter. Global sales of $282.5 million increased 1.1%. Breast imaging sales totaled $239.3 million, up 2.3% in constant currency, driven by continued adoption of our Genius 3D Mammography systems. Domestic imaging sales grew more rapidly and exceeded our internal expectations based on Genius placements, which increased both sequentially and year-over-year. 
We estimate the Genius systems are continuing to gain market share while our investments in customer marketing help us maintain stable prices amid fierce competition. We still have lots to look forward to in Breast Health. Genius systems represent less than 40% of our own mammography installed base today and by our estimate, less than 25% of the market as a whole. And we remain confident in the long-term conversion opportunity as evidence continues to mount on the benefits of Hologic's Genius exams for patients and physicians and as we differentiate ourselves competitively.
As evidence of this, mammography customers recently surveyed by the independent market research firm KLAS scored Hologic highest in overall product satisfaction. One Director of radiology said, ""Hologic seems to be the only company that really understands the tomosynthesis market. It was clear from our implementation and our usage of this system that they are a full generation ahead of other vendors. Everybody else is playing catch-up."" This is only one anecdotal comment, but it's consistent with the customer feedback we receive every day and validates our leadership position. 
As our installed base Genius 3D systems grows, our sales and marketing programs are focusing on ways to leverage this leadership position. For example, service revenue is becoming increasingly important and represents an annuity that complements and smooths out our capital sales. Some of you may not appreciate the size of our service business in Breast Health. To frame it for you, service revenue in this business exceeded $100 million in the quarter for the first time and grew at a mid single-digit rate.
Similarly, we have revamped our research and development efforts to capitalize on our growing Genius footprint and generated more continuous stream of product innovations. For example, we recently launched our new Affirm prone biopsy system, which provides a better patient experience and enables doctors to capitalize on the increased sensitivity of 3D technology. Although it's still early days, customer feedback on this system has been positive, both in the United States and internationally.
Another component of future growth in Breast Health will be our international business. While we still have a lot of work to do here, we are making good progress and are optimistic that the business is becoming healthier and more predictable as we create the foundation for solid growth in 2017 and beyond. In the third quarter, international Breast Health sales declined 2.9% in constant currency. But if we back out the headwind from divested and discontinued price, sales would have been flat. And on a sequential basis, sales increased slightly.
With this in mind, I want to remind everyone that last year's international Breast Health number was exceptionally strong in the fourth quarter. And as a result, we anticipate a year-over-year decline in the coming quarter before the business returns to growth in 2017. As we move into 2017, we do believe that the combination of multiple tailwinds are still underpenetrated 3D opportunity, growing service revenue, a revitalized R&D effort and international expansion will enable Breast Health to be an important contributor to corporate growth.
Now let's cover diagnostics, which is our largest business and greatest source of non-GAAP operating profit. Diagnostics reported sales of $309.9 million in the third quarter, growing 1.2% in constant currency. Within diagnostics, our cytology and molecular businesses performed well while our blood screening business declined as expected. Global sales of cytology in perinatal products totaled $122.2 million, growing 3.9% on a constant currency basis. Breaking this down a little further, both our ThinPrep and retail fibronectin franchises grew in the United States and internationally despite lingering headwinds from Pap interval expansion domestically.
Turning to molecular diagnostics. We posted global sales of $131.8 million, up 6.0% in constant currency. Excluding sales of our discontinued cystic fibrosis product, molecular sales would have grown at a high single-digit rate. Our domestic business was solid as our fully automated Panther system continues to accumulate new placements and competitive wins and as utilization of our assays for Trichomonas, HPV and chlamydia gonorrhea continues to grow. 
But the real standout here was our international business. Over the last couple of quarters, international molecular sales have turned slightly positive under new leadership, and we had added viral load assays to the Panther menu. Building on this, the business took a significant step ahead in the third quarter with constant currency growth exceeding 20%. 
In addition, we had a record quarter of Panther placements outside the United States, coupled with a significant step-up in per instrument utilization. All these data points have us feeling good about the potential for international molecular diagnostics to become a new driver of growth for the company over time.
Shifting back to the United States for a moment. During the third quarter, we gained an emergency use authorization for our Zika virus test for diagnostic use. In addition, blood banks began testing donated blood for Zika with our Procleix under our investigation new drug protocol. While we do not expect significant sales from these 2 new products, both of which run on the Panther system, our ability to rapidly develop of these test shows we can react quickly to public health emergencies in close cooperation with regulators and customers. In addition, should the Zika virus spread in the United States, we will be well positioned in the marketplace.
Apart from the highlight of the Zika IND, our blood screening business declined in the quarter as expected. Worldwide sales of blood screening products were $55.9 million, down 12.9%, with all the decline coming outside the United States. As in the second quarter, this decline was mainly due to stronger ordering in the prior year period to support testing at the Japanese Red Cross combined with continued trends toward lower blood utilization.
Before I turn the call over to Bob, let me wrap up the review of product sales by mentioning that our Skeletal Health division posted revenues of $23.0 million in the quarter. This represented a constant currency increase of 4.8% with growth both domestically and overseas primarily driven by our horizon bone density standard.
So in conclusion, we are very pleased with our third quarter financial results and with the progress we've made toward building a sustainable growth company. Despite very challenging prior year comps, all 4 of our businesses grew in the quarter, reflecting the many growth drivers at our disposal. 
Sales growth in the U.S. Breast Health slowed to a challenging prior year comp, but remained healthy. At the same time, strong results in surgical, molecular diagnostics and cytology demonstrated that Hologic is much more than a mammography company. We continue to execute well in the United States and made good progress building a foundation for international growth. We once again expanded profit margins and redeployed capital, contributing to EPS growth at the highest rate in many years. 
Now I will hand the call over to Bob."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. As a reminder, I will",1498,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. 
As a reminder, I will focus on non-GAAP results and percentage changes will be on a year-over-year basis unless otherwise noted. As Steve discussed, our revenue performance in the third quarter exceeded expectations, highlighted by global growth in all 4 business segments. This growth, coupled with favorable product mix and productivity gains, again drove improvements in gross and operating margins. At the same time, we continue to invest in initiatives that position us for long-term sustainable growth. Net-net, we delivered EPS growth well in excess of sales, reflecting the impact of operational improvements, capital deployment and in lower effective tax rate.
Now let's dive deeper into the third quarter income statement. Gross margin of 65.7% increased 50 basis points and benefited from the growth of our surgical, cytology and perinatal and Aptima franchises. We continue to manage pricing well as we focus on commercial excellence and our marketing initiatives highlight the clinical and economic value of our products. 
In addition, our operations teams continue to drive efficiencies and reduce cost across our supply chains. Total operating expenses of $229.2 million increased 3.1% in the third quarter. This increase was driven primarily by sales and marketing expense, which increased 15.5%.
Given our gross margin expansion, we have invested deliberately and opportunistically in commercial areas where we see a good return. This include our Genius marketing campaign in Breast Health, our cervical cancer co-testing initiatives in Diagnostics and efforts to gain competitive market share with NovaSure. These strategic initiatives are paying off through increased brand awareness, market share gains and price stability, all of which contribute to higher sales.
Despite the increased sales and marketing spending, operating margins improved 60 basis points in the quarter, slightly more than gross margins based primarily on leverage in general and administrative expenses. 
Moving down the P&L. Interest expense of $33.9 million was 12% lower than in prior year, due to our efforts to both reduce and restructure our debt. And in addition, our tax rate is improving earlier than expected based on changes in our in comics an internal restructurings implemented this year and last. We know estimate that our effective tax rate will be around 32% for the full year 2016.
We chewed up to this rate in the third quarter, reducing our effective rate to 30.6%, but expect the rate to normalize back to 32% in the fourth quarter. As a reminder, our tax rate was 34.25% just last year. So we are making good progress.
We are pleased that these efforts have enabled us to grow net profits even faster than operating profit. Our net margin was 20.2% in the quarter, a very strong level and an improvement of 190 basis points over the prior year. 
To wrap up the income statement review, diluted shares outstanding were 282 million in the third quarter, roughly 10 million lower than a year ago. Over the course of this year, we have worked to pay down a portion of the in-the-money converts to reduce the dilutive effects. And more recently, we have taken advantage of market volatilities to repurchase our common stock. 
In the third quarter, we bought back 3 million shares of stock for $101.2 million, which exhausted our prior $250 million repurchase authorization. Recently, our Board of Directors has approved an additional $500 million repurchase program, and we're very pleased to have that arrow in our quiver going forward. 
While we're pleased with the progress we've made, thus far in improving our capital structure and achieving a more competitive tax rate compared to other med tech companies, we know we can continue to improve. And we believe these improvements will help us deliver EPS growth much faster than revenue over an extended period of time.
Now I'd like to highlight a few balance sheet and cash flow items, beginning with inventory. Inventory decreased by $14.5 million or 4.9% compared to a year ago despite a 3.4% increase in sales. This speaks to strong alignment between the operations and sales teams, who know that every dollar saved in inventory serves as dry powder for debt reduction, acquisitions or share repurchase. 
And speaking of our debt, at the end of the third quarter, total debt outstanding was $3.4 billion, a decrease of more than $0.5 billion from the year ago. During the quarter, we paid off $175 million that had been outstanding on our $1 billion revolving line of credit using proceeds borrowed at a lower interest rate under a new $200 million accounts receivable securitization program.
Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization, or EBITDA, totaled $262.5 million in the third quarter, an increase of 5.1%. Based on EBITDA of more than $1 billion over the last 12 months, our leverage ratio calculated as net principal debt over EBITDA, stands at 2.97, the first time this ratio has fallen below 3 since the Gen-Probe acquisition.
In addition, we are well on our way to achieving our target leverage ratio of 2.5x by the end of fiscal 2017. Strong profit growth and lower debt have continued to improve our return on invested capital, or ROIC, which was 12.3% on a trailing 12-month basis, a 170 basis points increase over the prior year. 
Robust cash flows and minimal capital expenditures continue to be hallmarks of Hologic's financial performance. Operating cash flow was $246.2 million in the third quarter, an increase of 1.6%. Free cash flow, defined as operating cash flow less capital expenditures, was $225.1 million. Notably, free cash flow was 55.1% higher than non-GAAP net income. Our financial health clearly extends well beyond our P&L as we continue to focus on working capital and control our capital expenditures.
Now let's turn to our updated financial guidance for the full year and fourth quarter. At the midpoint, we are raising both revenue and non-GAAP EPS guidance based on the company's strong performance in the third quarter. Let's cover the revenue guidance first. 
For the full year, we are increasing our previous guidance by $10 million at the low end and now expect total revenues of between $2.82 billion and $2.83 billion for fiscal 2016. This represents solid mid single-digit growth of 4.3% to 4.6% on a reported basis, or 5% to 5.3% in constant currency terms, despite the headwind from divested in discontinued products. 
With only one quarter remaining in our fiscal year, this annual guidance obviously implies revenues of $714 million to $724 million in the fourth quarter. Compared to the prior year period, which is another tough comp, this range reflects revenue growth of 1.6% to 3.0% on a reported basis, or 2.1% to 3.6% in constant currency terms. In addition, our guidance includes an expected headwind of roughly $4.5 million from divested and discontinued products, which depresses our constant currency guidance by about 60 basis points.
Based on our revenue range, our fourth quarter guidance implies that revenues will be about the same or slightly above our third quarter actuals. We no longer expect the significant sequential step-up implied by our prior guidance as some revenue that we originally forecast in the fourth quarter materialize a little earlier than expected. In addition, we forecast another quarter of incremental softness in blood screening sales as inventories and ordering patterns continues to normalize.
Turning to our updated bottom line guidance. We now forecast non-GAAP EPS of between $1.93 and $1.94 for the full year. This translates to reported growth between 15.6% and 16.2% and constant currency growth between 16.9% and 17.5%. This earnings guidance is based on recent foreign exchange rates, a full year tax rate of 32% and diluted shares outstanding approximately 280 million for the full year.
This full year guidance translates to non-GAAP earnings per share of $0.49 to $0.50 in the fourth quarter. This represents growth of 14% to 16.3% on a reported basis or 15% to 17.3% in constant currency terms. Implicit in our fourth quarter guidance is a sequential increase in operating expenses, several million dollars of which relate to a change in the retirement provisions of our equity plan that will make it more consistent with peers. 
Before opening up the call for questions, I want to reiterate how pleased we are with the financial results we achieved so far in fiscal 2016. From a revenue perspective, our surgical business continues to exceed expectations. We still enjoy momentum with Genius 3D Mammography, remains pleased with our molecular diagnostics and ThinPrep businesses and are turning the corner internationally. And from an earnings perspective, we continue to generate tremendous growth through gross and operating margin improvement and lower tax rate and capital deployment.
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we are ready for the first question."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll move to our first question, which will come from Jonathan Groberg with UBS.",17,"[Operator Instructions] And we'll move to our first question, which will come from Jonathan Groberg with UBS."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution that benefit from the Zika that yo",64,"Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution that benefit from the Zika that you mentioned? I was just kind of curious if there was any if you can, any other color you can provide on that."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Jonathan, it's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the team, getting",211,"Yes, Jonathan, it's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the team, getting up to speed. And then we did launch. We got the clearance, if you recall, early this year, really, early this calendar year, to the viral loads. We've got the HCV, HPV and HIV. So they're rolling out in conjunction with the new leadership team and the Panther placements. And those things are really driving it. Zika, by the way, is not in those numbers. So that's really just our core women's health assays, plus the viral load. So I think what we're excited about, as we started to look forward in Diagnostics -- molecular is effectively been nonexistent outside the U.S., and not nonexistent, but pretty small. And now we're really getting that footprint. And as we are placing this Panther, starting feel like, okay, this is the beginning of the something that is really is sustainable and has good growth ahead of it. As well, the cytology business continues to take along as well with some modest growth outside the U.S. also."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the STD. And so I think we",135,"Hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the STD. And so I think we've got as competitive menu as anyone else does. So I think what we had seen is a series of quarter, strong quarterly placements for the last several quarters and we're starting to get those back on. They're up and running in that test a record. And so I think we're seeing that pull through and seeing the benefits of the Panther system, which we've seen here in the U.S. around benefits of automation and so forth, which I think will really play well, particularly in Europe."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I guess, if I can just follow-up, the basis for my question is, is there anything that you can learn from kind of a new management and how long it took? And what you're seeing this it all applicable to what you may be able to achieve in Breast Health? Or",57,"I guess, if I can just follow-up, the basis for my question is, is there anything that you can learn from kind of a new management and how long it took? And what you're seeing this it all applicable to what you may be able to achieve in Breast Health? Or are they just too different businesses?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","They are different business, but there is a lot to learn. I think, Jonathan, probably doing to think about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside the U.S, franc",284,"They are different business, but there is a lot to learn. I think, Jonathan, probably doing to think about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside the U.S, franchise by franchise. I think what we've seen, the new leader within the European diagnostics business, he is bringing a level of focus, he's building out a team. There were some people there, he's changed some out, got the others to operate up, but it really is starting to build it up. And I think that's what Eric Compton is really been driving, especially this year, is getting the right people in place for the longer term. Yes, just anecdotally, Bob and I happen to be in Japan last week. And again, half of our employees in Japan have been with us less than 1 year. So it truly is we look at the company of our size from the outside and think, okay, you just have to get it going and turn around what's there. This really is building it out. So I think we've seen some emerging signs in Diagnostics over the last couple of quarters, didn't want to quite say yet until we thought, okay, this is now sustainable. And I think we're in the same infrastructure building in Breast Health and other stuff. Breast Health because more dealers involved. We'll probably take a little longer. But I will tell you, underneath the surface, we're feeling very good where, as I always say, the infrastructure gets better before the numbers show that. And I think that's kind of the stages that we're in right now."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move next to Tycho Peterson with JPMorgan.",9,"We'll move next to Tycho Peterson with JPMorgan."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, wondering if you can talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there, particularly on NovaSure. Are you able to the sacred how much of that is, from a trace recall and maybe picking up some share there?",44,"Steve, wondering if you can talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there, particularly on NovaSure. Are you able to the sacred how much of that is, from a trace recall and maybe picking up some share there?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Great, Tycho. I think the way we should think about it right now is we're clearly benefiting in most of the NovaSure growth. I think we should say is candidly coming from a competitive recall, of which we still have another, call it, quarter, 1.5-is",220,"Sure. Great, Tycho. I think the way we should think about it right now is we're clearly benefiting in most of the NovaSure growth. I think we should say is candidly coming from a competitive recall, of which we still have another, call it, quarter, 1.5-ish quarter ahead of us with that. Having said that, it might everybody, as we said, this was our sixth straight quarter of double-digit growth, both domestically and globally, for our GYN serve business. So that business had turned it around and strength and erratically and was then well-poised when they -- in the competitive issue happened. So we're taking advantage of it. My issue continues to grow. And I think the way we think about our guided GYN serve business is we're not ready to declare it a sustainable double-digit grower, but it's clearly a very solid grower. And again, this is one where internationally, we're just in a very early stages as well. So again, it's moved from what I'd call an appendage on the company a couple of years ago to something you can actually start to meaningfully contribute to our total growth. It's also hugely accretive to our gross margin, operating margin. It's a great cash generator. There's a lot of good things, and it's helping on our tax rate, frankly."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Tycho, this is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter that what we are expecting in the fourth quarter r",95,"Hey, Tycho, this is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter that what we are expecting in the fourth quarter really on the back of the work that team has done there and the investments we've made in sales and marketing. So that's some of the -- we think that there still is legs there, as Steve said. But that ramp has actually happened nicely for us in the third quarter."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And just as a follow-up, a question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But you also talk about whether that's a good pro",83,"Okay. And just as a follow-up, a question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But you also talk about whether that's a good proxy for when you ultimately do rollout in the U.S. and what's in the latest thinking on timing. Could you have viral load here by the end of next year or is that more of a 2018 event?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It's still pretty small within Europe. It's not yet material to the company. But I think the initial signs are pretty good. And what's, I think, very encouraging to us is in Europe, we're launching from a much weaker base than where we are when we b",165,"Sure. It's still pretty small within Europe. It's not yet material to the company. But I think the initial signs are pretty good. And what's, I think, very encouraging to us is in Europe, we're launching from a much weaker base than where we are when we bring the viral loads to the United States. So when we bring the viral loads, which to the second part of your question, is really an '18, a fiscal 2018 and probably second half-ish of '18 by the time we have all 3. So we will have likely one much sooner. But by the time we have HPV, HCV and HIV, it'll be later on in '18. And by that point, we'll be launching in the U.S. from a much bigger installed base, much stronger position overall. So I think the fact we ever even have some success in Europe than other people's backyards is already an increasingly encouraging sign for when we do come to the stage."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we will move to Bill Quirk with Piper Jaffray.",12,"At this time, we will move to Bill Quirk with Piper Jaffray."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So I guess, Steve, just to start off on tomo here. I think your total positive perhaps than last quarter. And I'm curious if we can dig into why? I mean, is this anything to do with the competitive dynamic? I mean, many strikes me that with this potential",70,"So I guess, Steve, just to start off on tomo here. I think your total positive perhaps than last quarter. And I'm curious if we can dig into why? I mean, is this anything to do with the competitive dynamic? I mean, many strikes me that with this potentially an opportunity here over several years to take some incremental share from your to visible competitors in the mammography space domestically."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments, one of my comments on t",208,"Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments, one of my comments on the last call might have been more misinterpreted. I think what we're really seeing fundamentally in the Breast Health business is our ability to take more market share than I ever would have imagined, call it, 2, 2.5 years ago. But I think the business is also very encouraging. It's going to be stronger for longer. And while there's been so much obsession from the outside of what I call the peak followed by the cliff, we still see -- we're still, as we said in the script, we're less than 40% even into our own installed base. We're less than 25% even into the installed base in the marketplace. And as we're gaining market share, it says there is still a lot of runway ahead of us. What I'm trying to signal a long is I don't expect to kind of growth rates we've had historically, but the business fundamentally has a lot of great quarters still ahead of it."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Fantastic. Secondly, on surgical. Just spend a couple of minutes here on the mobile medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of try it before you buy it sort of d",62,"Fantastic. Secondly, on surgical. Just spend a couple of minutes here on the mobile medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of try it before you buy it sort of deal, Steve? Or are you still looking at a traditional products for the bag?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, thanks. As we've said, we're clearly looking for additional product for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, wi",220,"Sure, thanks. As we've said, we're clearly looking for additional product for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, with the competitive situation. And I think as we go forward, we're just beginning the business development efforts. And I think you'll see a series of things, whether it's a  very limited distribution deal like this trend one way, trying it with a few reps and that or outright acquisitions. I would say on the business development front, everybody should know, we've gotten much more active. We said no to a number of things over the last quarter or 2. And I think a lot of that has been our teams getting very much more disciplined about what we're looking at and more active. And I think, frankly, getting to the stage where you're saying no to deals and why is they know and which should we be looking for. I think as we go into '17, feeling better and better that will be finding some things that we will be saying yes to. But certainly, some maybe distribution. Some will be outright acquisition. I wouldn't view that as the model of what will necessarily be doing. We'll just be flexible."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we'll move to Doug Schenkel with Colin.",10,"At this time, we'll move to Doug Schenkel with Colin."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments, molecular is better-than-expected, particularly OUS and surgical growth was quite strong. You remain enthused about affirm and",128,"Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments, molecular is better-than-expected, particularly OUS and surgical growth was quite strong. You remain enthused about affirm and provider. Recognizing one quarter are usually does it make a trend. Would it be fair to say if you will a bit better about your ability to power through the impact of U.S. 3D growth plateauing than you did maybe even a quarter ago? And then for Bob, you beat the mid-point of guidance by, I think it's $17 million this quarter. You're increasing full year guidance at the mid-point by only $5 million. I was hoping you can provide a bridge between the quarter and the full year guide."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated, unless I truly believe there was a complete overreaction. And my strength does continue or my confidence continues to",163,"Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated, unless I truly believe there was a complete overreaction. And my strength does continue or my confidence continues to build as I watch each quarter play out. We were going up against a monster comp this quarter. And our team is still really, call it, 2 years old or less for the most part and wanting to make sure that we can deliver before we get out ahead of ourselves. So I think I feel a little bit better. But I think, overall, I feel very confident about where we're headed. I felt more confident than came off last time. So it's not a dramatic shift in how I feel, but it's clearly probably a dramatic shift in the perception, and I own that. But feeling very good about a lot of things we have going on."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Doug. Hey, this is Bob. Just a follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the mid-point versus the $17 million beat. If you call, our previous guidance included a fairly sharp sequ",173,"Yes, Doug. Hey, this is Bob. Just a follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the mid-point versus the $17 million beat. If you call, our previous guidance included a fairly sharp sequential increase in Q4 revenue. And some of that revenue, as I mentioned, actually earlier, materialized a little earlier than expected places like our surgical business. And then beyond that, we do see potential for incremental kind of sequential weakness within our blood screening businesses. So that business continues to normalize from an inventory perspective. So that said, our fourth quarter guidance still implies solid year-over-year growth despite another challenging comparison and the headwind of about 60 basis points from those they vested in discontinued products. So we feel good about the guidance. And just as important, maybe more importantly, our EPS guidance is even stronger, multiple -- a series of multiples above that for the fourth quarter, growing at 14% to 16% on an as-reported basis."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Jack Meehan with Barclays.",9,"We'll move along to Jack Meehan with Barclays."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with some of the commentary around the service contracts in Breast Health. And I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you h",82,"I wanted to start with some of the commentary around the service contracts in Breast Health. And I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit the inflection at this point last year in terms of the interim placements. Could you walk us through what you think the sustainable rate for that is a whether you seen better attachment with 3D placement?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Jack, this is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong in excess of 85%. And so I think that's",191,"Jack, this is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong in excess of 85%. And so I think that's a real testament to our sales teams and more importantly, our service teams and the customer satisfaction that we have with our products. So I don't see any change there. And I think what you would expect to see is a continued -- the nice part about that is a nice solid annuity in that probably mid single-digit growth rate area going forward. Some of this is we're actually transitioning from a 2D system to a 3D system, where you'll get the incremental benefit associated with a higher service contract. And then the beauty of actually the competitive share gains is you get the full benefit of the service contract on that. And we're seeing both of those as well. So we think that, that has a lot of legs, not only for the rest of this year, but certainly into '17 and beyond."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And one on the early success with viral load in Europe. Just where are you seeing some wins, where do you think you're differentiated in the market? Can you walk us through the value proposition for the Panther?",41,"Great. That's helpful. And one on the early success with viral load in Europe. Just where are you seeing some wins, where do you think you're differentiated in the market? Can you walk us through the value proposition for the Panther?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe.",28,"Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take a question now from David Lewis with Morgan Stanley.",12,"We'll take a question now from David Lewis with Morgan Stanley."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You said so much on this call, I thought maybe you make it the new Hologic tagline. But the reality, I like to maybe take that qualitative commentary and I",116,"I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You said so much on this call, I thought maybe you make it the new Hologic tagline. But the reality, I like to maybe take that qualitative commentary and I wonder if you could make it quantitative for us next year. I know it's too early to give guidance. But I think about the fourth quarter, there is stability. Your guidance for the fourth quarter suggests that still to continues. So as you think about next year, low single-digits versus mid single-digit revenue growth for the business, what -- are you comfortable in more of a mid single-digit outlook?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Dave, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have a soli",129,"Dave, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have a solid year in 2017. And we'd clearly be disappointed with the low single-digit 3% number that was mentioned last time. So wherever -- and I think the bigger point I'm trying to make last time is, by the way, wherever revenue guidance ends up, we believe we'll deliver EPS growth at a multiple of that. I think that was the broader point I was trying to make that help better, we're feeling about the earnings growth. But do feel incrementally better about the sales growth."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think that resonated. And a couple of points maybe 1 Stephen, 1 for Bob. I guess the first team is, Steve, M&A has not been a part of the story here since you arrived. You've given Bob's come to about the leverage and where you'll be by the end of",126,"Okay. I think that resonated. And a couple of points maybe 1 Stephen, 1 for Bob. I guess the first team is, Steve, M&A has not been a part of the story here since you arrived. You've given Bob's come to about the leverage and where you'll be by the end of '17. I wonder, is '17 a hunting period for M&A and sort of '18 is when we should expect more action? Are given what you see on cash flow, what Bob said about the levels of debt by the end of '17, is next year a year where M&A can become more active in terms of deal consummation? And can you give us any sense if that's true kind of size of those transactions?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now. So it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year. '17, I would expect",141,"Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now. So it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year. '17, I would expect we'll probably actually execute something in the '17 timeframe. Our hunting activities clearly ramped up in, I'd say, the last 3 to 6 months at our activities. And I think '17 will be likely, certainly would contribute as well to '18 growth in some of that. But again, we'll, as you know, we'll pounce when the opportunities are right and feel like we're in a position of that we could today. We are going to continue -- as we're talking about bolt-on, bite-size, kinds of things, we're not looking at billion dollar deals."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, just to build on that. I think what we feel we're very comfortable is that we have plenty of capacity to be able to do things when we want to and we will look at many more than we will ever do. And we will be very disciplined in our ap",93,"And I think, David, just to build on that. I think what we feel we're very comfortable is that we have plenty of capacity to be able to do things when we want to and we will look at many more than we will ever do. And we will be very disciplined in our approach to deal with deals. And so I mean, just in this last quarter, free cash flow of $225 million gives us a lot of flexibility. And we continue to use all levers to continue to drive that higher."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And we do, and David, I think you know from a couple of years back looking at it and talking about our exact comp plan. We are very focused on ROIC, and given the history of this company and where we've been. And that's still been part of it of a decision",74,"And we do, and David, I think you know from a couple of years back looking at it and talking about our exact comp plan. We are very focused on ROIC, and given the history of this company and where we've been. And that's still been part of it of a decision to say no to a few of the things we've been looking at. So we'll continue to be very disciplined on that."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think investors will certainly appreciate that, Steve. And then, lastly, Bob, just looking at the fourth quarter. As I mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarter wouldn't",84,"Okay. I think investors will certainly appreciate that, Steve. And then, lastly, Bob, just looking at the fourth quarter. As I mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarter wouldn't show the kind of year-on-year improvement you've been showing to the prior 3 quarters to start back on the envelope suggest the fourth quarter margin will be as robust year-on-year relative to the prior 3 quarters, and I'll jump back in queue."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably more importantly, the change in our retirement plan that I mentioned before will be effecti",52,"Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably more importantly, the change in our retirement plan that I mentioned before will be effective in our fourth quarter, that's roughly a $0.01 impact to the quarter."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Isaac Ro with Goldman Sachs.",10,"We'll move along to Isaac Ro with Goldman Sachs."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, just a question on tax rate just to start. You mentioned in your prepared comments on the internal restructuring initiativelys you've got carriers that's an ongoing process, like carries through the next year and as I look back and you're probably co",99,"Bob, just a question on tax rate just to start. You mentioned in your prepared comments on the internal restructuring initiativelys you've got carriers that's an ongoing process, like carries through the next year and as I look back and you're probably comments on tax rate in general, you've characterized 2016 as a foundational year with leverage to show up next year. So given you said things are moving a little faster, just curious if a lot of the leverage that you have hoped for next year has already played out or if we're still kind of in process?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers. And so that is one of the big focus areas that my team has got. And what",102,"Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers. And so that is one of the big focus areas that my team has got. And what I would say is it's too early to tell you specifically what our number in 2017 is. We actually have been able to pull forward. But what I will tell you is over time, we continue to have opportunities there and expect that effective tax rate to go down."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if think its in capital equipment in med tech, there's been pretty good talk so think that the dips and talk about maybe less than mammo then you would eve",115,"Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if think its in capital equipment in med tech, there's been pretty good talk so think that the dips and talk about maybe less than mammo then you would ever rise guest, given where we are in the adoption curve for tomo. So I'm just curious if you could put any more color feedback you're getting, at least in the U.S. with regards to customer appetite for mammography equipment. Is there anything else that's kind of causing a temporary slowdown in the adoption process that there might explain the trend here versus other categories of equipment?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","No, we're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull stuff",159,"No, we're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull stuff a little bit forward because they wanted to compete and operate. So we're not seeing that. There's just -- I kind of remind people, there's a fundamental limitation to how many systems can be installed. Use the auto industry as an example, right? If every company launch a new product next year, auto sales don't suddenly jump up from 16 million to 20 million. There's just natural rate of replacement that is still happening here. And I think that's what leads us back to the stronger for longer that, A, the market's not going to grow by 25% this year, but it's going to be there and it's there for us as we keep converting."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Isaac, this is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well. Those continue to meet and exceed our expectations.",38,"Yes, Isaac, this is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well. Those continue to meet and exceed our expectations."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move now to Vijay Kumar with Evercore ISI.",10,"We'll move now to Vijay Kumar with Evercore ISI."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I to think out loud on some of the moving parts for next year, right. So it looks like diagnostics -- is has",113,"So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I to think out loud on some of the moving parts for next year, right. So it looks like diagnostics -- is hasn't come in better. We're feeling better about Breast Health. And when we really think about next year, I know you have blood coming, declining maybe for the first half of next year with offsetting that, you have GYN. Is that sort of the mix when you talk balance, is this how we're supposed to think about that growth for next year?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. Sorry, I can't go into specific at this point. It didn't serve me well last time. We talk a",62,"Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. Sorry, I can't go into specific at this point. It didn't serve me well last time. We talk about next year. Fundamentally, we're feeling good about where this company is headed."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","That's fantastic. And maybe one question on breast imaging or breast, I guess, I know you guys launched the table launch. It maybe able to debt softer on the interventions site. We don't talk a lot about. I'm just trying to understand is this a function o",66,"That's fantastic. And maybe one question on breast imaging or breast, I guess, I know you guys launched the table launch. It maybe able to debt softer on the interventions site. We don't talk a lot about. I'm just trying to understand is this a function of does it allow you bundle your cable along with mammo systems. Is there an opportunity in that area?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, what's really in the interventional today is most of the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best product",120,"Yes, what's really in the interventional today is most of the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best product and we've got a great sales team, I think we have good, good hopes for the Affirm table and that will really be. We're in the very early stages right now of getting the quotes and getting the orders, this and sales process. So I do think that will be a nice contributor to start to kick in here in 2017 for us. And it will help just the overall Breast Health business."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","And next question is from Raj Smith with Jefferies.",9,"And next question is from Raj Smith with Jefferies."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe just starting on breast imaging for many. They're still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on extended coverage at this point or anything we can look forward to over the",49,"So maybe just starting on breast imaging for many. They're still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on extended coverage at this point or anything we can look forward to over the next few quarters?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think, Raj, we're deeply engaged in a lot of discussions. I think I said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the las",169,"Yes, I think, Raj, we're deeply engaged in a lot of discussions. I think I said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the last, I'd say, last 6 months or so. It's hard to predict timing. And I candidly frame modeling or whatever, I wouldn't assume we necessarily have anything this calendar year. Having said that, we are getting a couple of state mandates. And if you saw recently both the State of Illinois and the State of Connecticut have now mandated coverage. And we're probably, overall, in the 40% to 45%-ish coverage, maybe up to 50% in terms of corporate lives. But the private pay piece will be probably the next step-up for us. And having said that, just like prior to getting the incremental reimbursement from CMS, we're not sitting there waiting for this to come to sell our systems."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take the final question from Richard Newitter with Leerink Partners.",12,"We'll take the final question from Richard Newitter with Leerink Partners."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a quick one. I wouldn't know if you provided by the OUS Breast Health growth rate, did you guys give that number and your might last quarter on what the trend was?",33,"Just a quick one. I wouldn't know if you provided by the OUS Breast Health growth rate, did you guys give that number and your might last quarter on what the trend was?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Okay, go ahead, Bob.",5,"Sure. Okay, go ahead, Bob."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, down in constant currency 2.9%. And if you adjusted for the vested in discontinued, it's roughly flat.",18,"Yes, down in constant currency 2.9%. And if you adjusted for the vested in discontinued, it's roughly flat."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","What was the last?",4,"What was the last?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And sequentially, it was about flattish as well.",8,"And sequentially, it was about flattish as well."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Right, right.",2,"Right, right."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","[indiscernible] the last quarter?",4,"[indiscernible] the last quarter?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sorry, you faded out.",4,"Sorry, you faded out."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We just got a garble.",5,"We just got a garble."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?",21,"I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?"
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Improves, yes.",2,"Improves, yes."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Not so much, I think.",5,"Not so much, I think."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","This quarter versus last quarter, net of divestiture is about flat.",11,"This quarter versus last quarter, net of divestiture is about flat."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Flat.",1,"Flat."
108544,370563080,1014249,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening.",27,"Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike",52,"Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial",206,"Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks today, then we'll have a question-and-answer session.
Our third quarter press release is available now on the Investors section of our website, and we also will post our prepared remarks to our website shortly after we deliver them today. Finally, a replay of this call will be archived on our website through August 26.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known as well as unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release.
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from t",2331,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from turnaround story to sustainable growth company. 
Revenues of $717.4 million exceeded expectations as all 4 of our businesses grew on a global basis, despite a difficult comparison resulting from very strong results in the prior year period. 
In our last call, we focused on the emergence of our surgical business as a growth driver. This quarter, surgical led the way with exceptional performance, but we're also pleased with how our breast imaging, molecular diagnostics and cytology businesses performed. And we made progress in strengthening our international franchises, which we believe will be important contributors to future growth.
Our performance this quarter highlighted the breadth of our top line growth drivers, which is often overlooked. Even as performance has improved ahead of schedule in many areas, new drivers are beginning to emerge, thanks to the deliberate and proactive efforts of our team. And while this quarter is only a single data point, our results do give us increased confidence that revenue growth can continue at a healthy pace in the future. 
Our third quarter results also demonstrated once again our ability to increase profitability above and beyond already high levels. We boosted both gross and the operating margins even while reinvesting aggressively to drive future growth. We've been pleasantly surprised at our ability to achieve productivity gains and enjoying many other levers to drive earnings growth.
For example, strategies that we had expected to play out over the longer-term horizon are materializing sooner than expected. Various internal restructuring yielded a lower tax rate in the quarter. And the combination of strong cash flows and market volatility enabled us to buy back more shares. Together, all these efforts led to a very robust net margin of 20.2% in the quarter, non-GAAP earnings per share of $0.51 and excellent EPS growth of 18.6% on a non-GAAP basis.
Based on the strong earnings performance, we are raising our financial guidance for the year and now expect non-GAAP EPS of between $1.93 and $1.94. As a reminder, the mid-point of this new guidance is roughly $0.12 above our guidance at the beginning of the year. We're clearly exceeding our own expectations for a sustainable bottom line growth and feel good about our future prospects in this regard as well.
With that introduction out of the way, I'd like to walk through our revenue highlights in the balance of my remarks. Then Bob will discuss expenses, the rest of our financials and our updated guidance. Unless otherwise noted, percentage changes will be on a year-over-year basis. 
Starting with the big picture. Total revenues were $717.4 million in the third quarter, an increase of 3.4% on a reported basis or 3.6% in constant currency terms. These figures include a roughly $8 million headwind from divested and discontinued products, such as Sentinelle breast coils and the molecular test for cystic fibrosis. If we were to back out this headwind, total revenues would have been grown 4.8% in constant currency terms.
These growth rates are stacked on top of a very difficult comp from the prior year. As a reminder, in the third quarter of 2015, total revenues increased 12.2% in constant currency. So our ability to jump over a high bar this quarter gives us increasing confidence in the ability of our commercial organization to drive solid growth next year and beyond.
In terms of geography. U.S. sales grew 4.7% in the third quarter, continuing a string of good results and indicating the improvements we've made in commercial execution. We continued to enjoy strong leadership positions and good momentum in the domestic marketplace. 
International sales declined 1.2% on a reported basis, driven primarily by blood screening, as expected. In constant currency, international sales declined 0.4%, essentially flat. And if we were to normalize for divested and discontinued products, international sales would have increased slightly. It's also worth mentioning that international sales increased sequentially as well, an encouraging sign. 
Overall, we believe our international results in the third quarter show we are building a foundation for strong and consistent growth over time. Toward that end, our Chief Operating Officer, Eric Compton, has made good progress in filling out our international leadership team in recent months. In last quarter's call, we highlighted new executives in charge of European Breast Health and service as well as marketing, molecular diagnostics, surgical and regulatory. More recently, we have added new geographic sales leaders to run Latin America, Canada and Asia Pacific. So our efforts to upgrade talent are coming together nicely. 
Shifting to the types of revenue we generate. I want to emphasize that for all the attention our mammography systems receive, capital equipment represented just 23.4% of revenue in the third quarter. Said another way, more than 76% of our sales were recurring. More specifically, disposables, such as our diagnostic assays and surgical tools, represented 60.4%, 6-0 point 4 percent of sales, while service and other totaled 16.2% of sales.
Now let me discuss divisional revenues in the third quarter. I'll start with the growth leader in the quarter, our GYN Surgical business. A couple of years ago, no one would have said those words in the same sentence. But today, our team has achieved what others thought impossible. Worldwide surgical sales were $102 million, surpassing $100 million on a quarterly basis for the first time. Sales grew 19.8% in constant currency, the fastest growth rate for this division in recent memory. 
In the United States, the team delivered double-digit growth for the sixth consecutive quarter. And internationally, the business grew by nearly 40%, albeit off a very small base. 
As many of you know, a competitor recently withdrew its endometrial ablation product from the market. And to capitalize on this, we increased marketing and sales activities in the quarter. As a result, global sales of our NovaSure product totaled $61 million, an increase of 14.6% in constant currency. Not to be overlooked, sales of our MyoSure product for uterine fibroid removal also continued to show strength. Global MyoSure sales of $40.8 million increased 29.8% in constant currency. 
Now let's turn to Breast Health, which has received a lot of attention in recent months. While this is understandable and appropriate, it's just as important to appreciate that Hologic is much more than a mammography company today. Hopefully, our results this quarter help illustrate that point and provide confidence that the entire company can continue to grow revenue solidly and EPS much faster even as growth from 3D adoption naturally slows.
We're very pleased with our Breast Health performance in the quarter. Global sales of $282.5 million increased 1.1%. Breast imaging sales totaled $239.3 million, up 2.3% in constant currency, driven by continued adoption of our Genius 3D Mammography systems. Domestic imaging sales grew more rapidly and exceeded our internal expectations based on Genius placements, which increased both sequentially and year-over-year. 
We estimate the Genius systems are continuing to gain market share while our investments in customer marketing help us maintain stable prices amid fierce competition. We still have lots to look forward to in Breast Health. Genius systems represent less than 40% of our own mammography installed base today, and by our estimate, less than 25% of the market as a whole. And we remain confident in the long-term conversion opportunity as evidence continues to mount on the benefits of Hologic's Genius exams for patients and physicians and as we differentiate ourselves competitively.
As evidence of this, mammography customers recently surveyed by the independent market research firm KLAS scored Hologic highest in overall product satisfaction. One Director of radiology said, ""Hologic seems to be the only company that really understands the tomosynthesis market. It was clear from our implementation and our usage of their system that they are a full generation ahead of other vendors. Everybody else is playing catch-up."" This is only one anecdotal comment, but it's consistent with the customer feedback we receive every day and validates our leadership position. 
As our installed base Genius 3D systems grows, our sales and marketing programs are focusing on ways to leverage this leadership position. For example, service revenue is becoming increasingly important and represents an annuity that complements and smooths out our capital sales. Some of you may not appreciate the size of our service business in Breast Health. To frame it for you, service revenue in this business exceeded $100 million in the quarter for the first time and grew at a mid single-digit rate.
Similarly, we have revamped our research and development efforts to capitalize on our growing Genius footprint and generated more continuous stream of product innovations. For example, we recently launched our new Affirm prone biopsy system, which provides a better patient experience and enables doctors to capitalize on the increased sensitivity of 3D technology. Although it's still early days, customer feedback on this system has been positive, both in the United States and internationally.
Another component of future growth in Breast Health will be our international business. While we still have a lot of work to do here, we are making good progress and are optimistic that the business is becoming healthier and more predictable as we create the foundation for solid growth in 2017 and beyond. In the third quarter, international Breast Health sales declined 2.9% in constant currency. But if we back out the headwind from divested and discontinued products, sales would have been flat. And on a sequential basis, sales increased slightly.
With this in mind, I want to remind everyone that last year's international Breast Health number was exceptionally strong in the fourth quarter. And as a result, we anticipate a year-over-year decline in the coming quarter before the business returns to growth in 2017. As we move into 2017, we do believe that the combination of multiple tailwinds are still underpenetrated 3D opportunity, growing service revenue, a revitalized R&D effort and international expansion will enable Breast Health to be an important contributor to corporate growth.
Now let's cover diagnostics, which is our largest business and greatest source of non-GAAP operating profit. Diagnostics reported sales of $309.9 million in the third quarter, growing 1.2% in constant currency. Within diagnostics, our cytology and molecular businesses performed well while our blood screening business declined as expected. Global sales of cytology in perinatal products totaled $122.2 million, growing 3.9% on a constant currency basis. Breaking this down a little further, both our ThinPrep and fetal fibronectin franchises grew in the United States and internationally despite lingering headwinds from Pap interval expansion domestically.
Turning to molecular diagnostics. We posted global sales of $131.8 million, up 6.0% in constant currency. Excluding sales of our discontinued cystic fibrosis product, molecular sales would have grown at a high single-digit rate. Our domestic business was solid as our fully automated Panther system continues to accumulate new placements and competitive wins and as utilization of our assays for Trichomonas, HPV and chlamydia gonorrhea continues to grow. 
But the real standout here was our international business. Over the last couple of quarters, international molecular sales have turned slightly positive under new leadership, and we had added viral load assays to the Panther menu. Building on this, the business took a significant step ahead in the third quarter with constant currency growth exceeding 20%. 
In addition, we had a record quarter of Panther placements outside the United States, coupled with a significant step-up in per instrument utilization. All these data points have us feeling good about the potential for international molecular diagnostics to become a new driver of growth for the company over time.
Shifting back to the United States for a moment. During the third quarter, we gained an emergency use authorization for our Zika virus test for diagnostic use. In addition, blood banks began testing donated blood for Zika with our Procleix assay under an investigational new drug protocol. While we do not expect significant sales from these 2 new products, both of which run on the Panther system, our ability to rapidly develop these test shows we can react quickly to public health emergencies in close cooperation with regulators and customers. In addition, should the Zika virus spread in the United States, we will be well positioned in the marketplace.
Apart from the highlight of the Zika IND, our blood screening business declined in the quarter as expected. Worldwide sales of blood screening products were $55.9 million, down 12.9%, with all the decline coming outside the United States. As in the second quarter, this decline was mainly due to stronger ordering in the prior year period to support testing at the Japanese Red Cross combined with continued trends toward lower blood utilization.
Before I turn the call over to Bob, let me wrap up the review of product sales by mentioning that our Skeletal Health division posted revenues of $23.0 million in the quarter. This represented a constant currency increase of 4.8% with growth both domestically and overseas, primarily driven by our Horizon bone density scanner.
So in conclusion, we are very pleased with our third quarter financial results and with the progress we've made toward building a sustainable growth company. Despite very challenging prior year comps, all 4 of our businesses grew in the quarter, reflecting the many growth drivers at our disposal. 
Sales growth in the U.S. Breast Health slowed to a challenging prior year comp, but remained healthy. At the same time, strong results in surgical, molecular diagnostics and cytology demonstrated that Hologic is much more than a mammography company. We continued to execute well in the United States and made good progress building a foundation for international growth. We once again expanded profit margins and redeployed capital, contributing to EPS growth at the highest rate in many years. 
Now I will hand the call over to Bob."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. As a reminder, I will",1504,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. 
As a reminder, I will focus on non-GAAP results, and percentage changes will be on a year-over-year basis unless otherwise noted. As Steve discussed, our revenue performance in the third quarter exceeded expectations, highlighted by global growth in all 4 business segments. This growth, coupled with favorable product mix and productivity gains, again drove improvements in gross and operating margins. At the same time, we continued to invest in initiatives that position us for long-term sustainable growth. Net-net, we delivered EPS growth well in excess of sales, reflecting the impact of operational improvements, capital deployment and in lower effective tax rate.
Now let's dive deeper into the third quarter income statement. Gross margin of 65.7% increased 50 basis points and benefited from the growth of our surgical, cytology and perinatal and Aptima franchises. We continue to manage pricing well as we focus on commercial excellence, and our marketing initiatives highlight the clinical and economic value of our products. 
In addition, our operations teams continue to drive efficiencies and reduce cost across our supply chain. Total operating expenses of $229.2 million increased 3.1% in the third quarter. This increase was driven primarily by sales and marketing expense, which increased 15.5%.
Given our gross margin expansion, we have invested deliberately and opportunistically in commercial areas where we see a good return. These include our Genius marketing campaign in Breast Health, our cervical cancer co-testing initiatives in Diagnostics and efforts to gain competitive market share with NovaSure. These strategic initiatives are paying off through increased brand awareness, market share gains and price stability, all of which contribute to higher sales.
Despite the increased sales and marketing spending, operating margins improved 60 basis points in the quarter, slightly more than gross margins based primarily on leverage in general and administrative expenses. 
Moving down the P&L. Interest expense of $33.9 million was 12% lower than in prior year due to our efforts to both reduce and restructure our debt. And in addition, our tax rate is improving earlier than expected based on changes in our income mix and internal restructurings implemented this year and last. We now estimate that our effective tax rate will be around 32% for the full year 2016.
We trued up to this rate in the third quarter, reducing our effective rate to 30.6%, but we expect the rate to normalize back to 32% in the fourth quarter. As a reminder, our tax rate was 34.25% just last year. So we are making good progress.
We are pleased that these efforts have enabled us to grow net profits even faster than operating profit. Our net margin was 20.2% in the quarter, a very strong level and an improvement of 190 basis points over the prior year. 
To wrap up the income statement review, diluted shares outstanding were 282 million in the third quarter, roughly 10 million lower than a year ago. Over the course of this year, we have worked to pay down a portion of the in-the-money converts to reduce the dilutive effects. And more recently, we have taken advantage of market volatility to repurchase our common stock. 
In the third quarter, we bought back 3 million shares of stock for $101.2 million, which exhausted our prior $250 million repurchase authorization. Recently, our Board of Directors has approved an additional $500 million repurchase program, and we're very pleased to have that arrow in our quiver going forward. 
While we're pleased with the progress we've made, thus far, in improving our capital structure and achieving a more competitive tax rate compared to other med tech companies, we know we can continue to improve. And we believe these improvements will help us deliver EPS growth much faster than revenue over an extended period of time.
Now I'd like to highlight a few balance sheet and cash flow items, beginning with inventory. Inventory decreased by $14.5 million or 4.9% compared to a year ago despite a 3.4% increase in sales. This speaks to the strong alignment between the operations and sales teams, who know that every dollar saved in the inventory serves as dry powder for debt reduction, acquisitions or share repurchase. 
And speaking of our debt, at the end of the third quarter, total debt outstanding was $3.4 billion, a decrease of more than $0.5 billion from the year ago. During the quarter, we paid off $175 million that had been outstanding on our $1 billion revolving line of credit using proceeds borrowed at a lower interest rate under a new $200 million accounts receivable securitization program.
Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization, or EBITDA, totaled $262.5 million in the third quarter, an increase of 5.1%. Based on EBITDA of more than $1 billion over the last 12 months, our leverage ratio calculated as net principal debt over EBITDA, stands at 2.97. The first time this ratio has fallen below 3 since the Gen-Probe acquisition.
In addition, we are well on our way to achieving our target leverage ratio of 2.5x by the end of fiscal 2017. Strong profit growth and lower debt have continued to improve our return on invested capital, or ROIC, which was 12.3% on a trailing 12-month basis, a 170 basis points increase over the prior year. 
Robust cash flows and minimal capital expenditures continue to be hallmarks of Hologic's financial performance. Operating cash flow was $246.2 million in the third quarter, an increase of 1.6%. Free cash flow, defined as operating cash flow less capital expenditures, was $225.1 million. Notably, free cash flow was 55.1% higher than non-GAAP net income. Our financial health clearly extends well beyond our P&L as we continue to focus on working capital and control our capital expenditures.
Now let's turn to our updated financial guidance for the full year and fourth quarter. At the midpoint, we are raising both revenue and non-GAAP EPS guidance based on the company's strong performance in the third quarter. Let's cover the revenue guidance first. 
For the full year, we are increasing our previous guidance by $10 million at the low end and now expect total revenues of between $2.82 billion and $2.83 billion for fiscal 2016. This represents solid mid-single-digit growth of 4.3% to 4.6% on a reported basis, or 5% to 5.3% in constant currency terms, despite the headwind from divested and discontinued products. 
With only one quarter remaining in our fiscal year, this annual guidance obviously implies revenues of $714 million to $724 million in the fourth quarter. Compared to the prior year period, which is another tough comp, this range reflects revenue growth of 1.6% to 3.0% on a reported basis, or 2.1% to 3.6% in constant currency terms. In addition, our guidance includes an expected headwind of roughly $4.5 million from divested and discontinued products, which depresses our constant currency guidance by about 60 basis points.
Based on our revenue range, our fourth quarter guidance implies that revenues will be about the same or slightly above our third quarter actuals. We no longer expect the significant sequential step-up implied by our prior guidance as some revenue that we originally forecast in the fourth quarter materialize a little bit earlier than expected. In addition, we forecast another quarter of incremental softness in blood screening sales as inventories and ordering patterns continue to normalize.
Turning to our updated bottom line guidance. We now forecast non-GAAP EPS of between $1.93 and $1.94 for the full year. This translates to reported growth between 15.5%-- 15 .6% and 16.2%, and constant currency growth between 16.9% and 17.5%. This earnings guidance is based on recent foreign exchange rates, a full year tax rate of 32% and diluted shares outstanding approximately 288 million for the full year.
This full year guidance translates to non-GAAP earnings per share of $0.49 to $0.50 in the fourth quarter. This represents growth of 14% to 16.3% on a reported basis or 15% to 17.3% in constant currency terms. Implicit in our fourth quarter guidance is a sequential increase in operating expenses, several million dollars of which relate to a change in the retirement provisions of our equity plan that will make it more consistent with peers. 
Before opening up the call for questions, I want to reiterate how pleased we are with the financial results we achieved so far in fiscal 2016. From a revenue perspective, our surgical business continues to exceed expectations. We still enjoy a momentum with Genius 3D Mammography, remain pleased with our molecular diagnostics and ThinPrep businesses and are turning the corner internationally. And from an earnings perspective, we continue to generate tremendous growth through gross and operating margin improvement and lower tax rate and capital deployment.
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we are ready for the first question."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS.",17,"[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika th",65,"Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika that you mentioned? I'm just kind of curious if there were anything else you can -- any other color you can provide on that."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the te",214,"Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the team, getting up to speed. And then we did launch. We got the clearance, if you recall, early this year, what, really, early this calendar year, to the viral loads. We've got the HCV, HPV and HIV. So they're rolling out in conjunction with the new leadership team and the Panther placements. And those things are really driving it. Zika, by the way, is not in those numbers. So that's really just our core women's health assays, plus the viral load. So I think what we're excited about, as we started to look forward in Diagnostics -- molecular is effectively been nonexistent outside the U.S. and -- not nonexistent, but pretty small. And now we're really getting that footprint. And as we're placing this Panther, it's starting feel like, okay, this is the beginning of something that really is sustainable and have some good growth ahead of it. As well, the cytology business continues to tick along as well with some modest growth outside the U.S. also."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the",142,"I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the STD. And so I think we've got as competitive a menu as anyone else does. So I think what we had seen is a series of quarter -- strong quarterly placements for the last several quarters, and we're starting to get those back on. They're up and running in that tester record. And so I think we're seeing that pull through and seeing the benefits of the Panther system, which we've seen here in the U.S. around benefits of automation and so forth, which I think will really play well, particularly in Europe."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health",57,"I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health? Or are they just 2 different businesses?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside",287,"They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside the U.S. franchise by franchise. I think what we've seen, the new leader within the European diagnostics business, he's bringing a level of focus. He's building out a team. There were some people there. He's changed some out, gotten the others to operate up, but really is starting to build it up. And I think that's what Eric Compton has really been driving, especially this year, is getting the right people in place for the longer term. Yes, just anecdotally, Bob and I happen to be in Japan last week. And again, half of our employees in Japan have been with us less than a year. So it truly is, we look at the company of our size from the outside and think, okay, they just have to get it going and turn around what's there. This really is building it out. So I think we've seen some emerging signs in Diagnostics over the last couple of quarters, didn't want to quite say yet until we thought, okay, this is now sustainable. And I think we're in the same infrastructure building in Breast Health and other stuff. Breast Health because more dealers involved. We'll probably take a little bit longer. But I will tell you underneath the surface, we're feeling very good where, as I always say, the infrastructure gets better before the numbers show it. And I think that's kind of the stages that we're in right now."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move next to Tycho Peterson with JPMorgan.",9,"We'll move next to Tycho Peterson with JPMorgan."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there, particularly on NovaSure. Are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe pickin",44,"Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there, particularly on NovaSure. Are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe picking up some share there?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting in most of the NovaSure growth. I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarter",217,"Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting in most of the NovaSure growth. I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarter, 1.5-ish quarter ahead of us with that. Having said that, I'd remind everybody. As we said, this was our sixth straight quarter of double-digit growth, both domestically and globally, for our GYN surge business. So that business had turned it around, had strengthened dramatically and was then well poised when they -- competitive issue happened. So we're taking advantage of it. MyoSure continues to grow. And I think the way we think about our GYN surge business here is we're not ready to declare it a sustainable double-digit grower, but it's clearly a very solid grower. And again, this is one, where, internationally, we're just in the very early stages as well. So again, it's moved from, what I'd call, an appendage on the company a couple of years ago to something that can actually start to meaningfully contribute to our total growth. It's also hugely accretive to our gross margin, operating margin. It's a great cash generator. There's a lot of good things, and it's helping on our tax rate, frankly."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth qua",97,"Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth quarter really on the back of the work that, that team has done there and the investments we've made in sales and marketing. So that's some of the -- we think that there still is legs there, as Steve said. But that ramp has actually happened nicely for us in the third quarter."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that",86,"Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that's a good proxy for when you ultimately do rollout in the U.S.? And what's the latest thinking on timing? Could you have a viral load here by the end of next year? Or is that more of a 2018 event?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we",168,"Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we bring the viral loads to the United States. So when we bring the viral loads, which to the second part of your question, is really an '18, a fiscal 2018 and probably really second half-ish of '18 by the time we have all 3. So we will have likely one much sooner. But by the time we have HPV, HCV and HIV, it'll be later on in '18. And by that point, we'll be launching in the U.S. from a much bigger installed base, much stronger position overall. So I think the fact we're able to even have some success in Europe than other people's backyards is already an increasingly encouraging sign for it when we do come to the States."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we will move to Bill Quirk with Piper Jaffray.",12,"At this time, we will move to Bill Quirk with Piper Jaffray."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that",74,"So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that there's potentially an opportunity here over several years to take some incremental share from your 2 principle competitors in the mammography space domestically."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on",211,"Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on the last call might have been more misinterpreted. I think what we're really seeing fundamentally in the Breast Health business is our ability to take more market share than I ever would have imagined, call it, 2, 2.5 years ago. But I think the business is also very encouraging. It's going to be stronger for longer. And while there's been so much obsession from the outside of, what I call, the peak followed by the cliff, we still see -- we're still -- as we said in the script, we're less than 40% even into our own installed base. We're less than 25% even into the installed base in the marketplace. And as we're gaining market share, it says there is still a lot of runway ahead of us. What I've been trying to signal all along is, what, don't expect the kind of growth rates we've had historically. But the business fundamentally has a lot of great quarters still ahead of this."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort",63,"Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort of deal, Steve? Or are you still looking around at additional products for the bag?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, w",220,"Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, with the competitive situation. And I think as we go forward, we're just beginning the business development efforts. And I think you'll see a series of things, whether it's a very limited distribution deal like this one, where we're trying it with a few reps and that or 2 outright acquisitions. I would say on the business development front, everybody should know, we've gotten much more active. We've said no to a number of things over the last quarter or 2, and I think a lot of that has been our teams getting very much more disciplined about what we're looking at, and more active. And I think, frankly, getting to the stage where you're saying no to deals and why is the no and which we'd be looking for. I think as we go into '17, feeling better and better that we'll be finding some things that we will be saying yes to. But certainly, some maybe distribution, some will be outright acquisition. I wouldn't view that as the model of what we'll necessarily be doing. We'll just be flexible."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we'll move to Doug Schenkel with Cowen.",10,"At this time, we'll move to Doug Schenkel with Cowen."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly OUS, and surgical growth was quite strong. You remained enthused about Affirm a",128,"Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly OUS, and surgical growth was quite strong. You remained enthused about Affirm and Brevera. Recognizing one quarter usually doesn't make a trend. Would it be fair to say you feel a bit better about your ability to power through the impact of U.S. 3D growth plateauing than you did maybe even a quarter ago? And then for Bob, you beat the midpoint of guidance by -- I think it's $17 million this quarter. You're increasing full year guidance at the midpoint by only $5 million. I was hoping you could provide a bridge between the quarter and the full year guide."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence c",166,"Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence continues to build as I watch each quarter play out. We were going up against a monster comp this quarter. And our team is still really, call it, 2 years old or less for the most part and wanting to make sure that we can deliver before we get out ahead of ourselves. So I think I feel a little bit better. But I think, overall, I feel very confident about where we're headed. I felt more confident than came off last time. So it's not a dramatic shift in how I feel, but it's clearly probably a dramatic shift in the perception. And I own that, but feeling very good about a lot of things we have going on."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million beat. If you call, our previous guidance included a fairly sharp sequ",172,"Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million beat. If you call, our previous guidance included a fairly sharp sequential increase in Q4 revenue. And some of that revenue, as I mentioned actually earlier, materialized a little earlier than expected, places like our surgical business. And then beyond that, we do see potential for incremental kind of sequential weakness within our blood screening businesses. That business continues to normalize from an inventory perspective. So that said, our fourth quarter guidance still implies solid year-over-year growth despite another challenging comparison and a headwind of about 60 basis points from those divested and discontinued products, so we feel good about the guidance. And just as importantly, or maybe more importantly, our EPS guidance is even stronger, multiple -- a series of multiples above that for the fourth quarter growing at 14% to 16% on an as-reported basis."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Jack Meehan with Barclays.",9,"We'll move along to Jack Meehan with Barclays."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you h",82,"I wanted to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit the inflection at this point last year in terms of the interim placements. Could you walk us through what you think the sustainable rate for that is and whether you're seeing better attachment with 3D placement?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think t",193,"Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think that's a real testament to our sales teams, and more importantly, our service teams and the customer satisfaction that we have with our products. So I don't see any change there, and I think what you would expect to see is a continued -- the nice part about that is it's a nice, solid annuity in that probably mid single-digit growth rate area going forward. Some of this is we're actually transitioning from a 2D system to a 3D system, where you'll get the incremental benefit associated with a higher service contract. And then the beauty of actually the competitive share gains is you get the full benefit of the service contract on that, and we're seeing both of those as well. So we think that, that has a lot of legs not only for the rest of this year but certainly into '17 and beyond."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And one on the early success with the viral load in Europe. Just where are you seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?",43,"Great. That's helpful. And one on the early success with the viral load in Europe. Just where are you seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe.",28,"Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take a question now from David Lewis with Morgan Stanley.",12,"We'll take a question now from David Lewis with Morgan Stanley."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitat",120,"Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitative commentary, and I wonder if you could make it quantitative for us next year. I know it's too early to give guidance. But I think about the fourth quarter, there is stability. Your guidance for the fourth quarter suggests that stability continues. So as you think about next year, low single digits versus mid single-digit revenue growth for the business, what -- are you comfortable in more of a mid single-digit outlook?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have",131,"Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have a solid year in 2017, and we'd clearly be disappointed with the low single-digit 3% number that was mentioned last time. So wherever -- and I think the bigger point I was trying to make last time is, by the way, wherever revenue guidance ends up, we believe we'll deliver EPS growth at a multiple of that. I think that was the broader point I was trying to make that help better we're feeling about the earnings growth, but do feel incrementally better about the sales growth."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and",132,"Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and where you'll be by the end of '17. I wonder, is '17 a hunting period for M&A and sort of '18 is when we should expect more action? Or given what you see on cash flow and what Bob said about the levels of debt by the end of '17, is next year a year where M&A can become more active in terms of deal consummation? And can you give us any sense if that's true kind of size of those transactions?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect",142,"Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect we'll probably actually execute something in the '17 time frame. Our hunting activities clearly ramped up in, I'd say, the last 3 to 6 months at our activities. And I think '17 will be likely certainly would contribute as well to '18 growth in some of that. But again, we'll -- as you know, we'll pounce when the opportunities are right and feel like we're in a position that we could today. We are going to continue -- as we're talking about bolt-on, bite-size, kinds of things, we're not looking at billion dollar deals."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disc",97,"And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disciplined in our approach to deal with deals. And so I mean, just in this last quarter, free cash flow of $225 million gives us a lot of flexibility. And we continue to use all levers to continue to drive that higher."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exact comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of it, a deci",75,"We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exact comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of it, a decision to say no to a few of the things we've been looking at. So we'll continue to be very disciplined on that."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarte",86,"Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarter wouldn't show the kind of year-on-year improvement you've been showing to the prior 3 quarters? To start back on the envelope, math suggests the fourth quarter margin will be as robust year-on-year relative to the prior 3 quarters. And I'll jump back in queue."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effect",52,"Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effective in our fourth quarter. That's roughly a $0.01 impact to the quarter."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Isaac Ro with Goldman Sachs.",10,"We'll move along to Isaac Ro with Goldman Sachs."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comments",101,"Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comments on tax rate in general, you've characterized 2016 as a foundational year with leverage to show up next year. So given that you said things are moving a little faster, just curious if a lot of the leverage that you have hoped for next year was already played out or if we're still kind of in process?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what",102,"Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what I would say is it's too early to tell you specifically what our number in 2017 is. We actually have been able to pull forward. But what I will tell you is, over time, we continue to have opportunities there and expect that effective tax rate to go down."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets in the strings of cross areas categories.",137,"Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets in the strings of cross areas categories. And I think yourselves and your competitors have talked about maybe little less coat [ph] in mammo than you would have otherwise guessed given where we are in the adoption curve for tomo. So I'm just curious if you could put any more color on the feedback you're getting, at least, in the U.S. with regards to customer appetite for mammography equipment. Is there anything out there that's kind of causing a temporary slowdown in the adoption process that they might explain the trend here versus other categories of equipment?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull",163,"No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull stuff a little bit forward because they wanted to compete and offer it, so we're not seeing that. There is just -- I kind of remind people, there's a fundamental limitation to how many systems can be installed. Use the auto industry as an example, right? If every company launch a new product next year, auto sales don't suddenly jump up from 16 million to 20 million. There's just a natural rate of replacement that is still happening here. And I think that's what leads us back to the stronger for longer that, A, the market's not going to grow by 25% this year. But it's going to be there, and it's there for us as we keep converting."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations.",40,"Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move now to Vijay Kumar with Evercore ISI.",10,"We'll move now to Vijay Kumar with Evercore ISI."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en m",118,"So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en masse has to come in better. We're feeling better about Breast Health. And when we really think about next year, I know you have blood coming, declining maybe for the first half of next year. But offsetting that, you have GYN. Is that sort of the mix of -- when you talk about balance, is this how we're supposed to think about that growth for next year?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre",65,"Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre talk about the next year. Fundamentally, we're feeling good about where this company is headed."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","That's fantastic. And maybe one question on breast imaging or information in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about. I'm just trying",75,"That's fantastic. And maybe one question on breast imaging or information in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about. I'm just trying to understand is this a function of -- does this allow you to bundle your cable along with the mammo systems? Is there an opportunity in that area?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best pr",122,"Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best product and we've got a great sales team, I think we have good, good hopes for the Affirm table. And that will really be. The -- we're in the very early stages right now of getting the quotes and getting the orders, basically the sales process through. I do think that'll be a nice contributor to start to kick in here in 2017 for us, and it will help just the overall Breast Health business."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","And next question is from Raj Denhoy with Jefferies.",9,"And next question is from Raj Denhoy with Jefferies."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over",50,"So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over the next few quarters?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the",172,"Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the last, I'd say, last 6 months or so. It's hard to predict timing. And I -- candidly, for any modeling or whatever, I wouldn't assume we necessarily have anything this calendar year. Having said that, we are getting a couple of state mandates. And if you saw recently, both the State of Illinois and the State of Connecticut have now mandated coverage. And we're probably, overall, in the 40% to 45-ish percent coverage, maybe up to 50% in terms of covered lives. But the private pay piece will be probably the next step-up for us. And having said that, just like prior to getting the incremental reimbursement from CMS, we're not sitting there waiting for this to come to sell our systems."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take the final question from Richard Newitter with Leerink Partners.",12,"We'll take the final question from Richard Newitter with Leerink Partners."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a quick one. I wasn't sure if you provided it, but the OUS Breast Health growth rate, did you guys give that number? And can you remind us [indiscernible] last quarter on what the trend was?",37,"Just a quick one. I wasn't sure if you provided it, but the OUS Breast Health growth rate, did you guys give that number? And can you remind us [indiscernible] last quarter on what the trend was?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure.",1,"Sure."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Okay. Go ahead, Bob.",4,"Okay. Go ahead, Bob."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat.",18,"Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","What was the last?",4,"What was the last?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And sequentially, it was about flattish as well.",8,"And sequentially, it was about flattish as well."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Right, right.",2,"Right, right."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","[indiscernible] last quarter?",3,"[indiscernible] last quarter?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sorry, you faded out.",4,"Sorry, you faded out."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We just got a garble.",5,"We just got a garble."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?",21,"I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?"
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Improved, yes.",2,"Improved, yes."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Not so say much, I think.",7,"Yes. Not so say much, I think."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. This quarter versus the same quarter last year, net of divestiture is about flat.",15,"Yes. This quarter versus the same quarter last year, net of divestiture is about flat."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Flat, yes.",2,"Flat, yes."
108544,370563080,1014547,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening.",27,"Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike",52,"Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial",206,"Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks today, then we'll have a question-and-answer session.
Our third quarter press release is available now on the Investors section of our website, and we also will post our prepared remarks to our website shortly after we deliver them today. Finally, a replay of this call will be archived on our website through August 26.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known as well as unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release.
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from t",2330,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from turnaround story to sustainable growth company. 
Revenues of $717.4 million exceeded expectations as all 4 of our businesses grew on a global basis, despite a difficult comparison resulting from very strong results in the prior year period. 
In our last call, we focused on the emergence of our surgical business as a growth driver. This quarter, surgical led the way with exceptional performance, but we're also pleased with how our breast imaging, molecular diagnostics and cytology businesses performed. And we made progress in strengthening our international franchises, which we believe will be important contributors to future growth.
Our performance this quarter highlighted the breadth of our top line growth drivers, which is often overlooked. Even as performance has improved ahead of schedule in many areas, new drivers are beginning to emerge, thanks to the deliberate and proactive efforts of our team. And while this quarter is only a single data point, our results do give us increased confidence that revenue growth can continue at a healthy pace in the future. 
Our third quarter results also demonstrated once again our ability to increase profitability above and beyond already high levels. We boosted both gross and operating margins even while reinvesting aggressively to drive future growth. We've been pleasantly surprised at our ability to achieve productivity gains and enjoying many other levers to drive earnings growth.
For example, strategies that we had expected to play out over the longer-term horizon are materializing sooner than expected. Various internal restructuring yielded a lower tax rate in the quarter. And the combination of strong cash flows and market volatility enabled us to buy back more shares. Together, all these efforts led to a very robust net margin of 20.2% in the quarter, non-GAAP earnings per share of $0.51 and excellent EPS growth of 18.6% on a non-GAAP basis.
Based on the strong earnings performance, we are raising our financial guidance for the year and now expect non-GAAP EPS of between $1.93 and $1.94. As a reminder, the mid-point of this new guidance is roughly $0.12 above our guidance at the beginning of the year. We're clearly exceeding our own expectations for a sustainable bottom line growth and feel good about our future prospects in this regard as well.
With that introduction out of the way, I'd like to walk through our revenue highlights in the balance of my remarks. Then Bob will discuss expenses, the rest of our financials and our updated guidance. Unless otherwise noted, percentage changes will be on a year-over-year basis. 
Starting with the big picture. Total revenues were $717.4 million in the third quarter, an increase of 3.4% on a reported basis or 3.6% in constant currency terms. These figures include a roughly $8 million headwind from divested and discontinued products, such as Sentinelle breast coils and the molecular test for cystic fibrosis. If we were to back out this headwind, total revenues would have been grown 4.8% in constant currency terms.
These growth rates are stacked on top of a very difficult comp from the prior year. As a reminder, in the third quarter of 2015, total revenues increased 12.2% in constant currency. So our ability to jump over a high bar this quarter gives us increasing confidence in the ability of our commercial organization to drive solid growth next year and beyond.
In terms of geography. U.S. sales grew 4.7% in the third quarter, continuing a string of good results and indicating the improvements we've made in commercial execution. We continue to enjoy strong leadership positions and good momentum in the domestic marketplace. 
International sales declined 1.2% on a reported basis, driven primarily by blood screening, as expected. In constant currency, international sales declined 0.4%, essentially flat. And if we were to normalize for divested and discontinued products, international sales would have increased slightly. It's also worth mentioning that international sales increased sequentially as well, an encouraging sign. 
Overall, we believe our international results in the third quarter show we are building a foundation for strong and consistent growth over time. Toward that end, our Chief Operating Officer, Eric Compton, has made good progress in filling out our international leadership team in recent months. In last quarter's call, we highlighted new executives in charge of European Breast Health and Service as well as marketing, molecular diagnostics, surgical and regulatory. More recently, we have added new geographic sales leaders to run Latin America, Canada and Asia Pacific. So our efforts to upgrade talent are coming together nicely. 
Shifting to the types of revenue we generate. I want to emphasize that for all the attention our mammography systems receive, capital equipment represented just 23.4% of revenue in the third quarter. Said another way, more than 76% of our sales were recurring. More specifically, disposables, such as our diagnostic assays and surgical tools, represented 60.4%, 6-0 point 4 percent of sales, while service and other totaled 16.2% of sales.
Now let me discuss divisional revenues in the third quarter. I'll start with the growth leader in the quarter, our GYN Surgical business. A couple of years ago, no one would have said those words in the same sentence. But today, our team has achieved what others thought impossible. Worldwide surgical sales were $102 million, surpassing $100 million on a quarterly basis for the first time. Sales grew 19.8% in constant currency, the fastest growth rate for this division in recent memory. 
In the United States, the team delivered double-digit growth for the sixth consecutive quarter. And internationally, the business grew by nearly 40%, albeit off a very small base. 
As many of you know, a competitor recently withdrew its endometrial ablation product from the market. And to capitalize on this, we increased marketing and sales activities in the quarter. As a result, global sales of our NovaSure product totaled $61 million, an increase of 14.6% in constant currency. Not to be overlooked, sales of our MyoSure product for uterine fibroid removal also continued to show strength. Global MyoSure sales of $40.8 million increased 29.8% in constant currency. 
Now let's turn to Breast Health, which has received a lot of attention in recent months. While this is understandable and appropriate, it's just as important to appreciate that Hologic is much more than a mammography company today. Hopefully, our results this quarter help illustrate that point and provide confidence that the entire company can continue to grow revenue solidly and EPS much faster even as growth from 3D adoption naturally slows.
We're very pleased with our Breast Health performance in the quarter. Global sales of $282.5 million increased 1.1%. Breast imaging sales totaled $239.3 million, up 2.3% in constant currency, driven by continued adoption of our Genius 3D Mammography systems. Domestic imaging sales grew more rapidly and exceeded our internal expectations based on Genius placements, which increased both sequentially and year-over-year. 
We estimate the Genius systems are continuing to gain market share while our investments in customer marketing help us maintain stable prices amid fierce competition. We still have lots to look forward to in Breast Health. Genius systems represent less than 40% of our own mammography installed base today, and by our estimate, less than 25% of the market as a whole. And we remain confident in the long-term conversion opportunity as evidence continues to mount on the benefits of Hologic's Genius exams for patients and physicians and as we differentiate ourselves competitively.
As evidence of this, mammography customers recently surveyed by the independent market research firm KLAS scored Hologic highest in overall product satisfaction. One Director of radiology said, ""Hologic seems to be the only company that really understands the tomosynthesis market. It was clear from our implementation and our usage of their system that they are a full generation ahead of other vendors. Everybody else is playing catch-up."" This is only one anecdotal comment, but it's consistent with the customer feedback we receive every day and validates our leadership position. 
As our installed base Genius 3D systems grows, our sales and marketing programs are focusing on ways to leverage this leadership position. For example, service revenue is becoming increasingly important and represents an annuity that complements and smooths out our capital sales. Some of you may not appreciate the size of our service business in Breast Health. To frame it for you, service revenue in this business exceeded $100 million in the quarter for the first time and grew at a mid single-digit rate.
Similarly, we have revamped our research and development efforts to capitalize on our growing Genius footprint and generated more continuous stream of product innovations. For example, we recently launched our new Affirm prone biopsy system, which provides a better patient experience and enables doctors to capitalize on the increased sensitivity of 3D technology. Although it's still early days, customer feedback on this system has been positive, both in the United States and internationally.
Another component of future growth in Breast Health will be our international business. While we still have a lot of work to do here, we are making good progress and are optimistic that the business is becoming healthier and more predictable as we create the foundation for solid growth in 2017 and beyond. In the third quarter, international Breast Health sales declined 2.9% in constant currency. But if we back out the headwind from divested and discontinued products, sales would have been flat. And on a sequential basis, sales increased slightly.
With this in mind, I want to remind everyone that last year's international Breast Health number was exceptionally strong in the fourth quarter. And as a result, we anticipate a year-over-year decline in the coming quarter before the business returns to growth in 2017. As we move into 2017, we do believe that the combination of multiple tailwinds, our still underpenetrated 3D opportunity, growing service revenue, a revitalized R&D effort and international expansion will enable Breast Health to be an important contributor to corporate growth.
Now let's cover diagnostics, which is our largest business and greatest source of non-GAAP operating profit. Diagnostics reported sales of $309.9 million in the third quarter, growing 1.2% in constant currency. Within diagnostics, our cytology and molecular businesses performed well while our blood screening business declined as expected. Global sales of cytology in perinatal products totaled $122.2 million, growing 3.9% on a constant currency basis. Breaking this down a little further, both our ThinPrep and fetal fibronectin franchises grew in the United States and internationally despite lingering headwinds from Pap interval expansion domestically.
Turning to molecular diagnostics. We posted global sales of $131.8 million, up 6.0% in constant currency. Excluding sales of our discontinued cystic fibrosis product, molecular sales would have grown at a high single-digit rate. Our domestic business was solid as our fully automated Panther system continues to accumulate new placements and competitive wins and as utilization of our assays for Trichomonas, HPV and chlamydia gonorrhea continues to grow. 
But the real standout here was our international business. Over the last couple of quarters, international molecular sales have turned slightly positive under new leadership, and we had added viral load assays to the Panther menu. Building on this, the business took a significant step ahead in the third quarter with constant currency growth exceeding 20%. 
In addition, we had a record quarter of Panther placements outside the United States, coupled with a significant step-up in per instrument utilization. All these data points have us feeling good about the potential for international molecular diagnostics to become a new driver of growth for the company over time.
Shifting back to the United States for a moment. During the third quarter, we gained an emergency use authorization for our Zika virus test for diagnostic use. In addition, blood banks began testing donated blood for Zika with our Procleix assay under an investigational new drug protocol. While we do not expect significant sales from these 2 new products, both of which run on the Panther system, our ability to rapidly develop these test shows we can react quickly to public health emergencies in close cooperation with regulators and customers. In addition, should the Zika virus spread in the United States, we will be well positioned in the marketplace.
Apart from the highlight of the Zika IND, our blood screening business declined in the quarter as expected. Worldwide sales of blood screening products were $55.9 million, down 12.9%, with all the decline coming outside the United States. As in the second quarter, this decline was mainly due to stronger ordering in the prior year period to support testing at the Japanese Red Cross combined with continued trends toward lower blood utilization.
Before I turn the call over to Bob, let me wrap up the review of product sales by mentioning that our Skeletal Health division posted revenues of $23.0 million in the quarter. This represented a constant currency increase of 4.8% with growth both domestically and overseas, primarily driven by our Horizon bone density scanner.
So in conclusion, we are very pleased with our third quarter financial results and with the progress we've made toward building a sustainable growth company. Despite very challenging prior year comps, all 4 of our businesses grew in the quarter, reflecting the many growth drivers at our disposal. 
Sales growth in the U.S. Breast Health slowed to a challenging prior year comp, but remained healthy. At the same time, strong results in surgical, molecular diagnostics and cytology demonstrated that Hologic is much more than a mammography company. We continued to execute well in the United States and made good progress building a foundation for international growth. We once again expanded profit margins and redeployed capital, contributing to EPS growth at the highest rate in many years. 
Now I will hand the call over to Bob."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. As a reminder, I will",1503,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. 
As a reminder, I will focus on non-GAAP results, and percentage changes will be on a year-over-year basis unless otherwise noted. As Steve discussed, our revenue performance in the third quarter exceeded expectations, highlighted by global growth in all 4 business segments. This growth, coupled with favorable product mix and productivity gains, again drove improvements in gross and operating margins. At the same time, we continued to invest in initiatives that position us for long-term sustainable growth. Net-net, we delivered EPS growth well in excess of sales, reflecting the impact of operational improvements, capital deployment and a lower effective tax rate.
Now let's dive deeper into the third quarter income statement. Gross margin of 65.7% increased 50 basis points and benefited from the growth of our surgical, cytology and perinatal and Aptima franchises. We continue to manage pricing well as we focus on commercial excellence, and our marketing initiatives highlight the clinical and economic value of our products. 
In addition, our operations teams continue to drive efficiencies and reduce cost across our supply chain. Total operating expenses of $229.2 million increased 3.1% in the third quarter. This increase was driven primarily by sales and marketing expense, which increased 15.5%.
Given our gross margin expansion, we have invested deliberately and opportunistically in commercial areas where we see a good return. These include our Genius marketing campaign in Breast Health, our cervical cancer co-testing initiatives in Diagnostics and efforts to gain competitive market share with NovaSure. These strategic initiatives are paying off through increased brand awareness, market share gains and price stability, all of which contribute to higher sales.
Despite the increased sales and marketing spending, operating margins improved 60 basis points in the quarter, slightly more than gross margins based primarily on leverage in general and administrative expenses. 
Moving down the P&L. Interest expense of $33.9 million was 12% lower than in prior year due to our efforts to both reduce and restructure our debt. And in addition, our tax rate is improving earlier than expected based on changes in our income mix and internal restructurings implemented this year and last. We now estimate that our effective tax rate will be around 32% for the full year 2016.
We trued up to this rate in the third quarter, reducing our effective rate to 30.6%, but we expect the rate to normalize back to 32% in the fourth quarter. As a reminder, our tax rate was 34.25% just last year. So we are making good progress.
We are pleased that these efforts have enabled us to grow net profits even faster than operating profit. Our net margin was 20.2% in the quarter, a very strong level and an improvement of 190 basis points over the prior year. 
To wrap up the income statement review, diluted shares outstanding were 282 million in the third quarter, roughly 10 million lower than a year ago. Over the course of this year, we have worked to pay down a portion of the in-the-money converts to reduce the dilutive effects. And more recently, we have taken advantage of market volatility to repurchase our common stock. 
In the third quarter, we bought back 3 million shares of stock for $101.2 million, which exhausted our prior $250 million repurchase authorization. Recently, our Board of Directors has approved an additional $500 million repurchase program, and we're very pleased to have that arrow in our quiver going forward. 
While we're pleased with the progress we've made, thus far, in improving our capital structure and achieving a more competitive tax rate compared to other med tech companies, we know we can continue to improve. And we believe these improvements will help us deliver EPS growth much faster than revenue over an extended period of time.
Now I'd like to highlight a few balance sheet and cash flow items, beginning with inventory. Inventory decreased by $14.5 million or 4.9% compared to a year ago despite a 3.4% increase in sales. This speaks to the strong alignment between the operations and sales teams, who know that every dollar saved in the inventory serves as dry powder for debt reduction, acquisitions or share repurchase. 
And speaking of our debt, at the end of the third quarter, total debt outstanding was $3.4 billion, a decrease of more than $0.5 billion from a year ago. During the quarter, we paid off $175 million that had been outstanding on our $1 billion revolving line of credit using proceeds borrowed at a lower interest rate under a new $200 million accounts receivable securitization program.
Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization, or EBITDA, totaled $262.5 million in the third quarter, an increase of 5.1%. Based on EBITDA of more than $1 billion over the last 12 months, our leverage ratio calculated as net principal debt over EBITDA, stands at 2.97. The first time this ratio has fallen below 3 since the Gen-Probe acquisition.
In addition, we are well on our way to achieving our target leverage ratio of 2.5x by the end of fiscal 2017. Strong profit growth and lower debt have continued to improve our return on invested capital, or ROIC, which was 12.3% on a trailing 12-month basis, a 170 basis points increase over the prior year. 
Robust cash flows and minimal capital expenditures continue to be hallmarks of Hologic's financial performance. Operating cash flow was $246.2 million in the third quarter, an increase of 1.6%. Free cash flow, defined as operating cash flow less capital expenditures, was $225.1 million. Notably, free cash flow was 55.1% higher than non-GAAP net income. Our financial health clearly extends well beyond our P&L as we continue to focus on working capital and control our capital expenditures.
Now let's turn to our updated financial guidance for the full year and fourth quarter. At the midpoint, we are raising both revenue and non-GAAP EPS guidance based on the company's strong performance in the third quarter. Let's cover the revenue guidance first. 
For the full year, we are increasing our previous guidance by $10 million at the low end and now expect total revenues of between $2.82 billion and $2.83 billion for fiscal 2016. This represents solid mid-single-digit growth of 4.3% to 4.6% on a reported basis, or 5% to 5.3% in constant currency terms, despite the headwind from divested and discontinued products. 
With only one quarter remaining in our fiscal year, this annual guidance obviously implies revenues of $714 million to $724 million in the fourth quarter. Compared to the prior year period, which is another tough comp, this range reflects revenue growth of 1.6% to 3.0% on a reported basis, or 2.1% to 3.6% in constant currency terms. In addition, our guidance includes an expected headwind of roughly $4.5 million from divested and discontinued products, which depresses our constant currency guidance by about 60 basis points.
Based on our revenue range, our fourth quarter guidance implies that revenues will be about the same or slightly above our third quarter actuals. We no longer expect the significant sequential step-up implied by our prior guidance as some revenue that we originally forecast in the fourth quarter materialized a little bit earlier than expected. In addition, we forecast another quarter of incremental softness in blood screening sales as inventories and ordering patterns continue to normalize.
Turning to our updated bottom line guidance. We now forecast non-GAAP EPS of between $1.93 and $1.94 for the full year. This translates to reported growth between 15.5%-- 15 .6% and 16.2% in constant currency growth between 16.9% and 17.5%. This earnings guidance is based on recent foreign exchange rates, a full year tax rate of 32% and diluted shares outstanding approximately 288 million for the full year.
This full year guidance translates to non-GAAP earnings per share of $0.49 to $0.50 in the fourth quarter. This represents growth of 14% to 16.3% on a reported basis or 15% to 17.3% in constant currency terms. Implicit in our fourth quarter guidance is a sequential increase in operating expenses, several million dollars of which relate to a change in the retirement provisions of our equity plan that will make it more consistent with peers. 
Before opening up the call for questions, I want to reiterate how pleased we are with the financial results we achieved so far in fiscal 2016. From a revenue perspective, our surgical business continues to exceed expectations. We still enjoy momentum with Genius 3D Mammography, remain pleased with our molecular diagnostics and ThinPrep businesses and are turning the corner internationally. And from an earnings perspective, we continue to generate tremendous growth through gross and operating margin improvement and lower tax rate and capital deployment.
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we are ready for the first question."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS.",17,"[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika th",65,"Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika that you mentioned? I'm just kind of curious if there were anything else you can -- any other color you can provide on that."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the te",214,"Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the team, getting up to speed. And then we did launch-- we got the clearance, if you recall, early this year, what, really, early this calendar year, to the viral loads. We've got the HCV, HPV and HIV. So they're rolling out in conjunction with the new leadership team and the Panther placements. And those things are really driving it. Zika, by the way, is not in those numbers. So that's really just our core women's health assays, plus the viral load. So I think what we're excited about, as we start to look forward in Diagnostics -- molecular is effectively been nonexistent outside the U.S. and -- not nonexistent, but pretty small. And now we're really getting that footprint. And as we're placing this Panther, it's starting feel like, okay, this is the beginning of something that really is sustainable and have some good growth ahead of it. As well, the cytology business continues to tick along as well with some modest growth outside the U.S. also."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the",142,"I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the STD. And so I think we've got as competitive a menu as anyone else does. So I think what we had seen is a series of quarter -- strong quarterly placements for the last several quarters, and we're starting to get those back on. They're up and running in that tester record. And so I think we're seeing that pull through and seeing the benefits of the Panther system, which we've seen here in the U.S. around benefits of automation and so forth, which I think will really play well, particularly in Europe."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health",57,"I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health? Or are they just 2 different businesses?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside",287,"They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside the U.S. franchise by franchise. I think what we've seen, the new leader within the European diagnostics business, he's bringing a level of focus. He's building out a team. There were some people there. He's changed some out, gotten the others to operate up, but really is starting to build it up. And I think that's what Eric Compton has really been driving, especially this year, is getting the right people in place for the longer term. Yes, just anecdotally, Bob and I happened to be in Japan last week. And again, half of our employees in Japan have been with us less than a year. So it truly is, we look at a company of our size from the outside and think, okay, they just have to get it going and turn around what's there. This really is building it out. So I think we've seen some emerging signs in Diagnostics over the last couple of quarters, didn't want to quite say yet until we thought, okay, this is now sustainable. And I think we're in the same infrastructure building in Breast Health and other stuff. Breast Health because more dealers involved, we'll probably take a little bit longer. But I will tell you underneath the surface, we're feeling very good where, as I always say, the infrastructure gets better before the numbers show it. And I think that's kind of the stages that we're in right now."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move next to Tycho Peterson with JPMorgan.",9,"We'll move next to Tycho Peterson with JPMorgan."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there. Particularly on NovaSure, are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe pickin",44,"Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there. Particularly on NovaSure, are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe picking up some share there?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting and most of the NovaSure growth, I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarte",217,"Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting and most of the NovaSure growth, I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarter, 1.5-ish quarter ahead of us with that. Having said that, I'd remind everybody. As we said, this was our sixth straight quarter of double-digit growth, both domestically and globally, for our GYN surge business. So that business had turned it around, had strengthened dramatically and was then well poised when they -- competitive issue happened. So we're taking advantage of it. MyoSure continues to grow. And I think the way we think about our GYN surge business here is we're not ready to declare it a sustainable double-digit grower, but it's clearly a very solid grower. And again, this is one, where, internationally, we're just in the very early stages as well. So again, it's moved from, what I'd call, an appendage on the company a couple of years ago to something that can actually start to meaningfully contribute to our total growth. It's also hugely accretive to our gross margin, operating margin. It's a great cash generator. There's a lot of good things, and it's helping on our tax rate, frankly."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth qua",97,"Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth quarter really on the back of the work that, that team has done there and the investments we've made in sales and marketing. So that's some of the -- we think that there still is legs there, as Steve said. But that ramp has actually happened nicely for us in the third quarter."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that",86,"Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that's a good proxy for when you ultimately do rollout in the U.S.? And what's the latest thinking on timing? Could you have a viral load here by the end of next year? Or is that more of a 2018 event?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we",168,"Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we bring the viral loads to the United States. So when we bring the viral loads, which to the second part of your question, is really an '18, a fiscal 2018 and probably really second half-ish of '18 by the time we have all 3. So we will have likely one much sooner. But by the time we have HPV, HCV and HIV, it'll be later on in '18. And by that point, we'll be launching in the U.S. from a much bigger installed base,a much stronger position overall. So I think the fact we're able to even have some success in Europe than other people's backyards is already an increasingly encouraging sign for it when we do come to the States."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we will move to Bill Quirk with Piper Jaffray.",12,"At this time, we will move to Bill Quirk with Piper Jaffray."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that",74,"So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that there's potentially an opportunity here over several years to take some incremental share from your 2 principle competitors in the mammography space domestically."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on",211,"Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on the last call might have been more misinterpreted. I think what we're really seeing fundamentally in the Breast Health business is our ability to take more market share than I ever would have imagined, call it, 2, 2.5 years ago. But I think the business is also very encouraging. It's going to be stronger for longer. And while there's been so much obsession from the outside of, what I call, the peak followed by the cliff, we still see -- we're still -- as we said in the script, we're less than 40% even into our own installed base. We're less than 25% even into the installed base in the marketplace. And as we're gaining market share, it says there is still a lot of runway ahead of us. What I've been trying to signal all along is, what, don't expect the kind of growth rates we've had historically. But the business, fundamentally, has a lot of great quarters still ahead of this."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort",63,"Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort of deal, Steve? Or are you still looking around at additional products for the bag?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, w",222,"Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, with the competitive situation. And I think as we go forward, we're just beginning the business development efforts. And I think you'll see a series of things, whether it's a very limited distribution deal like this one, where we're trying it with a few reps and that or 2 outright acquisitions. I would say on the business development front, everybody should know, we've gotten much more active. We've said no to a number of things over the last quarter or 2, and I think a lot of that has been our teams getting very much more disciplined about what we're looking at, and more active. And I think, frankly, getting to the stage where you're saying no to deals and why is the no and what should we be looking for. I think as we go into '17, feeling better and better that we'll be finding some things that we will be saying yes to. But certainly, some may be distribution, some will be outright acquisition. I wouldn't view that as the model of what we'll necessarily be doing. We'll just be flexible."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we'll move to Doug Schenkel with Cowen.",10,"At this time, we'll move to Doug Schenkel with Cowen."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly O US, and surgical growth was quite strong. You remained enthused about Affirm",129,"Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly O US, and surgical growth was quite strong. You remained enthused about Affirm and Brevera. Recognizing one quarter usually doesn't make a trend, would it be fair to say you feel a bit better about your ability to power through the impact of U.S. 3D growth plateauing than you did maybe even a quarter ago? And then for Bob, you beat the midpoint of guidance by -- I think it's $17 million this quarter. You're increasing full year guidance at the midpoint by only $5 million. I was hoping you could provide a bridge between the quarter and the full year guide."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence c",166,"Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence continues to build as I watch each quarter play out. We were going up against a monster comp this quarter. And our team is still really, call it, 2 years old or less for the most part and wanting to make sure that we can deliver before we get out ahead of ourselves. So I think I feel a little bit better. But I think, overall, I feel very confident about where we're headed. I felt more confident than came off last time. So it's not a dramatic shift in how I feel, but it's clearly probably a dramatic shift in the perception. And I own that, but feeling very good about a lot of things we have going on."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million bead. If you call, our previous guidance included a fairly sharp sequ",173,"Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million bead. If you call, our previous guidance included a fairly sharp sequential increase in Q4 revenue. And some of that revenue, as I mentioned actually earlier, materialized a little earlier than expected, places like our surgical business. And then beyond that, we do see potential for incremental kind of sequential weakness within our blood screening businesses as that business continues to normalize from an inventory perspective. So that said, our fourth quarter guidance still implies solid year-over-year growth despite another challenging comparison and a headwind of about 60 basis points from those divested and discontinued products, so we feel good about the guidance. And just as importantly, or maybe more importantly, our EPS guidance is even stronger, multiple -- a series of multiples above that for the fourth quarter growing at 14% to 16% on an as-reported basis."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Jack Meehan with Barclays.",9,"We'll move along to Jack Meehan with Barclays."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I want to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit",82,"I want to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit the inflection at this point last year in terms of the interim placements. Could you walk us through what you think the sustainable rate for that is and whether you're seeing better attachment with 3D placement?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think t",193,"Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think that's a real testament to our sales teams, and more importantly, our service teams and the customer satisfaction that we have with our products. So I don't see any change there, and I think what you would expect to see is a continued -- the nice part about that is it's a nice, solid annuity in that probably mid single-digit growth rate area going forward. Some of this is we're actually transitioning from a 2D system to a 3D system, where you'll get the incremental benefit associated with a higher service contract. And then the beauty of actually the competitive share gains is you get the full benefit of the service contract on that, and we're seeing both of those as well. So we think that, that has a lot of legs not only for the rest of this year but certainly into '17 and beyond."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And one on the early success with the viral load in Europe. Just where you're seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?",42,"Great. That's helpful. And one on the early success with the viral load in Europe. Just where you're seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe.",28,"Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take a question now from David Lewis with Morgan Stanley.",12,"We'll take a question now from David Lewis with Morgan Stanley."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitat",120,"Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitative commentary, and I wonder if you could make it quantitative for us next year. I know it's too early to give guidance. But I think about the fourth quarter, there is stability. Your guidance for the fourth quarter suggests that stability continues. So as you think about next year, low single digits versus mid single-digit revenue growth for the business, what -- are you comfortable in more of a mid single-digit outlook?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have",131,"Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have a solid year in 2017, and we'd clearly be disappointed with the low single-digit 3% number that was mentioned last time. So whatever -- and I think the bigger point I was trying to make last time is, by the way, wherever revenue guidance ends up, we believe we'll deliver EPS growth at a multiple of that. I think that was the broader point I was trying to make that held better. We're feeling about the earnings growth, but do feel incrementally better about the sales growth."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and",132,"Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and where you'll be by the end of '17. I wonder, is '17 a hunting period for M&A and sort of '18 is when we should expect more action? Or given what you see on cash flow and what Bob said about the levels of debt by the end of '17, is next year a year where M&A can become more active in terms of deal consummation? And can you give us any sense if that's true kind of size of those transactions?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect",142,"Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect we'll probably actually execute something in the '17 time frame. Our hunting activities clearly ramped up in, I'd say, the last 3 to 6 months in our activities. And I think '17 will be likely, certainly would contribute as well to '18 growth in some of that. But again, we'll -- as you know, we'll pounce when the opportunities are right and feel like we're in a position that we could today. We are going to continue -- as we're talking about bolt-on, bite-size, kinds of things, we're not looking at billion dollar deals."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disc",97,"And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disciplined in our approach to deal with deals. And so I mean, just in this last quarter, free cash flow at $225 million gives us a lot of flexibility. And we continue to use all levers to continue to drive that higher."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exec comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of a decision",74,"We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exec comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of a decision to say no to a few of the things we've been looking at. So we'll continue to be very disciplined on that."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarte",86,"Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarter wouldn't show the kind of year-on-year improvement you've been showing to the prior 3 quarters. Just our back of the envelope math suggests the fourth quarter margin won't be as robust year-on-year relative to the prior 3 quarters. And I'll jump back in queue."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effect",52,"Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effective in our fourth quarter. That's roughly a $0.01 impact to the quarter."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Isaac Ro with Goldman Sachs.",10,"We'll move along to Isaac Ro with Goldman Sachs."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got. Curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comment",101,"Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got. Curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comments on tax rate in general, you've characterized 2016 as a foundational year with leverage to show up next year. So given that you said things are moving a little faster, just curious if a lot of the leverage that you have hoped for next year has already played out or if we're still kind of in process?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what",102,"Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what I would say is it's too early to tell you specifically what our number in 2017 is. We actually have been able to pull forward. But what I will tell you is, over time, we continue to have opportunities there and expect that effective tax rate to go down."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets of strength across various categories. An",134,"Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets of strength across various categories. And I think yourselves and your competitors have talked about maybe little less gold [ph] in mammo than you would have otherwise guessed given where we are in the adoption curve for tomo. So I'm just curious if you could put any more color on the feedback you're getting, at least, in the U.S. with regards to customer appetite for mammography equipment. Is there anything out there that's kind of causing a temporary slowdown in the adoption process that might explain the trend here versus other categories of equipment?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull",163,"No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull stuff a little bit forward because they wanted to compete and offer it, so we're not seeing that. There is just -- I kind of remind people, there's a fundamental limitation to how many systems can be installed. Use the auto industry as an example, right? If every company launched a new product next year, auto sales don't suddenly jump up from 16 million to 20 million. There's just a natural rate of replacement that is still happening here. And I think that's what leads us back to the stronger for longer that, A, the market's not going to grow by 25% this year. But it's going to be there, and it's there for us as we keep converting."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations.",40,"Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move now to Vijay Kumar with Evercore ISI.",10,"We'll move now to Vijay Kumar with Evercore ISI."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en m",118,"So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en masse has to come in better. We're feeling better about Breast Health. And when we really think about next year, I know you have blood coming, declining maybe for the first half of next year. But offsetting that, you have GYN. Is that sort of the mix of -- when you talk about balance, is this how we're supposed to think about that growth for next year?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre",65,"Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre talk about the next year. Fundamentally, we're feeling good about where this company is headed."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","That's fantastic. And maybe one question on breast imaging or information[ph] in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about it. I'm just",76,"That's fantastic. And maybe one question on breast imaging or information[ph] in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about it. I'm just trying to understand is this a function of -- does this allow you to bundle your cable along with the mammo systems? Is there an opportunity in that area?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best pr",122,"Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best product and we've got a great sales team, I think we have good, good hopes for the Affirm table. And that will really be. The -- we're in the very early stages right now of getting the quotes and getting the orders, basically the sales process through. I do think that'll be a nice contributor to start to kick in here in 2017 for us, and it will help just the overall Breast Health business."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","And next question is from Raj Denhoy with Jefferies.",9,"And next question is from Raj Denhoy with Jefferies."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over",50,"So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over the next few quarters?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the",172,"Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the last, I'd say, last 6 months or so. It's hard to predict timing. And I -- candidly, for any modeling or whatever, I wouldn't assume we necessarily have anything this calendar year. Having said that, we are getting a couple of state mandates. And if you saw recently, both the State of Illinois and the State of Connecticut have now mandated coverage. And we're probably, overall, in the 40% to 45-ish percent coverage, maybe up to 50% in terms of covered lives. But the private pay piece will be probably the next step-up for us. And having said that, just like prior to getting the incremental reimbursement from CMS, we're not sitting there waiting for this to come to sell our systems."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take the final question from Richard Newitter with Leerink Partners.",12,"We'll take the final question from Richard Newitter with Leerink Partners."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a quick one. I wasn't sure if you provided it, but the O US Breast Health growth rate, did you guys give that number? And can you remind us what it was last quarter on what the trend was?",40,"Just a quick one. I wasn't sure if you provided it, but the O US Breast Health growth rate, did you guys give that number? And can you remind us what it was last quarter on what the trend was?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure.",1,"Sure."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Okay. Go ahead, Bob.",4,"Okay. Go ahead, Bob."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat.",18,"Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","What was the last?",4,"What was the last?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And sequentially, it was about flattish as well.",8,"And sequentially, it was about flattish as well."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Right, right.",2,"Right, right."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","[indiscernible] last quarter?",3,"[indiscernible] last quarter?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sorry, you faded out.",4,"Sorry, you faded out."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We just got a garble.",5,"We just got a garble."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?",21,"I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?"
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Improved, yes.",2,"Improved, yes."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. About the same Richard.",5,"Yes. About the same Richard."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. This quarter versus the same quarter last year, net of divestiture is about flat.",15,"Yes. This quarter versus the same quarter last year, net of divestiture is about flat."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Flat, yes.",2,"Flat, yes."
108544,370563080,1014599,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening.",27,"Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike",52,"Good afternoon, and welcome to the Hologic, Inc. Third Quarter Fiscal 2016 Earnings Conference Call. My name is Matt, and I'm your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial",206,"Thank you, Matt. Good afternoon, and thanks for joining us for Hologic's Third Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; as well as Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks today, then we'll have a question-and-answer session.
Our third quarter press release is available now on the Investors section of our website, and we also will post our prepared remarks to our website shortly after we deliver them today. Finally, a replay of this call will be archived on our website through August 26.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known as well as unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release.
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from t",2330,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the third quarter of fiscal 2016. Our results were very solid and illustrate how far we've come and how quickly we're progressing on our journey from turnaround story to sustainable growth company. 
Revenues of $717.4 million exceeded expectations as all 4 of our businesses grew on a global basis, despite a difficult comparison resulting from very strong results in the prior year period. 
In our last call, we focused on the emergence of our surgical business as a growth driver. This quarter, surgical led the way with exceptional performance, but we're also pleased with how our breast imaging, molecular diagnostics and cytology businesses performed. And we made progress in strengthening our international franchises, which we believe will be important contributors to future growth.
Our performance this quarter highlighted the breadth of our top line growth drivers, which is often overlooked. Even as performance has improved ahead of schedule in many areas, new drivers are beginning to emerge, thanks to the deliberate and proactive efforts of our team. And while this quarter is only a single data point, our results do give us increased confidence that revenue growth can continue at a healthy pace in the future. 
Our third quarter results also demonstrated once again our ability to increase profitability above and beyond already high levels. We boosted both gross and operating margins even while reinvesting aggressively to drive future growth. We've been pleasantly surprised at our ability to achieve productivity gains and enjoying many other levers to drive earnings growth.
For example, strategies that we had expected to play out over the longer-term horizon are materializing sooner than expected. Various internal restructuring yielded a lower tax rate in the quarter. And the combination of strong cash flows and market volatility enabled us to buy back more shares. Together, all these efforts led to a very robust net margin of 20.2% in the quarter, non-GAAP earnings per share of $0.51 and excellent EPS growth of 18.6% on a non-GAAP basis.
Based on the strong earnings performance, we are raising our financial guidance for the year and now expect non-GAAP EPS of between $1.93 and $1.94. As a reminder, the mid-point of this new guidance is roughly $0.12 above our guidance at the beginning of the year. We're clearly exceeding our own expectations for a sustainable bottom line growth and feel good about our future prospects in this regard as well.
With that introduction out of the way, I'd like to walk through our revenue highlights in the balance of my remarks. Then Bob will discuss expenses, the rest of our financials and our updated guidance. Unless otherwise noted, percentage changes will be on a year-over-year basis. 
Starting with the big picture. Total revenues were $717.4 million in the third quarter, an increase of 3.4% on a reported basis or 3.6% in constant currency terms. These figures include a roughly $8 million headwind from divested and discontinued products, such as Sentinelle breast coils and the molecular test for cystic fibrosis. If we were to back out this headwind, total revenues would have been grown 4.8% in constant currency terms.
These growth rates are stacked on top of a very difficult comp from the prior year. As a reminder, in the third quarter of 2015, total revenues increased 12.2% in constant currency. So our ability to jump over a high bar this quarter gives us increasing confidence in the ability of our commercial organization to drive solid growth next year and beyond.
In terms of geography. U.S. sales grew 4.7% in the third quarter, continuing a string of good results and indicating the improvements we've made in commercial execution. We continue to enjoy strong leadership positions and good momentum in the domestic marketplace. 
International sales declined 1.2% on a reported basis, driven primarily by blood screening, as expected. In constant currency, international sales declined 0.4%, essentially flat. And if we were to normalize for divested and discontinued products, international sales would have increased slightly. It's also worth mentioning that international sales increased sequentially as well, an encouraging sign. 
Overall, we believe our international results in the third quarter show we are building a foundation for strong and consistent growth over time. Toward that end, our Chief Operating Officer, Eric Compton, has made good progress in filling out our international leadership team in recent months. In last quarter's call, we highlighted new executives in charge of European Breast Health and Service as well as marketing, molecular diagnostics, surgical and regulatory. More recently, we have added new geographic sales leaders to run Latin America, Canada and Asia Pacific. So our efforts to upgrade talent are coming together nicely. 
Shifting to the types of revenue we generate. I want to emphasize that for all the attention our mammography systems receive, capital equipment represented just 23.4% of revenue in the third quarter. Said another way, more than 76% of our sales were recurring. More specifically, disposables, such as our diagnostic assays and surgical tools, represented 60.4%, 6-0 point 4 percent of sales, while service and other totaled 16.2% of sales.
Now let me discuss divisional revenues in the third quarter. I'll start with the growth leader in the quarter, our GYN Surgical business. A couple of years ago, no one would have said those words in the same sentence. But today, our team has achieved what others thought impossible. Worldwide surgical sales were $102 million, surpassing $100 million on a quarterly basis for the first time. Sales grew 19.8% in constant currency, the fastest growth rate for this division in recent memory. 
In the United States, the team delivered double-digit growth for the sixth consecutive quarter. And internationally, the business grew by nearly 40%, albeit off a very small base. 
As many of you know, a competitor recently withdrew its endometrial ablation product from the market. And to capitalize on this, we increased marketing and sales activities in the quarter. As a result, global sales of our NovaSure product totaled $61 million, an increase of 14.6% in constant currency. Not to be overlooked, sales of our MyoSure product for uterine fibroid removal also continued to show strength. Global MyoSure sales of $40.8 million increased 29.8% in constant currency. 
Now let's turn to Breast Health, which has received a lot of attention in recent months. While this is understandable and appropriate, it's just as important to appreciate that Hologic is much more than a mammography company today. Hopefully, our results this quarter help illustrate that point and provide confidence that the entire company can continue to grow revenue solidly and EPS much faster even as growth from 3D adoption naturally slows.
We're very pleased with our Breast Health performance in the quarter. Global sales of $282.5 million increased 1.1%. Breast imaging sales totaled $239.3 million, up 2.3% in constant currency, driven by continued adoption of our Genius 3D Mammography systems. Domestic imaging sales grew more rapidly and exceeded our internal expectations based on Genius placements, which increased both sequentially and year-over-year. 
We estimate the Genius systems are continuing to gain market share while our investments in customer marketing help us maintain stable prices amid fierce competition. We still have lots to look forward to in Breast Health. Genius systems represent less than 40% of our own mammography installed base today, and by our estimate, less than 25% of the market as a whole. And we remain confident in the long-term conversion opportunity as evidence continues to mount on the benefits of Hologic's Genius exams for patients and physicians and as we differentiate ourselves competitively.
As evidence of this, mammography customers recently surveyed by the independent market research firm KLAS scored Hologic highest in overall product satisfaction. One Director of radiology said, ""Hologic seems to be the only company that really understands the tomosynthesis market. It was clear from our implementation and our usage of their system that they are a full generation ahead of other vendors. Everybody else is playing catch-up."" This is only one anecdotal comment, but it's consistent with the customer feedback we receive every day and validates our leadership position. 
As our installed base Genius 3D systems grows, our sales and marketing programs are focusing on ways to leverage this leadership position. For example, service revenue is becoming increasingly important and represents an annuity that complements and smooths out our capital sales. Some of you may not appreciate the size of our service business in Breast Health. To frame it for you, service revenue in this business exceeded $100 million in the quarter for the first time and grew at a mid single-digit rate.
Similarly, we have revamped our research and development efforts to capitalize on our growing Genius footprint and generated more continuous stream of product innovations. For example, we recently launched our new Affirm prone biopsy system, which provides a better patient experience and enables doctors to capitalize on the increased sensitivity of 3D technology. Although it's still early days, customer feedback on this system has been positive, both in the United States and internationally.
Another component of future growth in Breast Health will be our international business. While we still have a lot of work to do here, we are making good progress and are optimistic that the business is becoming healthier and more predictable as we create the foundation for solid growth in 2017 and beyond. In the third quarter, international Breast Health sales declined 2.9% in constant currency. But if we back out the headwind from divested and discontinued products, sales would have been flat. And on a sequential basis, sales increased slightly.
With this in mind, I want to remind everyone that last year's international Breast Health number was exceptionally strong in the fourth quarter. And as a result, we anticipate a year-over-year decline in the coming quarter before the business returns to growth in 2017. As we move into 2017, we do believe that the combination of multiple tailwinds, our still underpenetrated 3D opportunity, growing service revenue, a revitalized R&D effort and international expansion will enable Breast Health to be an important contributor to corporate growth.
Now let's cover diagnostics, which is our largest business and greatest source of non-GAAP operating profit. Diagnostics reported sales of $309.9 million in the third quarter, growing 1.2% in constant currency. Within diagnostics, our cytology and molecular businesses performed well while our blood screening business declined as expected. Global sales of cytology in perinatal products totaled $122.2 million, growing 3.9% on a constant currency basis. Breaking this down a little further, both our ThinPrep and fetal fibronectin franchises grew in the United States and internationally despite lingering headwinds from Pap interval expansion domestically.
Turning to molecular diagnostics. We posted global sales of $131.8 million, up 6.0% in constant currency. Excluding sales of our discontinued cystic fibrosis product, molecular sales would have grown at a high single-digit rate. Our domestic business was solid as our fully automated Panther system continues to accumulate new placements and competitive wins and as utilization of our assays for Trichomonas, HPV and chlamydia gonorrhea continues to grow. 
But the real standout here was our international business. Over the last couple of quarters, international molecular sales have turned slightly positive under new leadership, and we had added viral load assays to the Panther menu. Building on this, the business took a significant step ahead in the third quarter with constant currency growth exceeding 20%. 
In addition, we had a record quarter of Panther placements outside the United States, coupled with a significant step-up in per instrument utilization. All these data points have us feeling good about the potential for international molecular diagnostics to become a new driver of growth for the company over time.
Shifting back to the United States for a moment. During the third quarter, we gained an emergency use authorization for our Zika virus test for diagnostic use. In addition, blood banks began testing donated blood for Zika with our Procleix assay under an investigational new drug protocol. While we do not expect significant sales from these 2 new products, both of which run on the Panther system, our ability to rapidly develop these test shows we can react quickly to public health emergencies in close cooperation with regulators and customers. In addition, should the Zika virus spread in the United States, we will be well positioned in the marketplace.
Apart from the highlight of the Zika IND, our blood screening business declined in the quarter as expected. Worldwide sales of blood screening products were $55.9 million, down 12.9%, with all the decline coming outside the United States. As in the second quarter, this decline was mainly due to stronger ordering in the prior year period to support testing at the Japanese Red Cross combined with continued trends toward lower blood utilization.
Before I turn the call over to Bob, let me wrap up the review of product sales by mentioning that our Skeletal Health division posted revenues of $23.0 million in the quarter. This represented a constant currency increase of 4.8% with growth both domestically and overseas, primarily driven by our Horizon bone density scanner.
So in conclusion, we are very pleased with our third quarter financial results and with the progress we've made toward building a sustainable growth company. Despite very challenging prior year comps, all 4 of our businesses grew in the quarter, reflecting the many growth drivers at our disposal. 
Sales growth in the U.S. Breast Health slowed to a challenging prior year comp, but remained healthy. At the same time, strong results in surgical, molecular diagnostics and cytology demonstrated that Hologic is much more than a mammography company. We continued to execute well in the United States and made good progress building a foundation for international growth. We once again expanded profit margins and redeployed capital, contributing to EPS growth at the highest rate in many years. 
Now I will hand the call over to Bob."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. As a reminder, I will",1503,"Thank you, Steve, and good afternoon, everyone. I'm going to walk through the rest of our third quarter income statement, highlight a few balance sheet and cash flow items, and then wrap up with updated financial guidance for 2016. 
As a reminder, I will focus on non-GAAP results, and percentage changes will be on a year-over-year basis unless otherwise noted. As Steve discussed, our revenue performance in the third quarter exceeded expectations, highlighted by global growth in all 4 business segments. This growth, coupled with favorable product mix and productivity gains, again drove improvements in gross and operating margins. At the same time, we continued to invest in initiatives that position us for long-term sustainable growth. Net-net, we delivered EPS growth well in excess of sales, reflecting the impact of operational improvements, capital deployment and a lower effective tax rate.
Now let's dive deeper into the third quarter income statement. Gross margin of 65.7% increased 50 basis points and benefited from the growth of our surgical, cytology and perinatal and Aptima franchises. We continue to manage pricing well as we focus on commercial excellence, and our marketing initiatives highlight the clinical and economic value of our products. 
In addition, our operations teams continue to drive efficiencies and reduce cost across our supply chain. Total operating expenses of $229.2 million increased 3.1% in the third quarter. This increase was driven primarily by sales and marketing expense, which increased 15.5%.
Given our gross margin expansion, we have invested deliberately and opportunistically in commercial areas where we see a good return. These include our Genius marketing campaign in Breast Health, our cervical cancer co-testing initiatives in Diagnostics and efforts to gain competitive market share with NovaSure. These strategic initiatives are paying off through increased brand awareness, market share gains and price stability, all of which contribute to higher sales.
Despite the increased sales and marketing spending, operating margins improved 60 basis points in the quarter, slightly more than gross margins based primarily on leverage in general and administrative expenses. 
Moving down the P&L. Interest expense of $33.9 million was 12% lower than in prior year due to our efforts to both reduce and restructure our debt. And in addition, our tax rate is improving earlier than expected based on changes in our income mix and internal restructurings implemented this year and last. We now estimate that our effective tax rate will be around 32% for the full year 2016.
We trued up to this rate in the third quarter, reducing our effective rate to 30.6%, but we expect the rate to normalize back to 32% in the fourth quarter. As a reminder, our tax rate was 34.25% just last year. So we are making good progress.
We are pleased that these efforts have enabled us to grow net profits even faster than operating profit. Our net margin was 20.2% in the quarter, a very strong level and an improvement of 190 basis points over the prior year. 
To wrap up the income statement review, diluted shares outstanding were 282 million in the third quarter, roughly 10 million lower than a year ago. Over the course of this year, we have worked to pay down a portion of the in-the-money converts to reduce the dilutive effects. And more recently, we have taken advantage of market volatility to repurchase our common stock. 
In the third quarter, we bought back 3 million shares of stock for $101.2 million, which exhausted our prior $250 million repurchase authorization. Recently, our Board of Directors has approved an additional $500 million repurchase program, and we're very pleased to have that arrow in our quiver going forward. 
While we're pleased with the progress we've made, thus far, in improving our capital structure and achieving a more competitive tax rate compared to other med tech companies, we know we can continue to improve. And we believe these improvements will help us deliver EPS growth much faster than revenue over an extended period of time.
Now I'd like to highlight a few balance sheet and cash flow items, beginning with inventory. Inventory decreased by $14.5 million or 4.9% compared to a year ago despite a 3.4% increase in sales. This speaks to the strong alignment between the operations and sales teams, who know that every dollar saved in the inventory serves as dry powder for debt reduction, acquisitions or share repurchase. 
And speaking of our debt, at the end of the third quarter, total debt outstanding was $3.4 billion, a decrease of more than $0.5 billion from a year ago. During the quarter, we paid off $175 million that had been outstanding on our $1 billion revolving line of credit using proceeds borrowed at a lower interest rate under a new $200 million accounts receivable securitization program.
Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization, or EBITDA, totaled $262.5 million in the third quarter, an increase of 5.1%. Based on EBITDA of more than $1 billion over the last 12 months, our leverage ratio calculated as net principal debt over EBITDA, stands at 2.97. The first time this ratio has fallen below 3 since the Gen-Probe acquisition.
In addition, we are well on our way to achieving our target leverage ratio of 2.5x by the end of fiscal 2017. Strong profit growth and lower debt have continued to improve our return on invested capital, or ROIC, which was 12.3% on a trailing 12-month basis, a 170 basis points increase over the prior year. 
Robust cash flows and minimal capital expenditures continue to be hallmarks of Hologic's financial performance. Operating cash flow was $246.2 million in the third quarter, an increase of 1.6%. Free cash flow, defined as operating cash flow less capital expenditures, was $225.1 million. Notably, free cash flow was 55.1% higher than non-GAAP net income. Our financial health clearly extends well beyond our P&L as we continue to focus on working capital and control our capital expenditures.
Now let's turn to our updated financial guidance for the full year and fourth quarter. At the midpoint, we are raising both revenue and non-GAAP EPS guidance based on the company's strong performance in the third quarter. Let's cover the revenue guidance first. 
For the full year, we are increasing our previous guidance by $10 million at the low end and now expect total revenues of between $2.82 billion and $2.83 billion for fiscal 2016. This represents solid mid-single-digit growth of 4.3% to 4.6% on a reported basis, or 5% to 5.3% in constant currency terms, despite the headwind from divested and discontinued products. 
With only one quarter remaining in our fiscal year, this annual guidance obviously implies revenues of $714 million to $724 million in the fourth quarter. Compared to the prior year period, which is another tough comp, this range reflects revenue growth of 1.6% to 3.0% on a reported basis, or 2.1% to 3.6% in constant currency terms. In addition, our guidance includes an expected headwind of roughly $4.5 million from divested and discontinued products, which depresses our constant currency guidance by about 60 basis points.
Based on our revenue range, our fourth quarter guidance implies that revenues will be about the same or slightly above our third quarter actuals. We no longer expect the significant sequential step-up implied by our prior guidance as some revenue that we originally forecast in the fourth quarter materialized a little bit earlier than expected. In addition, we forecast another quarter of incremental softness in blood screening sales as inventories and ordering patterns continue to normalize.
Turning to our updated bottom line guidance. We now forecast non-GAAP EPS of between $1.93 and $1.94 for the full year. This translates to reported growth between 15.5%-- 15 .6% and 16.2% in constant currency growth between 16.9% and 17.5%. This earnings guidance is based on recent foreign exchange rates, a full year tax rate of 32% and diluted shares outstanding approximately 288 million for the full year.
This full year guidance translates to non-GAAP earnings per share of $0.49 to $0.50 in the fourth quarter. This represents growth of 14% to 16.3% on a reported basis or 15% to 17.3% in constant currency terms. Implicit in our fourth quarter guidance is a sequential increase in operating expenses, several million dollars of which relate to a change in the retirement provisions of our equity plan that will make it more consistent with peers. 
Before opening up the call for questions, I want to reiterate how pleased we are with the financial results we achieved so far in fiscal 2016. From a revenue perspective, our surgical business continues to exceed expectations. We still enjoy momentum with Genius 3D Mammography, remain pleased with our molecular diagnostics and ThinPrep businesses and are turning the corner internationally. And from an earnings perspective, we continue to generate tremendous growth through gross and operating margin improvement and lower tax rate and capital deployment.
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we are ready for the first question."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS.",17,"[Operator Instructions] And we'll move to our first question, which will be from Jonathan Groberg with UBS."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika th",65,"Can you maybe talk a little bit, Steve, about international and diagnostics? I think you said that was up 20% currency neutral record Panther placements. Was there anything beyond kind of new management, better execution? Did that benefit from the Zika that you mentioned? I'm just kind of curious if there were anything else you can -- any other color you can provide on that."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the te",214,"Yes, Jonathan, thank you. It's really, to be very clear, it is the new management that we put in place. We actually hired a new leader for our European diagnostics business really just about a year ago. It was last summer. And he has been revamping the team, getting up to speed. And then we did launch-- we got the clearance, if you recall, early this year, what, really, early this calendar year, to the viral loads. We've got the HCV, HPV and HIV. So they're rolling out in conjunction with the new leadership team and the Panther placements. And those things are really driving it. Zika, by the way, is not in those numbers. So that's really just our core women's health assays, plus the viral load. So I think what we're excited about, as we start to look forward in Diagnostics -- molecular is effectively been nonexistent outside the U.S. and -- not nonexistent, but pretty small. And now we're really getting that footprint. And as we're placing this Panther, it's starting feel like, okay, this is the beginning of something that really is sustainable and have some good growth ahead of it. As well, the cytology business continues to tick along as well with some modest growth outside the U.S. also."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the",142,"I was going to say -- hey, Jonathan. This is Bob. Just to build on what Steve was saying. I mean, I think really, what we're seeing right now is a very competitive assay menu when we're going up against the competitive nature with the viral loads and the STD. And so I think we've got as competitive a menu as anyone else does. So I think what we had seen is a series of quarter -- strong quarterly placements for the last several quarters, and we're starting to get those back on. They're up and running in that tester record. And so I think we're seeing that pull through and seeing the benefits of the Panther system, which we've seen here in the U.S. around benefits of automation and so forth, which I think will really play well, particularly in Europe."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health",57,"I guess, if I can just follow-up. The basis for my question is, is there anything that you can learn from kind of the new management? And how long it took? And what you're seeing that it's all applicable to what you may be able to achieve in Breast Health? Or are they just 2 different businesses?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside",287,"They are different business, but there is a lot to learn. And I think, Jonathan, probably the way to think the way about it is, as we started to describe really about this time last year, we really are moving in -- we're really a start-up company outside the U.S. franchise by franchise. I think what we've seen, the new leader within the European diagnostics business, he's bringing a level of focus. He's building out a team. There were some people there. He's changed some out, gotten the others to operate up, but really is starting to build it up. And I think that's what Eric Compton has really been driving, especially this year, is getting the right people in place for the longer term. Yes, just anecdotally, Bob and I happened to be in Japan last week. And again, half of our employees in Japan have been with us less than a year. So it truly is, we look at a company of our size from the outside and think, okay, they just have to get it going and turn around what's there. This really is building it out. So I think we've seen some emerging signs in Diagnostics over the last couple of quarters, didn't want to quite say yet until we thought, okay, this is now sustainable. And I think we're in the same infrastructure building in Breast Health and other stuff. Breast Health because more dealers involved, we'll probably take a little bit longer. But I will tell you underneath the surface, we're feeling very good where, as I always say, the infrastructure gets better before the numbers show it. And I think that's kind of the stages that we're in right now."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move next to Tycho Peterson with JPMorgan.",9,"We'll move next to Tycho Peterson with JPMorgan."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there. Particularly on NovaSure, are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe pickin",44,"Steve, wondering if you could talk about the sustainability of GYN surge. Obviously, you're seeing some good strength there. Particularly on NovaSure, are you able to disaggregate how much of that is coming from the [indiscernible] recall and maybe picking up some share there?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting and most of the NovaSure growth, I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarte",217,"Sure. Great question, Tycho. I think the way we should think about it right now is we're clearly benefiting and most of the NovaSure growth, I think we should say it's candidly coming from a competitive recall, which we still have another, call it, quarter, 1.5-ish quarter ahead of us with that. Having said that, I'd remind everybody. As we said, this was our sixth straight quarter of double-digit growth, both domestically and globally, for our GYN surge business. So that business had turned it around, had strengthened dramatically and was then well poised when they -- competitive issue happened. So we're taking advantage of it. MyoSure continues to grow. And I think the way we think about our GYN surge business here is we're not ready to declare it a sustainable double-digit grower, but it's clearly a very solid grower. And again, this is one, where, internationally, we're just in the very early stages as well. So again, it's moved from, what I'd call, an appendage on the company a couple of years ago to something that can actually start to meaningfully contribute to our total growth. It's also hugely accretive to our gross margin, operating margin. It's a great cash generator. There's a lot of good things, and it's helping on our tax rate, frankly."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth qua",97,"Yes. Hey, Tycho. This is Bob. Just to build on that. We actually referenced some of the exceeding expectations. We actually think that some of the share gains materialized a little earlier in the third quarter than what we were expecting in the fourth quarter really on the back of the work that, that team has done there and the investments we've made in sales and marketing. So that's some of the -- we think that there still is legs there, as Steve said. But that ramp has actually happened nicely for us in the third quarter."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that",86,"Okay. And then just as a follow-up to the question earlier on diagnostics. It's early days for viral load. I don't know if you can put any metrics around how that business has tracked relative to your expectations. But can you also talk about whether that's a good proxy for when you ultimately do rollout in the U.S.? And what's the latest thinking on timing? Could you have a viral load here by the end of next year? Or is that more of a 2018 event?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we",168,"Sure. It's still pretty small within Europe. It's not yet material to the company, but I think the initial signs are pretty good. And what's, I think, very encouraging to us is, in Europe, we're launching from a much weaker base than where we are when we bring the viral loads to the United States. So when we bring the viral loads, which to the second part of your question, is really an '18, a fiscal 2018 and probably really second half-ish of '18 by the time we have all 3. So we will have likely one much sooner. But by the time we have HPV, HCV and HIV, it'll be later on in '18. And by that point, we'll be launching in the U.S. from a much bigger installed base,a much stronger position overall. So I think the fact we're able to even have some success in Europe than other people's backyards is already an increasingly encouraging sign for it when we do come to the States."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we will move to Bill Quirk with Piper Jaffray.",12,"At this time, we will move to Bill Quirk with Piper Jaffray."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that",74,"So I guess, Steve, just to start off on tomo here. I think your tomo was a little more positive perhaps than last quarter, and I'm curious if we can dig into why. I mean, has that anything to do with the competitive dynamic? I mean, it strikes to me that there's potentially an opportunity here over several years to take some incremental share from your 2 principle competitors in the mammography space domestically."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on",211,"Sure, Bill, it's probably because I just met with our Breast Health sales leadership team earlier today. But no, aside from that, it -- we continue to feel very good about where that business is going. I think some of the comments -- one of my comments on the last call might have been more misinterpreted. I think what we're really seeing fundamentally in the Breast Health business is our ability to take more market share than I ever would have imagined, call it, 2, 2.5 years ago. But I think the business is also very encouraging. It's going to be stronger for longer. And while there's been so much obsession from the outside of, what I call, the peak followed by the cliff, we still see -- we're still -- as we said in the script, we're less than 40% even into our own installed base. We're less than 25% even into the installed base in the marketplace. And as we're gaining market share, it says there is still a lot of runway ahead of us. What I've been trying to signal all along is, what, don't expect the kind of growth rates we've had historically. But the business, fundamentally, has a lot of great quarters still ahead of this."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort",63,"Fantastic. Separately, on surgical. Just spend a couple of minutes here on the Bovie Medical deal. Is this a sort of, I guess, deal we should be expecting or deals we should be expecting in surgical going forward, kind of a ""try it before you buy it"" sort of deal, Steve? Or are you still looking around at additional products for the bag?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, w",222,"Sure, thanks. As we've said, we're clearly looking for additional products for surgical. Having said that, right now, I'm really glad we don't have much more because we've been handed this opportunity to permanently increase our market share, obviously, with the competitive situation. And I think as we go forward, we're just beginning the business development efforts. And I think you'll see a series of things, whether it's a very limited distribution deal like this one, where we're trying it with a few reps and that or 2 outright acquisitions. I would say on the business development front, everybody should know, we've gotten much more active. We've said no to a number of things over the last quarter or 2, and I think a lot of that has been our teams getting very much more disciplined about what we're looking at, and more active. And I think, frankly, getting to the stage where you're saying no to deals and why is the no and what should we be looking for. I think as we go into '17, feeling better and better that we'll be finding some things that we will be saying yes to. But certainly, some may be distribution, some will be outright acquisition. I wouldn't view that as the model of what we'll necessarily be doing. We'll just be flexible."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","At this time, we'll move to Doug Schenkel with Cowen.",10,"At this time, we'll move to Doug Schenkel with Cowen."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly O US, and surgical growth was quite strong. You remained enthused about Affirm",129,"Maybe first question for Steve, second question for Bob. Steve, in the third quarter, there were a number of nice developments. Molecular is better than expected, particularly O US, and surgical growth was quite strong. You remained enthused about Affirm and Brevera. Recognizing one quarter usually doesn't make a trend, would it be fair to say you feel a bit better about your ability to power through the impact of U.S. 3D growth plateauing than you did maybe even a quarter ago? And then for Bob, you beat the midpoint of guidance by -- I think it's $17 million this quarter. You're increasing full year guidance at the midpoint by only $5 million. I was hoping you could provide a bridge between the quarter and the full year guide."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence c",166,"Great. Thanks, Doug. I'd say I feel a little bit better. I think the truth is I've always felt a lot better than I probably communicated. On the last call, I truly believe there was a complete overreaction. And my strength does continue or my confidence continues to build as I watch each quarter play out. We were going up against a monster comp this quarter. And our team is still really, call it, 2 years old or less for the most part and wanting to make sure that we can deliver before we get out ahead of ourselves. So I think I feel a little bit better. But I think, overall, I feel very confident about where we're headed. I felt more confident than came off last time. So it's not a dramatic shift in how I feel, but it's clearly probably a dramatic shift in the perception. And I own that, but feeling very good about a lot of things we have going on."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million bead. If you call, our previous guidance included a fairly sharp sequ",173,"Yes, Doug. Hey, this is Bob. Just to follow-up on the second part of your question. Yes, as you mentioned, we did raise the guidance by $5 million at the midpoint versus the $17 million bead. If you call, our previous guidance included a fairly sharp sequential increase in Q4 revenue. And some of that revenue, as I mentioned actually earlier, materialized a little earlier than expected, places like our surgical business. And then beyond that, we do see potential for incremental kind of sequential weakness within our blood screening businesses as that business continues to normalize from an inventory perspective. So that said, our fourth quarter guidance still implies solid year-over-year growth despite another challenging comparison and a headwind of about 60 basis points from those divested and discontinued products, so we feel good about the guidance. And just as importantly, or maybe more importantly, our EPS guidance is even stronger, multiple -- a series of multiples above that for the fourth quarter growing at 14% to 16% on an as-reported basis."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Jack Meehan with Barclays.",9,"We'll move along to Jack Meehan with Barclays."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I want to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit",82,"I want to start with some of the commentary around the service contracts in Breast Health, and I think I caught this was the first quarter over $100 million. I know there's some moving parts around warranty and just how that's rolled through since you hit the inflection at this point last year in terms of the interim placements. Could you walk us through what you think the sustainable rate for that is and whether you're seeing better attachment with 3D placement?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think t",193,"Hey, Jack. This is Bob. I think from an attachment rate perspective, we continue to feel very good about our attachment rate. We haven't seen any incremental change, either up or down. And it continues to be very strong, in excess of 85%. And so I think that's a real testament to our sales teams, and more importantly, our service teams and the customer satisfaction that we have with our products. So I don't see any change there, and I think what you would expect to see is a continued -- the nice part about that is it's a nice, solid annuity in that probably mid single-digit growth rate area going forward. Some of this is we're actually transitioning from a 2D system to a 3D system, where you'll get the incremental benefit associated with a higher service contract. And then the beauty of actually the competitive share gains is you get the full benefit of the service contract on that, and we're seeing both of those as well. So we think that, that has a lot of legs not only for the rest of this year but certainly into '17 and beyond."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Great. That's helpful. And one on the early success with the viral load in Europe. Just where you're seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?",42,"Great. That's helpful. And one on the early success with the viral load in Europe. Just where you're seeing some wins? Where do you think you're differentiated in the market? Could you just walk us through the value proposition for the Panther?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe.",28,"Yes, I think it's the same benefits largely we have here, which is workflow automation. And the Panther system, the footprint is a very nice addition for Europe."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take a question now from David Lewis with Morgan Stanley.",12,"We'll take a question now from David Lewis with Morgan Stanley."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitat",120,"Steve, I was hoping you could -- it's hard to miss this qualitative commentary around stronger for longer. You just said it so much this call, I thought maybe you'd make it the new Hologic tagline. But the reality is I like you to maybe take that qualitative commentary, and I wonder if you could make it quantitative for us next year. I know it's too early to give guidance. But I think about the fourth quarter, there is stability. Your guidance for the fourth quarter suggests that stability continues. So as you think about next year, low single digits versus mid single-digit revenue growth for the business, what -- are you comfortable in more of a mid single-digit outlook?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have",131,"Hey, David, based on the market reaction following our last call, I think we'll stick to giving the guidance in our fourth quarter call rather than commenting on the number before we formally approve the budget. Having said that, we do believe we'll have a solid year in 2017, and we'd clearly be disappointed with the low single-digit 3% number that was mentioned last time. So whatever -- and I think the bigger point I was trying to make last time is, by the way, wherever revenue guidance ends up, we believe we'll deliver EPS growth at a multiple of that. I think that was the broader point I was trying to make that held better. We're feeling about the earnings growth, but do feel incrementally better about the sales growth."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and",132,"Okay. I think that resonated, Steve. And a couple of points maybe for -- one for Steve and one for Bob. I guess the first thing is, Steve, M&A has not been a part of the story here since you arrived. But you've given Bob's comments about the leverage and where you'll be by the end of '17. I wonder, is '17 a hunting period for M&A and sort of '18 is when we should expect more action? Or given what you see on cash flow and what Bob said about the levels of debt by the end of '17, is next year a year where M&A can become more active in terms of deal consummation? And can you give us any sense if that's true kind of size of those transactions?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect",142,"Yes, David, as you know, it's really hard to predict an exact timing. I'd say we're looking at stuff right now, so it could be any time. Having said that, just given the pragmatic realities of where we stand in our current fiscal year, '17, I would expect we'll probably actually execute something in the '17 time frame. Our hunting activities clearly ramped up in, I'd say, the last 3 to 6 months in our activities. And I think '17 will be likely, certainly would contribute as well to '18 growth in some of that. But again, we'll -- as you know, we'll pounce when the opportunities are right and feel like we're in a position that we could today. We are going to continue -- as we're talking about bolt-on, bite-size, kinds of things, we're not looking at billion dollar deals."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disc",97,"And I think, David, and just to build on that, I mean, I think what we feel we're very comfortable is, is that we have plenty of capacity to be able to do things when we want to. And we will look at many more than we will ever do, and we will be very disciplined in our approach to deal with deals. And so I mean, just in this last quarter, free cash flow at $225 million gives us a lot of flexibility. And we continue to use all levers to continue to drive that higher."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exec comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of a decision",74,"We do, and David, I think you know from a couple of years back looking at it, our -- and talking about our exec comp plan, we are very focused on ROIC, and given the history of this company and where we've been. And that's still been a part of a decision to say no to a few of the things we've been looking at. So we'll continue to be very disciplined on that."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarte",86,"Okay. I think investors will certainly appreciate that, Steve. And then lastly, Bob, just looking at the fourth quarter guidance. As you mentioned, the revenue trends look stable with the third quarter. Is there any reason why margins in the fourth quarter wouldn't show the kind of year-on-year improvement you've been showing to the prior 3 quarters. Just our back of the envelope math suggests the fourth quarter margin won't be as robust year-on-year relative to the prior 3 quarters. And I'll jump back in queue."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effect",52,"Yes. Just quickly, we talked about we anticipate continued commercial investments that are going to drive incrementally or sequentially from Q3 to Q4. And probably, more importantly, the change in our retirement plan that I mentioned before will be effective in our fourth quarter. That's roughly a $0.01 impact to the quarter."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move along to Isaac Ro with Goldman Sachs.",10,"We'll move along to Isaac Ro with Goldman Sachs."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got. Curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comment",101,"Bob, just a question on tax rate to start. You mentioned in your prepared comments on the internal restructuring initiatives, you've got. Curious if that's an ongoing process, like it carries through the next year. And as I look back on your prior comments on tax rate in general, you've characterized 2016 as a foundational year with leverage to show up next year. So given that you said things are moving a little faster, just curious if a lot of the leverage that you have hoped for next year has already played out or if we're still kind of in process?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what",102,"Yes. So we feel very good about the progress that we've been making, Isaac, and have been working very hard. As you know, our tax rate is much higher than any of our med tech peers, and so that is one of the big focus areas that my team has got. And what I would say is it's too early to tell you specifically what our number in 2017 is. We actually have been able to pull forward. But what I will tell you is, over time, we continue to have opportunities there and expect that effective tax rate to go down."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets of strength across various categories. An",134,"Okay. And then just the last one coming back to mammography. You covered a lot of ground there. But if I'd look at sort of what's going on broadly in capital equipment in med tech, there's been pretty good pockets of strength across various categories. And I think yourselves and your competitors have talked about maybe little less gold [ph] in mammo than you would have otherwise guessed given where we are in the adoption curve for tomo. So I'm just curious if you could put any more color on the feedback you're getting, at least, in the U.S. with regards to customer appetite for mammography equipment. Is there anything out there that's kind of causing a temporary slowdown in the adoption process that might explain the trend here versus other categories of equipment?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull",163,"No, Isaac. We're not seeing any real slowdown or pushback from the customer. It's just much a capacity issue of the hospitals to take what they have and natural replacement cycles more than anything. And I'd say, if anything, we've had more customers pull stuff a little bit forward because they wanted to compete and offer it, so we're not seeing that. There is just -- I kind of remind people, there's a fundamental limitation to how many systems can be installed. Use the auto industry as an example, right? If every company launched a new product next year, auto sales don't suddenly jump up from 16 million to 20 million. There's just a natural rate of replacement that is still happening here. And I think that's what leads us back to the stronger for longer that, A, the market's not going to grow by 25% this year. But it's going to be there, and it's there for us as we keep converting."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations.",40,"Yes. Hey, Isaac. This is Bob. Just one of the things that we look at that we continue to feel good about and pleased with is the actual bookings as well, and those continue to meet and exceed our expectations."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll move now to Vijay Kumar with Evercore ISI.",10,"We'll move now to Vijay Kumar with Evercore ISI."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en m",118,"So maybe I'll start with the big picture question, Steve. I know you said that you wouldn't comment on the '17 outlook. But just maybe, I mean, if I have to think out loud on some of the moving parts for next year, right, so it looks like diagnostics en masse has to come in better. We're feeling better about Breast Health. And when we really think about next year, I know you have blood coming, declining maybe for the first half of next year. But offsetting that, you have GYN. Is that sort of the mix of -- when you talk about balance, is this how we're supposed to think about that growth for next year?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre",65,"Vijay, I'd love to give you a better answer, but I really want to get the budget nailed. But I think we're feeling good about the trajectory of where we're headed. And sorry, I can't get specific at this point. But it didn't serve me well last time to pre talk about the next year. Fundamentally, we're feeling good about where this company is headed."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","That's fantastic. And maybe one question on breast imaging or information[ph] in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about it. I'm just",76,"That's fantastic. And maybe one question on breast imaging or information[ph] in the breast, I guess. I know you guys launched the cable launch, and it made you looked kind of softer on the interventions side. We don't talk a whole lot about it. I'm just trying to understand is this a function of -- does this allow you to bundle your cable along with the mammo systems? Is there an opportunity in that area?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best pr",122,"Yes, the -- what's really in the interventional today is mostly the disposable activity, and that has been under a little bit of pressure. I think as we do launch the table, whether it's bundling per se or just the fact that we've got probably the best product and we've got a great sales team, I think we have good, good hopes for the Affirm table. And that will really be. The -- we're in the very early stages right now of getting the quotes and getting the orders, basically the sales process through. I do think that'll be a nice contributor to start to kick in here in 2017 for us, and it will help just the overall Breast Health business."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","And next question is from Raj Denhoy with Jefferies.",9,"And next question is from Raj Denhoy with Jefferies."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over",50,"So maybe just staying on breast imaging for a minute. There's still lack of insurance coverage for, I think, most women in the United States for 3D imaging. Is there any progress on expanded coverage at this point? Or anything we can look forward to over the next few quarters?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the",172,"Yes. I think, Raj, we're deeply engaged in a lot of discussions. I think I've said historically, that was not -- the private pay competency was not something we had as much in our company. And -- but our team has really made a lot of progress just in the last, I'd say, last 6 months or so. It's hard to predict timing. And I -- candidly, for any modeling or whatever, I wouldn't assume we necessarily have anything this calendar year. Having said that, we are getting a couple of state mandates. And if you saw recently, both the State of Illinois and the State of Connecticut have now mandated coverage. And we're probably, overall, in the 40% to 45-ish percent coverage, maybe up to 50% in terms of covered lives. But the private pay piece will be probably the next step-up for us. And having said that, just like prior to getting the incremental reimbursement from CMS, we're not sitting there waiting for this to come to sell our systems."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","We'll take the final question from Richard Newitter with Leerink Partners.",12,"We'll take the final question from Richard Newitter with Leerink Partners."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","Just a quick one. I wasn't sure if you provided it, but the O US Breast Health growth rate, did you guys give that number? And can you remind us what it was last quarter on what the trend was?",40,"Just a quick one. I wasn't sure if you provided it, but the O US Breast Health growth rate, did you guys give that number? And can you remind us what it was last quarter on what the trend was?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sure.",1,"Sure."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes.",1,"Yes."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Okay. Go ahead, Bob.",4,"Okay. Go ahead, Bob."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat.",18,"Yes. Down in constant currency, 2.9%. And if you adjusted for the divested and discontinued, it's roughly flat."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","What was the last?",4,"What was the last?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","And sequentially, it was about flattish as well.",8,"And sequentially, it was about flattish as well."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Right, right.",2,"Right, right."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","[indiscernible] last quarter?",3,"[indiscernible] last quarter?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Sorry, you faded out.",4,"Sorry, you faded out."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","We just got a garble.",5,"We just got a garble."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Analysts","I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?",21,"I was just looking for the trend. What was that year-over-year growth rate trend from last quarter to the current quarter?"
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Improved, yes.",2,"Improved, yes."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. About the same Richard.",5,"Yes. About the same Richard."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Yes. This quarter versus the same quarter last year, net of divestiture is about flat.",15,"Yes. This quarter versus the same quarter last year, net of divestiture is about flat."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Executives","Flat, yes.",2,"Flat, yes."
108544,370563080,1014846,"Hologic Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Hologic, Inc.","Operator","Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening.",27,"Ladies and gentlemen, that is all the time we have for questions today. This now concludes Hologic's Third Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introd",53,"Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions] I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Camille. Good afternoon, everyone, and thank you for joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer.",219,"Thank you, Camille. Good afternoon, everyone, and thank you for joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob both have some prepared remarks today, and then we'll have a question-and-answer session.
Our fourth quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through November 25.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP financial measures can be found in our earnings release. Finally, any percentage changes that we discuss will be on a year-over-year basis, unless otherwise noted. 
Now I'd like to turn the call over to Steve MacMillan, Hologic CEO."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth c",1853,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth company. In addition, our results capped off a very good fiscal 2016, in which we delivered on our commitments. Today, our I'll first provide a high-level overview of our fourth quarter results. But since it's the end of our fiscal year, we'd also like to provide a strategic update on the journey we've shared over the last 3 years. We'll focus on a revenue and financial drivers for the full year and provide some color on the behind-the-scenes progress we're making in research and development. 
Let's start with our fourth quarter results. Revenue of $726.8 million grew 3.4% on a reported basis or 3.8% in constant currency, a healthy performance despite a difficult comparison to the prior year period. We also absorbed a headwind of nearly $4 million from divested and discontinued products. Net of these, total revenues would have grown 4.4% in constant currency. 
Our Surgical business again, set the pace with its seventh straight quarter of double-digit growth globally. We are also pleased with how our breast imaging and molecular diagnostics businesses performed and encouraged that new products began to contribute to growth. We'll come back to this point in a minute. 
In terms of geography, U.S. sales grew 7.4% in the quarter, continuing a string of strong results. Even if we exclude the $5 million royalty payment from our fourth quarter results, our growth rate accelerated on a sequential basis. 
As expected, international sales declined 9.6% as reported, or 7.8% in constant currency versus a difficult comparison in the prior year period. Apart from this tough comp, international Breast Health was stable sequentially in the quarter. There were also some pockets of strength globally namely molecular diagnostics and Surgical, both of which posted double-digit growth. Although these businesses are relatively small today outside the U.S., we believe they will be important growth drivers in 2017 and beyond. 
Profit margins remained robust in the quarter. Most importantly, non-GAAP net income grew 14.6%, more than 3x faster than sales. And our net margin of 20% increased by 190 basis points. With the benefit of additional capital deployment, we posted non-GAAP EPS of $0.52, or 20.9% better than in the prior year period. So all in all, we posted a very strong fourth quarter that exceeded expectations and capped off an excellent year. 
Thinking about the year as a whole, we made good progress in our journey from turnaround story to sustainable growth company. To date, our successes have been most visible in domestic sales execution, which in turn has driven the improved financial performance of the company. One of the first goals we established 3 years ago was to stabilize 2 highly profitable products that had been declining sharply: ThinPrep and NovaSure. In 2016, these products were more than stable, they returned to solid growth. Cytology and perinatal sales increased 2% on the year in constant currency. Even more impressive, NovaSure sales grew 10% in constant currency as our team capitalized on the market withdrawal of a competing product. 
As we stabilized ThinPrep and NovaSure, we also set out to maximize growth drivers such as Genius 3D Mammography systems and the Panther platform in molecular diagnostics. Both of these product performed well in 2016. 
Genius drove 5.2% constant-currency growth in total Breast Health sales in 2016 and we remained bullish on the opportunity ahead of us. While, there has been lots of debate about a key consistent placements, we have a fundamentally different and more positive view of the future. The 3D curve is very different than the 2D curve for a number of reasons. And we believe Breast Health sales will be stronger for longer than many anticipate. 
Although we placed about 3,600 systems in the United States as of the end of the fiscal year, the market is still underpenetrated. For example, 3D installations represent a little more than 40% of total Hologic mammography systems. And if you look at MQSA statistics, 3D installations represented just 1/4 of total systems. We have been placing roughly 300 units per quarter in the U.S. recently, and at this stage should enjoy many more quarters of solid performance. 
We are also gaining significant market share from our competitors. While our innovative marketing strategies enable us to maintain stable pricing. 
As our domestic installed base 3D units has grown, so is the related service opportunity. Breast Health service revenue again, exceeded $100 million in the quarter, and increased at a high single-digit rate boosting overall growth. This increase in service revenue, combined with the potential of new products, gives us confidence that Breast Health can continue to grow even as 3D adoption matures. 
Now let's turn to a second major growth driver, the Panther system, our fully automated diagnostics instrument. Panther helped our molecular business growth 7.8% in constant currency in 2016. Beyond increase sales of women's health test for chlamydia gonorrhea, HPV and Trichomonas. By the end of fiscal 2016, we have shipped more than 1,000 Panther units just to Diagnostics customers. And we are encouraged that a growing number of these placements are coming internationally. Panther shipments to customers outside the United States grew dramatically in 2016, and we believe we are just scratching the surface of this long-term opportunity. 
At the same time, our sales team is partnering with lab and physician customers to ensure that patients are tested according to the best clinical guidelines, providing better care, while increasing organic volumes. In fact, on a global basis, the average Panther generated more than $190,000 in assay revenue in 2016, a high single digit increase in utilization. And we are optimistic that this number will increase further as we roll out viral load assays in Europe and the United States. 
As we look back on fiscal 2016, the stabilization of ThinPrep and NovaSure, combined with strong growth Genius and Panther, drove excellent fully results. You might recall that 12 months ago, our initial guidance called for revenue of $2.81 billion to $2.84 billion for the year. We finished at $2.83 billion, so we delivered on our commitment. 
At the same time, we achieved significant margin improvement in 2016. For the year, non-GAAP gross margin was 65.6%, an impressive 140 basis points better than last year. This enabled us to make incremental investments in marketing and R&D to drive future growth, while still delivering operating income of 33.6%, 30 basis points better than in 2015. Combined with a lower tax rate and repurchases of both convertible debt and common shares, we posted non-GAAP earnings per share of $1.96 in 2016. This was 17.4% higher than in the prior year, and comfortably ahead of our original guidance. 
Looking beyond earnings, we're also very pleased with our cash flow in 2016, which is often underappreciated. We generated $787.2 million in operating cash with only $94.5 million in CapEx. And roughly half of this CapEx went toward revenue-generating instruments such as our Panther systems. As a result, free cash flow for the year was $692.7 million, 23.3% higher than non-GAAP net income. Our operations and finance teams deserve tremendous credit for making this happen. As one measure of their success, inventories at year-end 2016 were $8.4 million less than a year ago, even though product revenues were about $109 million higher. Taking a step further, inventories are now below the levels of even 2 years ago demonstrating tremendous progress by our team. 
Obviously these strong cash flows gave us the flexibility to continue improving our capital structure in 2016. We repurchased $274.2 million of convertible notes for $392.8 million during the year as well as 7.3 million shares of common stock for $250 million. As a result, our leverage ratio, net debt over EBITDA, has fallen to 2.8x, a little more than half what it was at the time of the Gen-Probe acquisition. In addition, diluted shares outstanding were slightly lower in 2016 than in the prior year, providing a boost to EPS. 
Before I turn the call over to Bob, I want to emphasize that strong cash flows also enabled us to invest appropriately and consistently in research and development, which increased about 8% this year, and we are just beginning to see the fruits of our labor. In the fourth quarter 2016, sales of key new products exceeded $10 million in revenue for the first time. These new products include viral assays in Diagnostics, the Affirm biopsy system in Breast Health and [indiscernible] in surgical. We recognize that $10 million is still small in the context of overall Hologic, but it's a good start. And we are optimistic about the potential of these products in 2017. 
In addition, our R&D pipeline is building behind the first wave of new products. In Diagnostic, we recently filed for regulatory approval of our Aptima hepatitis C viral load test in the United States, and anticipate launching it commercially in 2017 following the introduction of our HIV viral load assay. Sales of these products will become more meaningful in 2018 when we also have a hepatitis B assay available. We also filed recently for U.S. regulatory approval of our herpes test, which will compliment our existing portfolio of women's health products on the Panther system. And finally, we are beginning clinical trials for our respiratory assays on the next generation Panther Fusion system. 
In Breast Health, we have fundamentally reshaped our R&D strategy away from the boom-and-bust approach of the past toward a model that strives for continuous innovation, built around our leadership position in 3D mammography. The Affirm prone biopsy system fits in this vein; as does our upcoming Brevera product, which will provide realtime specimen radiography to improve breast biopsy workflow and the patient experience. We are hopeful that Brevera will begin to contribute to growth late in 2017 and more meaningfully in 2018. 
Finally, in Surgical, we are encouraged by the early success of our MyoSure REACH line extension, which is providing new capabilities to customers and therefore, helping expand the market. In the same way, we are working to leverage our market-leading position in endometrial ablation by launching internationally in next-generation NovaSure device that will improve patient comfort as well as physician usability. 
Compared to the dramatic improvement you've seen in U.S. sales execution, our progress in research and development is just becoming invisible. We have a lot of work to do in these areas but are excited about our early progress. In some ways, domestic sales execution represents the tip of the iceberg in terms of what's possible here. Below the surface, we are working diligently to boost new product innovation, build our international capabilities and further enhance profitability. As our new leadership team settles in and as talented, engaged employees at all levels of the organization continue to do their thing, we look forward to sharing more successes with you in 2017 and beyond. 
Now I will hand the call over to Bob."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise note",1744,"Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise noted, my commentary will focus on non-GAAP results and revenue growth rates will be expressed in constant currency. 
We closed out our fiscal year with results that surpassed expectations. Revenue grew at a healthy rate, and favorable gross margins allowed us to reinvest opportunistically in the business while still delivering strong bottom line growth. 
Albeit begin by discussing our surgical division, which remains the growth leader in the quarter with the sales of $101.5 million and growth of 17.6%. Fueling this growth was MyoSure where sales of $42.6 million grew 33.4%, thanks to the outstanding efforts of our commercial teams. In addition, NovaSure sales grew 8.7% as we continue to gain market share and capitalize on a competitive withdrawal. 
Now moving to Diagnostics. We posted sales of $311.9 million in the quarter, a solid growth rate of 3.1%. In molecular diagnostics, quarterly sales of $134.3 million increased 9.6%. As Steve noted, we booked a $5 million royalty payment this quarter but at the same time, we also absorbed a headwind of almost $3 million from our discontinued fibrosis product line. So the underlying trend in the business remained strong, and we continue to gain share and increased utilization of women's health assays on the fully automated Panther instrument.  In addition, international sales grew at a mid-teens rate, and we posted yet another record quarter of Panther placement outside the U.S., providing a strong platform for future growth. 
Elsewhere in Diagnostics, our cytology and perinatal products posted sales of $121 million, and increased slightly compared to the prior year period. Share gains for our ThinPrep product line continue to offset headwinds from longer cervical cancer screening interval. 
And finally, our blood business declined 6% as expected as we continue to see the impact of lower blood utilization and fluctuating order partners by our Grifols. Partially offsetting these headwinds were initiative sales of our Zika products. As we enter 2017, we believe macro trends toward lower blood utilization will continue to be a drag on sales growth. 
Now moving to Breast Health. We posted global sales of $292.3 million, and solid growth of 2.3% over another challenging comp. In the U.S., continued adoption of Genius 3D systems was supplemented by growing service annuity and our sales of our new Affirm prone biopsy system driving an increase of 7.2% in sales. Over the last 2 quarters, our U.S. Breast Health results have clearly illustrated a point we've made repeatedly in recent months, that the business can continue to grow despite increasingly challenging comps. 
And to round out our revenue discussion, Skeletal Health revenue is of $21.2 million decreased 17.3% in constant currency, due mainly to lower volumes of our floor scan mini C-arm products. 
Now moving down the income statement. Fourth quarter gross margins of 65.7% increased 110 basis points compared to the prior year period. Gross margins benefited from both geographic and product mix as well as continued pricing discipline and operational improvements. 
Total operating expenses of $235.5 million increased 7.7% in the fourth quarter. We continue to take advantage of improving gross margins to reinvest strategically in the business. For example, quarterly R&D spending increased 16.3%, and we're beginning to see some of the benefits as Steve discussed. In addition, as we mentioned last quarter, our change in the retirement provisions of our equity plan drove an additional $4 million of expense. Despite these investments, our non-GAAP operating margin remained a healthy 33.3% in the quarter. 
Below the line, we continue to make good progress in 2 areas that have been a priority for our financial organization. Based on lower debt levels, interest expense of $32.9 million in the fourth quarter declined 14.8%. At the same time, our non-GAAP effective tax rate of 31% in the quarter was more than 300 basis points lower than a year ago. While we are very pleased with the results we produced in a short amount of time, we are still beginning stages of this process and see continued opportunity ahead. 
And finally, to wrap up the fourth quarter income statement, non-GAAP EPS of $0.52 grew 20.9% compared to a year ago, much faster than sales growth. The multiple levers used to drive EPS growth in the quarter give us comfort in our ability to continue growing EPS at a multiple sales. 
Now let me turn to cash flows and the balance sheet. In the fourth quarter, adjusted EBITDA of $263.9 million improved 5.2%. We continue to focus on reducing our convertible debt. In the fourth quarter, we repurchased $47.6 million in principle of our 2037 notes for $81.3 million, and intend to redeem the remaining $12 million in cash when the notes are callable this December. Despite retiring a portion of our convertible debt and repurchasing shares over the course of 2016, we ended the year with $548.4 million in cash, an increase of $57.1 million compared to the prior year. We finished the year with total debt of $3.3 billion, a reduction of $0.3 billion compared to the prior year. And our leverage ratio, net debt over EBITDA, currently sits at 2.8x, close to our target of 2.5x. This combination of strong profit growth and lower debt not continues to drive improvement to return on invested capital. As of year-end, ROIC was 12.7% on a trailing 12-month basis, an increase of 180 basis points over the prior year. 
Now I'd like to cover our non-GAAP financial guidance for fiscal 2017. We are forecasting mid-single-digit revenue growth in '17 on top of increasingly challenging comps. We expect an improving operating margin and lower tax rate to drive EPS growth at roughly double the rate of sales growth. Specifically, we anticipate constant-currency revenue growth of between 4% and 5.5% in fiscal 2017. At recent exchange rates, this equates to sales of $2.94 billion to $2.98 billion on a reported basis with reported growth rates between 3.8% and 5.2%. As you update your forecast, we would encourage you to model at the middle of our guidance range at this early stage as we've tried to set realistic ranges that incorporate those potential upsides and downsides. 
Our guidance includes the net benefit of 3 extra selling days based on our fiscal calendar. Compared to the prior year period, we will gain 4 selling days in the first quarter. Although this will be the historically slow week between Christmas and New Year's, while we loose 1 day in the fourth quarter. We estimate this benefit to be between 50 and 70 basis points of sales growth with a negligible effect on EPS. At the same time, our guidance also includes a roughly $5 million headwind from products that we have either divested or recently decided to discontinue. In other words, our guidance would have been about 20 basis points higher if these products remained in our portfolio. 
In terms of divisional growth for 2017. Our guidance contemplates low to mid-single-digit in Diagnostic and Skeletal, mid-single-digit growth in Breast Health, and slightly higher growth in Surgical. In Diagnostics, molecular should leave the charge behind Panther in an expanded international menu, including urology assays. We forecast the cytology and perinatal sales will be flat to up slightly and we also expect blood to be flat to up slightly as new Zika sales offset negative macro trends. 
In Breast Health, we expect continued growth in Genius 3D Mammography, a growing service annuity, contributions from new products including the Affirm prone biopsy system and Brevera toward the end of the year, as well as a return to growth for our international business. 
In Surgical, we expect growth to be driven by MyoSure market expansion efforts and NovaSure share gains as well as international sales. 
Geographically, we expect our international business to begin contributing to growth in fiscal 2017, in line with the company's overall growth rate. 
In terms of the profitability, we forecast continued improvement in non-GAAP operating margin in 2017 but how we get there will be different than last year. In 2017, we forecast a slight improvement in non-GAAP gross margin percentage, combined with greater leverage from operating expenses, leading to more improvement in operating margin than we saw last year. All of these leads us to forecast that earnings per share will be between $2.12 and $2.16 in 2017. This represents growth of 8.5% to 10.6% in constant currency and reported growth of between 8.2% and 10.2%. Again, we encourage you to model at the middle of our guidance range at this early stage of the year. This guidance assumes a full year tax rate of approximately 31% and diluted shares outstanding of between 289 million and 291 million for the year. Our guidance does not assume any capital deployment beyond calling what's left of our 2730 -- 2037 convertible notes in December. 
Now let's cover guidance for the first quarter of fiscal 2017. We expect revenues of $720 million to $730 million, flattish on a sequential basis as the benefit from extra seeling days between Christmas and New Year's is offset with the normal seasonal decline we experienced due to our global sales meetings and conference in Breast Health. Compared to the prior year period, this range reflects revenue growth of 3.8% to 5.2% on a constant-currency basis and reported revenue growth of 3.6% to 5.0%. 
We forecast non-GAAP diluted earnings per share of $0.50 to $0.51 in the first quarter. This represents anticipated growth of 9.1% to 11.3% in constant-currency terms, or 8.7% to 10.9% on a reported basis. Compared to our fourth quarter actuals, please note that operating expenses will increase in the first quarter due to the timing of sales and marketing activities in the extra days. 
Before we open the call for questions, let me conclude by saying that our fourth quarter capped off another good year for the company. Our financial performance demonstrates that we were transforming from our turnaround story to a sustainable growth company. We feel confident about the foundation we've established heading into 2017, and have the levers necessary to deliver mid-single-digit revenue growth with EPS growth roughly double that rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions] Operator, we are ready for our first question."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] Our first question is from Brian Weinstein with William Blair.",12,"[Operator Instructions] Our first question is from Brian Weinstein with William Blair."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Breaking like a 108 year [ph] curse in a couple of hours, so I appreciate that. So as we look at your guidance range, you had clearly at a time that you're going to give a wider range and you certainly did that. I'm curious, you guided us to the midpoint",114,"Breaking like a 108 year [ph] curse in a couple of hours, so I appreciate that. So as we look at your guidance range, you had clearly at a time that you're going to give a wider range and you certainly did that. I'm curious, you guided us to the midpoint but on the high end and low end there e. Is that really a function of kind of how you expect new products to contribute, you talked about $10 million from that this quarter and whatnot but do you expect that new products early to differentiating factor between the high-end and the low end, and then the color around that will be helpful?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to don't no matter what we put into our forecast, it always come out a little differently. And I think just it's very prudent thing given, particularl",194,"Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to don't no matter what we put into our forecast, it always come out a little differently. And I think just it's very prudent thing given, particularly environment to have a slightly broader range. I do think we see a little more, if the new products are doing well, which we fully expect they will, I think it clearly pushes us towards that higher end. I think we get into that 5 percentage range if things take off. We always want to be a little cautious until we start to see the success. I will tell you, I think Affirm is also off to very nice start. MyoSure REACH off to a very nice should part. And these are really the first new products we've launched since we've come on. And also international molecular diagnostics business is really starting to take off. We had a couple of quarters there of double-digit growth as well. So there's a lot we feel good about. But again, still really early stages and a lot of play out."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","And this is Mike, just to build on that, some of these products haven't gotten full approval yet as well. There's an estimate of the timing to start with. But certainly, feel very good about our path there. But there is some flexibility there as well.",46,"And this is Mike, just to build on that, some of these products haven't gotten full approval yet as well. There's an estimate of the timing to start with. But certainly, feel very good about our path there. But there is some flexibility there as well."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And you mentioned you ask specifically in molecular diagnostics, and you think you talked about a return to growth next year somewhere in the mid-single digits or something overall. But can you talk about some of the things more specifically, OUS, that gu",60,"And you mentioned you ask specifically in molecular diagnostics, and you think you talked about a return to growth next year somewhere in the mid-single digits or something overall. But can you talk about some of the things more specifically, OUS, that guys are focused on what other product or focus on next year that could potentially add growth there?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think a couple of things we're excited about for international. First is the new leadership team there that's put in place. As we exit this year, we basically got a completely new leadership team internationally from how we entered the year. Other",145,"Yes, I think a couple of things we're excited about for international. First is the new leadership team there that's put in place. As we exit this year, we basically got a completely new leadership team internationally from how we entered the year. Other than our leader of the Diagnostics business in Europe, who's already showing and really been leading the way with great growth. But as I think as we look to international, the molecular diagnostics business out to be a real standout for us. I think Surgical continuing off of a smaller base, but continued to show good growth. And Breast Health will return to some growth as we're working a lot, tailored with our dealers and getting things in place there. So I think we feel incrementally significantly better answering this year that we did at this time, last year about international."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Tycho Peterson with JPMorgan.",9,"Our next question is from Tycho Peterson with JPMorgan."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Steve, want to actually focus on margins. Guidance assumes some nice operating margin. Can you talk a little bit the drivers? I know you've over invested during the growth boom, so can you maybe talk about some of the leverage couple from margin expansion",46,"Steve, want to actually focus on margins. Guidance assumes some nice operating margin. Can you talk a little bit the drivers? I know you've over invested during the growth boom, so can you maybe talk about some of the leverage couple from margin expansion in 2017?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, we clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well. And obviously, way high on EPS line. We've really -- I'd say those we expanded and invested more in our rate of sales will probably c",66,"Sure, we clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well. And obviously, way high on EPS line. We've really -- I'd say those we expanded and invested more in our rate of sales will probably come back into those being slightly leverageable relative to the rate of sales as we go into the current year."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?",40,"And as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We really applaud CIGNA. They obviously got onboard. I would tell you, it's a struggle with both aetna and United at this point. We're working through it. We would love them to take the same approach towards to their patients that CIGNA did, but we'",76,"Sure. We really applaud CIGNA. They obviously got onboard. I would tell you, it's a struggle with both aetna and United at this point. We're working through it. We would love them to take the same approach towards to their patients that CIGNA did, but we're working through with them and we basically have not assumed that they come and that could be an additional source of upside if or when they fall during the year."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk from Piper Jaffray.",10,"Our next question comes from Bill Quirk from Piper Jaffray."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just a couple of questions for the viral guys, obviously, glad to hear that everything's on track for the U.S. launches and if we're doing the math right, I think you should be accretive to the overall Diagnostics gross margins that. That said, we've also",88,"Just a couple of questions for the viral guys, obviously, glad to hear that everything's on track for the U.S. launches and if we're doing the math right, I think you should be accretive to the overall Diagnostics gross margins that. That said, we've also heard about some pricing pressure over Europe. And can you help us kind of the set the stage for us about what you expect in the U.S. and then maybe just a couple of words on what you're seeing in Europe thus far."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. To be clear, the virals will be a very small contributor in 2017 in the United States. And that's where they're going to be coming at a much better margin. So right now, they are contributing to the top line growth and certainly, top and bottom line",72,"Sure. To be clear, the virals will be a very small contributor in 2017 in the United States. And that's where they're going to be coming at a much better margin. So right now, they are contributing to the top line growth and certainly, top and bottom line in Europe. But the big pickup for us will really be more in '18 on the margin side as it relates to the virals."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements -- 2016 was a very good year at Panther placements specifically in Europe, but also internationally, in general. I think that's largely in the back",113,"Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements -- 2016 was a very good year at Panther placements specifically in Europe, but also internationally, in general. I think that's largely in the back of our viral system, our viral load assays. And we'll get the full benefit of that in 2017 as those instruments are replaced in kind of full year. The other thing is in that we have -- we noted that the revenue or pull through per Panther has increased. That's both in the U.S. as well as internationally. so i think that that's a harbinger for good growth going forward."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","On the overall pricing dynamics [indiscernible].",6,"On the overall pricing dynamics [indiscernible]."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, pricing is lower in the U.S -- in Europe. But it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated.",42,"Yes, pricing is lower in the U.S -- in Europe. But it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have Vijay Kumar with Evercore ISI.",8,"Next, we have Vijay Kumar with Evercore ISI."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I feel like your overall [indiscernible] just given what happened in glad to see this come through. Just may be one on the guidance on revenue. What does the guidance assume for OUS growth, international growth for next year, because I would have thought",62,"I feel like your overall [indiscernible] just given what happened in glad to see this come through. Just may be one on the guidance on revenue. What does the guidance assume for OUS growth, international growth for next year, because I would have thought just given what happened sequentially 3Q versus 4Q international trends, any color on the international will be helpful."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know the last couple of years, it's been way skewed to the U.S. has been generating most of the grow",123,"Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know the last couple of years, it's been way skewed to the U.S. has been generating most of the growth. But I think we see this year really [indiscernible]. Recall that the current quarter is not indicative of a trend given that last year's fourth quarter turns out -- there was a lot more put into the last year's fourth quarter than we fully understood just dealers what in to maintain our contracts against minimums and things like that. So I think again, we feel far better coming into this year and seeing expected growth."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then may be one for -- go ahead, Bob.",11,"Great. And then may be one for -- go ahead, Bob."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, just going to say, the other thing to bear in mind there, we had mentioned the blood screening business will be roughly flat to slightly up year-on-year, that was a big headed internationally through all of 2016 as the inventories in ordering pattern",69,"Yes, just going to say, the other thing to bear in mind there, we had mentioned the blood screening business will be roughly flat to slightly up year-on-year, that was a big headed internationally through all of 2016 as the inventories in ordering patterns of our partner, we're adjusting. So we expect to kind of lap that. So that gives us hope for turning that trajectory around as well."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then maybe one for you, Bob. You did mentioned that the guidance doesn't assume anything on the cap employment. I think on any -- on your prepared remarks you also highlighted the free cash generation, right. I guess, my question is, what the focus fo",54,"And then maybe one for you, Bob. You did mentioned that the guidance doesn't assume anything on the cap employment. I think on any -- on your prepared remarks you also highlighted the free cash generation, right. I guess, my question is, what the focus for cash cap deployment over the next 12 months?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&",98,"Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&A activities, and then finally, share repurchase. The latter of those 2 is hard to predict. And certainly, the convertible notes, we don't have those ability to actually call those formally until 2018. And so that's why we've done it. But we will be opportunistic as appropriate within the market."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Just to clarify, that would be fiscal 2018?",8,"Just to clarify, that would be fiscal 2018?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","December of 2017.",3,"December of 2017."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Doug Schenkel with Cowen and Company.",12,"And our next question comes from Doug Schenkel with Cowen and Company."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I guess, I have one question on just assumptions you're baking into guidance, it has a few parts to it. So I'll just rattle through these, and I'll get back in the queue. The first part is for new products, seems like you might assuming that new products",139,"I guess, I have one question on just assumptions you're baking into guidance, it has a few parts to it. So I'll just rattle through these, and I'll get back in the queue. The first part is for new products, seems like you might assuming that new products contribute about 100 basis points to fiscal '17 growth at the midpoint of guide, is that about, right? Secondly, what's your view on the sustainability of NovaSure growth given the benefit from competitive disruptions will annualized over the course of this fiscal year? Third, are there any major blood bank tenders that come up this year that we should be contemplating in our models? And lastly, how do you expect Panther utilization to increase above the $190,000 annualized figure that you provided in fiscal '17, based on geographic and menu expansion?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Doug, you sure you want to [indiscernible] ball?",8,"Doug, you sure you want to [indiscernible] ball?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","One question was [indiscernible] let me take -- it's Bob, I'll take that first on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had menti",299,"One question was [indiscernible] let me take -- it's Bob, I'll take that first on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned the 100 basis points, that's probably at the low end, maybe it's a little higher than that maybe 150 basis points probably at the midpoint to think about that and that's really driven behind the Affirm and Zika, probably the 2 largest new products. Brevera will happen, but it's in the back half of the year, and certainly some of the virals and U.S. will play role, but again, the majority of that will happen in 2018. So that's the first question. I think sustainability of NovaSure, we feel very good about that. But remember the formal withdrawal, the competitive product happened in our second quarter, so we expect to have larger and better growth in first and second quarters than we would have in the back half of the year a. We expect growth throughout the course of the year, but the first and second quarters will be bigger than the back half for NovaSure. In terms of the major blood banks, those are -- you need to ask Grifols, those are their customers. And so we're not going to be able to be in a position to answer that. And then in terms of Panther utilization, we do expect -- that's one of the big areas that we're very focused on is the continuing to not only place Panther systems but increase the utilization of the installed base. So I do expect that utilization to grow in line with the forecast that we had talked about for molecular business."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","We have Isaac Ro with Goldman Sachs.",7,"We have Isaac Ro with Goldman Sachs."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So just want to spend a minute talking about the innovation. You guys clearly done a great job restoring consistency in the core business, but maybe a little bit less appreciated than some of the new products you put out there, both the ones you mentioned",129,"So just want to spend a minute talking about the innovation. You guys clearly done a great job restoring consistency in the core business, but maybe a little bit less appreciated than some of the new products you put out there, both the ones you mentioned and maybe some of the ones you haven't talked about. So if I look at the R&D spend here, it's up, good amount year-on-year and just thinking a little bit about how to frame the way you guys are investing your R&D dollars going forward. May be when you talk a good about mathematically where you think your best then for your buck is invested and as we look over a multi-year period, how should we think about investment across the various divisions?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. If you take a macro view at it, Isaac, we've dramatically overhaul really the R&D organizations at all 3 businesses. And really proud -- it's taken some work and it's all been happening behind the scenes. But really trying to break that grand slam o",378,"Sure. If you take a macro view at it, Isaac, we've dramatically overhaul really the R&D organizations at all 3 businesses. And really proud -- it's taken some work and it's all been happening behind the scenes. But really trying to break that grand slam or the bombast ideas. So what we've got going on now is a lot of folks focused on both substantial innovation but also incremental innovation. And if you take our Surgical business as an example, we have launched NovaSure and launched MyoSure and never really did any product upgrades or anything through the years, just threw them out there and watch eventually price degrade or whatever else. So launching MyoSure REACH is a classic example of something that we're working on. We also just mentioned we're actually launching an upgraded NovaSure product outside the United States. You can imagine we'll be planning on bringing about to the United States once we get that to approval. Likewise, in Breast Health, instead of just focusing on the replacement for 3D tomo, saying, okay, what are we going to do in the meantime, and how can we leverage 3D? Well, the Affirm prone biopsy system, Brevera. There will be other things that are looking at in that vein as well. And again, we wanted to put some points on the board before we start talking about the future. Because as you know, words and the new same as it relates to effectively the Diagnostic business, there were things that were not truly in play when we got here, we turbocharged diffusion, the development of the Fushion platform, which is then opening up that ability to do the same kind of singles and doubles as it relates to future assays. And be able to broaden up the menu there. And again, those will be a lot of singles and doubles that will come behind the viral load programs. And we're really hunkered down early on to push viral loads through and across the finish line, those have been kind of up and down, on the end of and really put a sustained commitment and starting to feel very, very good about our ability in each of the divisions to be bringing in more steady stream of innovation."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Isaac, this is Bob. Just to build on what Steve's saying. I mean, Steve talks a lot about people making difference. And so over the last several years, we've really only focused on rebuilding the commercial teams but also the R&D teams. And so when I thin",166,"Isaac, this is Bob. Just to build on what Steve's saying. I mean, Steve talks a lot about people making difference. And so over the last several years, we've really only focused on rebuilding the commercial teams but also the R&D teams. And so when I think about the R&D spend, we spend roughly 8% any year -- any quarter, it can change. That's probably the right amount, but I think, right now, what we've done is fundamentally, as Steve mentioned, changed the mindset of the organizations in how they're going about actually developing products, linking R&D with marketing, truly having insight-driven innovation and creating that competitive advantage. We spent the most money as a percent of sales in our Diagnostic business, less in breast and in our Surgical businesses. I think that, that probably is going to stay roughly the same, but it's really the make up of it and the leadership making a big difference in terms of how we evaluate the innovation pipeline."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","That's really helpful color. And maybe just follow-up for Bob on the financial side of the guidance. Can you talk a little bit about tax planning, may be what's baked into your guidance for tax rate and are there any other opportunities like translate to",62,"That's really helpful color. And maybe just follow-up for Bob on the financial side of the guidance. Can you talk a little bit about tax planning, may be what's baked into your guidance for tax rate and are there any other opportunities like translate to a lower tax rate that moves the needle this fiscal year or maybe still longer-term thing?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017 and we're actually able to pull some things forward into 2016. So you saw one of the benefits in 2016",154,"Yes, I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017 and we're actually able to pull some things forward into 2016. So you saw one of the benefits in 2016 as being having a lower tax rate relative to '15. And so with that, we kind of -- we still see that kind of steady improvement but we have actually accelerated some of those efforts resulted in the lower tax rate in 2016. Longer term, we continue to evaluate kind of what that looks like. We're roughly on that 1 point per year I think the best probably reasonable way to model going forward, which ends in this 31% that we're talking about really is roughly 1 point better than where we were for the full year 2016. So that's the way I would think about it, Isaac."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And next, we have David Lewis with Morgan Stanley.",9,"And next, we have David Lewis with Morgan Stanley."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So a couple of quick ones here. First for Bob, and then -- 2 for Bob, one for Steve, it'll be fast, I promise. so Bob just going back to international if you do the math, you go sort of from single-digit declines to mid-single-digit growth, or you think o",111,"So a couple of quick ones here. First for Bob, and then -- 2 for Bob, one for Steve, it'll be fast, I promise. so Bob just going back to international if you do the math, you go sort of from single-digit declines to mid-single-digit growth, or you think of 10 points around of relative on 20% of your business, it's 2 points of growth so the key driver of the improvement in '17. Your comp adjusted growth for international though in the fourth quarter actually got worse. Can you just help us understand why fourth quarter actually slowed the comp adjusted but you're confident you get that reacceleration in '17?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, if you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had kind of an outsized number in Q4 of last year, which resulted in your comp adjusted numbers looking worse. But when we lo",194,"Yes, if you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had kind of an outsized number in Q4 of last year, which resulted in your comp adjusted numbers looking worse. But when we look at the fundamentals of the business and some of those pockets, things like molecular, Surgical, the trend in the stabilization of our Breast Health business, which is probably the biggest -- one of the biggest changes and then certainly we feel pretty clear about -- pretty decent line of sight into the inventory levels now with the blood screening business. I think those are the kind of building blocks that were headwinds last year that certainly will be -- or tailwinds going into 2017. I think Eric, as Steve mentioned, has done a tremendous job of really focusing the teams on fundamentals, we've gone to the regional basis, a bunch of new leaders there and I think they're just starting to get a hold on things. But I think we've seen good progress, a good momentum going into 2017 on those couple of areas."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And an un-fun question for you and a fun question for Steve. Stock-based compensation FASB [ph] changes, a, impact on earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think enthusiasm for Hologic postconferen",123,"Okay. And an un-fun question for you and a fun question for Steve. Stock-based compensation FASB [ph] changes, a, impact on earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think enthusiasm for Hologic postconference in September really wasn't about '17, it was really about the view that this business can deliver not just 1 year of 5% and 10% growth frankly but several years of 5% and 10% growth. So I wonder if you could synthesize for shareholders what are some of those business dynamics you're seeing that give you that confidence that this isn't just 1 good year, but it's a few good years to come now and I'll jump back in queue?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. The stock-based comp is.",5,"Sure. The stock-based comp is."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Immaterial.",1,"Immaterial."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","And I think David, as each year, when I look out, I'm almost far more worried about the year further out just as I was probably worried about '17 earlier in '16. And every year, what I keep saying is our teams just keep putting more new products in place,",193,"And I think David, as each year, when I look out, I'm almost far more worried about the year further out just as I was probably worried about '17 earlier in '16. And every year, what I keep saying is our teams just keep putting more new products in place, better people in place. And I probably feel better about the sustainability of this company than in any points since I've been here because I think by the time we go into '18 we'll going to have products hitting, we're going to have the international business that much further along, there's so much of what Eric's focus during this year. What we've been doing in international this year is really putting the foundation in place that I hope and wanted to be putting in place sooner but really weren't doing it. So I think just fundamentally, we just keep getting stronger and stronger. The comps will be getting tougher this and that but overall, feeling very good. We're going have a lot of stuff hitting in late '17 and into '18, and that's one of the pipeline stuff that really be coming through."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from the Anthony Petrone with Jefferies.",10,"Our next question is from the Anthony Petrone with Jefferies."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","May be one on molecular and an update on Breast Health OUS specifically. I'm just wondering, what the capital utilization rate of Panther is at $190,000, so just kind of looking ahead may be where that could actually go longer term not only for '17? And t",95,"May be one on molecular and an update on Breast Health OUS specifically. I'm just wondering, what the capital utilization rate of Panther is at $190,000, so just kind of looking ahead may be where that could actually go longer term not only for '17? And then on Breast Health, I guess, the question really is, Bob, going back in, I don't know, meetings you did speak about the 2D opportunity OUS as being pretty substantial over the next several years, so I'm just wondering if you can get an update on that opportunity specifically?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it roughly, 30%. It's probably a little higher than that, maybe 1/3 of the capacity and now, which means that there's still plenty of opportunities to grow",220,"Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it roughly, 30%. It's probably a little higher than that, maybe 1/3 of the capacity and now, which means that there's still plenty of opportunities to grow utilization on the instrumentation. It's never going to get to 100% but certainly, we have room to grow and if we look at TIGRIS, as an example, it's up in the 65% to 75% range utilization so there's still plenty of opportunity there from a [indiscernible] standpoint. In regards to Breast Health, yes, we are still enthusiastic about the opportunities both in 3D as well as 2D. I think the team has been focused and really looked at country-by-country, screening, guidelines, how we work with not only our dealers but also starting more importantly, with governments, and so forth and meeting some of the governments where they are. And the beauty of our 2D system is it's software upgradable to 3D, and so we have both the best 2D system as well as the best 3D system. And so that is still a strategy that we feel good about in the markets that we're focused on and an opportunity not only to place both 2D and 3D systems but have that opportunity for upgrade over time."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units target?",31,"Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units target?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, I don't know if we have a specific goal. It's really on the how confident and comfortable the lab is. At some States, they're going to want to a second Panther as a back up. So rather than focus on a capacity goal, what I would focus on really is we",75,"Yes, I don't know if we have a specific goal. It's really on the how confident and comfortable the lab is. At some States, they're going to want to a second Panther as a back up. So rather than focus on a capacity goal, what I would focus on really is we have plenty of opportunity to continue to grow utilization of our assays and our upcoming assays in the pipeline on the existing Panther."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Jack Meehan with Barclays.",9,"Our next question is from Jack Meehan with Barclays."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to follow up there on Panther, just wondering if you could given updated thoughts on the individual sexual health products, how they performed in the quarter? And then as time goes on, have you seen more cross-selling of the individual products m",69,"I wanted to follow up there on Panther, just wondering if you could given updated thoughts on the individual sexual health products, how they performed in the quarter? And then as time goes on, have you seen more cross-selling of the individual products maybe because you look at that lab, how many are using 1 test or 2 tests or all 3 with [indiscernible], any color will be great."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. We I'll talk to the last question, first. That's one of the reason that the utilization is growing the way it is that team, in particular, in the U.S. has done a fantastic have of being able to sell the entire menu, and really done a customer segment",162,"Yes. We I'll talk to the last question, first. That's one of the reason that the utilization is growing the way it is that team, in particular, in the U.S. has done a fantastic have of being able to sell the entire menu, and really done a customer segmentation that says, okay, if they got chlamydia, gonorrhea, are they testing for Trich, are they testing for HPV and that has really driven that utilization in the U.S. And it's starting to drive that utilization internationally as well now that we have the viral loads. I will tell you in terms of growth rates for our major assays, still obviously, the largest is our chlamydia, gonorrhea CT/GC assay, that grew in the low single digits. And then HPV and Trich continue to grow in excess of market. So those are gaining share. We feel good about our ability to continue to drive growth in '17 in those markets as well, or those assays."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And one more follow-up on Panther. In international, the success you've worked viral load is there a sense that you can say these customers now at certain percentage are using viral load, I guess, trying to get to use obviously with the strength of",72,"Great. And one more follow-up on Panther. In international, the success you've worked viral load is there a sense that you can say these customers now at certain percentage are using viral load, I guess, trying to get to use obviously with the strength of the U.S. fleet if there's a way that we can think about the commercial strategy here and what percentage we think would adopt the test over time?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we're in the early days with the viral loads. We just -- we launched those may be -- they  had a full complement 6, 9 months ago, obviously with the tender-based contracts in Europe. It takes some time. I think the good news is the leading indicat",78,"Yes. So we're in the early days with the viral loads. We just -- we launched those may be -- they  had a full complement 6, 9 months ago, obviously with the tender-based contracts in Europe. It takes some time. I think the good news is the leading indicator of that, which is Panther placements is happening. But it's probably a number that we expect to grow into '17 and '18 for sure, but it's still early days."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jon Block with Stifel.",9,"Our next question comes from Jon Block with Stifel."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I'll just ask 2 relatively quick ones. So Bob, the first one, I think guidance implies about 100 bps of at margin expansion, and you mentioned somewhat share between OpEx and gross margin expansion. So that leaves to 50 bps for gross margin down from roug",100,"I'll just ask 2 relatively quick ones. So Bob, the first one, I think guidance implies about 100 bps of at margin expansion, and you mentioned somewhat share between OpEx and gross margin expansion. So that leaves to 50 bps for gross margin down from roughly 140 bps this year and they certainly understand the headwinds by international growing faster in '17 relative to '16. But still these step downs. So can just talk to us that step down in gross margin expansion? And then are you still getting a good gross margin pull from your 3 major divisions?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, so certainly, we've got margin that are -- we finished FY '16 at almost 66% gross margin, that's nothing to be ashamed about. We feel good about that.",29,"Yes, so certainly, we've got margin that are -- we finished FY '16 at almost 66% gross margin, that's nothing to be ashamed about. We feel good about that."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","I'd rephrased that we're still continuing to expand as opposed to a step down from [indiscernible]",17,"I'd rephrased that we're still continuing to expand as opposed to a step down from [indiscernible]"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we benefited from Surgical being outsized growth. We still expect growth in our Surgical business but not",167,"Yes, exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we benefited from Surgical being outsized growth. We still expect growth in our Surgical business but not at a level that it had in 2016. So there's of product mix in there as well. I would tell you that our operations teams are incredibly focused on continuing to improve the operational aspects of the business and we established good pricing discipline. And I think there's still opportunities to improve margins. I think just perhaps not at the level of 2016 given some of that product mix that we had. And then in the OpEx margins, it's across -- it's going to be across the product lines or product areas. As Steve mentioned, we opportunistically look to investment marketing and the sum of the other areas. We have the ability to kind of -- to move some of those levers as we need to."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay, perfect, very helpful. And maybe Steve for you, just longer term on the Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through [indiscernible] and maybe more importantly, just to take a step back, if you",102,"Okay, perfect, very helpful. And maybe Steve for you, just longer term on the Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through [indiscernible] and maybe more importantly, just to take a step back, if you go apply upon MyoSure rarely do you have 30% sustainable growth and now at a point where you've got a product annualizing at over $150 million. So just maybe talk about the sustainability of why you're seeing that the set of growth rate and the just the market opportunity that is in front of Hologic for that product?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, I would say MyoSure is probably our wonderful continued surprise, that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year of which it looked to be slowing in the 20-ish range kind of really be excited. We'",187,"Sure, I would say MyoSure is probably our wonderful continued surprise, that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year of which it looked to be slowing in the 20-ish range kind of really be excited. We're not sure how high is up yet. And almost don't want to call the market. I think we're finding more and more avenues and more opportunities to tap into other procedures and things. So we continue even through the year, that growth rate has not slowed. [indiscernible] And I think we see that still be in a real growth driver for us. NovaSure wrinkly come back to earth in terms of growth rate. But again, going to be bringing used to that franchise, and we are just -- have of that we don't accept anything but than expectation of growth. Given an older businesses, and it's our job how to I'm confident the team will continue to find ways to keep growing what is a great, great product. But certainly, slower it's probably once we got through the competitive piece."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have from UBS, Jon Groberg.",7,"Next, we have from UBS, Jon Groberg."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just actually ask just one question. Steve, the capital deployment that was brought up earlier, can you just maybe talk about where you're at in terms of your teams' ability to do more M&A and whether or not you be disappointed if you didn't do something",74,"Just actually ask just one question. Steve, the capital deployment that was brought up earlier, can you just maybe talk about where you're at in terms of your teams' ability to do more M&A and whether or not you be disappointed if you didn't do something common M&A standpoint in 2017? It seems like with my confidence internationally honestly, the core business and U.S. is doing well. M&A piece to simply kicked in yet."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I would expect we'll likely do something in '17, it might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I do think ther",165,"Yes. I would expect we'll likely do something in '17, it might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I do think there may be come some opportunities. I would tell you, we look a lot of things, some of which we're patient on, and we want to make sure that they makes sense. So I'm seeing a lot more, I would say, if you look at the percentage of my time spent with the divisions on business development, deals today versus a year ago, it's a dramatic difference. And we've seen a lot of good things, a lot of things that may not yet be making the full hurdle because obviously we're very disciplined as we go. But I do feel good they are going to continue to be smart and sensible and that capably's that come along way."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our final question is from Mary Kate Gurman [ph] from Canaccord Genuity.",12,"Our final question is from Mary Kate Gurman [ph] from Canaccord Genuity."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Mary Kate [ph] on for Mark. I was hoping to ask, have you more favorable reimbursement decisions and 3D tomo as a result of the updated [indiscernible] guidelines similar to CIGNA? And along that line, do you anticipate new payers are coming on next quart",57,"Mary Kate [ph] on for Mark. I was hoping to ask, have you more favorable reimbursement decisions and 3D tomo as a result of the updated [indiscernible] guidelines similar to CIGNA? And along that line, do you anticipate new payers are coming on next quarter as a result of payers revising coverage decision in the New Year?"
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Mary Kate, we're certainly using the [indiscernible] guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily in the next quarter. Hopefully in the coming quarters, we would hope to contin",98,"Mary Kate, we're certainly using the [indiscernible] guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily in the next quarter. Hopefully in the coming quarters, we would hope to continue to make progress in there, but there's a lot of going on in the private pay word right now. And this isn't necessarily getting the full attention that we think it should but we'll continue to drive that and expect that over time will knock those barriers down. But I think all of those will be additional upside."
108544,403594883,1070830,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]I would now like to intro",53,"Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]
I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve a",216,"Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob, both, have some prepared remarks today, then we'll have a question-and-answer session.
Our fourth quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through November 25.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. 
Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP financial measures can be found in our earnings release. 
Finally, any percentage changes that we discuss will be on a year-over-year basis, unless otherwise noted. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth c",1857,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth company. In addition, our results capped off a very good fiscal 2016 in which we delivered on our commitments. 
Today, I'll first provide a high-level overview of our fourth quarter results. But since it's the end of our fiscal year, we'd also like to provide a strategic update on the journey we've shared over the last 3 years. We'll focus on our revenue and financial drivers for the full year and provide some color on the behind-the-scenes progress we're making in research and development. Let's start with our fourth quarter results. 
Revenue of $726.8 million grew 3.4% on a reported basis or 3.8% in constant currency, a healthy performance despite a difficult comparison to the prior year period. We also absorbed a headwind of nearly $4 million from divested and discontinued products. Net of these, total revenues would have grown 4.4% in constant currency. 
Our Surgical business again set the pace with its seventh straight quarter of double-digit growth globally. We are also pleased with how our breast imaging and molecular diagnostics businesses performed and encouraged that new products began to contribute to growth. We'll come back to this point in a minute. 
In terms of geography, U.S. sales grew 7.4% in the quarter, continuing a string of strong results. Even if we exclude the $5 million royalty payment from our fourth quarter results, our growth rate accelerated on a sequential basis. 
As expected, international sales declined 9.6% as reported or 7.8% in constant currency versus a difficult comparison in the prior year period. Apart from this tough comp, international Breast Health was stable sequentially in the quarter. There were also some pockets of strength globally, namely molecular diagnostics and Surgical, both of which posted double-digit growth. Although these businesses are relatively small today outside the U.S., we believe they will be important growth drivers in 2017 and beyond. 
Profit margins remained robust in the quarter. Most importantly, non-GAAP net income grew 14.6%, more than 3x faster than sales. And our net margin of 20% increased by 190 basis points. With the benefit of additional capital deployment, we posted non-GAAP EPS of $0.52 or 20.9% better than in the prior year period. 
So all in all, we posted a very strong fourth quarter that exceeded expectations and capped off an excellent year. 
Thinking about the year as a whole, we made good progress in our journey from turnaround story to sustainable growth company. To date, our successes have been most visible in domestic sales execution, which in turn has driven the improved financial performance of the company. 
One of the first goals we established 3 years ago was to stabilize 2 highly profitable products that had been declining sharply: ThinPrep and NovaSure. In 2016, these products were more than stable. They returned to solid growth. Cytology and perinatal sales increased 2% on the year in constant currency. Even more impressive, NovaSure sales grew 10% in constant currency as our team capitalized on the market withdrawal of a competing product. 
As we stabilized ThinPrep and NovaSure, we also set out to maximize growth drivers such as Genius 3D Mammography systems and the Panther platform in molecular diagnostics. Both of these products performed well in 2016. 
Genius drove 5.2% constant-currency growth in total Breast Health sales in 2016, and we remained bullish on the opportunity ahead of us. While there has been lots of debate about a peak in system placements, we have a fundamentally different and more positive view of the future. The 3D curve is very different than the 2D curve for a number of reasons, and we believe Breast Health sales will be stronger for longer than many anticipate. 
Although we've placed about 3,600 systems in the United States as of the end of the fiscal year, the market is still under penetrated. For example, 3D installations represent a little more than 40% of total Hologic mammography systems. And if you look at MQSA statistics, 3D installations represented just 1/4 of total systems. We have been placing roughly 300 units per quarter in the U.S. recently, and at this pace should enjoy many more quarters of solid performance. We are also gaining significant market share from our competitors. While our innovative marketing strategies enable us to maintain stable pricing. 
As our domestic installed base of 3D units has grown, so has the related service opportunity. Breast Health service revenue again exceeded $100 million in the quarter and increased at a high single-digit rate, boosting overall growth. This increase in service revenue, combined with the potential of new products, gives us confidence that Breast Health can continue to grow even as 3D adoption matures. 
Now let's turn to a second major growth driver, the Panther system, our fully automated diagnostics instrument. Panther helped our molecular business grow 7.8% in constant currency in 2016, behind increased sales of women's health tests for chlamydia and gonorrhea, HPV And Trichomonas. By the end of fiscal 2016, we had shipped more than 1,000 Panther units just to diagnostic customers. And we're encouraged that a growing number of these placements are coming internationally. Panther shipments to customers outside the United States grew dramatically in 2016, and we believe we are just scratching the surface of this long-term opportunity. 
At the same time, our sales team is partnering with lab and physician customers to ensure that patients are tested according to the best clinical guidelines, providing better care while increasing organic volumes. In fact, on a global basis, the average Panther generated more than $190,000 in assay revenue in 2016, a high single-digit increase in utilization. And we are optimistic that this number will increase further as we roll out viral load assays in Europe and the United States. 
As we look back on fiscal 2016, the stabilization of ThinPrep and NovaSure, combined with strong growth from Genius and Panther, drove excellent full year results. You might recall that 12 months ago, our initial guidance called for revenue of $2.81 billion to $2.84 billion for the year. We finished at $2.83 billion, so we delivered on our commitment. 
At the same time, we achieved significant margin improvement in 2016. For the year, non-GAAP gross margin was 65.6%, an impressive 140 basis points better than last year. This enabled us to make incremental investments in marketing and R&D to drive future growth while still delivering operating income of 33.6%, 30 basis points better than in 2015. 
Combined with a lower tax rate and repurchases of both convertible debt and common shares, we posted non-GAAP earnings per share of $1.96 in 2016. This was 17.4% higher than in the prior year and comfortably ahead of our original guidance. 
Looking beyond earnings, we're also very pleased with our cash flow in 2016, which is often underappreciated. We generated $787.2 million in operating cash with only $94.5 million in CapEx. And roughly half of this CapEx went toward revenue-generating instruments such as our Panther systems. As a result, free cash flow for the year was $692.7 million, 23.3% higher than non-GAAP net income. 
Our operations and finance teams deserve tremendous credit for making this happen. As one measure of their success, inventories at year-end 2016 were $8.4 million less than a year ago, even though product revenues were about $109 million higher. Taken a step further, inventories are now below the levels of even 2 years ago, demonstrating tremendous progress by our team. 
Obviously, these strong cash flows gave us the flexibility to continue improving our capital structure in 2016. We repurchased $274.2 million of convertible notes for $392.8 million during the year as well as 7.3 million shares of common stock for $250 million. As a result, our leverage ratio, net debt over EBITDA, has fallen to 2.8x, a little more than half what it was at the time of the Gen-Probe acquisition. In addition, diluted shares outstanding were slightly lower in 2016 than in the prior year, providing a boost to EPS. 
Before I turn the call over to Bob, I want to emphasize that strong cash flows also enabled us to invest appropriately and consistently in research and development, which increased about 8% this year. And we are just beginning to see the fruits of our labor. 
In the fourth quarter 2016, sales of key new products exceeded $10 million in revenue for the first time. These new products include viral assays in Diagnostics, the Affirm prone biopsy system in Breast Health and MyoSure REACH in Surgical. We recognize that $10 million is still small in the context of overall Hologic, but it's a good start. And we are optimistic about the potential of these products in 2017. 
In addition, our R&D pipeline is building behind the first wave of new products. In diagnostics, we recently filed for regulatory approval of our Aptima Hepatitis C viral load test in the United States and anticipate launching it commercially in 2017, following the introduction of our HIV viral load assay. Sales of these products will become more meaningful in 2018 when we also have a Hepatitis B assay available. We also filed recently for U.S. regulatory approval of a herpes test, which will complement our existing portfolio of women's health products on the Panther system. And finally, we are beginning clinical trials for our respiratory assays on the next-generation Panther Fusion system. 
In Breast Health, we have fundamentally reshaped our R&D strategy away from the boom-and-bust approach of the past toward a model that strives for continuous innovation built around our leadership position in 3D mammography. The Affirm prone biopsy system fits in this vein as does our upcoming Brevera product, which will provide real-time specimen radiography to improve breast biopsy workflow and the patient experience. We are hopeful that Brevera will begin to contribute to growth late in 2017 and more meaningfully in 2018. 
Finally, in Surgical, we are encouraged by the early success of our MyoSure REACH line extension, which is providing new capabilities to customers, and therefore, helping expand the market. In the same way, we are working to leverage our market-leading position in endometrial ablation by launching internationally a next-generation NovaSure device that will improve patient comfort as well as physician usability. 
Compared to the dramatic improvement you've seen in U.S. sales execution, our progress in research and development is just becoming visible. We have a lot of work to do in these areas but are excited about our early progress. 
In some ways, domestic sales execution represents the tip of the iceberg in terms of what's possible here. Below the surface, we are working diligently to boost new product innovation, build our international capabilities and further enhance profitability. As our new leadership team settles in and as talented, engaged employees at all levels of the organization continue to do their thing, we look forward to sharing more successes with you in 2017 and beyond. 
Now I will hand the call over to Bob."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise note",1742,"Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise noted, my commentary will focus on non-GAAP results, and revenue growth rates will be expressed in constant currency. 
We closed out our fiscal year with results that surpassed expectations. Revenue grew at a healthy rate, and favorable gross margins allowed us to reinvest opportunistically in the business while still delivering strong bottom line growth. 
I'll begin by discussing our Surgical division, which remained the growth leader in the quarter with sales of $101.5 million and growth of 17.6%. Fueling this growth was MyoSure, where sales of $42.6 million grew 33.4%, thanks to the outstanding efforts of our commercial team. In addition, NovaSure sales grew 8.7% as we continue to gain market share and capitalize on a competitive withdrawal. 
Now moving to Diagnostics. We posted sales of $311.9 million in the quarter, a solid growth rate of 3.1%. In molecular diagnostics, quarterly sales of $134.3 million increased 9.6%. As Steve noted, we booked a $5 million royalty payment this quarter. But at the same time, we also absorbed a headwind of almost $3 million from our discontinued cystic fibrosis product line. So the underlying trends in the business remain strong, and we continue to gain share and increase utilization of women's health assays on the fully automated Panther instrument.  In addition, international sales grew at a mid-teens rate, and we posted yet another record quarter of Panther placements outside the U.S., providing a strong platform for future growth. 
Elsewhere in Diagnostics, our cytology and perinatal products posted sales of $121 million and increased slightly compared to the prior year period. Share gains for our ThinPrep product line continue to offset headwinds from longer cervical cancer screening intervals. 
And finally, our blood business declined 6%, as expected, as we continue to see the impact of lower blood utilization and fluctuating order partners by our partner, Grifols. Partially offsetting these headwinds were initial sales of our Zika products. As we enter 2017, we believe macro trends toward lower blood utilization will continue to be a drag on sales growth. 
Now moving to Breast Health. We posted global sales of $292.3 million and solid growth of 2.3% over another challenging comp. In the U.S., continued adoption of Genius 3D systems was supplemented by growing service annuity and our sales of our new Affirm prone biopsy system, driving an increase of 7.2% in sales. Over the last 2 quarters, our U.S. Breast Health results have clearly illustrated a point we've made repeatedly in recent months that the business can continue to grow despite increasingly challenging comps. 
And to round out our revenue discussion, Skeletal Health revenues of $21.2 million decreased 17.3% in constant currency, due mainly to lower volumes of our Fluoroscan mini C-arm products. 
Now moving down the income statement. Fourth quarter gross margins of 65.7% increased 110 basis points compared to the prior year period. Gross margins benefited from both geographic and product mix as well as continued pricing discipline and operational improvements. 
Total operating expenses of $235.5 million increased 7.7% in the fourth quarter. We continue to take advantage of improving gross margins to reinvest strategically in the business. For example, quarterly R&D spending increased 16.3%, and we're beginning to see some of the benefits, as Steve discussed. In addition, as we mentioned last quarter, a change in the retirement provisions of our equity plan drove an additional $4 million of expense. Despite these investments, our non-GAAP operating margin remained a healthy 33.3% in the quarter. 
Below the line, we continue to make good progress in 2 areas that have been a priority for our finance organization. Based on lower debt levels, interest expense of $32.9 million in the fourth quarter declined 14.8%. At the same time, our non-GAAP effective tax rate of 31% in the quarter was more than 300 basis points lower than a year ago. While we are very pleased with the results we've produced in a short amount of time, we are still at the beginning stages of this process and see continued opportunity ahead. 
And finally, to wrap up the fourth quarter income statement, non-GAAP EPS of $0.52 grew 20.9% compared to a year ago, much faster than sales growth. The multiple levers used to drive EPS growth in the quarter give us comfort in our ability to continue growing EPS at a multiple of sales growth. 
Now let me turn to cash flows and the balance sheet. In the fourth quarter, adjusted EBITDA of $263.9 million improved 5.2%. 
We continue to focus on reducing our convertible debt. In the fourth quarter, we repurchased $47.6 million in principal of our 2037 notes for $81.3 million and intend to redeem the remaining $12 million in cash when the notes are callable this December. 
Despite retiring a portion of our convertible debt and repurchasing shares over the course of 2016, we ended the year with $548.4 million in cash, an increase of $57.1 million compared to the prior year. We finished the year with total debt of $3.3 billion a reduction of $0.3 billion compared to the prior year. And our leverage ratio, net debt over EBITDA, currently sits at 2.8x, close to our target of 2.5x. 
The combination of strong profit growth and lower debt continues to drive improvements to return on invested capital. As of year-end, ROIC was 12.7% on a trailing 12-month basis, an increase of 180 basis points over the prior year. 
Now I'd like to cover our non-GAAP financial guidance for fiscal 2017. We are forecasting mid-single-digit revenue growth in '17 on top of increasingly challenging comps. We expect an improving operating margin and lower tax rate to drive EPS growth at roughly double the rate of sales growth. 
Specifically, we anticipate constant-currency revenue growth of between 4% and 5.5% in fiscal 2017. At recent exchange rates, this equates to sales of $2.94 billion to $2.98 billion on a reported basis with reported growth rates between 3.8% and 5.2%. As you update your forecasts, we would encourage you to model at the middle of our guidance ranges at this early stage as we've tried to set realistic ranges that incorporate, both, those potential upsides and downsides. 
Our guidance includes the net benefit of 3 extra selling days based on our fiscal calendar. Compared to the prior years period, we will gain 4 selling days in the first quarter. Although this will be the historically slow week between Christmas and New Year's while we will lose one day in the fourth fiscal quarter. We estimate this benefit to be between 50 and 70 basis points of sales growth with a negligible effect on EPS. 
At the same time, our guidance also includes a roughly $5 million headwind from products that we have either divested or recently decided to discontinue. In other words, our guidance would have been about 20 basis points higher if these products remained in our portfolio. 
In terms of divisional growth for 2017, our guidance contemplates low- to mid-single-digit growth in Diagnostics and Skeletal, mid-single-digit growth in Breast Health and slightly higher growth in Surgical. 
In Diagnostics, molecular should lead the charge behind Panther and an expanded international menu, including virology assays. We forecast that cytology and perinatal sales will be flat to up slightly, and we also expect blood to be flat to up slightly as new Zika sales offset negative macro trends. 
In Breast Health, we expect continued growth in Genius 3D Mammography, a growing service annuity, contributions from new products, including the Affirm prone biopsy system and Brevera towards the end of the year, as well as a return to growth for our international business. 
In Surgical, we expect growth to be driven by MyoSure market expansion efforts and NovaSure share gains as well as international sales. 
Geographically, we expect our international business to begin contributing to growth in fiscal 2017, in line with the company's overall growth rate. 
In terms of profitability, we forecast continued improvement in non-GAAP operating margin in 2017, but how we get there will be different than last year. In 2017, we forecast a slight improvement in non-GAAP gross margin percentage, combined with greater leverage from operating expenses, leading to more improvement in operating margin than we saw last year. 
All of this leads us to forecast that earnings per share will be between $2.12 and $2.16 in 2017. This represents growth of 8.5% to 10.6% in constant currency and reported growth of between 8.2% and 10.2%. Again, we'd encourage you to model at the middle of our guidance range at this early stage of the year. 
This guidance assumes a full year tax rate of approximately 31% and diluted shares outstanding of between 289 million and 291 million for the year. Our guidance does not assume any capital deployment beyond calling what's left of our 2037 convertible notes in December. 
Now let's cover guidance for the first quarter of fiscal 2017. We expect revenues of $720 million to $730 million, flattish on a sequential basis as the benefit from extra selling days between Christmas and New Year's is offset by the normal seasonal decline we experienced due to our global sales meetings and the RSNA conference in Breast Health. Compared to the prior year period, this range reflects revenue growth of 3.8% to 5.2% on a constant-currency basis and reported revenue growth of 3.6% to 5.0%. 
We forecast non-GAAP diluted earnings per share of $0.50 to $0.51 in the first quarter. This represents anticipated growth of 9.1% to 11.3% in constant-currency terms or 8.7% to 10.9% on a reported basis. Compared to our fourth quarter actuals, please note that operating expenses will increase in the first quarter due to the timing of sales and marketing activities and the extra days. 
Before we open the call for questions, let me conclude by saying that our fourth quarter capped off another good year for the company. Our financial performance demonstrates that we are transforming from a turnaround story to a sustainable growth company. We feel confident about the foundation we have established heading into 2017 and have the levers necessary to deliver mid-single-digit revenue growth with EPS growth roughly double that rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions]"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] Our first question is from Brian Weinstein with William Blair.",12,"[Operator Instructions] Our first question is from Brian Weinstein with William Blair."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So as we look at your guidance range, you had clearly signaled ahead of time that you're going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a funct",99,"So as we look at your guidance range, you had clearly signaled ahead of time that you're going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a function of kind of how you expect new products to contribute? You talked about $10 million from that this quarter and whatnot. But do you expect that new products are really the differentiating factor between that high and the low end? And any color on that would be helpful."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given -- partic",198,"Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given -- particularly the environment, to have a slightly broader range. I do think we see a little more. If the new products are doing well, which we fully expect they will, I think it clearly pushes us towards that higher end. I think we get into that 5 percentage range as things take off. We always want to be a little cautious until we start to see the success. I will tell you, I think Affirm is off to a very nice start, MyoSure REACH off to a very nice start. And these are really the first new products we've launched since we've come on. And also, our international molecular diagnostics business is really starting to take off. We had a couple of quarters there of double-digit growth as well. So there's a lot we feel good about. But again, it's still very early stages and a lot to play out."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but certainly feel very good about our path there, but there is some flexibility there",51,"Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but certainly feel very good about our path there, but there is some flexibility there as well."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS,",69,"And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS, that you guys are focused on, some of the -- other products that you guys are focused on next year that potentially could add to growth there?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there that Compton has really put in place. As we exit this year, we basically got a completely new leadership team internationally from how we",148,"Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there that Compton has really put in place. As we exit this year, we basically got a completely new leadership team internationally from how we entered the year. Other than our leader of the Diagnostics business in Europe, who's already showing and really been leading the way with great growth. But I think as we look to international, the molecular diagnostics business ought to be a real standout for us. I think Surgical, continuing off of a smaller base but continuing to show good growth. And Breast Health will return to some growth as we're working a lot tighter with our dealers and getting things in place there. So I think we feel incrementally significantly better entering this year than we did at this time last year about international."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Tycho Peterson with JPMorgan.",9,"Our next question is from Tycho Peterson with JPMorgan."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull",50,"Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull from margin expansion in '17?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. We've really -- I'd say those we had expanded and invested more than our rate of sales will",68,"Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. We've really -- I'd say those we had expanded and invested more than our rate of sales will probably come back into those being slightly leverageable relative to the rate of sales as we go into the current year."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?",41,"And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're",76,"Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're working through with them. And we basically have not assumed that they come, and that could be an additional source of upside if or when they fall during the year."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think you should be accretive to the overall Diagnostic gross margins. That said, we've also",89,"Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think you should be accretive to the overall Diagnostic gross margins. That said, we've also heard about some pricing pressure over in Europe. And so can you help us kind of set the stage for us about what you expect in the U.S. and then maybe just a couple of words on what you're seeing in Europe thus far."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bot",74,"Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bottom line in Europe. But the big pickup for us will really be more in '18 on the margin side as it relates to the virals."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally, in general. I think that's largely in the back o",117,"Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally, in general. I think that's largely in the back of our viral system -- our viral load assays. And we'll get the full benefit of that in 2017 as those instruments that were placed get a -- kind of full year. The other thing is in that we have -- the -- we noted that the revenue or pull-through per Panther has increased. That's both in the U.S. as well as internationally. So I think that that's a harbinger for good growth going forward."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And just the overall pricing dynamics in Europe.",8,"And just the overall pricing dynamics in Europe."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated.",42,"Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have Vijay Kumar with Evercore ISI.",8,"Next, we have Vijay Kumar with Evercore ISI."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I feel like with overall weighting with [indiscernible] then just given what's happened in Medtech, I'd like to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for ne",67,"I feel like with overall weighting with [indiscernible] then just given what's happened in Medtech, I'd like to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for next year? Because I would have thought, just given what happened sequentially 3Q versus 4Q international trends, any color on the international would be helpful."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the gro",129,"Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the growth. But I think we see this year really being able to bounce. And recall the fourth -- the current quarter is not indicative of a trend given that last year's fourth quarter turns out -- there was a lot more put into that last year's fourth quarter than we fully understood, just dealers bought in to maintain their contracts against minimums and things like that. So I think, again, we feel far better coming into this year and seeing expected growth."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then maybe one for -- go ahead, Bob.",10,"Great. And then maybe one for -- go ahead, Bob."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and",73,"Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and ordering patterns of our partner were adjusting, so we expect to kind of lap that. So that gives us help for turning that trajectory around as well."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment firm. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's th",56,"And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment firm. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's the focus for cash cap deployment over the next 12 months?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&",98,"Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&A activities, and then finally, share repurchase. The latter of those 2 is hard to predict. And certainly, the convertible notes, we don't have those ability to actually call those formally until 2018. And so that's why we've done it. But we will be opportunistic as appropriate within the market."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And just to clarify, that would be fiscal 2018?",10,"Yes. And just to clarify, that would be fiscal 2018?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","December of 2017.",3,"December of 2017."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Doug Schenkel with Cowen and Company.",12,"And our next question comes from Doug Schenkel with Cowen and Company."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new",143,"I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new products contribute about 100 basis points to fiscal '17 growth at the midpoint of guide. Is that about right? Secondly, what's your view on the sustainability of NovaSure growth given the benefit from competitive disruptions will annualize over the course of this fiscal year? Third, are there any major blood bank tenders that come up this year that we should be contemplating in our models? And lastly, how do you expect Panther utilization to increase above the $190,000 annualized figure that you provided in fiscal '17 based on geographic and menu expansion?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Doug, you sure you don't want to throw a few more in there?",13,"Doug, you sure you don't want to throw a few more in there?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. T",307,"Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. That's probably at the low end. Maybe it's a little higher than that, maybe 150 basis points, probably at the midpoint to think about that, and that's really driven behind the Affirm and Zika. Those are probably the 2 largest new products. Brevera will happen, but it's in the back half of the year. And then certainly, some of the virals and so forth in the U.S. will play a role. But again, the majority of that will happen in 2018. So that's the first question. I think sustainability of NovaSure, we feel very good about that. But remember, the formal withdrawal of the competitive product happened in our second quarter, so we expect to have larger and better growth in first and second quarters than we would have in the back half of the year. We expect growth throughout the course of the year, but the first and second quarters will be bigger than the back half for NovaSure. In terms of the major blood banks, those are -- that's -- you need to ask Grifols that -- those are their customers, and so we're not going to be able to be in a position to answer that. And then in terms of Panther utilization, we do expect -- that's one of the big areas that we're focused on is continuing to not only place Panther systems but increase the utilization of the installed base. So I do expect that utilization to grow in line with the forecast that we had talked about for our molecular business."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next up, we have Isaac Ro with Goldman Sachs.",9,"Next up, we have Isaac Ro with Goldman Sachs."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So I just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've ment",131,"So I just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've mentioned and maybe some of the ones you haven't talked about. And so if I look at the R&D spend here, it's up good amount year-on-year and just thinking a little bit about how to frame the way you guys are investing your R&D dollars going forward. Maybe if you can talk a little bit mathematically where you think your best bank for your buck is invested. And as we look over a multiyear period, how should we think about investment across the various divisions?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. If you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses and really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that grand sla",383,"Sure. If you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses and really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that grand slam or the boom-bust ideas. So what we've got going on now is a lot of folks focused on both substantial innovation but also incremental innovation. And if you take our Surgical business as an example, we had launched NovaSure and launched MyoSure and never really did any product upgrades or anything through the year, just threw them out there and then watch eventually price degrade or whatever else. So launching MyoSure REACH is a classic example of something that we're working on. We also just mentioned we're actually launching an upgraded NovaSure product outside the United States. You can imagine we'll be planning on bringing that to the United States once we get that through approval. Likewise, in Breast Health, instead of just focusing on the replacement for 3D tomo, saying, ""Okay, what are we going to do in the meantime, and how can we leverage 3D?"" Well, the Affirm prone biopsy system, Brevera. There will be other things that we're looking at in that vein as well. And again, we wanted to put some points on the board before we start talking about the future, just as you know us realistically. And then the same as it relates to -- effectively the Diagnostics business, there were things that were not truly in play when we got here. We turbocharged the Fusion, the development of the Fusion platform, which is then opening up that ability to do the same kind of singles and doubles as it relates to future assays and be able to broaden out the menu there. And again, those will be a lot of singles and doubles that will come behind the viral load programs. And we really hunkered down early on to push the viral loads through and across the finish line. Those have kind of been up and down, on and off. And we've really put a sustained commitment and started to feel very, very good about our ability in each of the divisions to be bringing in more steady stream of innovation."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so w",169,"Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so when I think about the R&D spend, we spend roughly 8% any year -- any quarter, it can change. That's probably the right amount. But I think, right now, what we've done is fundamentally, as Steve mentioned, changed the mindset of the organizations on how they're going about actually developing products, linking R&D with marketing, truly having insight-driven innovation and creating that competitive advantage. We spend the most money as a percent of sales in our Diagnostics business, less in Breast and in our Surgical businesses. I think that, that probably is going to stay roughly the same. But it's really the makeup of it and the leadership making a big difference in terms of how we evaluate the innovation pipeline."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could",67,"That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could translate to a lower tax rate that moves the needle this fiscal year? Or is it maybe still a longer-term thing?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017, and we're actually able to pull some things forward into 2016. So you saw one of the benefits in 201",156,"Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017, and we're actually able to pull some things forward into 2016. So you saw one of the benefits in 2016 as being -- having a lower tax rate relative to '15. And so with that, we kind of -- we still see that kind of steady improvement, but we have actually accelerated some of those efforts resulted in the lower tax rate in 2016. Longer term, we continue to evaluate kind of what that looks like. We're roughly on that point per year I think the best -- probably a reasonable way to model going forward, which end in this 31% that we're talking about, really, is roughly a point better than where we were for the full year 2016. So that's the way I would think about it, Isaac."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And next, we have David Lewis with Morgan Stanley.",9,"And next, we have David Lewis with Morgan Stanley."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve. It will be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines to m",121,"So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve. It will be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines to mid-single-digit growth, where you pick up 10 points or relative on 20% of your business. It's 2 points of growth that's the key driver of the improvement in '17. Your comp-adjusted growth for international, though, in the fourth quarter actually got worse. So just -- can you just help us understand why fourth quarter actually slowed the comp adjusted, but you're confident you get that reacceleration in '17?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we lo",198,"Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we look at the fundamentals of the business and some of those pockets, things like molecular, Surgical, the trend and the stabilization of our Breast Health business, which is probably the biggest -- one of the biggest changes. And then certainly, we feel pretty clear about -- we have pretty decent line of sight into the inventory levels now with the blood-screening business. I think those are kind of the building blocks that were headwinds last year that's certainly will be -- or tailwinds going into 2017. I think Eric, as Steve mentioned, has done a tremendous job of really focusing the teams on the fundamentals. We've gone to the regional basis. We brought in a bunch of new leaders there, and I think they're just starting to get a hold on things. But I think we've seen good progress and good momentum going into 2017 on those couple of areas."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic po",130,"Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic post our conference in September really wasn't about '17. It was about sort of the view that this business can deliver not just 1 year of 5% and 10% growth, frankly, but several years of 5% and 10% growth. So I wonder if you just sort of synthesize for shareholders what are some of those business dynamics you're seeing that give you that confidence that this isn't just 1 good year, but it's a few good years to come? And then I'll jump back in queue."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. The stock-based comp piece, there's no...",7,"Sure. The stock-based comp piece, there's no..."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","No material impact.",3,"No material impact."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products",197,"And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products in place, better people in place. And I probably feel better about the sustainability of this company than in any points since I've been here. Because I think by the time we go into '18, we're going to have more products hitting. We're going to have the international business that much further along because so much of what Eric's focused here during this year. What we've been doing in international this year is really putting the foundation in place that I hope and wanted to be putting in place sooner, but we really weren't doing it. So I think just fundamentally, we just keep getting stronger and stronger. The comps will be getting tougher this and that. But overall, feeling very good. We're going have a lot of stuff hitting in late '17 and into '18, and that's when the pipeline stuff will really be coming through."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Anthony Petrone with Jefferies.",9,"Our next question is from Anthony Petrone with Jefferies."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And t",95,"Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And then on Breast Health, I guess the question really is, Bob, going back in, I don't know, at some meetings you did speak about the 2D opportunity OUS as being pretty substantial over the next several years, so I'm just wondering if we can get an update on that opportunity specifically?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow u",224,"Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow utilization on the instrumentation. It's never going to get to 100%. But certainly, we have room to grow. And if we look at TIGRIS, as an example, it's up in the 65% to 75% range utilization, so there's still plenty of opportunity there from a molecular standpoint. In regards to Breast Health, yes, we are still enthusiastic about the opportunities, both in 3D as well as 2D. I think the team has been focused and really looked at country by country, screening guidelines, how we work with, not only our dealers, but also starting more importantly, with governments and so forth and meeting some of the governments where they are. And the beauty of our 2D system is it's software upgradable to 3D, and so we have both the best 2D system as well as the best 3D system. And so that is still a strategy that we feel good about in the markets that we're focused on and an opportunity, not only to place both the 2D and the 3D systems, but have that opportunity for upgrade over time."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?",36,"Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, rea",77,"Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, really, is we have plenty of opportunity to continue to grow utilization of our assays and our upcoming assays in the pipeline on the existing Panther."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Jack Meehan with Barclays.",9,"Our next question is from Jack Meehan with Barclays."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual pro",72,"I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual products? Maybe just as you look at the labs, how many are using 1 test or 2 tests or all 3 with Trich? Any color will be great."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer s",166,"Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer segmentation that says, ""Okay, if they got chlamydia, gonorrhea, are they testing for Trich? Are they testing for HPV?"" And that has really driven that utilization in the U.S, and it's starting to drive that utilization internationally as well now that we have the viral loads. I will tell you in terms of growth rates for our major assay, it's still -- obviously, the largest is our chlamydia, gonorrhea CT/GC assay that grew in the low single digits. And then HPV and Trich continue to grow in excess of market, so those are gaining share. We feel good about our ability to continue to drive growth in '17 in those markets as well -- or those assays."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And one more follow-up on Panther. Just in international, the success you've had with viral load, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously w",78,"Great. And one more follow-up on Panther. Just in international, the success you've had with viral load, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously with the strength of the U.S. fleet, if there's a way that we can think about the commercial strategy here and what percentage we can think would adopt the test over time?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had a full complement 6, 9 months ago, obviously with the tender-based contracts in Europe. It takes some time. I think the good news is the leading indic",80,"Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had a full complement 6, 9 months ago, obviously with the tender-based contracts in Europe. It takes some time. I think the good news is the leading indicator of that, which is the Panther placements, is happening. But it is probably a number that we expect to grow into '17 and '18, for sure. But it's still early days."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jon Block with Stifel.",9,"Our next question comes from Jon Block with Stifel."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of at-margin expansion, and you mentioned somewhat share between OpEx and gross margin expansion. So that leaves about 50 bps for gross m",102,"Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of at-margin expansion, and you mentioned somewhat share between OpEx and gross margin expansion. So that leaves about 50 bps for gross margin down from roughly 140 bps this year. And I certainly understand the headwinds by international growing faster in '17 relative to '16 but still a decent step-down. So can just talk to us about that step-down in gross margin expansion? And then are you still getting a good gross margin pull from your 3 major divisions?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that.",29,"Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","I'd rephrased that we're still continuing to expand as opposed to a step-down from...",15,"I'd rephrased that we're still continuing to expand as opposed to a step-down from..."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business",174,"Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business but not at the level that it had in 2016. So there are some product mix in there as well. I will tell you that our operations teams are incredibly focused on continuing to improve the operational aspects of the business, and we established good pricing discipline. So and I think there are still opportunities to improve margins, I think just perhaps not at the level of 2016 given some of that product mix that we had. And then in the OpEx margins, it's across -- it's going to be across the product lines or product areas. We -- as Steve mentioned, we opportunistically look to invest in places like marketing and some the other areas. We have the ability to kind of -- to move some of those levers as we need to."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step ba",106,"Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step back, if you're going to rely upon MyoSure, I mean, rarely do you have 30% sustainable growth and now to the point where you've got a product annualizing at over $150 million. So just maybe talk about the sustainability of why you're seeing that sort of growth rate and just the market opportunity that you see in front of Hologic for that product?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. Yes. I would say MyoSure has been -- probably our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year of which it had looked to be slowing in the 20-ish range kind of reall",215,"Sure. Yes. I would say MyoSure has been -- probably our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year of which it had looked to be slowing in the 20-ish range kind of really be accelerating. We're not sure how high is up yet there. And I almost don't want to call the market. I think we're finding more and more avenues and more and more opportunities to tap into other procedures and things. So we continue -- even through the year, that growth rate has not yet slowed. We brought some news to it. And I think we see that as still being in real growth driver for us. NovaSure wrinkly come back to earth in terms of growth rates. But again, we're going to be bringing news to that franchise, and we're just -- we have adopted a mindset that we don't accept anything but an expectation of growth, even on the older businesses. And it's our job to figure out how to grow them. I'm confident that the team will continue to find ways to keep growing what is a great, great product. But certainly, a slower rate is probably once we got through the big competitive piece."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have from UBS, Jon Groberg.",7,"Next, we have from UBS, Jon Groberg."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- I'll actually just one question. Steve, the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do somethi",89,"Just -- I'll actually just one question. Steve, the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do something from an M&A standpoint in 2017? It seems like where you're at as a firm, you seem to have a little bit more confidence internationally. Obviously, the core business in the U.S. is doing well. The M&A piece hasn't really kicked in yet."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I",171,"Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I do think there may be -- come some opportunities. I would tell you, we've looked at a lot of things, some of which we're patient on, and we want to make sure that they make sense. So I'm seeing a lot more, I would say, if you look at my percentage of my time spent with the divisions on business development, deals today versus a year ago, it's a dramatic difference. And we've seen a lot of good things, a lot of things that may not yet be making the full hurdle because we're obviously being very disciplined as we go. But I do feel good that we're going to continue to be smart and sensible and the capabilities that come a long way."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our final question is from Mary Kate Gorman from Canaccord Genuity.",11,"Our final question is from Mary Kate Gorman from Canaccord Genuity."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3D tomo as a result of the updated NCCN guidelines similar to CIGNA? And along that line, do you anticipate new payers coming on next quarte",59,"Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3D tomo as a result of the updated NCCN guidelines similar to CIGNA? And along that line, do you anticipate new payers coming on next quarter as a result of payers revising coverage decisions in the New Year?"
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily in the next quarter. Hopefully, in the coming quarters, we would hope to continue",105,"Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily in the next quarter. Hopefully, in the coming quarters, we would hope to continue to make progress there. But there's a lot of prickliness [ph], frankly. There's a lot going on in the private pay world right now.  And this isn't necessarily getting the full attention that we think it should, but we will continue to drive that and expect that over time we'll knock those barriers down. But I think all of that will be additional upside."
108544,403594883,1071201,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]I would now like to intro",53,"Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]
I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve a",216,"Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob, both, have some prepared remarks today. Then we'll have a question-and-answer session.
Our fourth quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through November 25.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. 
Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP financial measures can be found in our earnings release. 
Finally, any percentage changes that we discuss will be on a year-over-year basis, unless otherwise noted. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth c",1857,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth company. In addition, our results capped off a very good fiscal 2016 in which we delivered on our commitments. 
Today, I'll first provide a high-level overview of our fourth quarter results. But since it's the end of our fiscal year, we'd also like to provide a strategic update on the journey we've shared over the last 3 years. We'll focus on our revenue and financial drivers for the full year and provide some color on the behind-the-scenes progress we're making in research and development. Let's start with our fourth quarter results. 
Revenue of $726.8 million grew 3.4% on a reported basis or 3.8% in constant currency, a healthy performance despite a difficult comparison to the prior year period. We also absorbed a headwind of nearly $4 million from divested and discontinued products. Net of these, total revenues would have grown 4.4% in constant currency. 
Our Surgical business again set the pace with its seventh straight quarter of double-digit growth globally. We are also pleased with how our breast imaging and molecular diagnostics businesses performed and encouraged that new products began to contribute to growth. We'll come back to this point in a minute. 
In terms of geography, U.S. sales grew 7.4% in the quarter, continuing a string of strong results. Even if we exclude the $5 million royalty payment from our fourth quarter results, our growth rate accelerated on a sequential basis. 
As expected, international sales declined 9.6% as reported or 7.8% in constant currency versus a difficult comparison in the prior year period. Apart from this tough comp, international Breast Health was stable sequentially in the quarter. There were also some pockets of strength globally, namely molecular diagnostics and Surgical, both of which posted double-digit growth. Although these businesses are relatively small today outside the U.S., we believe they will be important growth drivers in 2017 and beyond. 
Profit margins remained robust in the quarter. Most importantly, non-GAAP net income grew 14.6%, more than 3x faster than sales. And our net margin of 20% increased by 190 basis points. With the benefit of additional capital deployment, we posted non-GAAP EPS of $0.52 or 20.9% better than in the prior year period. 
So all in all, we posted a very strong fourth quarter that exceeded expectations and capped off an excellent year. 
Thinking about the year as a whole, we made good progress in our journey from turnaround story to sustainable growth company. To date, our successes have been most visible in domestic sales execution, which in turn has driven the improved financial performance of the company. 
One of the first goals we established 3 years ago was to stabilize 2 highly profitable products that had been declining sharply: ThinPrep and NovaSure. In 2016, these products were more than stable. They returned to solid growth. Cytology and perinatal sales increased 2% on the year in constant currency. Even more impressive, NovaSure sales grew 10% in constant currency as our team capitalized on the market withdrawal of a competing product. 
As we stabilized ThinPrep and NovaSure, we also set out to maximize growth drivers such as Genius 3-D Mammography systems and the Panther platform in molecular diagnostics. Both of these products performed well in 2016. 
Genius drove 5.2% constant-currency growth in total Breast Health sales in 2016, and we remain bullish on the opportunity ahead of us. While there has been lots of debate about a peak in system placements, we have a fundamentally different and more positive view of the future. The 3-D curve is very different than the 2-D curve for a number of reasons, and we believe Breast Health sales will be stronger for longer than many anticipate. 
Although we've placed about 3,600 systems in the United States as of the end of the fiscal year, the market is still underpenetrated. For example, 3-D installations represent a little more than 40% of total Hologic mammography systems. And if you look at MQSA statistics, 3-D installations represent just 1/4 of total systems. We have been placing roughly 300 units per quarter in the U.S. recently, and at this pace should enjoy many more quarters of solid performance. We are also gaining significant market share from our competitors. While our innovative marketing strategies enable us to maintain stable pricing. 
As our domestic installed base of 3-D units has grown, so has the related service opportunity. Breast Health service revenue again exceeded $100 million in the quarter and increased at a high single-digit rate, boosting overall growth. This increase in service revenue, combined with the potential of new products, gives us confidence that Breast Health can continue to grow even as 3-D adoption matures. 
Now let's turn to a second major growth driver, the Panther system, our fully automated diagnostics instrument. Panther helped our molecular business grow 7.8% in constant currency in 2016, behind increased sales of women's health tests for chlamydia and gonorrhea, HPV And Trichomonas. By the end of fiscal 2016, we had shipped more than 1,000 Panther units just to diagnostic customers. And we're encouraged that a growing number of these placements are coming internationally. Panther shipments to customers outside the United States grew dramatically in 2016, and we believe we are just scratching the surface of this long-term opportunity. 
At the same time, our sales team is partnering with lab and physician customers to ensure that patients are tested according to the best clinical guidelines, providing better care while increasing organic volumes. In fact, on a global basis, the average Panther generated more than $190,000 in assay revenue in 2016, a high single-digit increase in utilization. And we are optimistic that this number will increase further as we roll out viral load assays in Europe and the United States. 
As we look back on fiscal 2016, the stabilization of ThinPrep and NovaSure, combined with strong growth from Genius and Panther, drove excellent full year results. You might recall that 12 months ago, our initial guidance called for revenue of $2.81 billion to $2.84 billion for the year. We finished at $2.83 billion, so we delivered on our commitment. 
At the same time, we achieved significant margin improvement in 2016. For the year, non-GAAP gross margin was 65.6%, an impressive 140 basis points better than last year. This enabled us to make incremental investments in marketing and R&D to drive future growth while still delivering operating income of 33.6%, 30 basis points better than in 2015. 
Combined with a lower tax rate and repurchases of both convertible debt and common shares, we posted non-GAAP earnings per share of $1.96 in 2016. This was 17.4% higher than in the prior year and comfortably ahead of our original guidance. 
Looking beyond earnings, we're also very pleased with our cash flow in 2016, which is often underappreciated. We generated $787.2 million in operating cash with only $94.5 million in CapEx. And roughly half of this CapEx went toward revenue-generating instruments such as our Panther systems. As a result, free cash flow for the year was $692.7 million, 23.3% higher than non-GAAP net income. 
Our operations and finance teams deserve tremendous credit for making this happen. As one measure of their success, inventories at year-end 2016 were $8.4 million less than a year ago, even though product revenues were about $109 million higher. Taken a step further, inventories are now below the levels of even 2 years ago, demonstrating tremendous progress by our team. 
Obviously, these strong cash flows gave us the flexibility to continue improving our capital structure in 2016. We repurchased $274.2 million of convertible notes for $392.8 million during the year as well as 7.3 million shares of common stock for $250 million. As a result, our leverage ratio, net debt over EBITDA, has fallen to 2.8x, a little more than half what it was at the time of the Gen-Probe acquisition. In addition, diluted shares outstanding were slightly lower in 2016 than in the prior year, providing a boost to EPS. 
Before I turn the call over to Bob, I want to emphasize that strong cash flows also enabled us to invest appropriately and consistently in research and development, which increased about 8% this year. And we are just beginning to see the fruits of our labor. 
In the fourth quarter of 2016, sales of key new products exceeded $10 million in revenue for the first time. These new products include viral assays in Diagnostics, the Affirm prone biopsy system in Breast Health and MyoSure REACH in Surgical. We recognize that $10 million is still small in the context of overall Hologic, but it's a good start. And we are optimistic about the potential of these products in 2017. 
In addition, our R&D pipeline is building behind the first wave of new products. In diagnostics, we recently filed for regulatory approval of our Aptima Hepatitis C viral load test in the United States and anticipate launching it commercially in 2017, following the introduction of our HIV viral load assay. Sales of these products will become more meaningful in 2018 when we also have a Hepatitis B assay available. We also filed recently for U.S. regulatory approval of a herpes test, which will complement our existing portfolio of women's health products on the Panther system. And finally, we are beginning clinical trials for our respiratory assays on the next-generation Panther Fusion system. 
In Breast Health, we have fundamentally reshaped our R&D strategy away from the boom-and-bust approach of the past toward a model that strives for continuous innovation built around our leadership position in 3-D mammography. The Affirm prone biopsy system fits in this vein as does our upcoming Brevera product, which will provide real-time specimen radiography to improve breast biopsy workflow and the patient experience. We are hopeful that Brevera will begin to contribute to growth late in 2017 and more meaningfully in 2018. 
Finally, in Surgical, we are encouraged by the early success of our MyoSure REACH line extension, which is providing new capabilities to customers, and therefore, helping expand the market. In the same way, we are working to leverage our market-leading position in endometrial ablation by launching, internationally, a next-generation NovaSure device that will improve patient comfort as well as physician usability. 
Compared to the dramatic improvement you've seen in U.S. sales execution, our progress in research and development is just becoming visible. We have a lot of work to do in these areas but are excited about our early progress. 
In some ways, domestic sales execution represents the tip of the iceberg in terms of what's possible here. Below the surface, we are working diligently to boost new product innovation, build our international capabilities and further enhance profitability. As our new leadership team settles in and as talented, engaged employees at all levels of the organization continue to do their thing, we look forward to sharing more successes with you in 2017 and beyond. 
Now I will hand the call over to Bob."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise note",1742,"Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise noted, my commentary will focus on non-GAAP results, and revenue growth rates will be expressed in constant currency. 
We closed out our fiscal year with results that surpassed expectations. Revenue grew at a healthy rate, and favorable gross margins allowed us to reinvest opportunistically in the business while still delivering strong bottom line growth. 
I'll begin by discussing our Surgical division, which remained the growth leader in the quarter with sales of $101.5 million and growth of 17.6%. Fueling this growth was MyoSure, where sales of $42.6 million grew 33.4%, thanks to the outstanding efforts of our commercial team. In addition, NovaSure sales grew 8.7% as we continued to gain market share and capitalize on a competitive withdrawal. 
Now moving to Diagnostics. We posted sales of $311.9 million in the quarter, a solid growth rate of 3.1%. In molecular diagnostics, quarterly sales of $134.3 million increased 9.6%. As Steve noted, we booked a $5 million royalty payment this quarter. But at the same time, we also absorbed a headwind of almost $3 million from our discontinued cystic fibrosis product line. So the underlying trends in the business remain strong, and we continue to gain share and increase utilization of women's health assays on the fully automated Panther instrument. In addition, international sales grew at a mid-teens rate, and we posted yet another record quarter of Panther placements outside the U.S., providing a strong platform for future growth. 
Elsewhere in Diagnostics, our cytology and perinatal products posted sales of $121 million and increased slightly compared to the prior year period. Share gains for our ThinPrep product line continue to offset headwinds from longer cervical cancer screening intervals. 
And finally, our blood business declined 6%, as expected, as we continue to see the impact of lower blood utilization and fluctuating order patterns by our partner, Grifols. Partially offsetting these headwinds were initial sales of our Zika products. As we enter 2017, we believe macro trends towards lower blood utilization will continue to be a drag on sales growth. 
Now moving to Breast Health. We posted global sales of $292.3 million and solid growth of 2.3% over another challenging comp. In the U.S., continued adoption of Genius 3-D systems was supplemented by a growing service annuity and our sales of our new Affirm prone biopsy system, driving an increase of 7.2% in sales. Over the last 2 quarters, our U.S. Breast Health results have clearly illustrated a point we've made repeatedly in recent months: that the business can continue to grow despite increasingly challenging comps. 
And to round out our revenue discussion, Skeletal Health revenues of $21.2 million decreased 17.3% in constant currency, due mainly to lower volumes of our Fluoroscan mini C-arm products. 
Now moving down the income statement. Fourth quarter gross margins of 65.7% increased 110 basis points compared to the prior year period. Gross margins benefited from both geographic and product mix as well as continued pricing discipline and operational improvements. 
Total operating expenses of $235.5 million increased 7.7% in the fourth quarter. We continue to take advantage of improving gross margins to reinvest strategically in the business. For example, quarterly R&D spending increased 16.3%, and we're beginning to see some of the benefits, as Steve discussed. In addition, as we mentioned last quarter, a change in the retirement provisions of our equity plan drove an additional $4 million of expense. Despite these investments, our non-GAAP operating margin remained a healthy 33.3% in the quarter. 
Below the line, we continue to make good progress in 2 areas that have been a priority for our finance organization. Based on lower debt levels, interest expense of $32.9 million in the fourth quarter declined 14.8%. At the same time, our non-GAAP effective tax rate of 31% in the quarter was more than 300 basis points lower than a year ago. While we are very pleased with the results we've produced in a short amount of time, we are still at the beginning stages of this process and see continued opportunity ahead. 
And finally, to wrap up the fourth quarter income statement, non-GAAP EPS of $0.52 grew 20.9% compared to a year ago, much faster than sales growth. The multiple levers used to drive EPS growth in the quarter give us comfort in our ability to continue growing EPS at a multiple of sales. 
Now let me turn to cash flows and the balance sheet. In the fourth quarter, adjusted EBITDA of $263.9 million improved 5.2%. 
We continue to focus on reducing our convertible debt. In the fourth quarter, we repurchased $47.6 million in principal of our 2037 notes for $81.3 million and intend to redeem the remaining $12 million in cash when the notes are callable this December. 
Despite retiring a portion of our convertible debt and repurchasing shares over the course of 2016, we ended the year with $548.4 million in cash, an increase of $57.1 million compared to the prior year. We finished the year with total debt of $3.3 billion, a reduction of $0.3 billion compared to the prior year. And our leverage ratio, net debt over EBITDA, currently sits at 2.8x, close to our target of 2.5x. 
The combination of strong profit growth and lower debt continues to drive improvements to return on invested capital. As of year-end, ROIC was 12.7% on a trailing 12-month basis, an increase of 180 basis points over the prior year. 
Now I'd like to cover our non-GAAP financial guidance for fiscal 2017. We are forecasting mid-single-digit revenue growth in '17 on top of increasingly challenging comps. We expect an improving operating margin and lower tax rate to drive EPS growth at roughly double the rate of sales growth. 
Specifically, we anticipate constant-currency revenue growth of between 4% and 5.5% in fiscal 2017. At recent exchange rates, this equates to sales of $2.94 billion to $2.98 billion on a reported basis with reported growth rates between 3.8% and 5.2%. As you update your forecasts, we would encourage you to model at the middle of our guidance ranges at this early stage as we've tried to set realistic ranges that incorporate both those potential upsides and downsides. 
Our guidance includes the net benefit of 3 extra selling days based on our fiscal calendar. Compared to the prior year periods, we will gain 4 selling days in the first quarter. Although this will be the historically slow week between Christmas and New Year's while we will lose one day in the fourth fiscal quarter. We estimate this benefit to be between 50 and 70 basis points of sales growth with a negligible effect on EPS. 
At the same time, our guidance also includes a roughly $5 million headwind from products that we have either divested or recently decided to discontinue. In other words, our guidance would have been about 20 basis points higher if these products remained in our portfolio. 
In terms of divisional growth for 2017, our guidance contemplates low- to mid-single-digit growth in Diagnostics and Skeletal, mid-single-digit growth in Breast Health and slightly higher growth in Surgical. 
In Diagnostics, molecular should lead the charge behind Panther and an expanded international menu, including virology assays. We forecast that cytology and perinatal sales will be flat to up slightly, and we also expect blood to be flat to up slightly as new Zika sales offset negative macro trends. 
In Breast Health, we expect continued growth in Genius 3-D Mammography, a growing service annuity, contributions from new products, including the Affirm prone biopsy system and Brevera towards the end of the year, as well as a return to growth for our international business. 
In Surgical, we expect growth to be driven by MyoSure market expansion efforts and NovaSure share gains as well as international sales. 
Geographically, we expect our international business to begin contributing to growth in fiscal 2017, in line with the company's overall growth rate. 
In terms of profitability, we forecast continued improvement in non-GAAP operating margin in 2017, but how we get there will be different than last year. In 2017, we forecast a slight improvement in non-GAAP gross margin percentage, combined with greater leverage from operating expenses, leading to more improvement in operating margin than we saw last year. 
All of this leads us to forecast that earnings per share will be between $2.12 and $2.16 in 2017. This represents growth of 8.5% to 10.6% in constant currency and reported growth of between 8.2% and 10.2%. Again, we'd encourage you to model at the middle of our guidance range at this early stage of the year. 
This guidance assumes a full year tax rate of approximately 31% and diluted shares outstanding of between 289 million and 291 million for the year. Our guidance does not assume any capital deployment beyond calling what's left of our 2037 convertible notes in December. 
Now let's cover guidance for the first quarter of fiscal 2017. We expect revenues of $720 million to $730 million, flattish on a sequential basis as the benefit from extra selling days between Christmas and New Year's is offset by the normal seasonal decline we experienced due to our global sales meetings and the RSNA conference in Breast Health. Compared to the prior year period, this range reflects revenue growth of 3.8% to 5.2% on a constant-currency basis and reported revenue growth of 3.6% to 5.0%. 
We forecast non-GAAP diluted earnings per share of $0.50 to $0.51 in the first quarter. This represents anticipated growth of 9.1% to 11.3% in constant-currency terms or 8.7% to 10.9% on a reported basis. Compared to our fourth quarter actuals, please note that operating expenses will increase in the first quarter due to the timing of sales and marketing activities and the extra days. 
Before we open the call for questions, let me conclude by saying that our fourth quarter capped off another good year for the company. Our financial performance demonstrates that we are transforming from a turnaround story to a sustainable growth company. We feel confident about the foundation we have established heading into 2017 and have the levers necessary to deliver mid-single-digit revenue growth with EPS growth roughly double that rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions]"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] Our first question is from Brian Weinstein with William Blair.",12,"[Operator Instructions] Our first question is from Brian Weinstein with William Blair."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So as we look at your guidance range, you had clearly signaled ahead of time that you were going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a fun",99,"So as we look at your guidance range, you had clearly signaled ahead of time that you were going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a function of kind of how you expect new products to contribute? You talked about $10 million from that this quarter and whatnot. But do you expect that new products are really the differentiating factor between that high and low end? And any color on that would be helpful."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given particula",197,"Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given particularly the environment, to have a slightly broader range. I do think we see a little more. If the new products are doing well, which we fully expect they will, I think it clearly pushes us towards that higher end. I think we get into that 5 percentage range as things take off. We always want to be a little cautious until we start to see the success. I will tell you, I think Affirm is off to a very nice start, MyoSure REACH off to a very nice start. And these are really the first new products we've launched since we've come on. And also, our international molecular diagnostics business is really starting to take off. We've got a couple of quarters there of double-digit growth as well. So there's a lot we feel good about. But again, it's still very early stages and a lot to play out."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but -- we certainly feel very good about our path there, but there is some flexibility",53,"Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but -- we certainly feel very good about our path there, but there is some flexibility there as well."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS,",68,"And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS, that you guys are focused on? Some of the other products that you guys are focused on next year that potentially could add to growth there?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there Compton has really put in place. As we exit this year, we've basically got a completely new leadership team internationally from how we en",147,"Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there Compton has really put in place. As we exit this year, we've basically got a completely new leadership team internationally from how we entered the year. Other than our leader of the Diagnostics business in Europe, who's already showing and really been leading the way with great growth. But I think as we look to international, the molecular diagnostics business ought to be a real standout for us. I think Surgical, continuing off of a smaller base but continuing to show good growth. And Breast Health will return to some growth as we're working a lot tighter with our dealers and getting things in place there. So I think we feel, incrementally, significantly better entering this year than we did at this time last year about international."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Tycho Peterson with JPMorgan.",9,"Our next question is from Tycho Peterson with JPMorgan."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull",50,"Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull for margin expansion in '17?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. It was really -- I'd say those we had expanded and invested more than our rate of sales wil",69,"Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. It was really -- I'd say those we had expanded and invested more than our rate of sales will probably come back into those being slightly leverageable relative to the rate of sales as we go into the current year."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?",41,"And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're",76,"Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're working through with them. And we basically have not assumed that they come, and that could be an additional source of upside if or when they fall during the year."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think they should be accretive to the overall Diagnostic gross margins. That said, we've als",89,"Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think they should be accretive to the overall Diagnostic gross margins. That said, we've also heard about some pricing pressure over in Europe. And so can you help just kind of set the stage for us about what you expect in the U.S? And then maybe just a couple of words on what you're seeing in Europe thus far."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bot",74,"Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bottom line in Europe. But the big pickup for us will really be more in '18 on the margin side as it relates to the virals."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally in general. I think that's largely in the back of",114,"Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally in general. I think that's largely in the back of our viral system -- our viral load assays. And we'll get the full benefit of that in 2017 as those instruments that were placed get a kind of full year. The other thing is in that we have -- we noted that the revenue or pull-through per Panther has increased. That's both in the U.S. as well as internationally. So I think that that's a harbinger for good growth going forward."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And just the overall pricing dynamics in Europe.",8,"And just the overall pricing dynamics in Europe."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated.",42,"Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have Vijay Kumar with Evercore ISI.",8,"Next, we have Vijay Kumar with Evercore ISI."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I feel like we were all waiting with bated breath, just given what's happened in Medtech, but glad to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for next year? B",67,"I feel like we were all waiting with bated breath, just given what's happened in Medtech, but glad to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for next year? Because I would have thought, just given what happened sequentially 3Q versus 4Q international trends, any color on international would be helpful."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the gro",130,"Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the growth. But I think we see this year really being able to bounce. And recall the fourth -- the current quarter is not indicative of a trend given that last year's fourth quarter turns out -- there was a lot more put into that last year's fourth quarter than we fully understood, just as dealers bought in to maintain their contracts against minimums and things like that. So I think, again, we feel far better coming into this year and seeing expected growth."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then maybe one for -- go ahead, Bob.",10,"Great. And then maybe one for -- go ahead, Bob."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and",73,"Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and ordering patterns of our partner were adjusting, so we expect to kind of lap that. So that gives us help for turning that trajectory around as well."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment front. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's t",56,"And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment front. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's the focus for cash cap deployment over the next 12 months?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&",99,"Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&A activities, and then finally, share repurchase. The latter of those 2 is hard to predict. And certainly, the convertible notes, we don't have those -- ability to actually call those formally until 2018. And so that's why we've done it. But we will be opportunistic as appropriate within the market."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And just to clarify, that would be fiscal 2018.",10,"Yes. And just to clarify, that would be fiscal 2018."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","December of 2017.",3,"December of 2017."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Doug Schenkel with Cowen and Company.",12,"And our next question comes from Doug Schenkel with Cowen and Company."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new",143,"I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new products contribute about 100 basis points to fiscal '17 growth at the midpoint of guide. Is that about right? Secondly, what's your view on the sustainability of NovaSure growth given the benefit from competitive disruptions will annualize over the course of this fiscal year? Third, are there any major blood bank tenders that come up this year that we should be contemplating in our models? And lastly, how do you expect Panther utilization to increase above the $190,000 annualized figure that you provided in fiscal '17 based on geographic and menu expansion?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Doug, you sure you don't want to throw a few more in there?",13,"Doug, you sure you don't want to throw a few more in there?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. T",304,"Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. That's probably at the low end. Maybe it's a little higher than that, maybe 150 basis points, probably at the midpoint to think about that. And that's really driven behind the Affirm and Zika. Those are probably the 2 largest new products. Brevera will happen, but it's in the back half of the year. And then certainly, some of the virals and so forth in the U.S. will play a role. But again, the majority of that will happen in 2018. So that's the first question. I think sustainability of NovaSure, we feel very good about that. But remember, the formal withdrawal of the competitive product happened in our second quarter, so we expect to have larger and better growth in first and second quarters than we would add in the back half of the year. We expect growth throughout the course of the year, but the first and second quarters will be bigger than the back half for NovaSure. In terms of the major blood banks, those are -- you need to ask Grifols that, those are their customers, and so we're not going to be able to be in a position to answer that. And then in terms of Panther utilization, we do expect -- that's one of the big areas that we're focused on is continuing to not only place Panther systems but increase the utilization of the installed base. So I do expect that utilization to grow in line with the forecast that we had talked about for our molecular business."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next up, we have Isaac Ro with Goldman Sachs.",9,"Next up, we have Isaac Ro with Goldman Sachs."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've mentio",131,"So just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've mentioned and maybe some of the ones you haven't talked about. And so if I look at the R&D spend here, it's up good amount year-on-year and just thinking a little bit about how to frame the way you guys are investing your R&D dollars going forward. Maybe if you can talk a little bit about thematically, where you think your best bang for your buck is invested. And as we look over a multiyear period, how should we think about investment across the various divisions?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. I think if you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses. And really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that",385,"Sure. I think if you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses. And really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that grand slam or the boom-bust idea. So what we've got going on now is a lot of folks focused on both substantial innovation but also incremental innovation. And if you take our Surgical business as an example, we had launched NovaSure and launched MyoSure and never really did any product upgrades or anything through the years, just threw them out there and then watched eventually, price degrade or whatever else. So launching MyoSure REACH is a classic example of something that we're working on. We also just mentioned we're actually launching an upgraded NovaSure product outside the United States. You can imagine we'll be planning on bringing that to the United States once we get that through approval. Likewise, in Breast Health, instead of just focusing on the replacement for 3-D tomo, saying, ""Okay, what are we going to do in the meantime, and how can we leverage 3-D?"" Well, the Affirm prone biopsy system, Brevera. There will be other things that we're looking at in that vein as well. And again, we wanted to put some points on the board before we start talking about the future, just as you know us stylistically. And then the same as it relates to -- effectively the Diagnostics business, there were things that were not really in play when we got here. We turbocharged the Fusion, the development of the Fusion platform, which is then opening up that ability to do the same kind of singles and doubles as it relates to future assays and be able to broaden out the menu there. And again, those will be a lot of singles and doubles that will come behind the viral load programs. And we really hunkered down early on to push the viral loads through and across the finish line. Those have kind of been up and down, on and off. And we've really put a sustained commitment and started to feel very, very good about our ability in each of the divisions to be bringing in more steady stream of innovation."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so w",169,"Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so when I think about the R&D spend, we spend roughly 8%. Any year -- any quarter, it can change. That's probably the right amount. But I think, right now, what we've done is fundamentally, as Steve mentioned, changed the mind-set of the organizations and how they're going about actually developing products: linking R&D with marketing, truly having insight-driven innovation and creating that competitive advantage. We spend the most money as a percent of sales in our Diagnostics business, less in Breast and in our Surgical businesses. I think that, that probably is going to stay roughly the same. But it's really the makeup of it and the leadership making a big difference in terms of how we evaluate the innovation pipeline."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could",67,"That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could translate to a lower tax rate that moves the needle this fiscal year? Or is it maybe still a longer-term thing?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017. And we were actually able to pull some things forward into 2016. So you saw one of the benefits in 2",156,"Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017. And we were actually able to pull some things forward into 2016. So you saw one of the benefits in 2016 as being -- having a lower tax rate relative to '15. And so with that, we kind of -- we still see that kind of steady improvement, but we have actually accelerated some of those efforts resulted in the lower tax rate in 2016. Longer term, we continue to evaluate kind of what that looks like. We're roughly on that point per year, I think that that's probably a reasonable way to model going forward, which -- and this 31% that we're talking about, really, is roughly a point better than where we were for the full year 2016. So that's the way I would think about it, Isaac."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And next, we have David Lewis with Morgan Stanley.",9,"And next, we have David Lewis with Morgan Stanley."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve, but they'll be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines",120,"So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve, but they'll be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines to mid-single-digit growth, where you pick up 10 points or relative on 20% of your business. It's 2 points of growth that's the key driver of the improvement in '17. Your comp-adjusted growth for international, though, in the fourth quarter actually got worse. So just -- can you just help us understand why fourth quarter actually slowed, comp adjusted, but you're confident you get that reacceleration in '17?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had a kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we",199,"Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had a kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we look at the fundamentals of the business and some of those pockets, things like molecular, Surgical, the trend and the stabilization of our Breast Health business, which is probably the biggest -- one of the biggest changes. And then certainly, we feel pretty clear about -- we have pretty decent line of sight into the inventory levels now with the blood-screening business. I think those are kind of the building blocks that were headwinds last year that certainly will be -- or tailwinds going into 2017. I think Eric, as Steve mentioned, has done a tremendous job of really focusing the teams on the fundamentals. We've gone to the regional bases. We brought in a bunch of new leaders there, and I think they're just starting to get a hold on things. But I think we've seen good progress and good momentum going into 2017 on those couple of areas."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic po",130,"Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic post our conference in September really wasn't about '17. It was about sort of the view that this business can deliver not just 1 year of 5% and 10% growth, frankly, but several years of 5% and 10% growth. So I wonder if you'd just sort of synthesize for shareholders what are some of those business dynamics you're seeing that give you that confidence that this isn't just 1 good year, but it's a few good years to come? And then I'll jump back in queue."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. The stock-based comp piece, there's no impact.",8,"Sure. The stock-based comp piece, there's no impact."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","No material impact.",3,"No material impact."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products",197,"And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products in place, better people in place. And I probably feel better about the sustainability of this company than in any point since I've been here. Because I think by the time we go into '18, we're going to have more products hitting. We're going to have the international business that much further along. Because so much of what Eric's focused here during this year, what we've been doing in international this year is really putting the foundation in place that I'd hoped and wanted to be putting in place sooner. But we really weren't doing it. So I think just fundamentally, we just keep getting stronger and stronger. The comps will be getting tougher, this and that. But overall, feeling very good. We're going have a lot of stuff hitting in late '17 and into '18, and that's when the pipeline stuff will really be coming through."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Anthony Petrone with Jefferies.",9,"Our next question is from Anthony Petrone with Jefferies."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And t",95,"Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And then on Breast Health, I guess the question really is, Bob, going back in, I don't know, at some meetings you did speak about the 2-D opportunity OUS as being pretty substantial over the next several years, so I'm just wondering if we can get an update on that opportunity specifically?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow u",224,"Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow utilization on the instrumentation. It's never going to get to 100%. But certainly, we have room to grow. And if we look at TIGRIS, as an example, it's up in the 65% to 75% range in utilization, so there's still plenty of opportunity there from a molecular standpoint. In regards to Breast Health, yes, we are still enthusiastic about the opportunities, both in 3-D as well as 2-D. I think the team has been focused and really looked at country by country, screening guidelines, how we work with not only our dealers, but also starting more importantly, with governments and so forth and meeting some of the governments where they are. And the beauty of our 2-D system is it's software upgradable to 3-D, and so we have both the best 2-D system as well as the best 3-D system. And so that is still a strategy that we feel good about in the markets that we're focused on and an opportunity, not only to place both 2-D and the 3-D systems, but have that opportunity for upgrade over time."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?",36,"Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, rea",77,"Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, really, is we have plenty of opportunity to continue to grow utilization of our assays and our upcoming assays in the pipeline on the existing Panther."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Jack Meehan with Barclays.",9,"Our next question is from Jack Meehan with Barclays."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual pro",72,"I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual products? Maybe just as you look at the labs, how many are using 1 test or 2 tests or all 3 with Trich? Any color will be great."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer s",165,"Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer segmentation that says, ""Okay, if they've got chlamydia, gonorrhea, are they testing for Trich? Are they testing for HPV?"" And that has really driven that utilization in the U.S, and it's starting to drive that utilization internationally as well now that we have the viral loads. I will tell you in terms of growth rates for our major assay -- still, obviously, the largest is our chlamydia, gonorrhea CT/GC assay that grew in the low single digits. And then HPV and Trich continue to grow in excess of market, so those are gaining share. We feel good about our ability to continue to drive growth in '17 in those markets as well -- or those assays."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And one more follow-up on Panther. Just in international, the success you've had with viral loads, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously,",78,"Great. And one more follow-up on Panther. Just in international, the success you've had with viral loads, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously, with the strength of the U.S. fleet, if there's a way that we can think about the commercial strategy here and what percentage we can think would adopt the test over time?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had the full complement 6, 9 months ago, obviously with the tendered-based contracts in Europe. It takes some time. I think the good news is the leading i",80,"Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had the full complement 6, 9 months ago, obviously with the tendered-based contracts in Europe. It takes some time. I think the good news is the leading indicator of that, which is the Panther placements, is happening. But it is probably a number that we expect to grow into '17 and '18, for sure. But it's still early days."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jon Block with Stifel.",9,"Our next question comes from Jon Block with Stifel."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of Op margin expansion, and you mentioned somewhat shared between OpEx and gross margin expansion. So that leaves about 50 bps for gross",103,"Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of Op margin expansion, and you mentioned somewhat shared between OpEx and gross margin expansion. So that leaves about 50 bps for gross margin, down from roughly 140 bps this year. And I certainly understand the headwinds by international growing faster in '17 relative to '16 but still a decent step-down. So can just talk to us about that step-down in gross margin expansion? And then are you still getting a good gross margin pull from your 3 major divisions?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that.",29,"Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","I'd rephrase it that we're still continuing to expand as opposed to a step-down from...",16,"I'd rephrase it that we're still continuing to expand as opposed to a step-down from..."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business",175,"Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business but not at the level that it had in 2016. So there are some product mix in there as well. I will tell you that our operations teams are incredibly focused on continuing to improve the operational aspects of the business, and we established good pricing discipline. So -- and I think there are still opportunities to improve margins, I think just perhaps not at the level of 2016 given some of that product mix that we had. And then in the OpEx margins, it's across -- it's going to be across the product lines or product areas. We -- as Steve mentioned, we opportunistically look to invest in places like marketing and some the other areas. We have the ability to kind of -- to move some of those levers as we need to."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step ba",105,"Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step back, if you can opine upon MyoSure. I mean, rarely do you have 30% sustainable growth and now to the point where you've got a product annualizing at over $150 million. So just maybe talk about the sustainability of why you're seeing that sort of growth rate and just the market opportunity that you see in front of Hologic for that product?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. Yes. I would say MyoSure has been probably, our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year in which it had looked to be slowing in the 20-ish range kind of really",213,"Sure. Yes. I would say MyoSure has been probably, our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year in which it had looked to be slowing in the 20-ish range kind of really re-accelerate. We're not sure how high is up yet there. And I almost don't want to call the market. Because I think we're finding more and more avenues and more and more opportunities to tap into other procedures and things. So we continue -- even through the year, that growth rate has not yet slowed. We brought some news to it. And I think we see that as still being a real growth driver for us. NovaSure will clearly come back to earth in terms of growth rates. But again, we're going to be bringing news to that franchise, and we're just -- we have adopted a mind-set that we don't accept anything but an expectation of growth, even on the older businesses. And it's our job to figure out how to grow them. I'm confident that team will continue to find ways to keep growing what is a great, great product. But certainly, at slower rates probably, once we got through the big competitive piece."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have from UBS, Jon Groberg.",7,"Next, we have from UBS, Jon Groberg."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- I'll actually just ask one question. Steve, on the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do",92,"Just -- I'll actually just ask one question. Steve, on the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do something from an M&A standpoint in 2017? And it seems like where you're at as a firm, you seem to have a little bit more confidence internationally. Obviously, the core business in the U.S. is doing well. The M&A piece hasn't really kicked in yet."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I",171,"Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I do think there may be -- come some opportunities. I would tell you, we've looked at a lot of things, some of which we're patient on, and we want to make sure that they make sense. So I'm seeing a lot more. I would say, if you look at my percentage of my time spent with the divisions on business development deals today versus a year ago, it's a dramatic difference. And we've seen a lot of good things, a lot of things that may not yet be making the full hurdle because we're obviously being very disciplined as we go. But I do feel good that we're going to continue to be smart and sensible, and the capabilities that come a long way."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our final question is from Mary Kate Gorman from Canaccord Genuity.",11,"Our final question is from Mary Kate Gorman from Canaccord Genuity."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3-D tomo as a result of the updated NCCN guidelines, similar to CIGNA? And along that line, do you anticipate new payers coming on next quar",59,"Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3-D tomo as a result of the updated NCCN guidelines, similar to CIGNA? And along that line, do you anticipate new payers coming on next quarter as a result of payers revising coverage decisions in the New Year?"
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily, in the next quarter. Hopefully, in the coming quarters, we would hope to continu",106,"Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily, in the next quarter. Hopefully, in the coming quarters, we would hope to continue to make progress there. But there's a lot of pick on this [ph], frankly. There's a lot going on in the private pay world right now. And this isn't necessarily getting the full attention that we think it should, but we'll continue to drive that and expect that over time we'll knock those barriers down. But I think all of that will be additional upside."
108544,403594883,1071326,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]I would now like to intro",53,"Good afternoon, and welcome to the Hologic, Inc. Fourth Quarter Fiscal 2016 Earnings Conference Call. My name is Camille, and I'm your operator for today's call. Today's conference call is being recorded. [Operator Instructions]
I would now like to introduce Mike Watts, Vice President, Investor Relations and Corporate Communications, to begin the call."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve a",216,"Thank you, Camille. Good afternoon, everyone, and thanks joining us for Hologic's Fourth Quarter Fiscal 2016 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and CEO; and Bob McMahon, our Chief Financial Officer. Steve and Bob, both, have some prepared remarks today. Then we'll have a question-and-answer session.
Our fourth quarter press release is available now on the Investors section of our website. We also will post our prepared remarks to our website shortly after we deliver them. Finally, a replay of this call will be archived on our website through November 25.
Before we begin, I'd like to inform you that certain statements we make during this call will be forward looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement that's included in our earnings release and in our filings with the SEC. 
Also during this call, we will be discussing certain non-GAAP financial measures. A reconciliation to GAAP financial measures can be found in our earnings release. 
Finally, any percentage changes that we discuss will be on a year-over-year basis, unless otherwise noted. 
Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth c",1857,"Thank you, Mike, and good afternoon, everyone. We're pleased to discuss Hologic's financial results for the fourth quarter of fiscal 2016. We once again posted strong results that illustrate the progress we're making toward building a sustainable growth company. In addition, our results capped off a very good fiscal 2016 in which we delivered on our commitments. 
Today, I'll first provide a high-level overview of our fourth quarter results. But since it's the end of our fiscal year, we'd also like to provide a strategic update on the journey we've shared over the last 3 years. We'll focus on our revenue and financial drivers for the full year and provide some color on the behind-the-scenes progress we're making in research and development. Let's start with our fourth quarter results. 
Revenue of $726.8 million grew 3.4% on a reported basis or 3.8% in constant currency, a healthy performance despite a difficult comparison to the prior year period. We also absorbed a headwind of nearly $4 million from divested and discontinued products. Net of these, total revenues would have grown 4.4% in constant currency. 
Our Surgical business again set the pace with its seventh straight quarter of double-digit growth globally. We are also pleased with how our breast imaging and molecular diagnostics businesses performed and encouraged that new products began to contribute to growth. We'll come back to this point in a minute. 
In terms of geography, U.S. sales grew 7.4% in the quarter, continuing a string of strong results. Even if we exclude the $5 million royalty payment from our fourth quarter results, our growth rate accelerated on a sequential basis. 
As expected, international sales declined 9.6% as reported or 7.8% in constant currency versus a difficult comparison in the prior year period. Apart from this tough comp, international Breast Health was stable sequentially in the quarter. There were also some pockets of strength globally, namely molecular diagnostics and Surgical, both of which posted double-digit growth. Although these businesses are relatively small today outside the U.S., we believe they will be important growth drivers in 2017 and beyond. 
Profit margins remained robust in the quarter. Most importantly, non-GAAP net income grew 14.6%, more than 3x faster than sales. And our net margin of 20% increased by 190 basis points. With the benefit of additional capital deployment, we posted non-GAAP EPS of $0.52 or 20.9% better than in the prior year period. 
So all in all, we posted a very strong fourth quarter that exceeded expectations and capped off an excellent year. 
Thinking about the year as a whole, we made good progress in our journey from turnaround story to sustainable growth company. To date, our successes have been most visible in domestic sales execution, which in turn has driven the improved financial performance of the company. 
One of the first goals we established 3 years ago was to stabilize 2 highly profitable products that had been declining sharply: ThinPrep and NovaSure. In 2016, these products were more than stable. They returned to solid growth. Cytology and perinatal sales increased 2% on the year in constant currency. Even more impressive, NovaSure sales grew 10% in constant currency as our team capitalized on the market withdrawal of a competing product. 
As we stabilized ThinPrep and NovaSure, we also set out to maximize growth drivers such as Genius 3-D Mammography systems and the Panther platform in molecular diagnostics. Both of these products performed well in 2016. 
Genius drove 5.2% constant-currency growth in total Breast Health sales in 2016, and we remain bullish on the opportunity ahead of us. While there has been lots of debate about a peak in system placements, we have a fundamentally different and more positive view of the future. The 3-D curve is very different than the 2-D curve for a number of reasons, and we believe Breast Health sales will be stronger for longer than many anticipate. 
Although we've placed about 3,600 systems in the United States as of the end of the fiscal year, the market is still underpenetrated. For example, 3-D installations represent a little more than 40% of total Hologic mammography systems. And if you look at MQSA statistics, 3-D installations represent just 1/4 of total systems. We have been placing roughly 300 units per quarter in the U.S. recently, and at this pace should enjoy many more quarters of solid performance. We are also gaining significant market share from our competitors. While our innovative marketing strategies enable us to maintain stable pricing. 
As our domestic installed base of 3-D units has grown, so has the related service opportunity. Breast Health service revenue again exceeded $100 million in the quarter and increased at a high single-digit rate, boosting overall growth. This increase in service revenue, combined with the potential of new products, gives us confidence that Breast Health can continue to grow even as 3-D adoption matures. 
Now let's turn to a second major growth driver, the Panther system, our fully automated diagnostics instrument. Panther helped our molecular business grow 7.8% in constant currency in 2016, behind increased sales of women's health tests for chlamydia and gonorrhea, HPV And Trichomonas. By the end of fiscal 2016, we had shipped more than 1,000 Panther units just to diagnostic customers. And we're encouraged that a growing number of these placements are coming internationally. Panther shipments to customers outside the United States grew dramatically in 2016, and we believe we are just scratching the surface of this long-term opportunity. 
At the same time, our sales team is partnering with lab and physician customers to ensure that patients are tested according to the best clinical guidelines, providing better care while increasing organic volumes. In fact, on a global basis, the average Panther generated more than $190,000 in assay revenue in 2016, a high single-digit increase in utilization. And we are optimistic that this number will increase further as we roll out viral load assays in Europe and the United States. 
As we look back on fiscal 2016, the stabilization of ThinPrep and NovaSure, combined with strong growth from Genius and Panther, drove excellent full year results. You might recall that 12 months ago, our initial guidance called for revenue of $2.81 billion to $2.84 billion for the year. We finished at $2.83 billion, so we delivered on our commitment. 
At the same time, we achieved significant margin improvement in 2016. For the year, non-GAAP gross margin was 65.6%, an impressive 140 basis points better than last year. This enabled us to make incremental investments in marketing and R&D to drive future growth while still delivering operating income of 33.6%, 30 basis points better than in 2015. 
Combined with a lower tax rate and repurchases of both convertible debt and common shares, we posted non-GAAP earnings per share of $1.96 in 2016. This was 17.4% higher than in the prior year and comfortably ahead of our original guidance. 
Looking beyond earnings, we're also very pleased with our cash flow in 2016, which is often underappreciated. We generated $787.2 million in operating cash with only $94.5 million in CapEx. And roughly half of this CapEx went toward revenue-generating instruments such as our Panther systems. As a result, free cash flow for the year was $692.7 million, 23.3% higher than non-GAAP net income. 
Our operations and finance teams deserve tremendous credit for making this happen. As one measure of their success, inventories at year-end 2016 were $8.4 million less than a year ago, even though product revenues were about $109 million higher. Taken a step further, inventories are now below the levels of even 2 years ago, demonstrating tremendous progress by our team. 
Obviously, these strong cash flows gave us the flexibility to continue improving our capital structure in 2016. We repurchased $274.2 million of convertible notes for $392.8 million during the year as well as 7.3 million shares of common stock for $250 million. As a result, our leverage ratio, net debt over EBITDA, has fallen to 2.8x, a little more than half what it was at the time of the Gen-Probe acquisition. In addition, diluted shares outstanding were slightly lower in 2016 than in the prior year, providing a boost to EPS. 
Before I turn the call over to Bob, I want to emphasize that strong cash flows also enabled us to invest appropriately and consistently in research and development, which increased about 8% this year. And we are just beginning to see the fruits of our labor. 
In the fourth quarter of 2016, sales of key new products exceeded $10 million in revenue for the first time. These new products include viral assays in Diagnostics, the Affirm prone biopsy system in Breast Health and MyoSure REACH in Surgical. We recognize that $10 million is still small in the context of overall Hologic, but it's a good start. And we are optimistic about the potential of these products in 2017. 
In addition, our R&D pipeline is building behind the first wave of new products. In diagnostics, we recently filed for regulatory approval of our Aptima Hepatitis C viral load test in the United States and anticipate launching it commercially in 2017, following the introduction of our HIV viral load assay. Sales of these products will become more meaningful in 2018 when we also have a Hepatitis B assay available. We also filed recently for U.S. regulatory approval of a herpes test, which will complement our existing portfolio of women's health products on the Panther system. And finally, we are beginning clinical trials for our respiratory assays on the next-generation Panther Fusion system. 
In Breast Health, we have fundamentally reshaped our R&D strategy away from the boom-and-bust approach of the past toward a model that strives for continuous innovation built around our leadership position in 3-D mammography. The Affirm prone biopsy system fits in this vein as does our upcoming Brevera product, which will provide real-time specimen radiography to improve breast biopsy workflow and the patient experience. We are hopeful that Brevera will begin to contribute to growth late in 2017 and more meaningfully in 2018. 
Finally, in Surgical, we are encouraged by the early success of our MyoSure REACH line extension, which is providing new capabilities to customers, and therefore, helping expand the market. In the same way, we are working to leverage our market-leading position in endometrial ablation by launching, internationally, a next-generation NovaSure device that will improve patient comfort as well as physician usability. 
Compared to the dramatic improvement you've seen in U.S. sales execution, our progress in research and development is just becoming visible. We have a lot of work to do in these areas but are excited about our early progress. 
In some ways, domestic sales execution represents the tip of the iceberg in terms of what's possible here. Below the surface, we are working diligently to boost new product innovation, build our international capabilities and further enhance profitability. As our new leadership team settles in and as talented, engaged employees at all levels of the organization continue to do their thing, we look forward to sharing more successes with you in 2017 and beyond. 
Now I will hand the call over to Bob."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise note",1742,"Thank you. Steve, and good afternoon, everyone. I'm going to provide more detail on our divisional revenue performance, review the rest of our fourth quarter financials and then discuss our revenue -- our financial guidance for 2017. Unless otherwise noted, my commentary will focus on non-GAAP results, and revenue growth rates will be expressed in constant currency. 
We closed out our fiscal year with results that surpassed expectations. Revenue grew at a healthy rate, and favorable gross margins allowed us to reinvest opportunistically in the business while still delivering strong bottom line growth. 
I'll begin by discussing our Surgical division, which remained the growth leader in the quarter with sales of $101.5 million and growth of 17.6%. Fueling this growth was MyoSure, where sales of $42.6 million grew 33.4%, thanks to the outstanding efforts of our commercial team. In addition, NovaSure sales grew 8.7% as we continued to gain market share and capitalize on a competitive withdrawal. 
Now moving to Diagnostics. We posted sales of $311.9 million in the quarter, a solid growth rate of 3.1%. In molecular diagnostics, quarterly sales of $134.3 million increased 9.6%. As Steve noted, we booked a $5 million royalty payment this quarter. But at the same time, we also absorbed a headwind of almost $3 million from our discontinued cystic fibrosis product line. So the underlying trends in the business remain strong, and we continue to gain share and increase utilization of women's health assays on the fully automated Panther instrument. In addition, international sales grew at a mid-teens rate, and we posted yet another record quarter of Panther placements outside the U.S., providing a strong platform for future growth. 
Elsewhere in Diagnostics, our cytology and perinatal products posted sales of $121 million and increased slightly compared to the prior year period. Share gains for our ThinPrep product line continue to offset headwinds from longer cervical cancer screening intervals. 
And finally, our blood business declined 6%, as expected, as we continue to see the impact of lower blood utilization and fluctuating order patterns by our partner, Grifols. Partially offsetting these headwinds were initial sales of our Zika products. As we enter 2017, we believe macro trends towards lower blood utilization will continue to be a drag on sales growth. 
Now moving to Breast Health. We posted global sales of $292.3 million and solid growth of 2.3% over another challenging comp. In the U.S., continued adoption of Genius 3-D systems was supplemented by a growing service annuity and our sales of our new Affirm prone biopsy system, driving an increase of 7.2% in sales. Over the last 2 quarters, our U.S. Breast Health results have clearly illustrated a point we've made repeatedly in recent months: that the business can continue to grow despite increasingly challenging comps. 
And to round out our revenue discussion, Skeletal Health revenues of $21.2 million decreased 17.3% in constant currency, due mainly to lower volumes of our Fluoroscan mini C-arm products. 
Now moving down the income statement. Fourth quarter gross margins of 65.7% increased 110 basis points compared to the prior year period. Gross margins benefited from both geographic and product mix as well as continued pricing discipline and operational improvements. 
Total operating expenses of $235.5 million increased 7.7% in the fourth quarter. We continue to take advantage of improving gross margins to reinvest strategically in the business. For example, quarterly R&D spending increased 16.3%, and we're beginning to see some of the benefits, as Steve discussed. In addition, as we mentioned last quarter, a change in the retirement provisions of our equity plan drove an additional $4 million of expense. Despite these investments, our non-GAAP operating margin remained a healthy 33.3% in the quarter. 
Below the line, we continue to make good progress in 2 areas that have been a priority for our finance organization. Based on lower debt levels, interest expense of $32.9 million in the fourth quarter declined 14.8%. At the same time, our non-GAAP effective tax rate of 31% in the quarter was more than 300 basis points lower than a year ago. While we are very pleased with the results we've produced in a short amount of time, we are still at the beginning stages of this process and see continued opportunity ahead. 
And finally, to wrap up the fourth quarter income statement, non-GAAP EPS of $0.52 grew 20.9% compared to a year ago, much faster than sales growth. The multiple levers used to drive EPS growth in the quarter give us comfort in our ability to continue growing EPS at a multiple of sales. 
Now let me turn to cash flows and the balance sheet. In the fourth quarter, adjusted EBITDA of $263.9 million improved 5.2%. 
We continue to focus on reducing our convertible debt. In the fourth quarter, we repurchased $47.6 million in principal of our 2037 notes for $81.3 million and intend to redeem the remaining $12 million in cash when the notes are callable this December. 
Despite retiring a portion of our convertible debt and repurchasing shares over the course of 2016, we ended the year with $548.4 million in cash, an increase of $57.1 million compared to the prior year. We finished the year with total debt of $3.3 billion, a reduction of $0.3 billion compared to the prior year. And our leverage ratio, net debt over EBITDA, currently sits at 2.8x, close to our target of 2.5x. 
The combination of strong profit growth and lower debt continues to drive improvements to return on invested capital. As of year-end, ROIC was 12.7% on a trailing 12-month basis, an increase of 180 basis points over the prior year. 
Now I'd like to cover our non-GAAP financial guidance for fiscal 2017. We are forecasting mid-single-digit revenue growth in '17 on top of increasingly challenging comps. We expect an improving operating margin and lower tax rate to drive EPS growth at roughly double the rate of sales growth. 
Specifically, we anticipate constant-currency revenue growth of between 4% and 5.5% in fiscal 2017. At recent exchange rates, this equates to sales of $2.94 billion to $2.98 billion on a reported basis with reported growth rates between 3.8% and 5.2%. As you update your forecasts, we would encourage you to model at the middle of our guidance ranges at this early stage as we've tried to set realistic ranges that incorporate both those potential upsides and downsides. 
Our guidance includes the net benefit of 3 extra selling days based on our fiscal calendar. Compared to the prior year periods, we will gain 4 selling days in the first quarter. Although this will be the historically slow week between Christmas and New Year's while we will lose one day in the fourth fiscal quarter. We estimate this benefit to be between 50 and 70 basis points of sales growth with a negligible effect on EPS. 
At the same time, our guidance also includes a roughly $5 million headwind from products that we have either divested or recently decided to discontinue. In other words, our guidance would have been about 20 basis points higher if these products remained in our portfolio. 
In terms of divisional growth for 2017, our guidance contemplates low- to mid-single-digit growth in Diagnostics and Skeletal, mid-single-digit growth in Breast Health and slightly higher growth in Surgical. 
In Diagnostics, molecular should lead the charge behind Panther and an expanded international menu, including virology assays. We forecast that cytology and perinatal sales will be flat to up slightly, and we also expect blood to be flat to up slightly as new Zika sales offset negative macro trends. 
In Breast Health, we expect continued growth in Genius 3-D Mammography, a growing service annuity, contributions from new products, including the Affirm prone biopsy system and Brevera towards the end of the year, as well as a return to growth for our international business. 
In Surgical, we expect growth to be driven by MyoSure market expansion efforts and NovaSure share gains as well as international sales. 
Geographically, we expect our international business to begin contributing to growth in fiscal 2017, in line with the company's overall growth rate. 
In terms of profitability, we forecast continued improvement in non-GAAP operating margin in 2017, but how we get there will be different than last year. In 2017, we forecast a slight improvement in non-GAAP gross margin percentage, combined with greater leverage from operating expenses, leading to more improvement in operating margin than we saw last year. 
All of this leads us to forecast that earnings per share will be between $2.12 and $2.16 in 2017. This represents growth of 8.5% to 10.6% in constant currency and reported growth of between 8.2% and 10.2%. Again, we'd encourage you to model at the middle of our guidance range at this early stage of the year. 
This guidance assumes a full year tax rate of approximately 31% and diluted shares outstanding of between 289 million and 291 million for the year. Our guidance does not assume any capital deployment beyond calling what's left of our 2037 convertible notes in December. 
Now let's cover guidance for the first quarter of fiscal 2017. We expect revenues of $720 million to $730 million, flattish on a sequential basis as the benefit from extra selling days between Christmas and New Year's is offset by the normal seasonal decline we experienced due to our global sales meetings and the RSNA conference in Breast Health. Compared to the prior year period, this range reflects revenue growth of 3.8% to 5.2% on a constant-currency basis and reported revenue growth of 3.6% to 5.0%. 
We forecast non-GAAP diluted earnings per share of $0.50 to $0.51 in the first quarter. This represents anticipated growth of 9.1% to 11.3% in constant-currency terms or 8.7% to 10.9% on a reported basis. Compared to our fourth quarter actuals, please note that operating expenses will increase in the first quarter due to the timing of sales and marketing activities and the extra days. 
Before we open the call for questions, let me conclude by saying that our fourth quarter capped off another good year for the company. Our financial performance demonstrates that we are transforming from a turnaround story to a sustainable growth company. We feel confident about the foundation we have established heading into 2017 and have the levers necessary to deliver mid-single-digit revenue growth with EPS growth roughly double that rate. 
With that, I will ask the operator to open up the call for questions. [Operator Instructions]"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","[Operator Instructions] Our first question is from Brian Weinstein with William Blair.",12,"[Operator Instructions] Our first question is from Brian Weinstein with William Blair."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So as we look at your guidance range, you had clearly signaled ahead of time that you were going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a fun",99,"So as we look at your guidance range, you had clearly signaled ahead of time that you were going to give a wider range, and you certainly did that. I'm curious, you guided us to the midpoint. But on the high end and the low end there, is that really a function of kind of how you expect new products to contribute? You talked about $10 million from that this quarter and whatnot. But do you expect that new products are really the differentiating factor between that high and low end? And any color on that would be helpful."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given particula",197,"Sure, Brian. The new products will certainly be a piece of it. I think we've been all around long enough to know no matter what we put into our forecast, it always comes out a little differently. And I just think it's a very prudent thing, given particularly the environment, to have a slightly broader range. I do think we see a little more. If the new products are doing well, which we fully expect they will, I think it clearly pushes us towards that higher end. I think we get into that 5 percentage range as things take off. We always want to be a little cautious until we start to see the success. I will tell you, I think Affirm is off to a very nice start, MyoSure REACH off to a very nice start. And these are really the first new products we've launched since we've come on. And also, our international molecular diagnostics business is really starting to take off. We've got a couple of quarters there of double-digit growth as well. So there's a lot we feel good about. But again, it's still very early stages and a lot to play out."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but -- we certainly feel very good about our path there, but there is some flexibility",53,"Okay. This is Mike, just to build on that is some of these products haven't gotten full approval yet as well. And so we -- there is an estimate of timing to start with but -- we certainly feel very good about our path there, but there is some flexibility there as well."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS,",68,"And you mentioned OUS, specifically in molecular diagnostics. And I think you talked about a return to growth next year somewhere in, I think, maybe mid-single digits or something overall. But can you talk about some of the things, more specifically OUS, that you guys are focused on? Some of the other products that you guys are focused on next year that potentially could add to growth there?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there Compton has really put in place. As we exit this year, we've basically got a completely new leadership team internationally from how we en",147,"Yes. I think there's -- a couple of things we're excited about for international. First is the leadership team there Compton has really put in place. As we exit this year, we've basically got a completely new leadership team internationally from how we entered the year. Other than our leader of the Diagnostics business in Europe, who's already showing and really been leading the way with great growth. But I think as we look to international, the molecular diagnostics business ought to be a real standout for us. I think Surgical, continuing off of a smaller base but continuing to show good growth. And Breast Health will return to some growth as we're working a lot tighter with our dealers and getting things in place there. So I think we feel, incrementally, significantly better entering this year than we did at this time last year about international."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Tycho Peterson with JPMorgan.",9,"Our next question is from Tycho Peterson with JPMorgan."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull",50,"Steve, I want to actually focus on margins. Guidance assumes some nice operating margin expansion. Can you talk a little bit about the drivers? I know you've overinvested during the growth boom, so can you maybe talk about some of the levers you can pull for margin expansion in '17?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. It was really -- I'd say those we had expanded and invested more than our rate of sales wil",69,"Sure. We've clearly invested heavily, Tycho, especially on the marketing and the R&D fronts as this year was coming in well and obviously way high on the EPS line. It was really -- I'd say those we had expanded and invested more than our rate of sales will probably come back into those being slightly leverageable relative to the rate of sales as we go into the current year."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?",41,"And then as we think about Breast Health, CIGNA is obviously the first to move forward with reimbursement coming from routine screening. Can you talk a little bit about how that's progressed and where you see other payers along that path?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're",76,"Sure. We really applaud CIGNA. They obviously got on board. I would tell you, it's a struggle with both Aetna and United at this point. We're working through it. We would love them to take the same approach towards their patients that CIGNA did, but we're working through with them. And we basically have not assumed that they come, and that could be an additional source of upside if or when they fall during the year."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Bill Quirk with Piper Jaffray.",10,"Our next question comes from Bill Quirk with Piper Jaffray."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think they should be accretive to the overall Diagnostic gross margins. That said, we've als",89,"Great. Just a couple of questions on virals, guys. Obviously, glad to hear that everything is on track for the U.S. launches. And if we're doing the math right, I think they should be accretive to the overall Diagnostic gross margins. That said, we've also heard about some pricing pressure over in Europe. And so can you help just kind of set the stage for us about what you expect in the U.S? And then maybe just a couple of words on what you're seeing in Europe thus far."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bot",74,"Sure. To be clear, the virals will be a very small contributor in 2017 in the United States, and that's where they're going to be coming at a much better margin. So the -- right now, they are contributing to the top line growth, and certainly, top and bottom line in Europe. But the big pickup for us will really be more in '18 on the margin side as it relates to the virals."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally in general. I think that's largely in the back of",114,"Yes. And I think in Europe, we're seeing good traction there, Bill. We talked about the Panther placements. 2016 was a very good year in Panther placements, specifically in Europe, but also internationally in general. I think that's largely in the back of our viral system -- our viral load assays. And we'll get the full benefit of that in 2017 as those instruments that were placed get a kind of full year. The other thing is in that we have -- we noted that the revenue or pull-through per Panther has increased. That's both in the U.S. as well as internationally. So I think that that's a harbinger for good growth going forward."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And just the overall pricing dynamics in Europe.",8,"And just the overall pricing dynamics in Europe."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated.",42,"Yes. Pricing is lower in the U.S -- in Europe, but it's pretty much as expected from -- based on our models. It's a little lower outside the U.S. than in the U.S. but not anything different than what we had anticipated."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have Vijay Kumar with Evercore ISI.",8,"Next, we have Vijay Kumar with Evercore ISI."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I feel like we were all waiting with bated breath, just given what's happened in Medtech, but glad to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for next year? B",67,"I feel like we were all waiting with bated breath, just given what's happened in Medtech, but glad to see this come through. Just maybe one on the guidance on the revenue. What does the guidance assume for OUS growth, international growth for next year? Because I would have thought, just given what happened sequentially 3Q versus 4Q international trends, any color on international would be helpful."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the gro",130,"Sure. It basically is in line with the total company growth rate next year. So I'd say we're picturing actually balanced growth for the first time. As you know, the last couple of years, it's been way skewed to the U.S. has been generating most of the growth. But I think we see this year really being able to bounce. And recall the fourth -- the current quarter is not indicative of a trend given that last year's fourth quarter turns out -- there was a lot more put into that last year's fourth quarter than we fully understood, just as dealers bought in to maintain their contracts against minimums and things like that. So I think, again, we feel far better coming into this year and seeing expected growth."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And then maybe one for -- go ahead, Bob.",10,"Great. And then maybe one for -- go ahead, Bob."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and",73,"Yes. I was just going to say, the other thing to bear in mind there is we had mentioned that the blood screening business will be roughly flat to slightly up year-on-year. That was a big headwind internationally through all of 2016 as the inventories and ordering patterns of our partner were adjusting, so we expect to kind of lap that. So that gives us help for turning that trajectory around as well."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment front. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's t",56,"And then maybe one for you, Bob. You did mention that the guidance doesn't assume anything on the cap deployment front. I mean, just -- and I think in your prepared remarks you also highlighted free cash generation, right? I guess, my question is what's the focus for cash cap deployment over the next 12 months?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&",99,"Yes. We continue to focus on -- we mentioned that in December, we plan to call the first tranche of the remaining amount of that first tranche of convertible notes. I think outside of that, we continue to be focused on debt paydown as well as growth in M&A activities, and then finally, share repurchase. The latter of those 2 is hard to predict. And certainly, the convertible notes, we don't have those -- ability to actually call those formally until 2018. And so that's why we've done it. But we will be opportunistic as appropriate within the market."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. And just to clarify, that would be fiscal 2018.",10,"Yes. And just to clarify, that would be fiscal 2018."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","December of 2017.",3,"December of 2017."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","That's correct.",3,"That's correct."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And our next question comes from Doug Schenkel with Cowen and Company.",12,"And our next question comes from Doug Schenkel with Cowen and Company."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new",143,"I guess I have one question on just assumptions you're baking into guidance. It has a few parts to it. So I'll just rattle through these, and then I'll get back in the queue. The first part is for new products. It seems like you might be assuming that new products contribute about 100 basis points to fiscal '17 growth at the midpoint of guide. Is that about right? Secondly, what's your view on the sustainability of NovaSure growth given the benefit from competitive disruptions will annualize over the course of this fiscal year? Third, are there any major blood bank tenders that come up this year that we should be contemplating in our models? And lastly, how do you expect Panther utilization to increase above the $190,000 annualized figure that you provided in fiscal '17 based on geographic and menu expansion?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Doug, you sure you don't want to throw a few more in there?",13,"Doug, you sure you don't want to throw a few more in there?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. T",304,"Let me -- Hey, Doug, it's Bob. I'll take the -- first, on the new products, we feel very good about that. We mentioned the $10 million in Q4. We obviously expect that to grow throughout the course of 2017. And I think you had mentioned 100 basis points. That's probably at the low end. Maybe it's a little higher than that, maybe 150 basis points, probably at the midpoint to think about that. And that's really driven behind the Affirm and Zika. Those are probably the 2 largest new products. Brevera will happen, but it's in the back half of the year. And then certainly, some of the virals and so forth in the U.S. will play a role. But again, the majority of that will happen in 2018. So that's the first question. I think sustainability of NovaSure, we feel very good about that. But remember, the formal withdrawal of the competitive product happened in our second quarter, so we expect to have larger and better growth in first and second quarters than we would add in the back half of the year. We expect growth throughout the course of the year, but the first and second quarters will be bigger than the back half for NovaSure. In terms of the major blood banks, those are -- you need to ask Grifols that, those are their customers, and so we're not going to be able to be in a position to answer that. And then in terms of Panther utilization, we do expect -- that's one of the big areas that we're focused on is continuing to not only place Panther systems but increase the utilization of the installed base. So I do expect that utilization to grow in line with the forecast that we had talked about for our molecular business."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next up, we have Isaac Ro with Goldman Sachs.",9,"Next up, we have Isaac Ro with Goldman Sachs."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've mentio",131,"So just want to spend a minute talking about innovation. You guys have clearly done a great job restoring consistency in the core business but maybe a little bit less appreciated than some of the new products you put out there, both the ones you've mentioned and maybe some of the ones you haven't talked about. And so if I look at the R&D spend here, it's up good amount year-on-year and just thinking a little bit about how to frame the way you guys are investing your R&D dollars going forward. Maybe if you can talk a little bit about thematically, where you think your best bang for your buck is invested. And as we look over a multiyear period, how should we think about investment across the various divisions?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. I think if you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses. And really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that",385,"Sure. I think if you take a macro view at it, Isaac, we've dramatically overhauled, really, the R&D organizations in all 3 businesses. And really proud -- it's taken some work, and it's all been happening behind the scenes but really trying to break that grand slam or the boom-bust idea. So what we've got going on now is a lot of folks focused on both substantial innovation but also incremental innovation. And if you take our Surgical business as an example, we had launched NovaSure and launched MyoSure and never really did any product upgrades or anything through the years, just threw them out there and then watched eventually, price degrade or whatever else. So launching MyoSure REACH is a classic example of something that we're working on. We also just mentioned we're actually launching an upgraded NovaSure product outside the United States. You can imagine we'll be planning on bringing that to the United States once we get that through approval. Likewise, in Breast Health, instead of just focusing on the replacement for 3-D tomo, saying, ""Okay, what are we going to do in the meantime, and how can we leverage 3-D?"" Well, the Affirm prone biopsy system, Brevera. There will be other things that we're looking at in that vein as well. And again, we wanted to put some points on the board before we start talking about the future, just as you know us stylistically. And then the same as it relates to -- effectively the Diagnostics business, there were things that were not really in play when we got here. We turbocharged the Fusion, the development of the Fusion platform, which is then opening up that ability to do the same kind of singles and doubles as it relates to future assays and be able to broaden out the menu there. And again, those will be a lot of singles and doubles that will come behind the viral load programs. And we really hunkered down early on to push the viral loads through and across the finish line. Those have kind of been up and down, on and off. And we've really put a sustained commitment and started to feel very, very good about our ability in each of the divisions to be bringing in more steady stream of innovation."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so w",169,"Yes. Isaac, this is Bob. Just to build on what Steve is saying. I mean, Steve talks a lot about people make a difference. And so over the last several years, we've really not only focused on rebuilding the commercial teams but also the R&D teams. And so when I think about the R&D spend, we spend roughly 8%. Any year -- any quarter, it can change. That's probably the right amount. But I think, right now, what we've done is fundamentally, as Steve mentioned, changed the mind-set of the organizations and how they're going about actually developing products: linking R&D with marketing, truly having insight-driven innovation and creating that competitive advantage. We spend the most money as a percent of sales in our Diagnostics business, less in Breast and in our Surgical businesses. I think that, that probably is going to stay roughly the same. But it's really the makeup of it and the leadership making a big difference in terms of how we evaluate the innovation pipeline."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could",67,"That's really helpful color. And maybe just a follow-up for Bob on the financial side of the guidance. Could you talk a little bit about tax planning, maybe what's baked into your guidance this year for tax rate? And are there any opportunities that could translate to a lower tax rate that moves the needle this fiscal year? Or is it maybe still a longer-term thing?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017. And we were actually able to pull some things forward into 2016. So you saw one of the benefits in 2",156,"Yes. I think it's still a longer-term thing, Isaac. We were -- if you recall, we didn't anticipate anything actually really starting to happen until 2017. And we were actually able to pull some things forward into 2016. So you saw one of the benefits in 2016 as being -- having a lower tax rate relative to '15. And so with that, we kind of -- we still see that kind of steady improvement, but we have actually accelerated some of those efforts resulted in the lower tax rate in 2016. Longer term, we continue to evaluate kind of what that looks like. We're roughly on that point per year, I think that that's probably a reasonable way to model going forward, which -- and this 31% that we're talking about, really, is roughly a point better than where we were for the full year 2016. So that's the way I would think about it, Isaac."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","And next, we have David Lewis with Morgan Stanley.",9,"And next, we have David Lewis with Morgan Stanley."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve, but they'll be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines",120,"So a couple of quick ones here. First for Bob, and then I got -- I have 2 for Bob, 1 for Steve, but they'll be fast, I promise. So Bob, just coming back to international for a second here. If you do the math, you go sort of from mid-single-digit declines to mid-single-digit growth, where you pick up 10 points or relative on 20% of your business. It's 2 points of growth that's the key driver of the improvement in '17. Your comp-adjusted growth for international, though, in the fourth quarter actually got worse. So just -- can you just help us understand why fourth quarter actually slowed, comp adjusted, but you're confident you get that reacceleration in '17?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had a kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we",199,"Yes. If you look at the kind of the trends of the business on a sequential basis, that's where we feel confident. We knew that we had a kind of an outsized number in Q4 of last year, which resulted in your comp-adjusted numbers looking worse. But when we look at the fundamentals of the business and some of those pockets, things like molecular, Surgical, the trend and the stabilization of our Breast Health business, which is probably the biggest -- one of the biggest changes. And then certainly, we feel pretty clear about -- we have pretty decent line of sight into the inventory levels now with the blood-screening business. I think those are kind of the building blocks that were headwinds last year that certainly will be -- or tailwinds going into 2017. I think Eric, as Steve mentioned, has done a tremendous job of really focusing the teams on the fundamentals. We've gone to the regional bases. We brought in a bunch of new leaders there, and I think they're just starting to get a hold on things. But I think we've seen good progress and good momentum going into 2017 on those couple of areas."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic po",130,"Okay. And then an un-fun question for you and a fun question for Steve. Stock-based compensation FASB changes, any impact on your earnings for '17? And then for Steve, fiscal '17 guidance is in line, I think positive. I think the enthusiasm for Hologic post our conference in September really wasn't about '17. It was about sort of the view that this business can deliver not just 1 year of 5% and 10% growth, frankly, but several years of 5% and 10% growth. So I wonder if you'd just sort of synthesize for shareholders what are some of those business dynamics you're seeing that give you that confidence that this isn't just 1 good year, but it's a few good years to come? And then I'll jump back in queue."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. The stock-based comp piece, there's no impact.",8,"Sure. The stock-based comp piece, there's no impact."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","No material impact.",3,"No material impact."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products",197,"And I think, David, as -- each year, when I look out, I'm always far more worried about the year further out, just as I was probably more worried about '17 earlier in '16. And every year, what I keep seeing is our teams just keep putting more new products in place, better people in place. And I probably feel better about the sustainability of this company than in any point since I've been here. Because I think by the time we go into '18, we're going to have more products hitting. We're going to have the international business that much further along. Because so much of what Eric's focused here during this year, what we've been doing in international this year is really putting the foundation in place that I'd hoped and wanted to be putting in place sooner. But we really weren't doing it. So I think just fundamentally, we just keep getting stronger and stronger. The comps will be getting tougher, this and that. But overall, feeling very good. We're going have a lot of stuff hitting in late '17 and into '18, and that's when the pipeline stuff will really be coming through."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Anthony Petrone with Jefferies.",9,"Our next question is from Anthony Petrone with Jefferies."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And t",95,"Maybe one on molecular and an update on Breast Health, OUS specifically. I'm just wondering what the capital utilization rate of Panther is at $190,000. So just kind of looking ahead, maybe where that could actually go longer term, not only for '17. And then on Breast Health, I guess the question really is, Bob, going back in, I don't know, at some meetings you did speak about the 2-D opportunity OUS as being pretty substantial over the next several years, so I'm just wondering if we can get an update on that opportunity specifically?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow u",224,"Sure. So on the molecular utilization at the $190,000, I think we had talked about previously, call it, roughly 30%. It's probably a little higher than that now, maybe 1/3 of the capacity now, which means that there's still plenty of opportunity to grow utilization on the instrumentation. It's never going to get to 100%. But certainly, we have room to grow. And if we look at TIGRIS, as an example, it's up in the 65% to 75% range in utilization, so there's still plenty of opportunity there from a molecular standpoint. In regards to Breast Health, yes, we are still enthusiastic about the opportunities, both in 3-D as well as 2-D. I think the team has been focused and really looked at country by country, screening guidelines, how we work with not only our dealers, but also starting more importantly, with governments and so forth and meeting some of the governments where they are. And the beauty of our 2-D system is it's software upgradable to 3-D, and so we have both the best 2-D system as well as the best 3-D system. And so that is still a strategy that we feel good about in the markets that we're focused on and an opportunity, not only to place both 2-D and the 3-D systems, but have that opportunity for upgrade over time."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?",36,"Just -- that's helpful. Just a follow-up there would be is 50% to 60% the goal for Panther in terms of capacity utilization? And is there a round number for OUS mammography units that you target?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, rea",77,"Yes. I don't know if we have a specific goal. It's really on the -- how confident and comfortable the lab is. At some states, they're going to want a second Panther as the -- as a backup. So rather than focus on a capacity goal, what I would focus on, really, is we have plenty of opportunity to continue to grow utilization of our assays and our upcoming assays in the pipeline on the existing Panther."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question is from Jack Meehan with Barclays.",9,"Our next question is from Jack Meehan with Barclays."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual pro",72,"I wanted to follow up there on Panther. Just was wondering if you could give any updated thoughts on the individual sexual health products, how they performed in the quarter. And then as time goes on, have you seen more cross-selling of the individual products? Maybe just as you look at the labs, how many are using 1 test or 2 tests or all 3 with Trich? Any color will be great."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer s",165,"Yes. Maybe I'll talk to the last question, first. That's one of the reasons that the utilization is growing the way it is, is the team, in particular, in the U.S., has done a fantastic job of being able to sell the entire menu and really done a customer segmentation that says, ""Okay, if they've got chlamydia, gonorrhea, are they testing for Trich? Are they testing for HPV?"" And that has really driven that utilization in the U.S, and it's starting to drive that utilization internationally as well now that we have the viral loads. I will tell you in terms of growth rates for our major assay -- still, obviously, the largest is our chlamydia, gonorrhea CT/GC assay that grew in the low single digits. And then HPV and Trich continue to grow in excess of market, so those are gaining share. We feel good about our ability to continue to drive growth in '17 in those markets as well -- or those assays."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And one more follow-up on Panther. Just in international, the success you've had with viral loads, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously,",78,"Great. And one more follow-up on Panther. Just in international, the success you've had with viral loads, is there a sense that you can say these customers now at certain percentage are using viral load? And I guess what I'm trying to get to is obviously, with the strength of the U.S. fleet, if there's a way that we can think about the commercial strategy here and what percentage we can think would adopt the test over time?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had the full complement 6, 9 months ago, obviously with the tendered-based contracts in Europe. It takes some time. I think the good news is the leading i",80,"Yes. So we're still in the early days of the viral loads. We just -- we launched those maybe -- they had the full complement 6, 9 months ago, obviously with the tendered-based contracts in Europe. It takes some time. I think the good news is the leading indicator of that, which is the Panther placements, is happening. But it is probably a number that we expect to grow into '17 and '18, for sure. But it's still early days."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our next question comes from Jon Block with Stifel.",9,"Our next question comes from Jon Block with Stifel."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of Op margin expansion, and you mentioned somewhat shared between OpEx and gross margin expansion. So that leaves about 50 bps for gross",103,"Great. And I'll try to ask 2 relatively quick ones. So Bob, the first one, I think the guidance implies about 100 bps of Op margin expansion, and you mentioned somewhat shared between OpEx and gross margin expansion. So that leaves about 50 bps for gross margin, down from roughly 140 bps this year. And I certainly understand the headwinds by international growing faster in '17 relative to '16 but still a decent step-down. So can just talk to us about that step-down in gross margin expansion? And then are you still getting a good gross margin pull from your 3 major divisions?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that.",29,"Yes. So certainly, we've got margins that are -- we finished FY '16 at almost 66% gross margin. That's nothing to be ashamed about. We feel good about that."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","I'd rephrase it that we're still continuing to expand as opposed to a step-down from...",16,"I'd rephrase it that we're still continuing to expand as opposed to a step-down from..."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business",175,"Yes, yes. Exactly. And the international business certainly is a lower-margin business, which is going to impact some of that. And then certainly in 2016, we've benefited from Surgical being outsized growth. We still expect growth in our Surgical business but not at the level that it had in 2016. So there are some product mix in there as well. I will tell you that our operations teams are incredibly focused on continuing to improve the operational aspects of the business, and we established good pricing discipline. So -- and I think there are still opportunities to improve margins, I think just perhaps not at the level of 2016 given some of that product mix that we had. And then in the OpEx margins, it's across -- it's going to be across the product lines or product areas. We -- as Steve mentioned, we opportunistically look to invest in places like marketing and some the other areas. We have the ability to kind of -- to move some of those levers as we need to."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step ba",105,"Okay, perfect, very helpful. And then just, Steve, maybe for you. Just longer term on that Surgical division, is the right way to think about NovaSure sort of flattish once you cycle through Thermachoice? And maybe more importantly, just to take a step back, if you can opine upon MyoSure. I mean, rarely do you have 30% sustainable growth and now to the point where you've got a product annualizing at over $150 million. So just maybe talk about the sustainability of why you're seeing that sort of growth rate and just the market opportunity that you see in front of Hologic for that product?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Sure. Yes. I would say MyoSure has been probably, our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year in which it had looked to be slowing in the 20-ish range kind of really",213,"Sure. Yes. I would say MyoSure has been probably, our wonderful continued surprise that it's been able to generate, as you just said, 2 straight years of 30%-plus growth after a year in which it had looked to be slowing in the 20-ish range kind of really re-accelerate. We're not sure how high is up yet there. And I almost don't want to call the market. Because I think we're finding more and more avenues and more and more opportunities to tap into other procedures and things. So we continue -- even through the year, that growth rate has not yet slowed. We brought some news to it. And I think we see that as still being a real growth driver for us. NovaSure will clearly come back to earth in terms of growth rates. But again, we're going to be bringing news to that franchise, and we're just -- we have adopted a mind-set that we don't accept anything but an expectation of growth, even on the older businesses. And it's our job to figure out how to grow them. I'm confident that team will continue to find ways to keep growing what is a great, great product. But certainly, at slower rates probably, once we got through the big competitive piece."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Next, we have from UBS, Jon Groberg.",7,"Next, we have from UBS, Jon Groberg."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Just -- I'll actually just ask one question. Steve, on the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do",92,"Just -- I'll actually just ask one question. Steve, on the capital deployment that was brought up earlier, can you maybe just talk about where you're at in terms of your teams' ability to do more M&A, whether or not you'd be disappointed if you didn't do something from an M&A standpoint in 2017? And it seems like where you're at as a firm, you seem to have a little bit more confidence internationally. Obviously, the core business in the U.S. is doing well. The M&A piece hasn't really kicked in yet."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I",171,"Yes. Thanks, Jon. I would expect we'll likely do something in '17. It might be very small, might be more mid-sized, not really sure yet. I think our still relentless focus has been always on keeping the base business growing at a healthy rate. And then I do think there may be -- come some opportunities. I would tell you, we've looked at a lot of things, some of which we're patient on, and we want to make sure that they make sense. So I'm seeing a lot more. I would say, if you look at my percentage of my time spent with the divisions on business development deals today versus a year ago, it's a dramatic difference. And we've seen a lot of good things, a lot of things that may not yet be making the full hurdle because we're obviously being very disciplined as we go. But I do feel good that we're going to continue to be smart and sensible, and the capabilities that come a long way."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Our final question is from Mary Kate Gorman from Canaccord Genuity.",11,"Our final question is from Mary Kate Gorman from Canaccord Genuity."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Analysts","Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3-D tomo as a result of the updated NCCN guidelines, similar to CIGNA? And along that line, do you anticipate new payers coming on next quar",59,"Mary Kate on for Mark Massaro. I was hoping to ask have you begun to see more favorable reimbursement decisions in 3-D tomo as a result of the updated NCCN guidelines, similar to CIGNA? And along that line, do you anticipate new payers coming on next quarter as a result of payers revising coverage decisions in the New Year?"
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Executives","Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily, in the next quarter. Hopefully, in the coming quarters, we would hope to continu",106,"Thanks, Mary Kate. We're certainly using the NCCN guidelines and the additional clinical data to try to drive additional private pay. I would not expect anything necessarily, in the next quarter. Hopefully, in the coming quarters, we would hope to continue to make progress there. But there's a lot of pick on this [ph], frankly. There's a lot going on in the private pay world right now. And this isn't necessarily getting the full attention that we think it should, but we'll continue to drive that and expect that over time we'll knock those barriers down. But I think all of that will be additional upside."
108544,403594883,1073306,"Hologic Inc., Q4 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Hologic, Inc.","Operator","Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening.",26,"Thank you. That is all the time we have for questions today. This now concludes Hologic's Fourth Quarter Fiscal 2016 Earnings Call. Have a good evening."
